Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abdominal Abscess
Percutaneous treatment of intrabdominal abscess: urokinase versus saline serum in 100 cases using two surgical scoring systems in a randomized trial.
Abdominal Abscess
[Utility of urokinase in percutaneous drainage treatment of intra-abdominal abscesses.]
Abortion, Habitual
Could the defects in the endometrial extracellular matrix during the implantation be a cause for impaired fertility?
Abscess
Adjuvant urokinase therapy in percutaneous drainage of a multiloculated splenic abscess.
Abscess
Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat.
Abscess
Cutaneous infiltrates of histiocytosis X contain plasminogen activator-bearing epidermotropic dendritic cells different from Langerhans cells.
Abscess
Effect of intracavitary injection of urokinase in the experimentally induced early pyogenic liver abscess of the rabbit.
Abscess
Fluid flow during percutaneous drainage procedures: an in vitro study of the effects of fluid viscosity, catheter size, and adjunctive urokinase.
Abscess
Intracavitary urokinase for enhancement of percutaneous abscess drainage: phase II trial.
Abscess
Intraperitoneal thrombolytic agents in relapsing or persistent peritonitis of patients on continuous ambulatory peritoneal dialysis.
Abscess
Percutaneous treatment of intrabdominal abscess: urokinase versus saline serum in 100 cases using two surgical scoring systems in a randomized trial.
Abscess
Safety of intracavitary urokinase with percutaneous abscess drainage.
Abscess
Ultrasound-guided drainages and sclerotherapy.
Abscess
Use of urokinase in percutaneous drainage of large breast abscesses.
Abscess
Young Investigator Award. In vivo treatment of infected prosthetic graft material with urokinase: an animal model.
Abscess
[Usefulness of urokinase in intraabdominal abscesses.]
Acantholysis
American Academy of Dermatology 1999 Awards for Young Investigators in Dermatology. Pemphigus vulgaris IgG regulates expression of urokinase receptor and junctional proteins that may contribute to acantholysis.
Acantholysis
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Acantholysis
Functional involvement of urokinase-type plasminogen activator receptor in pemphigus acantholysis.
Acantholysis
In vivo studies on the involvement of urokinase in pemphigus acantholysis.
Acantholysis
Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG.
Acantholysis
Pemphigus IgG induces expression of urokinase plasminogen activator receptor on the cell surface of cultured keratinocytes.
Acantholysis
Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice.
Acantholysis
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Acantholysis
Role of plasminogen activator in pemphigus vulgaris.
Acantholysis
Strict correlation between uPAR and plakoglobin expression in pemphigus vulgaris.
Acantholysis
Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis.
Acantholysis
[The role of urokinase-type plasminogen activator in the pathogenesis of pemphigus]
Acidosis
A new approach to the treatment of experimental septic shock.
Acquired Immunodeficiency Syndrome
Altered levels of urokinase on monocytes and in serum of children with AIDS; effects on lymphocyte activation and surface marker expression.
Acquired Immunodeficiency Syndrome
Dysregulated proteolysis in AIDS.
Acquired Immunodeficiency Syndrome
The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.
Acute Coronary Syndrome
Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase.
Acute Coronary Syndrome
Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of acute coronary syndrome.
Acute Coronary Syndrome
Safety and efficacy of abciximab use in conjunction with intracoronary urokinase in patients requiring angioplasty.
Acute Coronary Syndrome
Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes.
Acute Coronary Syndrome
Soluble Urokinase Plasminogen Activator Receptor for Risk Prediction in Patients Admitted with Acute Chest Pain.
Acute Coronary Syndrome
[Urokinase-type plasminogen activator and its inhibitor type 1 in the diagnosis of evolving complications in coronary heart disease]
Acute Kidney Injury
Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
Acute Kidney Injury
Acute renal allograft dysfunction in the setting of deep venous thrombosis: a case of successful urokinase thrombolysis and a review of the literature.
Acute Kidney Injury
Cell Cycle Biomarkers and Soluble Urokinase-Type Plasminogen Activator Receptor for the Prediction of Sepsis-Induced Acute Kidney Injury Requiring Renal Replacement Therapy: A Prospective, Exploratory Study.
Acute Kidney Injury
Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery.
Acute Kidney Injury
Endarterial urokinase in childhood hemolytic uremic syndrome.
Acute Kidney Injury
Postpartum acute renal failure: possible role for endarterial urokinase.
Acute Kidney Injury
RAGE and ?V?3-integrin are essential for suPAR signaling in podocytes.
Acute Kidney Injury
Soluble Urokinase Receptor and Acute Kidney Injury.
Acute Kidney Injury
Soluble Urokinase Receptor and Acute Kidney Injury. Reply.
Acute Kidney Injury
Urokinase (UK) activity in acute renal failure.
Acute Kidney Injury
[Physiopathology of urokinase excretion as studied on the model of acute kidney failure]
Acute Kidney Injury
[Urokinase (UK) activity in acute renal failure]
Acute Kidney Injury
[Urokinase excretion and fibrinolysis in consumption coagulopathy and acute kidney failure]
Acute Lung Injury
Association between urokinase haplotypes and outcome from infection-associated acute lung injury.
Acute Lung Injury
Hyaluronan fragments induce plasminogen activator inhibitor-1 and inhibit urokinase activity in mouse alveolar macrophages: a potential mechanism for impaired fibrinolytic activity in acute lung injury.
Acute Lung Injury
Induction of urokinase-type plasminogen activator receptor by IL-1 beta.
Acute Lung Injury
Involvement of the urokinase kringle domain in lipopolysaccharide-induced acute lung injury.
Acute Lung Injury
Lack of durable protection against cotton smoke-induced acute lung injury in sheep by nebulized single chain urokinase plasminogen activator or tissue plasminogen activator.
Acute Lung Injury
Nebulization of Single-Chain Tissue-Type and Single-Chain Urokinase Plasminogen Activator for Treatment of Inhalational Smoke-Induced Acute Lung Injury.
Acute Lung Injury
Post-transcriptional regulation of urokinase-type plasminogen activator receptor expression in lipopolysaccharide-induced acute lung injury.
Acute Lung Injury
The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability.
Acute Lung Injury
Urokinase Plasminogen Activator Regulates Pulmonary Arterial Contractility and Vascular Permeability in Mice.
Acute Lung Injury
Urokinase-type plasminogen activator (uPA) induces pulmonary microvascular endothelial permeability through low density lipoprotein receptor-related protein (LRP)-dependent activation of endothelial nitric-oxide synthase.
Acute Lung Injury
Urokinase-Type Plasminogen Activator Inhibits Efferocytosis of Neutrophils.
Acute Lung Injury
Wood Bark Smoke Induces Lung and Pleural Plasminogen Activator Inhibitor 1 and Stabilizes its mRNA in Porcine Lung Cells.
Acute-On-Chronic Liver Failure
Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure.
Adenocarcinoma
2,3,7,8-Tetrachlorodibenzo-p-dioxin increases mRNA levels for interleukin-1beta, urokinase plasminogen activator, and tumor necrosis factor-alpha in human uterine endometrial adenocarcinoma RL95-2 cells.
Adenocarcinoma
Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I).
Adenocarcinoma
Antigen expression associated with lymph node metastasis in gastric adenocarcinomas.
Adenocarcinoma
Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Adenocarcinoma
Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells.
Adenocarcinoma
Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues.
Adenocarcinoma
Correlation between urokinase-type plasminogen activator production and the metastasizing ability of two murine mammary adenocarcinomas.
Adenocarcinoma
Detection of cathepsin B, plasminogen activators and plasminogen activator inhibitor in human non-small lung cancer cell lines.
Adenocarcinoma
Dexamethasone decreases urokinase plasminogen activator mRNA stability in MAT 13762 rat mammary carcinoma cells.
Adenocarcinoma
Early detection of pancreatic cancers in liquid biopsies by ultrasensitive fluorescence nanobiosensors.
Adenocarcinoma
Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Adenocarcinoma
Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.
Adenocarcinoma
Enhancement of urokinase-type plasminogen activator activity during the growth of a murine mammary adenocarcinoma.
Adenocarcinoma
Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma.
Adenocarcinoma
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Adenocarcinoma
Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma.
Adenocarcinoma
Expression of cancer stem cell markers is prognostic in metastatic gastroesophageal adenocarcinoma.
Adenocarcinoma
Expression of ETS-1 is correlated with urokinase-type plasminogen activator and poor prognosis in pulmonary adenocarcinoma.
Adenocarcinoma
Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.
Adenocarcinoma
Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
Adenocarcinoma
Helicobacter pylori induces plasminogen activator inhibitor 2 in gastric epithelial cells through nuclear factor-kappaB and RhoA: implications for invasion and apoptosis.
Adenocarcinoma
High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.
Adenocarcinoma
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Adenocarcinoma
Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer.
Adenocarcinoma
Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma.
Adenocarcinoma
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Adenocarcinoma
Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas.
Adenocarcinoma
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Adenocarcinoma
Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Adenocarcinoma
Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.
Adenocarcinoma
Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor beta.
Adenocarcinoma
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
Adenocarcinoma
Overproduction of urokinase-type plasminogen activator is regulated by phospholipase D- and protein kinase C-dependent pathways in murine mammary adenocarcinoma cells.
Adenocarcinoma
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer.
Adenocarcinoma
Plasminogen Activation System in Rectal Adenocarcinoma.
Adenocarcinoma
Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
Adenocarcinoma
Plasminogen activator profiles in neoplastic tissues of the human colon.
Adenocarcinoma
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Adenocarcinoma
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Adenocarcinoma
Plasminogen activators in (pre)malignant conditions of the colorectum.
Adenocarcinoma
Plasminogen activators in oesophageal carcinoma.
Adenocarcinoma
Post-transcriptional regulation of urokinase plasminogen activator gene expression occurs in the nucleus of BC1 rat mammary tumor cells.
Adenocarcinoma
Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction, and cardia evaluated by uPAR-immunohistochemistry.
Adenocarcinoma
Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.
Adenocarcinoma
Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Adenocarcinoma
Purification and characterization of an inhibitor of plasminogen activator released by rat mammary adenocarcinoma cells.
Adenocarcinoma
Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells.
Adenocarcinoma
Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells.
Adenocarcinoma
Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery.
Adenocarcinoma
Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines.
Adenocarcinoma
Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Adenocarcinoma
Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction.
Adenocarcinoma
Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Adenocarcinoma
Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Adenocarcinoma
The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.
Adenocarcinoma
The first international urokinase/warfarin trial in colorectal cancer.
Adenocarcinoma
The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Adenocarcinoma
Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.
Adenocarcinoma
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma.
Adenocarcinoma
TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells.
Adenocarcinoma
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
Adenocarcinoma
Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma.
Adenocarcinoma
Urokinase-type plasminogen activator activity increases during the growth of two murine mammary adenocarcinomas with different metastasizing abilities.
Adenocarcinoma
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
Adenocarcinoma
Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.
Adenocarcinoma
Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro.
Adenocarcinoma of Lung
Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines.
Adenocarcinoma of Lung
Enhanced urokinase-type plasminogen activator activity by extracellular matrix protein obtained from highly metastatic human lung adenocarcinoma cell line.
Adenocarcinoma of Lung
HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression.
Adenocarcinoma of Lung
Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma.
Adenocarcinoma of Lung
Intrabronchial orthotopic propagation of human lung adenocarcinoma--characterizations of tumorigenicity, invasion and metastasis.
Adenocarcinoma of Lung
Pharmacokinetics of single chain forms of urokinase-type plasminogen activator.
Adenocarcinoma of Lung
Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator.
Adenocarcinoma of Lung
Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures.
Adenocarcinoma of Lung
The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
Adenocarcinoma of Lung
Urokinase-type plasminogen activator and its specific receptor in high metastatic and non-metastatic cell lines derived from human lung adenocarcinoma.
Adenoma
A urokinase-type plasminogen activator deficiency diminishes the frequency of intestinal adenomas in Apc(Min/+) mice.
Adenoma
Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas.
Adenoma
Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors.
Adenoma
Effect of anthraquinone-laxatives on the proliferation and urokinase secretion of normal, premalignant and malignant colonic epithelial cells.
Adenoma
Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Adenoma
Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum.
Adenoma
Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Adenoma
Plasmin-catalyzed proteolysis in colorectal neoplasia.
Adenoma
Role of urokinase in colorectal neoplasia.
Adenoma
The expression of p53, Ki-67 and urokinase plasminogen activator receptor in colorectal adenomas with true invasion and pseudoinvasion.
Adenoma
The Plasminogen System in Microdissected Colonic Mucosa Distant from an Isolated Adenoma.
Adenoma
Tumor-promoter-enhanced destruction of noninvasive human benign colon tumor cells by cocultivated carcinoma cells.
Adenoma
Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Adenoma
Urokinase secretion from human colon carcinomas induced by endogenous diglycerides.
Adenomatous Polyposis Coli
Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme.
Adenomatous Polyps
BMP pathway suppression is an early event in inflammation-driven colon neoplasmatogenesis of uPA-deficient mice.
Adenomatous Polyps
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Adenomatous Polyps
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?
Adenomatous Polyps
Plasminogen activators in human colorectal neoplasia.
Adenomatous Polyps
Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme.
AIDS Dementia Complex
The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.
Airway Obstruction
Plastic bronchitis occurring late after the Fontan procedure: treatment with aerosolized urokinase.
Airway Obstruction
[Plastic bronchitis. A case report and review of the literature]
Albuminuria
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
Alopecia
Enoxaparin-induced alopecia in patients with cerebral venous thrombosis.
Alveolar Bone Loss
Association of gene polymorphisms for plasminogen activators with alveolar bone loss.
Alzheimer Disease
A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer's disease.
Alzheimer Disease
Association of late-onset Alzheimer disease with a genotype of PLAU, the gene encoding urokinase-type plasminogen activator on chromosome 10q22.2.
Alzheimer Disease
Association of tagSNPs in the urokinase-plasminogen activator (PLAU) gene with Alzheimer's disease and associated quantitative traits.
Alzheimer Disease
Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene.
Alzheimer Disease
Excessive urokinase-type plasminogen activator activity in the euglobulin fraction of patients with Alzheimer-type dementia.
Alzheimer Disease
Genetic association of urokinase-type plasminogen activator gene rs2227564 site polymorphism with sporadic Alzheimer's disease in the Han Chinese population.
Alzheimer Disease
Meta-analysis of the association between urokinase-plasminogen activator gene rs2227564 polymorphism and Alzheimer's disease.
Alzheimer Disease
The urokinase-plasminogen activator (PLAU) gene is not associated with late onset Alzheimer's disease.
Alzheimer Disease
The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-epsilon4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Abeta(1-42) level.
Ameloblastoma
Presence of Myofibroblasts and Expression of Matrix Metalloproteinase-2 (MMP-2) in Ameloblastomas Correlate with Rupture of the Osseous Cortical.
Amnesia
[FDG-PET in an amnestic and hypersomnic patient with bilateral paramedian thalamic infarction]
Amyloidosis
Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review.
Amyloidosis
Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase.
Amyloidosis
[Fibrinolytic activity of the urine during chronic glomerulonephritis and amyloidosis]
Amyloidosis
[Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis]
Amyotrophic Lateral Sclerosis
A role for the urokinase-type plasminogen activator system in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
The urokinase system of plasminogen activator plays a role in amyotrophic lateral sclerosis (ALS) pathogenesis.
Anaphylaxis
Alteplase use for prevention of central line occlusion in a preterm infant.
Anaphylaxis
Clinical utility of novel agents in the treatment of central venous catheter occlusion.
Anaphylaxis
Highly probable anaphylactic reaction to systemic thrombolytic therapy with high dose urokinase in a child with a prosthetic valve.
Anaphylaxis
Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase.
Anaphylaxis
Pulsus paradoxus in anaphylactic shock due to urokinase administration.
Anaphylaxis
Rational treatment of empyema in children.
Anaphylaxis
The management of anaphylactoid reactions to urokinase.
Anaphylaxis
Treatment of urokinase-related anaphylactoid reaction with intravenous famotidine.
Anaphylaxis
Urokinase protocol for free-flap salvage following prolonged venous thrombosis.
Anaphylaxis
[An allergic reaction due to i.v. urokinase administration]
Anaphylaxis
[Cannulation of the internal jugular vein with 2 silastic catheters. A new method of vascular access for hemodialysis]
Anaphylaxis
[Thrombolysis with Urokinase after anaphylaxis caused by streptokinase treatment (author's transl)]
Anemia
Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma.
Anemia, Aplastic
Properties of urokinase type-plasminogen activator found in chest fluid.
Anemia, Iron-Deficiency
Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma.
Anencephaly
Amniotic fluid fibrinolytic system in fetal neural tube defects.
Aneurysm
A multimodal concept in patients after severe aneurysmal subarachnoid hemorrhage: results of a controlled single centre prospective randomized multimodal phase I/II trial on cerebral vasospasm.
Aneurysm
Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease.
Aneurysm
Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms.
Aneurysm
Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice.
Aneurysm
Association between urokinase-plasminogen activator gene T4065C polymorphism and risk of mitral valve prolapse.
Aneurysm
Case presentations of neuroradiologic interventions for acute cerebrovascular disease.
Aneurysm
Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall.
Aneurysm
Extracellular proteolysis in the development and progression of atherosclerosis.
Aneurysm
Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis.
Aneurysm
Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses.
Aneurysm
Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins.
Aneurysm
Multiple coronary artery aneurysms in an adult associated with extensive thrombus formation resulting in acute myocardial infarction: successful treatment with intracoronary urokinase, intravenous heparin, and oral anticoagulation.
Aneurysm
Outcome after Preoperative or Intraoperative Use of Intra-arterial Urokinase Thrombolysis for Acute Popliteal Artery Thrombosis and Leg Ischemia.
Aneurysm
Popliteal venous aneurysm with pulmonary embolism.
Aneurysm
Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1.
Aneurysm
Rebleeding from a vertebral artery dissecting aneurysm after endovascular internal trapping: adverse effect of intrathecal urokinase injection or incomplete occlusion?-case report-.
Aneurysm
Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor.
Aneurysm
Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis evaluation in transgenic animals.
Aneurysm
Serine proteases and cardiac function.
Aneurysm
Soluble urokinase plasminogen activator receptor in patients with abdominal aortic aneurysm.
Aneurysm
Success of thrombolysis as a predictor of outcome in acute thrombosis of popliteal aneurysms.
Aneurysm
Vascular aneurysms: a perspective.
Aneurysm
[Effects of urokinase type plasminogen activator and plasminogen activator inhibitor-1 expressions on the formation of aneurysm of perimembranous ventricular septal defect].
Aneurysm
[Radiological interventional procedures for the acute abdomen]
Aneurysm, Dissecting
Rebleeding from a vertebral artery dissecting aneurysm after endovascular internal trapping: adverse effect of intrathecal urokinase injection or incomplete occlusion?-case report-.
Aneurysm, False
Distal embolization from an unsuspected external iliac artery pseudoaneurysm: diagnosis during urokinase infusion.
Aneurysm, Ruptured
Development of a kit to treat subarachnoid hemorrhage by intrathecal simple urokinase infusion (ITSUKI) therapy: preliminary results in patients with World Federation of Neurological Surgery (WFNS) grade V subarachnoid hemorrhage.
Aneurysm, Ruptured
Microcatheter intrathecal urokinase infusion into cisterna magna for prevention of cerebral vasospasm: preliminary report.
Angina Pectoris
Antithrombotic treatment in stable coronary syndromes: long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris.
Angina Pectoris
Chronic-intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris--a pilot study.
Angina Pectoris
Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomized dose-response trial.
Angina Pectoris
Long-term Urokinase Therapy and Isovolemic Hemodilution: A Clinical and Hemodynamic Comparison in Patients with Refractory Angina Pectoris.
Angina Pectoris
Spinal cord stimulation: a comparison of efficacy versus other novel treatments for refractory angina pectoris.
Angina Pectoris
Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: results of the ECAPTURE study. European Concerted Action on Prevention from Thrombosis by URokinase Enhancement.
Angina Pectoris
[Antithrombotic therapy in chronic coronary syndromes--value of thrombocyte aggregation inhibition, anticoagulation and chronic thrombolysis]
Angina Pectoris
[Assessment of the anti-ischemic effect in patients with therapy refractory angina pectoris in end-stage coronary heart disease--results of chronic intermittent urokinase therapy]
Angina Pectoris
[Chronic intermittent urokinase therapy in inoperable end-stage coronary disease with therapy refractory angina pectoris symptoms]
Angina Pectoris
[Chronic intermittent urokinase therapy in therapy-refractory angina pectoris]
Angina Pectoris
[Chronic intermittent urokinase therapy: anti-ischemic and hemodynamic effects]
Angina Pectoris
[Conservative therapeutic approaches in terminal coronary heart disease. Chronic intermittent urokinase therapy]
Angina Pectoris
[Rheological determinants of end-organ damage]
Angina, Stable
Plasma urokinase antigen and C-reactive protein predict angina recurrence after coronary angioplasty.
Angina, Unstable
Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA Trial. TAUSA Investigators. Thrombolysis and Angioplasty in Unstable Angina trial.
Angina, Unstable
Adjunctive thrombolytic therapy for angioplasty in ischemic rest angina: results of a double-blind randomized pilot study.
Angina, Unstable
Effects of urokinase and heparin on minimal cross-sectional area of the culprit narrowing in unstable angina pectoris.
Angina, Unstable
Intracoronary urokinase as an adjunct to percutaneous transluminal coronary angioplasty in patients with complex coronary narrowings or angioplasty-induced complications.
Angina, Unstable
Randomized clinical trial of urokinase versus heparin in unstable angina.
Angina, Unstable
Randomized trial of thrombolysis versus heparin in unstable angina.
Angina, Unstable
Safety and efficacy of urokinase during elective coronary angioplasty.
Angina, Unstable
Thrombolytic therapy in refractory unstable angina: the role of Holter monitoring.
Angina, Unstable
Urokinase plus heparin versus aspirin in unstable angina and non-Q-wave myocardial infarction.
Angina, Unstable
Use of urokinase in unstable angina.
Angina, Unstable
[Effect of low molecular weight heparin on unstable angina]
Angioedema
Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase.
Angioedemas, Hereditary
Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema.
Ankylosis
Biological activities of phosphocitrate: a potential meniscal protective agent.
Anterior Spinal Artery Syndrome
Anterior spinal artery syndrome.
Anthrax
A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.
Anthrax
Antitumor efficacy of a urokinase activation-dependent anthrax toxin.
Anthrax
Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
Anthrax
Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.
Anthrax
Imaging specific cell surface protease activity in living cells using reengineered bacterial cytotoxins.
Anthrax
Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).
Anthrax
Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Anthrax
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Anthrax
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis.
Antiphospholipid Syndrome
Fatal cerebral infarction in an asymptomatic young patient with primary antiphospholipid syndrome.
Antithrombin III Deficiency
Fibrinolytic therapy for renal vein thrombosis in the child.
Aortic Aneurysm
Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms.
Aortic Aneurysm
Aortic Aneurysm Rupture After Urokinase Treatment for Acute Limb Ischemia in Two Patients After EVAR.
Aortic Aneurysm
Inhibitors of urokinase type plasminogen activator and cytostatic activity from crude plants extracts.
Aortic Aneurysm, Abdominal
Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice.
Aortic Aneurysm, Abdominal
Soluble urokinase plasminogen activator receptor in patients with abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
The controversial role of the urokinase system in abdominal aortic aneurysm formation and rupture.
Aortic Aneurysm, Abdominal
Urokinase-Type Plasminogen Activator Deficiency in Bone Marrow-Derived Cells Augments Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms.
Aortic Aneurysm, Abdominal
Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
[Expression of urokiase-type plasminogen activator and matrix metalloproteinases in human tissue of abdominal aortic aneurysm]
Aortic Rupture
Aortic Aneurysm Rupture After Urokinase Treatment for Acute Limb Ischemia in Two Patients After EVAR.
Aortic Valve Stenosis
Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).
Aortic Valve Stenosis
SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis.
Appendicitis
Can serum soluble urokinase plasminogen activator receptor be an effective marker in the diagnosis of appendicitis and differentiation of complicated cases?
Appendicitis
Diagnostic Value of Serum Urokinase-Type Plasminogen Activator Receptor in Children With Acute Appendicitis.
Appendicitis
Progress of tissue injury in appendicitis involves the serine proteases uPA and PAI-1.
Appendicitis
The diagnostic value of serum urokinase-type plasminogen activator receptor in acute appendicitis.
Arachnoiditis
Intrathecal urokinase as a treatment for intraventricular hemorrhage in the preterm infant.
Arachnoiditis
The effect of urokinase in preventing the formation of epidural fibrosis and/or leptomeningeal arachnoiditis.
Arterial Occlusive Diseases
Initial results of reteplase in the treatment of acute lower extremity arterial occlusions.
Arterial Occlusive Diseases
Low-dose intermittent urokinase therapy in chronic symptomatic end-stage arterial disease--clinical relevance for patients with coronary artery disease or peripheral arterial occlusive disease.
Arterial Occlusive Diseases
The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
Arterial Occlusive Diseases
Thrombolytic therapy in peripheral arterial occlusive disease: mechanisms of action and drugs available.
Arterial Occlusive Diseases
[Experience with urokinase in chronic arterial occlusive disease and long-standing phlebothrombosis]
Arterial Occlusive Diseases
[Intraarterial urokinase infusion therapy for arterial occlusive disease of the pelvis and extremities with special reference to short-term high dose infusion]
Arterial Occlusive Diseases
[Results of in situ arterial thrombolysis by the combination of urokinase and lysyl plasminogen in acute arterial occlusive diseases of the lower limbs]
Arterial Occlusive Diseases
[Short-term intra-arterial infusion with ultrahigh-dose urokinase in treatment of peripheral arterial occlusive disease]
Arteriovenous Fistula
Comparative efficacy and safety of local and peripheral venous thrombolytic therapy with urokinase for thrombosed hemodialysis arteriovenous fistulas.
Arteriovenous Fistula
Local fibrinolysis in native arteriovenous fistulas of haemodialysis patients.
Arteriovenous Fistula
Urokinase treatment for arteriovenous fistulae declotting in dialyzed patients.
Arteriovenous Malformations
Assessment of Complication Types and Rates Related to Diagnostic Angiography and Interventional N euroradiologic Procedures. A Four Year Review (1993-1996).
Arteriovenous Malformations
Intra-arterial urokinase for treatment of retrograde thrombosis following resection of an arteriovenous malformation. Case report.
Arthritis
Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation.
Arthritis
Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis.
Arthritis
Antibody-Mediated Neutralization of uPA Proteolytic Function Reduces Disease Progression in Mouse Arthritis Models.
Arthritis
Arthritis simulating thrombosis on urokinase scan.
Arthritis
Cathepsin B and cystatin C play an inflammatory role in gouty arthritis of the knee.
Arthritis
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Arthritis
Expression of the VEGF receptor-3 in osteoarthritic chondrocytes: stimulation by interleukin-1 beta and association with beta 1-integrins.
Arthritis
Identification and preclinical development of an anti-proteolytic uPA antibody for rheumatoid arthritis.
Arthritis
Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer.
Arthritis
Plasminogen activators in synovial fluid and plasma from patients with arthritis.
Arthritis
SURVIVIN IS AN ESSENTIAL MEDIATOR OF ARTHRITIS INTERACTING WITH UROKINASE SIGNALLING.
Arthritis
The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.
Arthritis
Tissue-type plasminogen activator deficiency exacerbates arthritis.
Arthritis
Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis.
Arthritis
Urokinase-type plasminogen activator and arthritis progression: contrasting roles in systemic and monoarticular arthritis models.
Arthritis
Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement.
Arthritis, Experimental
Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis.
Arthritis, Experimental
Antibody-Mediated Neutralization of uPA Proteolytic Function Reduces Disease Progression in Mouse Arthritis Models.
Arthritis, Experimental
Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis.
Arthritis, Experimental
Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells.
Arthritis, Gouty
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Arthritis, Gouty
Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Arthritis, Infectious
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Arthritis, Rheumatoid
Antisense oligonucleotides against the urokinase receptor: a therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer.
Arthritis, Rheumatoid
Antisense targeting of the urokinase receptor blocks urokinase-dependent proliferation, chemoinvasion, and chemotaxis of human synovial cells and chondrocytes in vitro.
Arthritis, Rheumatoid
Association between urokinase gene 3'-UTR T/C polymorphism and Chinese patients with rheumatoid arthritis in Taiwan.
Arthritis, Rheumatoid
Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis.
Arthritis, Rheumatoid
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Arthritis, Rheumatoid
Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis.
Arthritis, Rheumatoid
Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Arthritis, Rheumatoid
Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis.
Arthritis, Rheumatoid
Double-blind controlled assessment of the effect of intra-articular hydrocortisone and urokinase in rheumatoid arthritis.
Arthritis, Rheumatoid
Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Arthritis, Rheumatoid
Exacerbation of antigen-induced arthritis in urokinase-deficient mice.
Arthritis, Rheumatoid
Increased proteolytic activity on the surface of monocytes from patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Intra-articular urokinase in rheumatoid arthritis.
Arthritis, Rheumatoid
Plasminogen activators in synovial fluid and plasma from patients with arthritis.
Arthritis, Rheumatoid
Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Release of the Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) by Activated Neutrophils in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Serum levels of the soluble urokinase plasminogen activator receptor (suPAR) correlates with disease activity in early rheumatoid arthritis and reflects joint damage over time.
Arthritis, Rheumatoid
Significance of serine proteinase and matrix metalloproteinase systems in the destruction of human articular cartilage.
Arthritis, Rheumatoid
Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission.
Arthritis, Rheumatoid
Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population.
Arthritis, Rheumatoid
Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.
Arthritis, Rheumatoid
Suppression of urokinase-type plasminogen activator mRNA levels in human fibrosarcoma cells and synovial fibroblasts by anti-inflammatory glucocorticoids.
Arthritis, Rheumatoid
The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets.
Arthritis, Rheumatoid
Urokinase in rheumatoid arthritis: causal or coincidental?
Arthritis, Rheumatoid
Urokinase-mediated fibrinolysis in the synovial fluid of rheumatoid arthritis patients may be affected by the inactivation of single chain urokinase type plasminogen activator by thrombin.
Arthritis, Rheumatoid
Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement.
Arthritis, Rheumatoid
[Analysis of blood coagulation and fibrinolysis in rheumatoid arthritis using the urokinase activated thromboelastography]
Arthritis, Rheumatoid
[Blood coagulation, fibrinolysis and various values of Lansbury's activity index in rheumatoid arthritis patients]
Arthritis, Rheumatoid
[Levels of matrix metalloproteinase-3 and urokinase-type plasminogen activator in knee synovial fluids from patients with rheumatoid arthritis and osteoarthritis]
Arthritis, Rheumatoid
[Membrane and cytoplasmic expression of urokinase-type plasminogen activator receptor in synovial tissues of rheumatoid arthritis patients]
Aspergillosis
Invasive aspergillosis in leukemic children.
Asthma
Airway and peripheral uPAR is elevated in asthma, and identifies a severe, non-atopic subset of patients.
Asthma
Association of urokinase-type plasminogen activator with asthma and atopy.
Asthma
Cigarette Smoke Induces uPAR in Vivo and Isoforms Selectively Contribute to Bronchial Epithelial Phenotype.
Asthma
Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge.
Asthma
Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model.
Asthma
Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients.
Asthma
Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling.
Asthma
PLAUR polymorphisms and lung function in UK smokers.
Asthma
PLAUR polymorphisms are associated with asthma, PLAUR levels, and lung function decline.
Asthma
Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy.
Asthma
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
Asthma
The biomarkers suPAR and blood eosinophils are associated with hospital readmissions and mortality in asthma - a retrospective cohort study.
Asthma
Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma.
Asthma
Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma.
Asthma
[The fibrinolytic system of bronchial asthma patients in the late terms of pregnancy]
Astrocytoma
Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells.
Astrocytoma
Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo.
Astrocytoma
Increased expression of low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas.
Astrocytoma
Protein Kinase C-{alpha} Mediated Regulation of Low-Density Lipoprotein Receptor Related Protein and Urokinase Increases Astrocytoma Invasion.
Astrocytoma
Radiation-induced blood-brain barrier damage in astrocytoma: relation to elevated gelatinase B and urokinase.
Astrocytoma
Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma.
Astrocytoma
Urokinase induces receptor mediated brain tumor cell migration and invasion.
Astrocytoma
Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain.
Atherosclerosis
Automated, PCR-RFLP genotyping of the urokinase gene.
Atherosclerosis
Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
Atherosclerosis
Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).
Atherosclerosis
Extracellular proteolysis in the development and progression of atherosclerosis.
Atherosclerosis
Fatty acids differentially modify the expression of urokinase type plasminogen activator receptor in monocytes.
Atherosclerosis
Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis.
Atherosclerosis
Hepatic Overexpression of Soluble Urokinase Receptor (uPAR) Suppresses Diet-Induced Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (LDLR-/-) Mice.
Atherosclerosis
Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease.
Atherosclerosis
Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow.
Atherosclerosis
Inhibitor of plasminogen activator in human arterial wall. I. Histochemical study.
Atherosclerosis
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.
Atherosclerosis
Level of Macrophage uPA Expression Is an Important Determinant of Atherosclerotic Lesion Growth in Apoe-/- Mice.
Atherosclerosis
Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death.
Atherosclerosis
Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins.
Atherosclerosis
Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro.
Atherosclerosis
Native atherosclerosis and vein graft arterialization: association with increased urokinase receptor expression in vitro and in vivo.
Atherosclerosis
Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice.
Atherosclerosis
Reduced beta3-endonexin levels are associated with enhanced urokinase-type plasminogen activator receptor expression in ApoE-/- mice.
Atherosclerosis
Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor.
Atherosclerosis
Relation of urokinase-type plasminogen activator expression to presence and severity of atherosclerotic lesions in human coronary arteries.
Atherosclerosis
Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias.
Atherosclerosis
Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis evaluation in transgenic animals.
Atherosclerosis
Significant association of urokinase plasminogen activator Pro141Leu with serum lipid profiles in a Japanese population.
Atherosclerosis
Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
Atherosclerosis
Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.
Atherosclerosis
Successful silencing of plasminogen activator inhibitor-1 in human vascular endothelial cells using small interfering RNA.
Atherosclerosis
The urokinase system in the pathogenesis of atherosclerosis.
Atherosclerosis
The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.
Atherosclerosis
Thrombosis and atherosclerosis.
Atherosclerosis
Urokinase plasminogen activator (uPA) stimulates cholesterol biosynthesis in macrophages through activation of SREBP-1 in a PI3-kinase and MEK-dependent manner.
Atherosclerosis
Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism.
Atherosclerosis
Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-?B pathway in osteoclasts.
Atherosclerosis
Urokinase receptor surface expression regulates monocyte migration and is associated with accelerated atherosclerosis.
Atherosclerosis
Urokinase-type plasminogen activator downregulates paraoxonase 1 expression in hepatocytes by stimulating peroxisome proliferator-activated receptor-? nuclear export.
Atherosclerosis
[Increase of the membrane-bound urokinase level in monocytes from patients with atherosclerosis is accompanied by decrease of urokinase-induced myocyte migration]
Atherosclerosis
[Plasminogen activator of urokinase-type: mechanisms of involvement in vessel remodeling and angiogenesis, gene therapy approaches to ischemia]
Atrial Fibrillation
Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation.
Atrial Fibrillation
Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation.
Atrial Fibrillation
Low level of low-density lipoprotein cholesterol is related with increased hemorrhagic transformation after acute ischemic cerebral infarction.
Atrial Fibrillation
Management of acute superior mesenteric artery occlusion.
Atrial Fibrillation
Preoperative Levels of the Soluble Urokinase-Type Plasminogen Activator Receptor as Predictor for New Episodes of Atrial Fibrillation After Vascular Surgery.
Atrial Fibrillation
Randomized clinical stroke trials in 2007.
Atrial Fibrillation
Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Predictor of Incident Atrial Fibrillation.
Autoimmune Diseases
Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study.
Autoimmune Diseases
The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis.
Bacteremia
A prospective double-blind randomized trial of urokinase flushes to prevent bacteremia resulting from luminal colonization of subcutaneous central venous catheters.
Bacteremia
Antibiotic lock with vancomycin and urokinase can successfully treat colonized central venous catheters in pediatric cancer patients.
Bacteremia
Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome.
Bacteremia
Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia.
Bacteremia
Failure of urokinase to resolve Broviac catheter-related bacteremia in children.
Bacteremia
Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.
Bacteremia
Persistent catheter-related bacteremia: clearance with antibiotics and urokinase.
Bacteremia
Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias.
Bacteremia
Urokinase in the treatment of bacteremia and candidemia in patients with right atrial catheters.
Bacterial Infections
Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.
Bacterial Infections
Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes.
Bacterial Infections
Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis.
Bacterial Infections
Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD.
Bacterial Infections
The urokinase receptor. A cell surface, regulated chemokine.
Behcet Syndrome
Urokinase plasminogen activator receptor levels in Behcet's disease.
Bile Duct Diseases
[SPECTROPHOTOMETRIC AND COLORIMETRIC DETERMINATION OF UROKINASE IN THE BLOOD OF PATIENTS WITH LIVER AND BILE DUCT DISEASES.]
Biliary Atresia
Elevation of serum urokinase plasminogen activator receptor and liver stiffness in postoperative biliary atresia.
Biliary Atresia
Hepatocytes buried in the cirrhotic livers of patients with biliary atresia proliferate and function in the livers of urokinase-type plasminogen activator-NOG mice.
Biliary Tract Neoplasms
Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.
Blindness
Comparison of intra-arterial thrombolysis with conventional treatment in patients with acute central retinal artery occlusion.
Blister
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Blister
Hemorrhagic bullae as a complication of urokinase therapy for hemodialysis catheter thrombosis.
Blister
Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice.
Blister
Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann.
Blister
Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.
Blister
[Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]
Bloom Syndrome
Biological activities of phosphocitrate: a potential meniscal protective agent.
Bone Resorption
Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor.
Bone Resorption
Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
Bone Resorption
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
Bone Resorption
The role of the plasminogen system in bone resorption in vitro.
Bone Resorption
Thrombomodulin is synthesized by osteoblasts, stimulated by 1,25-(OH)2D3 and activates protein C at their cell membrane.
Bone Resorption
uPA Attenuated LPS-induced Inflammatory Osteoclastogenesis through the Plasmin/PAR-1/Ca(2+)/CaMKK/AMPK Axis.
Brain Death
Fatal cerebral infarction in an asymptomatic young patient with primary antiphospholipid syndrome.
Brain Edema
Correlation of tumor plasminogen activator with peritumoral cerebral edema. A CT and biochemical study.
Brain Edema
Surgical improvement of brain edema related to hypertensive intracerebral hemorrhage.
Brain Infarction
Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate.
Brain Injuries
Coagulopathy in the Setting of Mild Traumatic Brain Injury: Truths and Consequences.
Brain Injuries
Decreased levels of active uPA and KLK8 assessed by [(111) In]MICA-401 binding correlate with the seizure burden in an animal model of temporal lobe epilepsy.
Brain Injuries
Deficiency of urokinase-type plasminogen activator and its receptor affects social behavior and increases seizure susceptibility.
Brain Injuries
Future Perspectives on the Fibrinolytic Therapy of Intracerebral Hemorrhages.
Brain Injuries
Stereotactic cisternal lavage in patients with aneurysmal subarachnoid hemorrhage with urokinase and nimodipine for the prevention of secondary brain injury (SPLASH): study protocol for a randomized controlled trial.
Brain Injuries
The effects of blood pressure and urokinase on brain injuries after experimental cerebral infarction in rats.
Brain Injuries
Tissue plasminogen activator-independent roles of neuroserpin in the central nervous system.
Brain Injuries
Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window.
Brain Injuries
uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK.
Brain Injuries
Urokinase plasminogen activator impairs SNP and PGE2 cerebrovasodilation after brain injury through activation of LRP and ERK MAPK.
Brain Injuries
Urokinase-type plasminogen activator regulates neurodegeneration and neurogenesis but not vascular changes in the mouse hippocampus after status epilepticus.
Brain Injuries, Traumatic
Altered NO function contributes to impairment of uPA and tPA cerebrovasodilation after brain injury.
Brain Injuries, Traumatic
Epileptogenesis after traumatic brain injury in Plau-deficient mice.
Brain Ischemia
Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate.
Brain Ischemia
Stenting as a Rescue Treatment After Failure of Mechanical Thrombectomy for Anterior Circulation Large Artery Occlusion.
Brain Ischemia
Urokinase-type Plasminogen Activator Promotes Synaptic Recovery in the Ischemic Brain.
Brain Ischemia
[Effects of rhubarb aglycone combined with thrombolysis on brain microvascular basement membrane impairment in rats with thrombus-occluded cerebral ischemia].
Brain Ischemia
[Protective effects of Ginkgo biloba extract on focal cerebral ischemia and thrombogenesis of carotid artery in rats]
Brain Neoplasms
A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Brain Neoplasms
Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors.
Brain Neoplasms
Different types of plasminogen activator activity in human brain tumours: relation with peritumoral oedema?
Brain Neoplasms
Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
Brain Neoplasms
Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors.
Brain Neoplasms
Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.
Brain Neoplasms
Metastatic brain tumour and fibrinopeptides.
Brain Neoplasms
Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours.
Brain Neoplasms
Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.
Brain Neoplasms
Purification and characterization of the plasminogen activator secreted by a rat brain tumor cell line in culture.
Brain Neoplasms
Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin.
Brain Neoplasms
Trial of anticancer pellet in malignant brain tumours; 5 FU and urokinase embedded in silastic.
Brain Neoplasms
Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity.
Brain Neoplasms
Urokinase induces receptor mediated brain tumor cell migration and invasion.
Brain Neoplasms
Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain.
Brain Neoplasms
Urokinase-derived peptide UP-7 suppresses tumor angiogenesis and metastasis through inhibition of FAK activation.
Brain Neoplasms
Urokinase-targeted fusion by oncolytic Sendai virus eradicates orthotopic glioblastomas by pronounced synergy with interferon-? gene.
Brain Neoplasms
[Treatment of brain tumors with anticancer pellet--experimental and clinical study (author's transl)]
Breast Cyst
Urokinase and tissue-type plasminogen activators are present in breast cyst fluids.
Breast Neoplasms
(-)-Epigallocatechin gallate derivatives reduce the expression of both urokinase plasminogen activator and plasminogen activator inhibitor-1 to inhibit migration, adhesion, and invasion of MDA-MB-231 cells.
Breast Neoplasms
A high cytosol value of urokinase-type plasminogen activator (uPA) may be predictive of early relapse in primary breast cancer.
Breast Neoplasms
A novel approach for identification of tumor-associated antigens expressed on the surface of tumor cells.
Breast Neoplasms
A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo.
Breast Neoplasms
A personalized approach to cancer treatment: how biomarkers can help.
Breast Neoplasms
A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue.
Breast Neoplasms
A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols.
Breast Neoplasms
A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen.
Breast Neoplasms
Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression.
Breast Neoplasms
Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells.
Breast Neoplasms
Alpha(v) integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells.
Breast Neoplasms
An Activatable Polymeric Reporter for Near-Infrared Fluorescent and Photoacoustic Imaging of Invasive Cancer.
Breast Neoplasms
An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Breast Neoplasms
An Au-Se nanoprobe for the evaluation of the invasive potential of breast cancer cells via imaging the sequential activation of uPA and MMP-2.
Breast Neoplasms
An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.
Breast Neoplasms
Anti-metastatic effect of Smilax china L. extract on MDA-MB-231 cells.
Breast Neoplasms
Anti-urokinase-type plasminogen activator monoclonal antibodies inhibit the proliferation of human breast cancer cell lines in vitro.
Breast Neoplasms
Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer.
Breast Neoplasms
Antigen levels of urokinase type plasminogen activator and its inhibitors in primary breast cancer.
Breast Neoplasms
Antimetastatic Potential of PAI-1-Specific RNA Aptamers.
Breast Neoplasms
Assessment of c-erbB2 and vascular endothelial growth factor mRNA expression in fine-needle aspirates from early breast carcinomas: pre-operative determination of malignant potential.
Breast Neoplasms
Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.
Breast Neoplasms
Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Breast Neoplasms
Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer.
Breast Neoplasms
Binding of urokinase to specific receptor sites on human breast cancer membranes.
Breast Neoplasms
Biochemical markers in breast cancer: which ones are clinically useful?
Breast Neoplasms
Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma.
Breast Neoplasms
Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
Breast Neoplasms
Biological mechanisms in breast cancer invasiveness: relevance to preventive interventions.
Breast Neoplasms
Biomarkers associated with breast cancer are associated with obesity.
Breast Neoplasms
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Breast Neoplasms
Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice.
Breast Neoplasms
Breast cancer statistics and markers.
Breast Neoplasms
Calcitonin inhibits invasion of breast cancer cells: Involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Breast Neoplasms
Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment.
Breast Neoplasms
Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
Breast Neoplasms
Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells.
Breast Neoplasms
Cell Signaling by Urokinase-type Plasminogen Activator Receptor Induces Stem Cell-like Properties in Breast Cancer Cells.
Breast Neoplasms
Cell surface expression of urokinase receptor in normal mammary epithelial cells and breast cancer cell lines.
Breast Neoplasms
Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer.
Breast Neoplasms
Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
Breast Neoplasms
Changes in uPA, PAI-1, and TGF-? Production during Breast Cancer Cell Interaction with Human Mesenchymal Stroma/Stem-Like Cells (MSC).
Breast Neoplasms
Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures.
Breast Neoplasms
Characterization of cancer cell lines established from two human metastatic breast cancers.
Breast Neoplasms
Clinical implications of urokinase and tissue type plasminogen activators and their inhibitor (PAI-1) in breast cancer tissue.
Breast Neoplasms
Clinical relevance of biologic factors in male breast cancer.
Breast Neoplasms
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
Breast Neoplasms
Clinical relevance of the urokinase plasminogen activator system in breast cancer.
Breast Neoplasms
Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
Breast Neoplasms
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
Breast Neoplasms
Clinical uses of tumor markers: a critical review.
Breast Neoplasms
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Breast Neoplasms
Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
Breast Neoplasms
Clinicopathologic analysis of macrophage infiltrates in breast carcinoma.
Breast Neoplasms
Co-expression of urokinase with haptoglobin in human carcinomas.
Breast Neoplasms
Combined effect of green tea and Ganoderma lucidum on invasive behavior of breast cancer cells.
Breast Neoplasms
Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Breast Neoplasms
Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells.
Breast Neoplasms
Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma.
Breast Neoplasms
Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues.
Breast Neoplasms
Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients.
Breast Neoplasms
Comparison of the tumor associated proteases cathepsin D (CATH D) and urokinase-type plasminogen activator (uPA) in cytosols of human breast cancer patients.
Breast Neoplasms
Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Breast Neoplasms
Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
Breast Neoplasms
Conditionally activating optical contrast agent with enhanced sensitivity via gold nanoparticle plasmon energy transfer: feasibility study.
Breast Neoplasms
Confocal fluorescence microscopy of urokinase plasminogen activator receptor and cathepsin D in human MDA-MB-231 breast cancer cells migrating in reconstituted basement membrane.
Breast Neoplasms
Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma.
Breast Neoplasms
Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
Breast Neoplasms
Curcumin inhibits metastatic progression of breast cancer cell through suppression of urokinase-type plasminogen activator by NF-kappa B signaling pathways.
Breast Neoplasms
Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness.
Breast Neoplasms
Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells.
Breast Neoplasms
Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells.
Breast Neoplasms
Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.
Breast Neoplasms
Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma.
Breast Neoplasms
Design and testing of a packaged microfluidic cell for the multiplexed electrochemical detection of cancer markers.
Breast Neoplasms
Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive near-infrared reporter.
Breast Neoplasms
Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients.
Breast Neoplasms
Development of U11-functionalized gold nanoparticles for selective targeting of urokinase plasminogen activator receptor-positive breast cancer cells.
Breast Neoplasms
Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer.
Breast Neoplasms
Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
Breast Neoplasms
Disregulation of urokinase plasminogen activator gene in breast cancer.
Breast Neoplasms
Docosahexaenoic Acid Downregulates EGF-Induced Urokinase Plasminogen Activator and Matrix Metalloproteinase 9 Expression by Inactivating EGFR/ErbB2 Signaling in SK-BR3 Breast Cancer Cells.
Breast Neoplasms
Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
Breast Neoplasms
Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection.
Breast Neoplasms
Effect of hypoxia on cellular adhesion to vitronectin and fibronectin.
Breast Neoplasms
Effect of macrophages on breast cancer cell proliferation, and on expression of hormone receptors, uPAR and HER-2.
Breast Neoplasms
Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231.
Breast Neoplasms
Effects of specific DNMT-gene depletion on cancer cell transformation and breast cancer cell invasion; towards selective DNMT inhibitors.
Breast Neoplasms
Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells.
Breast Neoplasms
EndoPredict versus uPA/PAI-1 in breast cancer: Comparison of markers and association with clinicopathological parameters.
Breast Neoplasms
Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression.
Breast Neoplasms
Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating alpha(v)beta5 vitronectin receptor cell surface expression.
Breast Neoplasms
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Breast Neoplasms
Enhanced Expression of Rab27A Gene by Breast Cancer Cells Promoting Invasiveness and the Metastasis Potential by Secretion of Insulin-Like Growth Factor-II.
Breast Neoplasms
Enhanced stability of urokinase-type plasminogen activator mRNA in metastatic breast cancer MDA-MB-231 cells and LLC-PK1 cells down-regulated for protein kinase C--correlation with cytoplasmic heterogeneous nuclear ribonucleoprotein C.
Breast Neoplasms
Enterolactone Suppresses Proliferation, Migration and Metastasis of MDA-MB-231 Breast Cancer Cells Through Inhibition of uPA Induced Plasmin Activation and MMPs-Mediated ECM Remodeling
Breast Neoplasms
Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue.
Breast Neoplasms
ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation.
Breast Neoplasms
Estradiol preferentially enhances extracellular tissue plasminogen activators of MCF-7 breast cancer cells.
Breast Neoplasms
European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer.
Breast Neoplasms
Evidence for the clinical use of tumour markers.
Breast Neoplasms
Exposure of mcf-7 breast cancer cells to electromagnetic fields up-regulates the plasminogen activator system.
Breast Neoplasms
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Breast Neoplasms
Expression of cathepsin D, stromelysin-3, and urokinase by reactive stromal cells on breast carcinoma prognosis.
Breast Neoplasms
Expression of colony-stimulating factor-1 and its receptor (the protein product of c-fms) in invasive breast tumor cells. Induction of urokinase production via this pathway?
Breast Neoplasms
Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Breast Neoplasms
Expression of proteinases and inhibitors in human breast cancer progression and survival.
Breast Neoplasms
Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.
Breast Neoplasms
Expression of urokinase plasminogen activator (uPA) in the leukocytes and tissues of patients with benign and malignant breast lesions.
Breast Neoplasms
Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
Breast Neoplasms
External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
Breast Neoplasms
Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
Breast Neoplasms
Fibrinolytic Activity of Circulating Microvesicles Is Associated with Progression of Breast Cancer.
Breast Neoplasms
Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells.
Breast Neoplasms
Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression.
Breast Neoplasms
Glucocorticoid (GC)-mediated down-regulation of urokinase plasminogen activator expression via the serum and GC regulated kinase-1/forkhead box O3a pathway.
Breast Neoplasms
Green tea polyphenols modulate secretion of urokinase plasminogen activator (uPA) and inhibit invasive behavior of breast cancer cells.
Breast Neoplasms
Growth inhibition of MDA-MB-231 cell line by peptides designed based on uPA.
Breast Neoplasms
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Breast Neoplasms
HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer.
Breast Neoplasms
Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.
Breast Neoplasms
High concentration of urokinase-type plasminogen activator receptor in the serum of women with primary breast cancer.
Breast Neoplasms
High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast.
Breast Neoplasms
High levels of cathepsin B predict poor outcome in patients with breast cancer.
Breast Neoplasms
High levels of uPA and PAI-1 predict a good response to anthracyclines.
Breast Neoplasms
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Breast Neoplasms
Hormonal modulation of plasminogen activator: an approach to prediction of human breast tumor responsiveness.
Breast Neoplasms
HPLC-MS/MS analysis of mesupron and its application to a pharmacokinetic study in rats.
Breast Neoplasms
Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity.
Breast Neoplasms
Human cytomegalovirus interleukin-10 enhances matrigel invasion of MDA-MB-231 breast cancer cells.
Breast Neoplasms
Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels.
Breast Neoplasms
Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer.
Breast Neoplasms
Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance.
Breast Neoplasms
Immunoassays of urokinase (uPA) and its type-1 inhibitor (PAI-1) in detergent extracts of breast cancer tissue.
Breast Neoplasms
Immunoelectron microscopy of the receptor for urokinase plasminogen activator and cathepsin D in the human breast cancer cell line MDA-MB-231.
Breast Neoplasms
Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours.
Breast Neoplasms
Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
Breast Neoplasms
Immunohistologic evaluation of invasion-associated proteases in breast carcinoma.
Breast Neoplasms
Impaired MicroRNA Processing Facilitates Breast Cancer Cell Invasion by Upregulating Urokinase-Type Plasminogen Activator Expression.
Breast Neoplasms
Impairment of breast cancer cell invasion by COX-2-specific inhibitor NS398: roles of CXCR4 and of uPA system.
Breast Neoplasms
In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells.
Breast Neoplasms
In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells.
Breast Neoplasms
In vitro suppression of urokinase plasminogen activator in breast cancer cells--a comparison of two antisense strategies.
Breast Neoplasms
In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
Breast Neoplasms
Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis.
Breast Neoplasms
Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.
Breast Neoplasms
Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Breast Neoplasms
Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins.
Breast Neoplasms
Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
Breast Neoplasms
Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells.
Breast Neoplasms
Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues.
Breast Neoplasms
Inhibition of breast carcinoma and trophoblast cell invasiveness by vascular endothelial growth factor.
Breast Neoplasms
Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator.
Breast Neoplasms
Inhibition of receptor-dependent urokinase signaling by specific Ser to Glu substitutions.
Breast Neoplasms
Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells.
Breast Neoplasms
Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
Breast Neoplasms
Inhibition of urokinase-type plasminogen activator expression by dihydroartemisinin in breast cancer cells.
Breast Neoplasms
Integrin ?3 and its ligand regulate the expression of uPA through p38 MAPK in breast cancer.
Breast Neoplasms
Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.
Breast Neoplasms
Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression.
Breast Neoplasms
Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Breast Neoplasms
Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
Breast Neoplasms
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
Breast Neoplasms
Invasive capacity and regulation of urokinase-type plasminogen activator in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells, and a transfectant (S30) stably expressing ER.
Breast Neoplasms
Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA.
Breast Neoplasms
LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system.
Breast Neoplasms
Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.
Breast Neoplasms
Lipids isolated from bone induce the migration of human breast cancer cells.
Breast Neoplasms
Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.
Breast Neoplasms
Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence.
Breast Neoplasms
Mature breast adipocytes promote breast cancer cell motility.
Breast Neoplasms
Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer.
Breast Neoplasms
Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer.
Breast Neoplasms
Metastatic effect of LY-6K gene in breast cancer cells.
Breast Neoplasms
Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells.
Breast Neoplasms
Molecular photoacoustic tomography of breast cancer using receptor targeted magnetic iron oxide nanoparticles as contrast agents.
Breast Neoplasms
MRTF-A and STAT3 promote MDA-MB-231 cell migration via hypermethylating BRSM1.
Breast Neoplasms
Multiparametric prognostic evaluation of biological factors in primary breast cancer.
Breast Neoplasms
Multiplex sensing of protease and kinase enzyme activity via orthogonal coupling of quantum dot-peptide conjugates.
Breast Neoplasms
N-Alkylisatin-Loaded Liposomes Target the Urokinase Plasminogen Activator System in Breast Cancer.
Breast Neoplasms
N-WASP activation by a beta1-integrin-dependent mechanism supports PI3K-independent chemotaxis stimulated by urokinase-type plasminogen activator.
Breast Neoplasms
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Breast Neoplasms
Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells.
Breast Neoplasms
New data on chemotherapy in the adjuvant setting.
Breast Neoplasms
New prognostic and predictive factors in breast cancer.
Breast Neoplasms
NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4.
Breast Neoplasms
Nimbolide inhibits invasion and migration, and down-regulates uPAR chemokine gene expression, in two breast cancer cell lines.
Breast Neoplasms
Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
Breast Neoplasms
NIR Fluorophore-Hollow Gold Nanosphere Complex for Cancer Enzyme-Triggered Detection and Hyperthermia.
Breast Neoplasms
Novel medicinal mushroom blend suppresses growth and invasiveness of human breast cancer cells.
Breast Neoplasms
Novel methods for the determination of the angiogenic activity of human tumors.
Breast Neoplasms
Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue.
Breast Neoplasms
Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
Breast Neoplasms
Optimized immunohistochemistry in combination with image analysis: A reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer.
Breast Neoplasms
Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells.
Breast Neoplasms
Osteopontin induces soluble urokinase-type plasminogen activator receptor production and release.
Breast Neoplasms
Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells.
Breast Neoplasms
Overexpression of PSMC2 promotes the tumorigenesis and development of human breast cancer via regulating plasminogen activator urokinase (PLAU).
Breast Neoplasms
Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
Breast Neoplasms
Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes.
Breast Neoplasms
Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis.
Breast Neoplasms
Oxygen-mediated regulation of tumor cell invasiveness. Involvement of a nitric oxide signaling pathway.
Breast Neoplasms
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.
Breast Neoplasms
Phellinus linteus suppresses growth, angiogenesis and invasive behaviour of breast cancer cells through the inhibition of AKT signalling.
Breast Neoplasms
Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator.
Breast Neoplasms
Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients.
Breast Neoplasms
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Breast Neoplasms
Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells.
Breast Neoplasms
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Breast Neoplasms
Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Breast Neoplasms
Plasminogen activator inhibitor-1 in cancer research.
Breast Neoplasms
Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.
Breast Neoplasms
Plasminogen activator system in human breast cancer.
Breast Neoplasms
Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
Breast Neoplasms
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Breast Neoplasms
Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Breast Neoplasms
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients.
Breast Neoplasms
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Breast Neoplasms
Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Breast Neoplasms
Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.
Breast Neoplasms
Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Breast Neoplasms
Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA.
Breast Neoplasms
Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR.
Breast Neoplasms
Prognosis and prediction of response in breast cancer: the current role of the main biological markers.
Breast Neoplasms
Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer.
Breast Neoplasms
Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Breast Neoplasms
Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.
Breast Neoplasms
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours.
Breast Neoplasms
Prognostic importance of the uPa/PAI-1 complex in breast cancer.
Breast Neoplasms
Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer.
Breast Neoplasms
Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.
Breast Neoplasms
Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.
Breast Neoplasms
Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
Breast Neoplasms
Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer.
Breast Neoplasms
Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis.
Breast Neoplasms
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
Breast Neoplasms
Prognostic Significance of the Urokinase Type PlasminogenActivator(u-PA) System in Node-Negative Breast Cancer.
Breast Neoplasms
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Breast Neoplasms
Prognostic significance of tumor-related proteases as a function of the estrogen receptor status.
Breast Neoplasms
Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
Breast Neoplasms
Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
Breast Neoplasms
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
Breast Neoplasms
Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
Breast Neoplasms
Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Breast Neoplasms
Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.
Breast Neoplasms
Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.
Breast Neoplasms
Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
Breast Neoplasms
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.
Breast Neoplasms
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Breast Neoplasms
Protease nexin-1 expression is altered in human breast cancer.
Breast Neoplasms
Proteases as prognostic markers in cancer.
Breast Neoplasms
Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue.
Breast Neoplasms
Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts.
Breast Neoplasms
PTHrP [67-86] regulates the expression of stress proteins in breast cancer cells inducing modifications in urokinase-plasminogen activator and MMP-1 expression.
Breast Neoplasms
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Breast Neoplasms
Quantification of uPA receptor expression in human breast cancer cell lines by cRT-PCR.
Breast Neoplasms
Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
Breast Neoplasms
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Breast Neoplasms
Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells.
Breast Neoplasms
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Breast Neoplasms
Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients.
Breast Neoplasms
Recent advances in the field of anti-cancer immunotherapy.
Breast Neoplasms
Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.
Breast Neoplasms
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Breast Neoplasms
Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Breast Neoplasms
Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients.
Breast Neoplasms
Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.
Breast Neoplasms
Relationship between Circulating Tumor Cells, Blood Coagulation, and Urokinase-Plasminogen-Activator System in Early Breast Cancer Patients.
Breast Neoplasms
Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes.
Breast Neoplasms
Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Breast Neoplasms
Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.
Breast Neoplasms
Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis.
Breast Neoplasms
Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling.
Breast Neoplasms
RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells.
Breast Neoplasms
RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.
Breast Neoplasms
Role of IGF-1R in mediating breast cancer invasion and metastasis.
Breast Neoplasms
ROLE OF PLASMINOGEN ACTIVATOR INHIBITOR-1 IN UROKINASE'S PARADOXICAL IN VIVO TUMOR SUPPRESSING OR PROMOTING EFFECTS.
Breast Neoplasms
Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer.
Breast Neoplasms
Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Breast Neoplasms
S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer.
Breast Neoplasms
Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221.
Breast Neoplasms
Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
Breast Neoplasms
Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
Breast Neoplasms
Signalling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: new insights from protein microarray analysis.
Breast Neoplasms
Sodium Salicylate Inhibits Urokinase Activity in MDA MB-231 Breast Cancer Cells.
Breast Neoplasms
Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.
Breast Neoplasms
Some pyrazole and pyrazolo[3,4-d]pyrimidine derivatives: synthesis and anticancer evaluation.
Breast Neoplasms
Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-kappaB/AP-1-dependent and -independent pathways.
Breast Neoplasms
Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.
Breast Neoplasms
Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation.
Breast Neoplasms
Stimulation of urokinase-type plasminogen activator expression by blockage of E-cadherin-dependent cell-cell adhesion.
Breast Neoplasms
Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression.
Breast Neoplasms
Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.
Breast Neoplasms
Suppression of FOXQ1 in benzyl isothiocyanate-mediated inhibition of epithelial-mesenchymal transition in human breast cancer cells.
Breast Neoplasms
Suppression of Proliferation and Invasive Behavior of Human Metastatic Breast Cancer Cells by Dietary Supplement BreastDefend.
Breast Neoplasms
Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor.
Breast Neoplasms
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Breast Neoplasms
Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428.
Breast Neoplasms
Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.
Breast Neoplasms
Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.
Breast Neoplasms
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.
Breast Neoplasms
Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells.
Breast Neoplasms
Synergistic induction of apoptosis by combination treatment with mesupron and auranofin in human breast cancer cells.
Breast Neoplasms
Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.
Breast Neoplasms
Synthesis and Characterization of an (111)In-Labeled Peptide for the in Vivo Localization of Human Cancers Expressing the Urokinase-Type Plasminogen Activator Receptor (uPAR).
Breast Neoplasms
Synthesis and in vivo preclinical evaluation of an (18)F labeled uPA inhibitor as a potential PET imaging agent.
Breast Neoplasms
Targeting a methioninase-containing fusion protein to breast cancer urokinase receptors inhibits growth and migration.
Breast Neoplasms
Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation.
Breast Neoplasms
Targeting uPAR with Antagonistic Recombinant Human Antibodies in Aggressive Breast Cancer.
Breast Neoplasms
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Breast Neoplasms
TFRC and ACTB as the best reference genes to quantify Urokinase Plasminogen Activator in breast cancer.
Breast Neoplasms
The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer.
Breast Neoplasms
The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.
Breast Neoplasms
The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
Breast Neoplasms
The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
Breast Neoplasms
The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.
Breast Neoplasms
The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor.
Breast Neoplasms
The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line.
Breast Neoplasms
The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: a new avenue for breast cancer therapy.
Breast Neoplasms
The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer.
Breast Neoplasms
The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease.
Breast Neoplasms
The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.
Breast Neoplasms
The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes.
Breast Neoplasms
The topology of plasminogen binding and activation on the surface of human breast cancer cells.
Breast Neoplasms
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.
Breast Neoplasms
The urokinase plasminogen activator system in breast cancer invasion and metastasis.
Breast Neoplasms
The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue.
Breast Neoplasms
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Breast Neoplasms
The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Breast Neoplasms
The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro.
Breast Neoplasms
Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.
Breast Neoplasms
Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
Breast Neoplasms
Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
Breast Neoplasms
Tissue extraction procedures for investigation of urokinase plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in human breast carcinomas.
Breast Neoplasms
Tissue plasminogen activators in breast cancer.
Breast Neoplasms
Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
Breast Neoplasms
Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation.
Breast Neoplasms
Transcriptomic pathway analysis of urokinase receptor silenced breast cancer cells: a microarray study.
Breast Neoplasms
Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells.
Breast Neoplasms
Transforming growth factor-beta 1, beta 2, and beta 3, urokinase and parathyroid hormone-related peptide expression in 8701-BC breast cancer cells and clones.
Breast Neoplasms
Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity.
Breast Neoplasms
Tumor markers in breast cancer- European Group on Tumor Markers recommendations.
Breast Neoplasms
Tumor markers in breast cancer--evaluation of their clinical usefulness.
Breast Neoplasms
Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Breast Neoplasms
Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.
Breast Neoplasms
Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.
Breast Neoplasms
Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms.
Breast Neoplasms
Tumor-associated urokinase-type plasminogen activator: significance in breast cancer.
Breast Neoplasms
Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase.
Breast Neoplasms
uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.
Breast Neoplasms
uPA-PAI-1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils.
Breast Neoplasms
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.
Breast Neoplasms
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
Breast Neoplasms
Urokinase and macrophages in tumour angiogenesis.
Breast Neoplasms
Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells.
Breast Neoplasms
Urokinase expression in course of benign and malignant mammary lesions: comparison between nodular and healthy tissues.
Breast Neoplasms
Urokinase is a negative modulator of Egf-dependent proliferation and motility in the two breast cancer cell lines MCF-7 and MDA-MB-231.
Breast Neoplasms
Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer.
Breast Neoplasms
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.
Breast Neoplasms
Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.
Breast Neoplasms
Urokinase plasminogen activator and prognosis in breast cancer.
Breast Neoplasms
Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
Breast Neoplasms
Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer.
Breast Neoplasms
Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer.
Breast Neoplasms
Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer.
Breast Neoplasms
Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer.
Breast Neoplasms
Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue.
Breast Neoplasms
Urokinase Plasminogen Activator Receptor (uPAR): A Potential Indicator of Invasion for In Situ Breast Cancer.
Breast Neoplasms
Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Breast Neoplasms
Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay.
Breast Neoplasms
Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
Breast Neoplasms
Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease.
Breast Neoplasms
Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer.
Breast Neoplasms
Urokinase receptor expression is upregulated by cell culture sparsity in breast cancer cell line BT-20.
Breast Neoplasms
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.
Breast Neoplasms
Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer.
Breast Neoplasms
Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
Breast Neoplasms
Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor.
Breast Neoplasms
Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer.
Breast Neoplasms
Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer.
Breast Neoplasms
Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay.
Breast Neoplasms
Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
Breast Neoplasms
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.
Breast Neoplasms
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Breast Neoplasms
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Breast Neoplasms
Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK).
Breast Neoplasms
Urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer: studies at both protein and mRNA level.
Breast Neoplasms
Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Breast Neoplasms
Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
Breast Neoplasms
Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.
Breast Neoplasms
Urokinase-type Plasminogen Activator and Plasminogen-activator-inhibitor Type 1 Predict Metastases in Good Prognosis Breast Cancer Patients.
Breast Neoplasms
Urokinase-type plasminogen activator antigen and early relapse in breast cancer.
Breast Neoplasms
Urokinase-type plasminogen activator in ascites obtained from the patient with mammary cancer.
Breast Neoplasms
Urokinase-type plasminogen activator induces proliferation in breast cancer cells.
Breast Neoplasms
Urokinase-type plasminogen activator receptor inhibits apoptosis in triple-negative breast cancer through miR-17/20a suppression of death receptors 4 and 5.
Breast Neoplasms
Urokinase-type plasminogen activator system and breast cancer (Review).
Breast Neoplasms
Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Breast Neoplasms
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Breast Neoplasms
Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer.
Breast Neoplasms
Vasodilator-Stimulated Phosphoprotein (VASP) depletion from breast cancer MDA-MB-231 cells inhibits tumor spheroid invasion through downregulation of Migfilin, ?-catenin and urokinase-plasminogen activator (uPA).
Breast Neoplasms
Virtual Screening Targeting the Urokinase Receptor, Biochemical and Cell-Based Studies, Synthesis, Pharmacokinetic Characterization, and Effect on Breast Tumor Metastasis.
Breast Neoplasms
Visualizing Breast Cancer Cell Proliferation and Invasion for Assessing Drug Efficacy with a Fluorescent Nanoprobe.
Breast Neoplasms
Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture.
Breast Neoplasms
Vitronectin binding to urokinase receptor in human breast cancer.
Breast Neoplasms
Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.
Breast Neoplasms
[A plasminogen regulation system in brain tumors].
Breast Neoplasms
[Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system]
Breast Neoplasms
[Clinical and prognostic significance of tumor-associated proteases in gynecologic oncology]
Breast Neoplasms
[Clinical evaluation of various antineoplastic agents combined with urokinase--a comparison between urokinase from tissue culture (TCUK) and urine-derived urokinase (UUK)]
Breast Neoplasms
[D-dimer and plasminogen activator of the urokinase type: personal experiences with breast cancer]
Breast Neoplasms
[Experimental study of anti-metastasis effect of urokinase amino-terminal fragment gene on human breast cancer cells]
Breast Neoplasms
[Expression and significance of urokinase-type plasminogen activator in breast cancer]
Breast Neoplasms
[Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer]
Breast Neoplasms
[Relation between angiogenesis, fibrinolysis and invasion/metastasis in breast cancer]
Breast Neoplasms
[Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma]
Bronchial Spasm
Rigors and bronchospasm with urokinase after streptokinase.
Bronchitis
Plastic bronchitis occurring late after the Fontan procedure: treatment with aerosolized urokinase.
Bronchitis
[Regulation of fibrinolysis by lymphocytes in inflammatory diseases of the bronchopulmonary system]
Bronchopulmonary Dysplasia
No association of urokinase gene 3'-UTR polymorphism with bronchopulmonary dysplasia for ventilated preterm infants.
Bronchopulmonary Dysplasia
Predictive value of soluble urokinase plasminogen activator receptor, soluble ST2, and IL-33 in bronchopulmonary dysplasia.
Brucellosis
[Can Mannose-Binding Lectin and Plasma Level of Soluble Urokinase Receptor be Used in Diagnosis and Treatment Monitorization of Brucellosis Patients?].
Budd-Chiari Syndrome
Budd-Chiari syndrome: early intervention with angioplasty and thrombolytic therapy.
Budd-Chiari Syndrome
Treatment of Budd-Chiari syndrome with urokinase following predilation in patients with old inferior vena cava thrombosis.
Budd-Chiari Syndrome
Urokinase treatment of Budd-Chiari syndrome.
Candidemia
Urokinase in the treatment of bacteremia and candidemia in patients with right atrial catheters.
Carcinogenesis
Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy.
Carcinogenesis
Dietary Supplementation with Methylseleninic Acid Inhibits Mammary Tumorigenesis and Metastasis in Male MMTV-PyMT Mice.
Carcinogenesis
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Carcinogenesis
Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
Carcinogenesis
HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor.
Carcinogenesis
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Carcinogenesis
Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum.
Carcinogenesis
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Carcinogenesis
Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis.
Carcinogenesis
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
Carcinogenesis
Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model.
Carcinogenesis
Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activator.
Carcinogenesis
Novel patents and cancer therapies for transforming growth factor-beta and urokinase type plasminogen activator: potential use of their interplay in tumorigenesis.
Carcinogenesis
Overexpression of PSMC2 promotes the tumorigenesis and development of human breast cancer via regulating plasminogen activator urokinase (PLAU).
Carcinogenesis
Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis.
Carcinogenesis
Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer.
Carcinogenesis
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Carcinogenesis
Predicting high risk disease using serum and DNA biomarkers.
Carcinogenesis
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Carcinogenesis
Screening and identification of hub genes in pancreatic cancer by integrated bioinformatics analysis.
Carcinogenesis
Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance.
Carcinogenesis
The effect of essential fatty acids on growth and urokinase-type plasminogen activator production in human prostate DU-145 cells.
Carcinogenesis
The effect of gamma-linolenic acid and eicosapentaenoic acid on urokinase activity.
Carcinogenesis
The plasminogen activator inhibitor "paradox" in cancer.
Carcinogenesis
The Urokinase Receptor Supports Tumorigenesis of Human Malignant Pleural Mesothelioma Cells.
Carcinogenesis
Tissue plasminogen activator-independent roles of neuroserpin in the central nervous system.
Carcinogenesis
Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients.
Carcinogenesis
[Endothelial cell proteases and their modulation by platelets]
Carcinoma
(-)-Epigallocatechin-3-gallate (EGCG) inhibits HGF-induced invasion and metastasis in hypopharyngeal carcinoma cells.
Carcinoma
A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resection and surveillance of urothelial cell carcinoma.
Carcinoma
A novel 3-dimensional culture system as an in vitro model for studying oral cancer cell invasion.
Carcinoma
A novel model for metastasis suppression involving regulation of nuclear precursor messenger-RNA stability.
Carcinoma
ADAM-17 expression in breast cancer correlates with variables of tumor progression.
Carcinoma
Altered expression of the urokinase receptor homologue, C4.4A, in invasive areas of human esophageal squamous cell carcinoma.
Carcinoma
Amplification of the Urokinase-Type Plasminogen Activator Receptor (uPAR) Gene in Ductal Pancreatic Carcinomas Identifies a Clinically High-Risk Group.
Carcinoma
Amurubicinol-induced eotaxin-3 expression in human NCI-H69 small cell lung carcinoma cells.
Carcinoma
An immunohistochemical assessment of cathepsin D in gastric carcinoma: its impact on clinical prognosis.
Carcinoma
An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture.
Carcinoma
Angiostatin generation by human pancreatic cancer.
Carcinoma
Anticancer evaluation of some newly synthesized N-nicotinonitrile derivative.
Carcinoma
Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice.
Carcinoma
Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
Carcinoma
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Carcinoma
Association of Urokinase Gene 3'-UTR T/C polymorphism with bladder cancer.
Carcinoma
Augmented membrane type 1 matrix metalloproteinase (MT1-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis.
Carcinoma
Autocrine and paracrine regulation of tissue inhibitor of metalloproteinases, transin, and urokinase gene expression in metastatic and nonmetastatic mammary carcinoma cells.
Carcinoma
Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors.
Carcinoma
Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma.
Carcinoma
Bound plasminogen is rate-limiting for cell-surface-mediated activation of plasminogen by urokinase.
Carcinoma
Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.
Carcinoma
Cell surface antigens in renal tumour cells: detection by immunoluminescence and enzymatic analysis.
Carcinoma
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Carcinoma
Changes in the expression of matrix proteases and of the transcription factor c-Ets-1 during progression of precancerous bronchial lesions.
Carcinoma
Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder.
Carcinoma
Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - ?1 (TGF-?1) and potential effects on migration and invasion.
Carcinoma
Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Carcinoma
Clinical relevance of urokinase-type plasminogen activator and its inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix.
Carcinoma
Co-expression of urokinase with haptoglobin in human carcinomas.
Carcinoma
Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma.
Carcinoma
Comparative studies on urokinase and plasminogen activator from cultured pancreatic carcinoma.
Carcinoma
Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues.
Carcinoma
Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells.
Carcinoma
Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines.
Carcinoma
Correlation between expression of urokinase-type plasminogen activator receptor and metastasis in gastric carcinoma.
Carcinoma
Demonstration of a possible link between high grade malignancy in dimethylbenz[a]anthracene-induced rat mammary carcinoma and increased urokinase plasminogen activator content.
Carcinoma
Deregulated activation of matriptase in breast cancer cells.
Carcinoma
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Carcinoma
Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma.
Carcinoma
Determination of the effects of epidermal growth factor on urokinase secretion and urokinase receptor display in a well-differentiated human colon carcinoma cell line.
Carcinoma
Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines.
Carcinoma
Dexamethasone decreases urokinase plasminogen activator mRNA stability in MAT 13762 rat mammary carcinoma cells.
Carcinoma
Different mechanisms contribute to simultaneous inhibition of urokinase and tissue-type plasminogen activators by glucocorticoids in human ovarian carcinoma cells.
Carcinoma
Differential expression levels of urokinase-type plasminogen activator and cathepsin D in locally advanced laryngeal squamous cell carcinoma: clinical implications.
Carcinoma
Differential expression of MMP and uPA systems and prognostic relevance of their expression in esophageal squamous cell carcinoma.
Carcinoma
Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Carcinoma
Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma.
Carcinoma
Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines.
Carcinoma
Diversity and modulation of plasminogen activator activity in human transitional carcinoma cell lines.
Carcinoma
DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression.
Carcinoma
Drug resistant tumor cells have increased levels of tumor markers for invasion and metastasis.
Carcinoma
Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B.
Carcinoma
DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Carcinoma
E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma.
Carcinoma
Effect of anthraquinone-laxatives on the proliferation and urokinase secretion of normal, premalignant and malignant colonic epithelial cells.
Carcinoma
Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines.
Carcinoma
Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion.
Carcinoma
Effect of urokinase on growth and metastases of rabbit V2 carcinoma.
Carcinoma
Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Carcinoma
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Carcinoma
Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice.
Carcinoma
EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma.
Carcinoma
ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts.
Carcinoma
Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.
Carcinoma
Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
Carcinoma
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
Carcinoma
Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of alpha6beta1 integrin.
Carcinoma
Ets2 transcription factor in normal and neoplastic human breast tissue.
Carcinoma
Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line.
Carcinoma
Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma.
Carcinoma
Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo.
Carcinoma
Expression and activation of proteases in co-cultures.
Carcinoma
Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.
Carcinoma
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Carcinoma
Expression of ETS-1 is correlated with urokinase-type plasminogen activator and poor prognosis in pulmonary adenocarcinoma.
Carcinoma
Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population.
Carcinoma
Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma.
Carcinoma
Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.
Carcinoma
Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Carcinoma
Expression of the urokinase receptor regulates focal adhesion assembly and cell migration in adenoid cystic carcinoma cells.
Carcinoma
Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion.
Carcinoma
Expression of urokinase and urinary trypsin inhibitor in metastatic and non-metastatic murine Lewis lung carcinoma cells.
Carcinoma
Expression of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of the oral tongue.
Carcinoma
Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma.
Carcinoma
Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas.
Carcinoma
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Carcinoma
Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Carcinoma
Expression of urokinase-type plasminogen-activator in various human thyroid tissues.
Carcinoma
Expression, subcellular distribution and plasma membrane binding of cathepsin B and gelatinases in bone metastatic tissue.
Carcinoma
Fecal diglycerides as selective endogenous mitogens for premalignant and malignant human colonic epithelial cells.
Carcinoma
Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells.
Carcinoma
Fibrinolytic activity of in vitro cultivated human bladder cell lines.
Carcinoma
Ganglioside GM3 promotes carcinoma cell proliferation via urokinase plasminogen activator-induced extracellular signal-regulated kinase-independent p70S6 kinase signaling.
Carcinoma
Gastric mucosal plasminogen activators in Helicobacter pylori infection.
Carcinoma
Glucocorticoid sensitivity of OVCA 433 human ovarian carcinoma cells: inhibition of plasminogen activators, cell growth, and morphological alterations.
Carcinoma
Glutathione and glutathione S-transferases as early markers for ovarian carcinomas: case series.
Carcinoma
Growth inhibition of vascular smooth muscle cells derived from urokinase receptor (u-PAR)-deficient mice in the presence of carcinoma cells.
Carcinoma
Helicobacter pylori infection influences expression of genes related to angiogenesis and invasion in human gastric carcinoma cells.
Carcinoma
Helicobacter pylori stimulates urokinase plasminogen activator receptor expression and cell invasiveness through reactive oxygen species and NF-kappaB signaling in human gastric carcinoma cells.
Carcinoma
High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
Carcinoma
High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma.
Carcinoma
High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane.
Carcinoma
Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression.
Carcinoma
Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.
Carcinoma
Immunohistochemical analysis of PAI-2 (plasminogen activator inhibitor type 2) and p53 protein in early gastric cancer patients with recurrence: a preliminary report.
Carcinoma
Immunohistochemical Determination of ETS-1 Oncoprotein Expression in Urothelial Carcinomas of the Urinary Bladder.
Carcinoma
Immunohistochemical expressions of uPA and its receptor uPAR and their prognostic significant in urinary bladder carcinoma.
Carcinoma
Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
Carcinoma
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Carcinoma
Immunolocalization of the components of the plasminogen activating system in breast carcinoma tissue.
Carcinoma
Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum.
Carcinoma
Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture.
Carcinoma
In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Carcinoma
In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells.
Carcinoma
In vitro plasminogen activator activity in human brain tumors.
Carcinoma
In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Carcinoma
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Carcinoma
Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate.
Carcinoma
Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Carcinoma
Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.
Carcinoma
Increased urokinase activity to antigen ratio in human renal-cell carcinoma.
Carcinoma
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
Carcinoma
Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells.
Carcinoma
Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells.
Carcinoma
Induction of urokinase activity and malignant phenotype in bladder carcinoma cells after transfection of the activated Ha-ras oncogene.
Carcinoma
Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.
Carcinoma
Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo.
Carcinoma
Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428.
Carcinoma
Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model.
Carcinoma
Inhibition of N-linked oligosaccharide processing in tumor cells is associated with enhanced tissue inhibitor of metalloproteinases (TIMP) gene expression.
Carcinoma
Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system.
Carcinoma
Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
Carcinoma
Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model.
Carcinoma
Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
Carcinoma
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.
Carcinoma
Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase.
Carcinoma
Invasive neoplastic uroepithelial cells express high-levels of urokinase receptor and plasminogen receptor, alpha-enolase.
Carcinoma
Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells.
Carcinoma
Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines.
Carcinoma
Keratinocytes and head and neck squamous cell carcinoma cells regulate urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in fibroblasts.
Carcinoma
Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
Carcinoma
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.
Carcinoma
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Carcinoma
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Carcinoma
Low interleukin-1alpha messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinoma.
Carcinoma
Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.
Carcinoma
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Carcinoma
Mechanisms of the development of osteoblastic metastases.
Carcinoma
Melanocyte mediated paracrine induction of extracellular matrix degrading proteases in squamous cell carcinoma cells.
Carcinoma
Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.
Carcinoma
Modulation of the plasminogen activator cascade during enhanced epidermal proliferation in vivo.
Carcinoma
Modulation of the urokinase receptor in human colon cell lines by N,N-dimethylformamide.
Carcinoma
Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.
Carcinoma
Molecular cloning, sequencing, and expression in Escherichia coli of human preprourokinase cDNA.
Carcinoma
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Carcinoma
Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue.
Carcinoma
Occurrence of components of fibrinolytic pathways in situ in laryngeal cancer.
Carcinoma
Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells.
Carcinoma
Paracrine factor and cell-cell contact-mediated induction of protease and c-ets gene expression in malignant keratinocyte/dermal fibroblast cocultures.
Carcinoma
Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas.
Carcinoma
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Carcinoma
Plasma urokinase-type plasminogen activator correlates to bone scintigraphy in prostatic carcinoma.
Carcinoma
Plasmin-catalyzed proteolysis in colorectal neoplasia.
Carcinoma
Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens.
Carcinoma
Plasminogen activators in human colorectal neoplasia.
Carcinoma
Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining.
Carcinoma
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Carcinoma
Plasminogen activators in oesophageal carcinoma.
Carcinoma
Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression.
Carcinoma
Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
Carcinoma
Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells.
Carcinoma
Post-transcriptional regulation of urokinase mRNA. Identification of a novel urokinase mRNA-binding protein in human lung epithelial cells in vitro.
Carcinoma
Posttranscriptional regulation of urokinase receptor gene expression in human lung carcinoma and mesothelioma cells in vitro.
Carcinoma
Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
Carcinoma
Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy.
Carcinoma
Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma.
Carcinoma
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Carcinoma
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Carcinoma
Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer.
Carcinoma
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
Carcinoma
Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus.
Carcinoma
Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.
Carcinoma
Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
Carcinoma
Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma.
Carcinoma
Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.
Carcinoma
Prognostic value of urokinase plasminogen activator for prostatic carcinoma.
Carcinoma
PTHrP [67-86] regulates the expression of stress proteins in breast cancer cells inducing modifications in urokinase-plasminogen activator and MMP-1 expression.
Carcinoma
Redundant regulation of urokinase plasminogen activator transcription by the two major isozymes of cAMP-dependent protein kinase.
Carcinoma
Regulation of CSF-1 receptor expression.
Carcinoma
Regulation of human squamous cell carcinoma plasma membrane associated urokinase plasminogen activator by epidermal growth factor.
Carcinoma
Regulation of plasminogen activator activity in transitional carcinoma cell lines by wound site growth factors.
Carcinoma
Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta.
Carcinoma
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Carcinoma
Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line.
Carcinoma
Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene.
Carcinoma
Regulation of urokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity.
Carcinoma
Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells.
Carcinoma
Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies.
Carcinoma
Relationship between plasminogen activators and stomach carcinoma stage.
Carcinoma
Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival.
Carcinoma
Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma.
Carcinoma
Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Carcinoma
Retinoic acid priming potentiates the induction of urokinase-type plasminogen activator by cyclic adenosine monophosphate in mouse mammary carcinoma cells.
Carcinoma
RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo.
Carcinoma
Role of urokinase in colorectal neoplasia.
Carcinoma
Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Carcinoma
Secretion of plasminogen activators by human colorectal and gastric tumor explants.
Carcinoma
Semiautomatic landmark-based two-dimensional-three-dimensional image fusion in living mice: correlation of near-infrared fluorescence imaging of Cy5.5-labeled antibodies with flat-panel volume computed tomography.
Carcinoma
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China.
Carcinoma
Silencing of uPAR via RNA interference inhibits invasion and migration of oral tongue squamous cell carcinoma.
Carcinoma
Simultaneous stimulation of urokinase and tissue-type plasminogen activators by phorbol esters in human ovarian carcinoma cells.
Carcinoma
Sodium butyrate differentially modulates plasminogen activator inhibitor type-1, urokinase plasminogen activator, and its receptor in a human colon carcinoma cell.
Carcinoma
Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.
Carcinoma
Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report.
Carcinoma
Some pyrazole and pyrazolo[3,4-d]pyrimidine derivatives: synthesis and anticancer evaluation.
Carcinoma
Specific stimulation by estradiol of tissue-type plasminogen activator production in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.
Carcinoma
Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors.
Carcinoma
Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions.
Carcinoma
Studies of possible mechanisms for the effect of urokinase therapy in small cell carcinoma of the lung.
Carcinoma
Surface-bound plasmin induces selective proteolysis of insulin-like-growth-factor (IGF)-binding protein-4 (IGFBP-4) and promotes autocrine IGF-II bio-availability in human colon-carcinoma cells.
Carcinoma
Synergistic transcriptional activation of the mouse urokinase plasminogen activator (uPA) gene and of its enhancer activator protein 1 (AP1) site by cAMP and retinoic acid.
Carcinoma
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Carcinoma
T1 breast cancer: identification of patients at low risk of axillary lymph node metastases.
Carcinoma
Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Carcinoma
The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.
Carcinoma
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
Carcinoma
The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy.
Carcinoma
The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase.
Carcinoma
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Carcinoma
The malignant conversion step of mouse skin carcinogenesis.
Carcinoma
The plasminogen activator inhibitor system in colon cancer cell lines is influenced by the CO(2) pneumoperitoneum.
Carcinoma
The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report.
Carcinoma
The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor.
Carcinoma
The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells.
Carcinoma
The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Carcinoma
The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
Carcinoma
The urokinase/PAI-2 complex: a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein.
Carcinoma
Tissue plasminogen activator activity in prostatic cancer.
Carcinoma
Tissue plasminogen activator and urokinase in normal, dysplastic and cancerous squamous epithelium of the uterine cervix.
Carcinoma
Transcription levels of invasion-related genes in prostate cancer cells are modified by inhibitors of tyrosine kinase.
Carcinoma
Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.
Carcinoma
Transcriptional induction of urokinase in cultured human kidney carcinoma cells by tetradecanoyl-phorbol-acetate.
Carcinoma
Transforming growth factor-beta 1 is a potent inducer of plasminogen activator inhibitor type-1 in human glioblastoma and carcinoma cell lines.
Carcinoma
Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo.
Carcinoma
Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
Carcinoma
Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling.
Carcinoma
Tumor necrosis factor stimulates urokinase-type plasminogen activator and inhibitor type 1 production in A549 lung carcinoma cells: treatment of monolayer and tridimensional cultures.
Carcinoma
Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines.
Carcinoma
Tumor-promoter-enhanced destruction of noninvasive human benign colon tumor cells by cocultivated carcinoma cells.
Carcinoma
Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes.
Carcinoma
Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma.
Carcinoma
Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx.
Carcinoma
uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery.
Carcinoma
Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
Carcinoma
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Carcinoma
Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity.
Carcinoma
Urokinase excretion in patients with carcinoma.
Carcinoma
Urokinase expression by tumor suppressor protein p53: a novel role in mRNA turnover.
Carcinoma
Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Carcinoma
Urokinase plasminogen activator in ovarian cancer.
Carcinoma
Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas.
Carcinoma
Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC).
Carcinoma
Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries.
Carcinoma
Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma.
Carcinoma
Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Carcinoma
Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo.
Carcinoma
Urokinase receptor up-regulation in head and neck squamous cell carcinoma.
Carcinoma
Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Carcinoma
Urokinase secretion from human colon carcinomas induced by endogenous diglycerides.
Carcinoma
Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Carcinoma
Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
Carcinoma
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Carcinoma
Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Carcinoma
Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions.
Carcinoma
Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas.
Carcinoma
Urokinase-type plasminogen activator biosynthesis is induced by the EJ-Ha-ras oncogene in CL26 mouse colon carcinoma cells.
Carcinoma
Urokinase-type plasminogen activator expression and proliferation stimulation in head and neck squamous cell carcinoma in vitro and in situ.
Carcinoma
Urokinase-type plasminogen activator expression in human prostate carcinomas.
Carcinoma
Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
Carcinoma
Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.
Carcinoma
Urokinase-type plasminogen activator receptor expression in adenoid cystic carcinoma of the skull base.
Carcinoma
Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
Carcinoma
Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
Carcinoma
[Antisense RNA for urokinase receptor inhibits the invasiveness and metastasis of lung carcinoma]
Carcinoma
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma]
Carcinoma
[Effect of down regulation of laminin receptor on urokinase-type plasminogen activator expression in human bile duct carcinoma cells]
Carcinoma
[Effect of hypoxia on the expression of urokinase-type plasminogen activator in human tongue squamous cell carcinoma cells (Tca8113)]
Carcinoma
[Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
Carcinoma
[Expression of cyclooxygenase-2 and urokinase plasminogen activator in gastric carcinoma and the clinical significance thereof]
Carcinoma
[Expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in gastric carcinoma]
Carcinoma
[Expressions and clinical significance of urokinase-type activator (uPA) and uPA receptor (uPAR) in laryngeal squamous cell carcinoma]
Carcinoma
[Expressions and clinical significance of urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) in tongue squamous cell carcinoma.]
Carcinoma
[Gelatinases A and B and their endogenous regulators in the corpus uteri in squamous cell cervical carcinoma].
Carcinoma
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
Carcinoma
[Matrix metalloproteinases 2 and 9, their endogenous regulators, and angiotensin-converting enzyme in cervical squamous cell carcinoma].
Carcinoma
[Methylation status of uPA promoter in laryngeal squamous cell carcinoma]
Carcinoma
[Multiple emboli from a cardiac metastasis of a renal-cell carcinoma]
Carcinoma
[Pathogenesis and progression of scirrhous carcinoma]
Carcinoma
[Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
Carcinoma
[Studies on alpha 2 macroglobulin deficiency in association with cancer metastasis]
Carcinoma
[The effect of heat shock on the expression of urokinase-type plasminogen activator in human tongue squamous cell carcinoma cell line (Tca8113)]
Carcinoma
[The expression and significance of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of hypopharynx]
Carcinoma
[The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma]
Carcinoma
[The expression of urokinase-type plasminogen activator in oral squamous cell carcinoma]
Carcinoma
[The relationship between the activation of ERK and the up-regulation of uPA in laryngeal squamous cell carcinoma]
Carcinoma
[The role of urokinase type plasminogen activator in invasion of bile duct carcinoma]
Carcinoma
[The study of plasminogen activator in renal cell carcinoma with special remarks on urokinase type plasminogen activator]
Carcinoma
[Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms]
Carcinoma
[u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast]
Carcinoma
[Urokinase-type plasminogen activator (uPA) and its inhibitor--new prognostic factors in oral squamous cell carcinoma]
Carcinoma
[Value of p53, urokinase plasminogen activator, PAI-1 and Ki-67 in vulvar carcinoma]
Carcinoma in Situ
Changes in the expression of matrix proteases and of the transcription factor c-Ets-1 during progression of precancerous bronchial lesions.
Carcinoma in Situ
T1 breast cancer: identification of patients at low risk of axillary lymph node metastases.
Carcinoma, Adenoid Cystic
Expression of the urokinase receptor regulates focal adhesion assembly and cell migration in adenoid cystic carcinoma cells.
Carcinoma, Adenoid Cystic
Urokinase-type plasminogen activator receptor expression in adenoid cystic carcinoma of the skull base.
Carcinoma, Basal Cell
Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.
Carcinoma, Basal Cell
Expression, subcellular distribution and plasma membrane binding of cathepsin B and gelatinases in bone metastatic tissue.
Carcinoma, Basal Cell
Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.
Carcinoma, Basal Cell
Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas.
Carcinoma, Ductal
High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast.
Carcinoma, Ductal
Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue.
Carcinoma, Ductal
Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.
Carcinoma, Ductal, Breast
Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
Carcinoma, Hepatocellular
A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells.
Carcinoma, Hepatocellular
Anti-invasion effects of 6-shogaol and 6-gingerol, two active components in ginger, on human hepatocarcinoma cells.
Carcinoma, Hepatocellular
Baicalein Inhibits the Invasion and Metastatic Capabilities of Hepatocellular Carcinoma Cells via Down-Regulation of the ERK Pathway.
Carcinoma, Hepatocellular
Cellular mechanisms of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MAPK signaling in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Characterization of the binding of plasminogen activators to plasma membranes from human liver.
Carcinoma, Hepatocellular
Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Dexamethasone induction of an inhibitor of plasminogen activator in HTC hepatoma cells.
Carcinoma, Hepatocellular
Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis.
Carcinoma, Hepatocellular
Dioscorea nipponica Attenuates Migration and Invasion by Inhibition of Urokinase-Type Plasminogen Activator through Involving PI3K/Akt and Transcriptional Inhibition of NF-[Formula: see text]B and SP-1 in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase.
Carcinoma, Hepatocellular
Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection.
Carcinoma, Hepatocellular
Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Evaluation of the Association of Urokinase Plasminogen Activator System Gene Polymorphisms with Susceptibility and Pathological Development of Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Carcinoma, Hepatocellular
Hispolon suppresses SK-Hep1 human hepatoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen activator through the PI3K/Akt and ERK signaling pathways.
Carcinoma, Hepatocellular
Human HuH-7 hepatoma cells express urokinase and plasminogen activator inhibitor-1: identification, characterization and regulation by inflammatory mediators.
Carcinoma, Hepatocellular
Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion.
Carcinoma, Hepatocellular
Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
Carcinoma, Hepatocellular
Korean Red Ginseng Suppresses Metastasis of Human Hepatoma SK-Hep1 Cells by Inhibiting Matrix Metalloproteinase-2/-9 and Urokinase Plasminogen Activator.
Carcinoma, Hepatocellular
Licochalcone A Suppresses Migration and Invasion of Human Hepatocellular Carcinoma Cells through Downregulation of MKK4/JNK via NF-?B Mediated Urokinase Plasminogen Activator Expression.
Carcinoma, Hepatocellular
MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo.
Carcinoma, Hepatocellular
Prognostic role of urokinase plasminogen activator in hepatocellular carcinoma: A protocol for systematic review and meta analysis.
Carcinoma, Hepatocellular
Proteomic identification of LASP-1 down-regulation after RNAi urokinase silencing in human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Rationale for clinical trials of coagulation: reactive drugs in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Reactive oxygen species regulate the generation of urokinase plasminogen activator in human hepatoma cells via MAPK pathways after treatment with hepatocyte growth factor.
Carcinoma, Hepatocellular
RNA interference against urokinase in hepatocellular carcinoma xenografts in nude mice.
Carcinoma, Hepatocellular
Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
Carcinoma, Hepatocellular
Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Stable expression of antisense urokinase mRNA inhibits the proliferation and invasion of human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer.
Carcinoma, Hepatocellular
Terminalia catappa attenuates urokinase-type plasminogen activator expression through Erk pathways in Hepatocellular carcinoma.
Carcinoma, Hepatocellular
Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells.
Carcinoma, Hepatocellular
Urokinase antigen in plasma of patients with liver cirrhosis and hepatoma.
Carcinoma, Hepatocellular
Urokinase induces stromal cell-derived factor-1 expression in human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Urokinase plasminogen activator predicts poor prognosis in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Urokinase-type plasminogen activator (uPA) stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2.
Carcinoma, Hepatocellular
Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells.
Carcinoma, Hepatocellular
[Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients]
Carcinoma, Hepatocellular
[Urokinase-type plasminogen activator (uPA), uPA receptor (uPA-R) and inhibitors (PA I -1) expression in hepatocellular carcinoma in relation to cancer invasion/metastasis and prognosis]
Carcinoma, Intraductal, Noninfiltrating
Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ.
Carcinoma, Intraductal, Noninfiltrating
Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ.
Carcinoma, Intraductal, Noninfiltrating
Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue.
Carcinoma, Intraductal, Noninfiltrating
Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
Carcinoma, Intraductal, Noninfiltrating
Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue.
Carcinoma, Intraductal, Noninfiltrating
Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.
Carcinoma, Large Cell
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Carcinoma, Lewis Lung
Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice.
Carcinoma, Lewis Lung
Expression of urokinase and urinary trypsin inhibitor in metastatic and non-metastatic murine Lewis lung carcinoma cells.
Carcinoma, Lewis Lung
Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.
Carcinoma, Lewis Lung
Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model.
Carcinoma, Lewis Lung
Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
Carcinoma, Lewis Lung
Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model.
Carcinoma, Lewis Lung
Regulation of CSF-1 receptor expression.
Carcinoma, Lewis Lung
Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma.
Carcinoma, Neuroendocrine
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Carcinoma, Non-Small-Cell Lung
Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
Aeroallergen Der p 2 promotes motility of human non-small cell lung cancer cells via toll-like receptor-mediated up-regulation of urokinase-type plasminogen activator and integrin/focal adhesion kinase signaling.
Carcinoma, Non-Small-Cell Lung
Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma.
Carcinoma, Non-Small-Cell Lung
Graphene nanosheets as an electric mediator for ultrafast sensing of urokinase plasminogen activator receptor-A biomarker of cancer.
Carcinoma, Non-Small-Cell Lung
Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Carcinoma, Non-Small-Cell Lung
Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Carcinoma, Non-Small-Cell Lung
Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic value of urokinase plasminogen activator system in non-small cell lung cancer: A systematic review and meta-analysis.
Carcinoma, Non-Small-Cell Lung
Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival.
Carcinoma, Non-Small-Cell Lung
The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC).
Carcinoma, Non-Small-Cell Lung
The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Urokinase plasminogen activator receptor induced non-small cell lung cancer invasion and metastasis requires NHE1 transporter expression and transport activity.
Carcinoma, Non-Small-Cell Lung
Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis.
Carcinoma, Non-Small-Cell Lung
[Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer]
Carcinoma, Ovarian Epithelial
Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression.
Carcinoma, Ovarian Epithelial
Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Carcinoma, Ovarian Epithelial
In vitro invasion assays.
Carcinoma, Ovarian Epithelial
Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells.
Carcinoma, Ovarian Epithelial
Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC).
Carcinoma, Ovarian Epithelial
Urokinase plasminogen activator in ovarian cancer.
Carcinoma, Ovarian Epithelial
Urokinase Plasminogen Activator System Targeted Delivery of Nanobins as a Novel Ovarian Cancer Therapeutics.
Carcinoma, Papillary
Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid.
Carcinoma, Papillary
Immunohistochemical evaluation of urokinase plasminogen activator receptor in noninvasive and early invasive urothelial papillary neoplasia.
Carcinoma, Papillary
Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis.
Carcinoma, Renal Cell
Cell surface antigens in renal tumour cells: detection by immunoluminescence and enzymatic analysis.
Carcinoma, Renal Cell
Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Carcinoma, Renal Cell
Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues.
Carcinoma, Renal Cell
Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells.
Carcinoma, Renal Cell
Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.
Carcinoma, Renal Cell
Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Carcinoma, Renal Cell
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Carcinoma, Renal Cell
Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
Carcinoma, Renal Cell
Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.
Carcinoma, Renal Cell
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Carcinoma, Renal Cell
Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.
Carcinoma, Renal Cell
Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.
Carcinoma, Renal Cell
Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells.
Carcinoma, Renal Cell
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Carcinoma, Renal Cell
Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma.
Carcinoma, Renal Cell
Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.
Carcinoma, Renal Cell
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Carcinoma, Renal Cell
Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carcinoma, Renal Cell
[The study of plasminogen activator in renal cell carcinoma with special remarks on urokinase type plasminogen activator]
Carcinoma, Small Cell
Studies of possible mechanisms for the effect of urokinase therapy in small cell carcinoma of the lung.
Carcinoma, Small Cell
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Carcinoma, Squamous Cell
Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.
Carcinoma, Squamous Cell
Clinical relevance of urokinase-type plasminogen activator and its inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix.
Carcinoma, Squamous Cell
Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion.
Carcinoma, Squamous Cell
Epidermal growth factor and 12-tetradecanoyl phorbol 13-acetate induction of urokinase in A431 cells.
Carcinoma, Squamous Cell
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Carcinoma, Squamous Cell
Expression of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of the oral tongue.
Carcinoma, Squamous Cell
Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma.
Carcinoma, Squamous Cell
Gangliosides inhibit urokinase-type plasminogen activator (uPA)-dependent squamous carcinoma cell migration by preventing uPA receptor/alphabeta integrin/epidermal growth factor receptor interactions.
Carcinoma, Squamous Cell
Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
Carcinoma, Squamous Cell
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Carcinoma, Squamous Cell
In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Carcinoma, Squamous Cell
Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Carcinoma, Squamous Cell
Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.
Carcinoma, Squamous Cell
Keratinocytes and head and neck squamous cell carcinoma cells regulate urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in fibroblasts.
Carcinoma, Squamous Cell
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Carcinoma, Squamous Cell
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Carcinoma, Squamous Cell
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Carcinoma, Squamous Cell
Melanocyte mediated paracrine induction of extracellular matrix degrading proteases in squamous cell carcinoma cells.
Carcinoma, Squamous Cell
Paracrine factor and cell-cell contact-mediated induction of protease and c-ets gene expression in malignant keratinocyte/dermal fibroblast cocultures.
Carcinoma, Squamous Cell
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Carcinoma, Squamous Cell
Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
Carcinoma, Squamous Cell
Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus.
Carcinoma, Squamous Cell
Purification and characterization of single-chain urokinase-type plasminogen activator (pro-urokinase) from human A431 cells.
Carcinoma, Squamous Cell
Regulation of human squamous cell carcinoma plasma membrane associated urokinase plasminogen activator by epidermal growth factor.
Carcinoma, Squamous Cell
Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line.
Carcinoma, Squamous Cell
Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene.
Carcinoma, Squamous Cell
Separation and characterization of nonphosphorylated and serine-phosphorylated urokinase. Catalytic properties and sensitivity to plasminogen activator inhibitor type 1.
Carcinoma, Squamous Cell
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China.
Carcinoma, Squamous Cell
Silencing of uPAR via RNA interference inhibits invasion and migration of oral tongue squamous cell carcinoma.
Carcinoma, Squamous Cell
Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors.
Carcinoma, Squamous Cell
The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.
Carcinoma, Squamous Cell
The Mr 17500 region of the A chain of urokinase is required for interaction with a specific receptor in A431 cells.
Carcinoma, Squamous Cell
Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa.
Carcinoma, Squamous Cell
Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx.
Carcinoma, Squamous Cell
Urokinase receptor up-regulation in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Carcinoma, Squamous Cell
Urokinase-type plasminogen activator expression and proliferation stimulation in head and neck squamous cell carcinoma in vitro and in situ.
Carcinoma, Squamous Cell
Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
[Effect of hypoxia on the expression of urokinase-type plasminogen activator in human tongue squamous cell carcinoma cells (Tca8113)]
Carcinoma, Squamous Cell
[Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
Carcinoma, Squamous Cell
[Expressions and clinical significance of urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) in tongue squamous cell carcinoma.]
Carcinoma, Squamous Cell
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
Carcinoma, Squamous Cell
[Matrix metalloproteinases 2 and 9, their endogenous regulators, and angiotensin-converting enzyme in cervical squamous cell carcinoma].
Carcinoma, Squamous Cell
[Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
Carcinoma, Squamous Cell
[The effect of heat shock on the expression of urokinase-type plasminogen activator in human tongue squamous cell carcinoma cell line (Tca8113)]
Carcinoma, Squamous Cell
[The expression and significance of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of hypopharynx]
Carcinoma, Transitional Cell
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Carcinoma, Transitional Cell
Association of Urokinase Gene 3'-UTR T/C polymorphism with bladder cancer.
Carcinoma, Transitional Cell
In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Carcinoma, Transitional Cell
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
Carcinoma, Transitional Cell
The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report.
Carcinoma, Transitional Cell
[The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma]
Cardiomegaly
Serine proteases and cardiac function.
Cardiomyopathies
A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure.
Cardiomyopathies
Persistent plasminogen activator inhibitor 1 gene expression in cardiac transplant recipients with idiopathic dilated cardiomyopathy.
Cardiomyopathy, Dilated
ERK1/2 mediates the lipopolysaccharide-induced upregulation of FGF-2, uPA, MMP-2, MMP-9 and cellular migration in cardiac fibroblasts.
Cardiomyopathy, Dilated
Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells.
Cardiomyopathy, Dilated
Persistent plasminogen activator inhibitor 1 gene expression in cardiac transplant recipients with idiopathic dilated cardiomyopathy.
Cardiotoxicity
Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Cardiovascular Diseases
Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals.
Cardiovascular Diseases
Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation.
Cardiovascular Diseases
Associations of suPAR with lifestyle and cardiometabolic risk factors.
Cardiovascular Diseases
Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.
Cardiovascular Diseases
Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study.
Cardiovascular Diseases
Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
Cardiovascular Diseases
Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
Cardiovascular Diseases
Effect of simvastatin and ezetimibe on suPAR levels and outcomes.
Cardiovascular Diseases
Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor.
Cardiovascular Diseases
Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels.
Cardiovascular Diseases
Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase-type plasminogen activator receptor (suPAR) levels.
Cardiovascular Diseases
Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.
Cardiovascular Diseases
Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction.
Cardiovascular Diseases
Plasma soluble urokinase plasminogen activator receptor (suPAR) level is associated with myocardial impairment assessed with advanced echocardiography in Type 1 Diabetes Patients with normal ejection fraction and without known heart disease or end stage renal disease.
Cardiovascular Diseases
Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Cardiovascular Diseases
Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of acute coronary syndrome.
Cardiovascular Diseases
Prognostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity C-Reactive Protein on Postoperative Mortality in Patients Undergoing Elective On-Pump Cardiac Surgery.
Cardiovascular Diseases
Randomized clinical stroke trials in 2007.
Cardiovascular Diseases
Serine proteases and cardiac function.
Cardiovascular Diseases
Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity.
Cardiovascular Diseases
Sex- and age-related differences in the predictive capability of circulating biomarkers: from the MONICA 10 cohort.
Cardiovascular Diseases
Soluble urokinase plasminogen activation receptor - An emerging new biomarker of cardiovascular disease and critical illness.
Cardiovascular Diseases
Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.
Cardiovascular Diseases
Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism.
Cardiovascular Diseases
Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis.
Cardiovascular Diseases
Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease.
Cardiovascular Diseases
Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study.
Cardiovascular Diseases
Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema.
Cardiovascular Diseases
Streptokinase: An Efficient Enzyme in Cardiac Medicine.
Cardiovascular Diseases
Successful silencing of plasminogen activator inhibitor-1 in human vascular endothelial cells using small interfering RNA.
Cardiovascular Diseases
Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients.
Cardiovascular Diseases
Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: results of the ECAPTURE study. European Concerted Action on Prevention from Thrombosis by URokinase Enhancement.
Cardiovascular Diseases
Use of a proximity extension assay proteomics chip to discover new biomarkers associated with albuminuria.
Cardiovascular Diseases
Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention.
Carotid Artery Diseases
The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.
Carotid Artery Diseases
Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques.
Carotid Artery Diseases
Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
Carotid Artery Diseases
Urokinase-type plasminogen activator receptor is associated with macrophages and plaque rupture in symptomatic carotid atherosclerosis.
Carotid Stenosis
Percutaneous transluminal angioplasty for acute thrombotic occlusion of the cervical internal carotid artery using a perfusion balloon catheter.
Cataract
Sub-Tenon's urokinase injection-assisted vitrectomy in early treatment of suprachoroidal hemorrhage: Four cases report.
Catheter-Related Infections
Method using urokinase and an antibiotic to avoid device removal in central venous catheter-related infections.
Catheter-Related Infections
Persistent catheter-related bacteremia: clearance with antibiotics and urokinase.
Catheter-Related Infections
Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies.
Cellulitis
A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin.
Central Nervous System Diseases
Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.
Central Nervous System Neoplasms
Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms.
Central Nervous System Neoplasms
Use of urokinase in pediatric hematology/oncology patients.
Cerebral Hemorrhage
A review of stereotaxy and lysis for intracranial hemorrhage.
Cerebral Hemorrhage
An effective treatment for cerebral hemorrhage: minimally invasive craniopuncture combined with urokinase infusion therapy.
Cerebral Hemorrhage
Application of a rheolytic thrombectomy device in the treatment of dural sinus thrombosis: a new technique.
Cerebral Hemorrhage
Bleeding complications after basilar artery fibrinolysis with tissue plasminogen activator.
Cerebral Hemorrhage
Cerebral amyloid angiopathy-related intracerebral hemorrhage: Feasibility and safety of bedside catheter hematoma evacuation with urokinase.
Cerebral Hemorrhage
Comparison of frame-based and frameless stereotactic hematoma puncture and subsequent fibrinolytic therapy for the treatment of supratentorial deep seated spontaneous intracerebral hemorrhage.
Cerebral Hemorrhage
Efficacy of tissue plasminogen activator in the lysis of thrombosis of the cerebral venous sinus.
Cerebral Hemorrhage
Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate.
Cerebral Hemorrhage
Failure of peripheral arterial thrombolysis due to elevated plasminogen activator inhibitor type 1.
Cerebral Hemorrhage
Frameless stereotactic aspiration for spontaneous intracerebral hemorrhage and subsequent fibrinolysis using urokinase.
Cerebral Hemorrhage
In-Vitro Study of Urokinase Thrombolysis Following Stereotactic Aspiration of Intracerebral Hematoma.
Cerebral Hemorrhage
Intra-Arterial Thrombolysis Improves the Prognosis of Acute Ischemic Stroke Patients without Large Vessel Occlusion.
Cerebral Hemorrhage
Intracerebral hemorrhage complicating urokinase infusion into an occluded aortocoronary bypass graft.
Cerebral Hemorrhage
Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke.
Cerebral Hemorrhage
Management of non-traumatic intraventricular hemorrhage.
Cerebral Hemorrhage
No exacerbation of perihematomal edema with intraclot urokinase in patients with spontaneous intracerebral hemorrhage.
Cerebral Hemorrhage
Safety of thrombolytic therapy with urokinase or recombinant tissue plasminogen activator for peripheral arterial occlusion: a comprehensive compilation of published work.
Cerebral Hemorrhage
Superior sagittal sinus thrombosis: a clinical and experimental study.
Cerebral Hemorrhage
The release of thromboxane B2 and 6-keto-PGF1 alpha following pulmonary embolism.
Cerebral Hemorrhage
Tissue-type plasminogen activator improves neurological functions in a rat model of thromboembolic stroke.
Cerebral Hemorrhage
Urokinase vs Tissue-Type Plasminogen Activator for Thrombolytic Evacuation of Spontaneous Intracerebral Hemorrhage in Basal Ganglia.
Cerebral Hemorrhage
Urokinase, a promising candidate for fibrinolytic therapy for intracerebral hemorrhage.
Cerebral Hemorrhage
Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia.
Cerebral Hemorrhage
[A case of successful thromobolytic therapy in a patient with cerebral embolism during angiography]
Cerebral Hemorrhage
[New methods of intensive therapy in stroke: hemicraniectomy in patients with complete middle cerebral artery infarction and treatment of intracerebral and intraventricular hemorrhage with urokinase]
Cerebral Infarction
A clinical study of transcranial ultrasound as an adjuvant therapy for progressive cerebral infarction.
Cerebral Infarction
A pilot study of urokinase therapy in cerebral infarction.
Cerebral Infarction
Comparative study of intravenous thrombolysis with rt-PA and urokinase for patients with acute cerebral infarction.
Cerebral Infarction
Comparative study on the efficacy and safety of alteplase and urokinase in the treatment of acute cerebral infarction.
Cerebral Infarction
Controlled trial of combined urokinase and dextran sulfate therapy in patients with acute cerebral infarction.
Cerebral Infarction
Dynamic change of coagulation and anticoagulation markers of patients with acute cerebral infarction during intravenous urokinase thrombolysis.
Cerebral Infarction
Dynamical levels of plasma F(1+2) and D-dimer in patients with acute cerebral infarction during intravenous urokinase thrombolysis.
Cerebral Infarction
Effects of Intra-arterial Urokinase on a Non-human Primate Thromboembolic Stroke Model.
Cerebral Infarction
Evaluation of reperfusion and recovery of brain function before and after intracarotid arterial urokinase therapy in acute cerebral infarction with brain SPECT.
Cerebral Infarction
Fatal cerebral infarction in an asymptomatic young patient with primary antiphospholipid syndrome.
Cerebral Infarction
Impact of low-dose urokinase in peritoneal dialysis on serum oxidative stress, nitric oxide and endothelin in cerebral infarction complicated with uremia.
Cerebral Infarction
Influencing Factors of Recanalization after Intravenous Thrombolysis with Urokinase in Acute Cerebral Infarction Patients.
Cerebral Infarction
Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery.
Cerebral Infarction
Kawasaki Disease Complicated by Late-Onset Fatal Cerebral Infarction: A Case Report and Literature Review.
Cerebral Infarction
Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in early focal cerebral infarction following urokinase thrombolysis in rats.
Cerebral Infarction
Mechanically assisted intra-arterial thrombolysis in acute cerebral infarction.
Cerebral Infarction
Selective and superselective infusion of urokinase for embolic stroke.
Cerebral Infarction
Stroke research in China.
Cerebral Infarction
The effects of blood pressure and urokinase on brain injuries after experimental cerebral infarction in rats.
Cerebral Infarction
The serum levels of MMP-9, MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction.
Cerebral Infarction
Treatment efficacy of arterial urokinase thrombolysis combined with mechanical thrombectomy for acute cerebral infarction and its influence on neuroprotective factors and factors for neurological injury.
Cerebral Infarction
Vasospasm prevention with postoperative intrathecal thrombolytic therapy: a retrospective comparison of urokinase, tissue plasminogen activator, and cisternal drainage alone.
Cerebral Infarction
[A case of unruptured A1 aneurysm causing ischemic compression to the medial proximal striate artery]
Cerebral Infarction
[Brain attack in Japan, now and future]
Cerebral Infarction
[Case of cholesterol crystal embolism occurring after treatment of cerebral infarction with urokinase]
Cerebral Infarction
[Clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery]
Cerebral Infarction
[Clinical study on ultra-early intravenous thrombolysis with high-dose urokinase in treatment of acute cerebral infarction]
Cerebral Infarction
[Endovascular embolization of cerebral arteriovenous malformation]
Cerebral Infarction
[Expression of urokinase-type plasminogen activator and its receptor in plasma of patients with cerebral infarction]
Cerebral Infarction
[Intraarterial injection of low molecular weight dextran and urokinase for acute cerebral infarction]
Cerebral Infarction
[Problems in urokinase therapy in cerebral infarction]
Cerebral Infarction
[Protective effects of Ginkgo biloba extract on focal cerebral ischemia and thrombogenesis of carotid artery in rats]
Cerebral Infarction
[Risk factors for intracerebral hemorrhage after intravenous thrombolysis in acute cerebral infarction]
Cerebral Infarction
[Studies on blood coagulation and fibrinolytic activities in the cases of cerebral infarction treated with urokinase. 2nd Report -- espeically changes of coagulofibrinolytic system before and after UK infusion (author's transl)]
Cerebral Infarction
[Studies on blood coagulation and fibrinolytic activities in the three cases of cerebral infarction treated with urokinase. 1st report--120,000 I.U. administrated-- (author's transl)]
Cerebral Infarction
[Successful treatment of thoracic drainage using urokinase for empyema in an elderly man].
Cerebral Infarction
[The treatment of acute cerebral infarction with urokinase and tissue plasminogen activator]
Cerebral Infarction
[Thrombolysis of cerebral thromboembolism by urokinase in an animal model]
Cerebral Infarction
[Thrombolytic agents in cerebral infarctions]
Cerebrovascular Disorders
Changes of the levels of antithrombin III in patients with cerebrovascular diseases.
Cerebrovascular Disorders
Corrigendum to "Comparative Analysis of Fibrinolytic Properties of Alteplase, Tenecteplase and Urokinase in an in Vitro Clot Model of Intracerebral Haemorrhage. [Journal of Stroke and Cerebrovascular Diseases, Vol. 29, No. 9 (September), 2020: 105073]".
Cerebrovascular Disorders
Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke.
Cerebrovascular Disorders
Intraoperative high-dose regional urokinase infusion for cerebrovascular occlusion after carotid endarterectomy.
Cerebrovascular Disorders
[Intraarterial urokinase infusion therapy with superselective catheterization for acute occlusive cerebrovascular disease]
Cervical Intraepithelial Neoplasia
Expression of MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical intraepithelial neoplasia.
Cholangiocarcinoma
High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.
Cholangiocarcinoma
Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients.
Cholangiocarcinoma
Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer.
Cholecystitis
Hemorrhagic cholecystitis with hemobilia: treatment with percutaneous cholecystostomy and transcatheter urokinase.
Cholera
Isolation of a mutant LLC-PK1 cell line defective in hormonal responsiveness. A pleiotropic lesion in receptor function.
Cholera
Modulations of functional activity in differentiated macrophages are accompanied by early and transient increase or decrease in c-fos gene transcription.
Cholesteatoma
Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma.
Cholesteatoma
Plasminogen activators in tissue extract of aural cholesteatoma.
Chondrosarcoma
CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells.
Chondrosarcoma
Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.
Chondrosarcoma
Involvement of the soluble urokinase receptor in chondrosarcoma cell mobilization.
Chondrosarcoma
Kunitz-type protease inhibitor bikunin disrupts phorbol ester-induced oligomerization of CD44 variant isoforms containing epitope v9 and subsequently suppresses expression of urokinase-type plasminogen activator in human chondrosarcoma cells.
Chondrosarcoma
Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma.
Chondrosarcoma
Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Chondrosarcoma
The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells.
Chondrosarcoma
[New findings in orthopedic pathology]
Chordoma
Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma.
Chordoma
Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Choriocarcinoma
Inhibition of cytotrophoblastic (JEG-3) cell invasion by interleukin 12 involves an interferon gamma-mediated pathway.
Choriocarcinoma
Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells.
Choriocarcinoma
Protein C and its inhibitor in malignancy.
Choroidal Effusions
Sub-Tenon's urokinase injection-assisted vitrectomy in early treatment of suprachoroidal hemorrhage: Four cases report.
Choroidal Neovascularization
Effect of a novel octapeptide urokinase fragment, A6, on experimental choroidal neovascularization in the monkey.
Choroidal Neovascularization
Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model.
Choroidal Neovascularization
Role of urokinase inhibitors in choroidal neovascularization.
Choroidal Neovascularization
The Urokinase Receptor-Derived Peptide UPARANT Mitigates Angiogenesis in a Mouse Model of Laser-Induced Choroidal Neovascularization.
Chronic Limb-Threatening Ischemia
Effect of Systemic Urokinase Infusion After Lower Limb Percutaneous Transluminal Angioplasty on Limb Salvage Rate in Patients with Late-stage Critical Limb Ischemia.
Chronic Limb-Threatening Ischemia
Intermittent intravenous urokinase for critical limb ischemia in diabetic foot ulceration.
Chronic Urticaria
Blood urokinase plasminogen activator system in chronic urticaria.
Classical Swine Fever
Coordinated expression of vascular endothelial growth factor A and urokinase-type plasminogen activator contributes to classical swine fever virus Shimen infection in macrophages.
coagulation factor xiia deficiency
[Congenital deficiency of factor Xii and spontaenous venous thrombosis treated with urokinase]
Colitis
BMP pathway suppression is an early event in inflammation-driven colon neoplasmatogenesis of uPA-deficient mice.
Colitis
Inflammation-driven colon neoplasmatogenesis in uPA-deficient mice is associated with an increased expression of Runx transcriptional regulators.
Colitis
Inflammation-induced colon cancer in uPA-deficient mice is associated with a deregulated expression of Notch signaling pathway components.
Colitis
Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization.
Colitis, Ulcerative
Abnormalities of the urokinase system in colonic crypt cells from patients with ulcerative colitis.
Colitis, Ulcerative
Use of thrombolytic therapy in cerebral venous sinus thrombosis with ulcerative colitis.
Colitis, Ulcerative
[Fibrinogen-guided thrombolysis with urokinase of a portal and mesenterial venous thrombosis during an acute episode of ulcerative colitis]
Colitis, Ulcerative
[Urokinase plasminogen activator (u-PA) and urokinase type plasminogen activator receptor (u-PAR) in children with ulcerative colitis.]
Colonic Diseases
Butyrate is a potent inhibitor of urokinase secretion by normal colonic epithelium in vitro.
Colonic Neoplasms
A pharmacological analysis of the cholinergic regulation of urokinase-type plasminogen activator secretion in the human colon cancer cell line, HT-29.
Colonic Neoplasms
Amiloride modulates urokinase gene expression at both transcription and post-transcription levels in human colon cancer cells.
Colonic Neoplasms
Aspirin upregulates expression of urokinase type plasminogen activator receptor (uPAR) gene in human colon cancer cells through AP1.
Colonic Neoplasms
Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway.
Colonic Neoplasms
beta-Catenin and NF-kappaB cooperate to regulate the uPA/uPAR system in cancer cells.
Colonic Neoplasms
Chromosomal localization of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes: implications in colorectal cancer.
Colonic Neoplasms
Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.
Colonic Neoplasms
Correlation between tumor proliferation and tumor tissue level of urokinase-type plasminogen activator.
Colonic Neoplasms
Decreased urokinase receptor expression by overexpression of the plasminogen activator in a colon cancer cell line.
Colonic Neoplasms
Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization.
Colonic Neoplasms
Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness.
Colonic Neoplasms
Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells.
Colonic Neoplasms
Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade.
Colonic Neoplasms
Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line.
Colonic Neoplasms
Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation.
Colonic Neoplasms
Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma.
Colonic Neoplasms
Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab.
Colonic Neoplasms
Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis.
Colonic Neoplasms
GATA6 promotes colon cancer cell invasion by regulating urokinase plasminogen activator gene expression.
Colonic Neoplasms
Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells.
Colonic Neoplasms
Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer.
Colonic Neoplasms
Inflammation-induced colon cancer in uPA-deficient mice is associated with a deregulated expression of Notch signaling pathway components.
Colonic Neoplasms
Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
Colonic Neoplasms
Inhibition of colon cancer metastasis by a 3'- end antisense urokinase receptor mRNA in a nude mouse model.
Colonic Neoplasms
Insensitivity of laminin degradation directed by receptor bound urokinase to PAI-1 in cultured colon cancer.
Colonic Neoplasms
Integrated bioprocess for the production and isolation of urokinase from animal cell culture using supermacroporous cryogel matrices.
Colonic Neoplasms
Interferon-alpha (Intron A) upregulates urokinase-type plasminogen activator receptor gene expression.
Colonic Neoplasms
Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display.
Colonic Neoplasms
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.
Colonic Neoplasms
Lithocholic acid upregulates uPAR and cell invasiveness via MAPK and AP-1 signaling in colon cancer cells.
Colonic Neoplasms
Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
Colonic Neoplasms
Macrophage inhibitory cytokine-1 (MIC-1) and subsequent urokinase-type plasminogen activator mediate cell death responses by ribotoxic anisomycin in HCT-116 colon cancer cells.
Colonic Neoplasms
Plasticity in Urokinase-Type Plasminogen Activator Receptor (uPAR) Display in Colon Cancer Yields Metastable Subpopulations Oscillating in Cell Surface uPAR Density--Implications in Tumor Progression.
Colonic Neoplasms
Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation.
Colonic Neoplasms
Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach.
Colonic Neoplasms
Requirement of the enzymatic and signaling activities of plasmin for phorbol-ester-induced scattering of colon cancer cells.
Colonic Neoplasms
Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.
Colonic Neoplasms
Selective suicide gene therapy of colon cancer exploiting the urokinase plasminogen activator receptor promoter.
Colonic Neoplasms
Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation.
Colonic Neoplasms
Sodium butyrate inhibits expression of urokinase and its receptor mRNAs at both transcription and post-transcription levels in colon cancer cells.
Colonic Neoplasms
Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis.
Colonic Neoplasms
The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.
Colonic Neoplasms
Transcriptional activation of the urokinase receptor gene in invasive colon cancer.
Colonic Neoplasms
Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1.
Colonic Neoplasms
Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
Colonic Neoplasms
Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Colonic Neoplasms
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
Colonic Neoplasms
Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of colon cancer HCT116 cell line to TRAIL via JNK-p53 pathway.
Colonic Neoplasms
Wnt/?-catenin signaling mediates the antitumor activity of magnolol in colorectal cancer cells.
Colonic Neoplasms
[Assay and detection methods for urokinase-type plasminogen activator and its related-factors]
Colonic Neoplasms
[The role of p38 MAPK in gastrin-induced u-PA expression in human colon cancer cells]
Colorectal Neoplasms
A C/T polymorphism in the urokinase-type plasminogen activator gene in colorectal cancer.
Colorectal Neoplasms
A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer.
Colorectal Neoplasms
A Preliminary Study of the Value of Plasma microRNA-193b and Soluble Urokinase-Type Plasminogen Activator Receptor in Identifying Patients with Early-Stage Colorectal Cancer and.
Colorectal Neoplasms
Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Colorectal Neoplasms
Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I).
Colorectal Neoplasms
Anti-cancer effect of Aquaporin 5 silencing in colorectal cancer cells in association with inhibition of Wnt/?-catenin pathway.
Colorectal Neoplasms
Antigen levels of the urokinase-type plasminogen activator and its gene polymorphisms in colorectal cancer.
Colorectal Neoplasms
Antigen levels of urokinase-type plasminogen activator receptor and its gene polymorphism related to microvessel density in colorectal cancer.
Colorectal Neoplasms
Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer.
Colorectal Neoplasms
Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system.
Colorectal Neoplasms
Beta-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors.
Colorectal Neoplasms
Beta-catenin--a linchpin in colorectal carcinogenesis?
Colorectal Neoplasms
Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma.
Colorectal Neoplasms
Butyrate is a potent inhibitor of urokinase secretion by normal colonic epithelium in vitro.
Colorectal Neoplasms
Chromosomal localization of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes: implications in colorectal cancer.
Colorectal Neoplasms
Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
Colorectal Neoplasms
Clinicopathologic significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogenous metastasis.
Colorectal Neoplasms
Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers.
Colorectal Neoplasms
Combined expression of urokinase-type plasminogen activator and proliferating cell nuclear antigen at the deepest invasive portion correlates with colorectal cancer prognosis.
Colorectal Neoplasms
Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression.
Colorectal Neoplasms
Correlation between metastatic potential and variants from colorectal tumor cell line HT-29.
Colorectal Neoplasms
Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization.
Colorectal Neoplasms
Enzymatic function of multiple origins regulates the progression of colorectal cancer and the development of metastases.
Colorectal Neoplasms
Epithelial and stromal cell urokinase plasminogen activator receptor expression differentially correlates with survival in rectal cancer stages B and C patients.
Colorectal Neoplasms
Evaluation of alpha 1-antitrypsin and the levels of mRNA expression of matrix metalloproteinase 7, urokinase type plasminogen activator receptor and COX-2 for the diagnosis of colorectal cancer.
Colorectal Neoplasms
Evidence for the clinical use of tumour markers.
Colorectal Neoplasms
Gelsolin Induces Colorectal Tumor Cell Invasion via Modulation of the Urokinase-Type Plasminogen Activator Cascade.
Colorectal Neoplasms
Gelsolin-Cu/ZnSOD interaction alters intracellular reactive oxygen species levels to promote cancer cell invasion.
Colorectal Neoplasms
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Colorectal Neoplasms
Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy.
Colorectal Neoplasms
Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
Colorectal Neoplasms
Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.
Colorectal Neoplasms
Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.
Colorectal Neoplasms
Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers.
Colorectal Neoplasms
Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Colorectal Neoplasms
Novel Inhibitors of Urokinase-type Plasminogen Activators: 4-(3H-imidazo[4,5-b]pyridin-2-yl)-N-Substituted Benzamide and Benzamidine Compounds.
Colorectal Neoplasms
Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas.
Colorectal Neoplasms
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Colorectal Neoplasms
Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid.
Colorectal Neoplasms
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Colorectal Neoplasms
Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens.
Colorectal Neoplasms
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?
Colorectal Neoplasms
Plasminogen activators in human colorectal neoplasia.
Colorectal Neoplasms
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.
Colorectal Neoplasms
Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
Colorectal Neoplasms
Prognostic role of urokinase plasminogen activator receptor in gastric and colorectal cancer: A systematic review and meta-analysis.
Colorectal Neoplasms
Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Colorectal Neoplasms
Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor.
Colorectal Neoplasms
Regional variations of urokinase-type plasminogen activator in human colorectal cancer: a quantitative study by image analysis.
Colorectal Neoplasms
Role of urokinase in colorectal neoplasia.
Colorectal Neoplasms
Role of urokinase, its receptor, and serpins in colorectal carcinoma.
Colorectal Neoplasms
Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma.
Colorectal Neoplasms
Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas.
Colorectal Neoplasms
Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer.
Colorectal Neoplasms
Stromal cell-derived factor-1/CXC receptor 4 and b1 integrin interaction regulates urokinase-type plasminogen activator expression in human colorectal cancer cells.
Colorectal Neoplasms
Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect.
Colorectal Neoplasms
Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver.
Colorectal Neoplasms
The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study.
Colorectal Neoplasms
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
Colorectal Neoplasms
The expression of urokinase type plasminogen activator is a novel prognostic factor in dukes B and C colorectal cancer.
Colorectal Neoplasms
The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology.
Colorectal Neoplasms
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
Colorectal Neoplasms
Urokinase receptor and colorectal cancer survival.
Colorectal Neoplasms
Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
Colorectal Neoplasms
Urokinase receptor genotypes in colorectal cancer.
Colorectal Neoplasms
Urokinase type plasminogen activator receptor expression in colorectal neoplasms.
Colorectal Neoplasms
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Colorectal Neoplasms
Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.
Colorectal Neoplasms
Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Colorectal Neoplasms
Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.
Colorectal Neoplasms
Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme.
Colorectal Neoplasms
Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
Colorectal Neoplasms
Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer.
Colorectal Neoplasms
Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator.
Colorectal Neoplasms
[Comparative analysis of metastatic variants from the colorectal tumor cell line HT-29]
Colorectal Neoplasms
[Effect of jianpi-jiedu formula on tumor angiogenesis-relevant genes expression in colorectal cancer].
Colorectal Neoplasms
[Significance in gene expression of matrix metalloproteinase-9, urokinase-type plasminogen activator and tissue inhibitor of metalloproteinase for metastases of gastric and/or colo-rectal cancer]
Colorectal Neoplasms
[The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer]
Coma
Acute vertebral-basilar thrombosis. Angiologic-clinical comparison and therapeutic implications.
Coma
Endovascular thrombolysis in deep cerebral venous thrombosis.
Coma
Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial.
Coma
Management of primary intracerebral hematomas.
Coma
Thrombolytic therapy and posterior circulation extracranial-intracranial bypass for acute basilar artery thrombosis. Case report.
Coma
Twist drill craniostomy for traumatic acute subdural hematoma in the elderly: case series and literature review.
Coma
Urokinase treatment for severe neurological complications in a patient with thrombotic thrombocytopenic purpura.
Coma
[Multianalysis of short-term prognostic factors in surgical practices for hypertensive intracerebral hemorrhage]
Common Variable Immunodeficiency
Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency.
Communicable Diseases
Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Communicable Diseases
Plasma Level of Soluble Urokinase-type Plasminogen Activator Receptor Predicts the Severity of Acute Alcohol Pancreatitis.
Communicable Diseases
Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group.
Communicable Diseases
Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection.
Communicable Diseases
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.
Communicable Diseases
suPAR as a prognostic biomarker in sepsis.
Communicable Diseases
suPAR: the molecular crystal ball.
Communicable Diseases
The Diagnostic and Prognostic Value of Supar in Patients With Sepsis: A Systematic Review and Meta-Analysis.
Conjunctivitis, Allergic
Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Corneal Neovascularization
The role of the fibrinolytic system in corneal angiogenesis.
Corneal Neovascularization
Trehalose treatment accelerates the healing of UVB-irradiated corneas. Comparative immunohistochemical studies on corneal cryostat sections and corneal impression cytology.
Corneal Perforation
Immunohistochemical localization of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and ?2-antiplasmin in human corneal perforation: a case report.
Coronary Aneurysm
Intracoronary urokinase in Kawasaki disease: treatment and prevention of myocardial infarction.
Coronary Aneurysm
[Clinical analysis of intravenous urokinase treatment of 10 cases with Kawasaki disease complicated with thrombus in coronary aneurysm]
Coronary Artery Disease
Antithrombotic treatment in stable coronary syndromes: long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris.
Coronary Artery Disease
Automated, PCR-RFLP genotyping of the urokinase gene.
Coronary Artery Disease
Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.
Coronary Artery Disease
Chronic-intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris--a pilot study.
Coronary Artery Disease
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Coronary Artery Disease
Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease.
Coronary Artery Disease
Increased Urokinase-Type Plasminogen Activator Receptor Expression on Circulating Monocytes Is Correlated with Clinical Instability and Long-Term Adverse Cardiac Events in Patients with Coronary Artery Disease.
Coronary Artery Disease
Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomized dose-response trial.
Coronary Artery Disease
Long-term Urokinase Therapy and Isovolemic Hemodilution: A Clinical and Hemodynamic Comparison in Patients with Refractory Angina Pectoris.
Coronary Artery Disease
Low-dose intermittent urokinase therapy in chronic symptomatic end-stage arterial disease--clinical relevance for patients with coronary artery disease or peripheral arterial occlusive disease.
Coronary Artery Disease
Multibiomarker analysis in patients with acute myocardial infarction.
Coronary Artery Disease
Multimarker Approach to Identify Patients with Coronary Artery Disease at High Risk for Subsequent Cardiac Adverse Events: The Multi-Biomarker Study.
Coronary Artery Disease
Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Coronary Artery Disease
Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease.
Coronary Artery Disease
Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients.
Coronary Artery Disease
Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events.
Coronary Artery Disease
Soluble Urokinase Plasminogen Activator Receptor Level Is an Independent Predictor of the Presence and Severity of Coronary Artery Disease and of Future Adverse Events.
Coronary Artery Disease
Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
Coronary Artery Disease
Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease.
Coronary Artery Disease
Soluble urokinase-type plasminogen activator receptor: a useful biomarker for coronary artery disease and clinical outcomes?
Coronary Artery Disease
Stenting the stent: alternative strategy for treating in-stent restenosis.
Coronary Artery Disease
SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease.
Coronary Artery Disease
Urokinase plasminogen activator system in humans with stable coronary artery disease.
Coronary Artery Disease
[Antithrombotic therapy in chronic coronary syndromes--value of thrombocyte aggregation inhibition, anticoagulation and chronic thrombolysis]
Coronary Artery Disease
[Chronic intermittent urokinase therapy: anti-ischemic and hemodynamic effects]
Coronary Artery Disease
[Clinical significance of the cardiovascular risk factor fibrinogen in secondary prevention]
Coronary Artery Disease
[Risk factors for coronary artery disease stimulate urokinase receptor expression on monocytes]
Coronary Disease
Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase-type plasminogen activator receptor (suPAR) levels.
Coronary Disease
[Chronic intermittent urokinase therapy in inoperable end-stage coronary disease with therapy refractory angina pectoris symptoms]
Coronary Disease
[Chronic intermittent urokinase therapy in therapy-refractory angina pectoris]
Coronary Disease
[Conservative therapeutic approaches in terminal coronary heart disease. Chronic intermittent urokinase therapy]
Coronary Disease
[Relationship between atherosclerotic plaque characteristics and extracellular matrix metalloproteinase inducer and urokinase-type plasminogen activator in patients with coronary artery disease].
Coronary Disease
[Symptomatic therapy refractory myocardial ischemia in coronary heart disease. Chronic intermittent urokinase therapy and invasive therapeutic measures]
Coronary Disease
[Urokinase-type plasminogen activator and its inhibitor type 1 in the diagnosis of evolving complications in coronary heart disease]
Coronary Occlusion
Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
Coronary Occlusion
Intracoronary urokinase in acute myocardial infarction: prevalence of total coronary occlusion during the early hours, effects on myocardial infarct size and left ventricular function, and outcome of residual coronary stenosis.
Coronary Occlusion
Management of complicated coronary angioplasty by intracoronary urokinase and immediate re-angioplasty.
Coronary Occlusion
Myocardial infarction after cryoablation surgery for Wolff-Parkinson-White syndrome.
Coronary Occlusion
Pathomorphological changes in experimentally induced canine myocardial infarction.
Coronary Occlusion
Prolonged urokinase infusion for chronic total native coronary occlusions: clinical, angiographic, and treatment observations.
Coronary Occlusion
The use of urokinase in acute myocardial infarction: report of two cases.
Coronary Occlusion
Urokinase in thrombotic coronary occlusion.
Coronary Restenosis
Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis.
Coronary Stenosis
Intracoronary urokinase in acute myocardial infarction: prevalence of total coronary occlusion during the early hours, effects on myocardial infarct size and left ventricular function, and outcome of residual coronary stenosis.
Coronary Stenosis
Treatment of intracoronary thrombus with local urokinase infusion using a new, site-specific drug delivery system: the Dispatch catheter.
Coronary Stenosis
[Left ventricular asynergy in patients with impending myocardial infarction: two-dimensional echocardiographic assessment]
Coronary Thrombosis
A novel modified tissue-type plasminogen activator (t-PA), E6010, gradually increases coronary blood flow after thrombolysis compared with native t-PA, urokinase and balloon catheter occlusion-reperfusion.
Coronary Thrombosis
Additional myocardial salvage by coadministration of the epoprostenol analog taprostene to recombinant single-chain urokinase-type plasminogen activator in a canine coronary thrombosis model.
Coronary Thrombosis
Antiplatelet effects of urokinase and their clinical implications.
Coronary Thrombosis
Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
Coronary Thrombosis
Coronary thrombolysis. Comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase.
Coronary Thrombosis
Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.
Coronary Thrombosis
Low-dose antithrombotic treatment in coronary thrombosis of kawasaki disease.
Coronary Thrombosis
Low-dose i.v. urokinase for coronary thrombosis in Kawasaki disease.
Coronary Thrombosis
Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
Coronary Thrombosis
[Comparison of the efficacy of intravenous urokinase and defibrase on 6-hour-old canine coronary thrombosis]
Coronary Thrombosis
[Effects of intracoronary or intravenous urokinase on canine coronary thrombosis]
Coronary Thrombosis
[Late effect of intracoronary urokinase. Apropos of a case of recurrent coronary thrombosis after angioplasty]
Coronary Thrombosis
[Role of urokinase in the acute phase of myocardial infarction]
Coronary Thrombosis
[Significance of coronary thrombosis for chronic myocardial ischemia]
COVID-19
Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study.
COVID-19
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
COVID-19
Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients.
COVID-19
Evaluation of the relationship between KIM-1 and suPAR levels and clinical severity in COVID-19 patients: A different perspective on suPAR.
COVID-19
SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung.
COVID-19
Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department.
COVID-19
Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients.
COVID-19
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.
COVID-19
Unclear Issues Regarding COVID-19.
Craniocerebral Trauma
Effects of minimally invasive approaches on chronic subdural hematoma by novel YL-1 puncture needle and burr-hole methods.
Craniocerebral Trauma
Endovascular treatment of traumatic dural sinus thrombosis: case report.
Craniocerebral Trauma
Sagittal sinus thrombosis following minor head injury treated with continuous urokinase infusion.
Craniocerebral Trauma
[Monitoring of coagulation activity in cases with head injuries, with special reference to a urokinase resistance test]
Creutzfeldt-Jakob Syndrome
Cortical neurons of Creutzfeldt-Jakob disease patients express the urokinase-type plasminogen activator receptor.
Crohn Disease
Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
Cryptococcosis
Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection.
Cystadenocarcinoma
Expression of urokinase-type plasminogen-activator (upa) and its receptor (upar) in human ovarian-cancer cells and in-vitro invasion capacity.
Cystic Fibrosis
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
Cysts
A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470.
Cysts
Contrast-enhanced ultrasound evaluation of a refractory ovarian endometrial cyst and ultrasound-guided aspiration sclerotherapy using urokinase and lauromacrogol.
Cysts
Drilling skull plus injection of urokinase in the treatment of epidural haematoma: a preliminary study.
Cysts
Fluid characteristics of benign ovarian cysts: correlation with recurrence after puncture.
Cysts
Medical therapy with tranexamic acid in autosomal dominant polycystic kidney disease patients with severe haematuria.
Cysts
Novel Minimally Invasive Treatment Strategy for Acute Traumatic Epidural Hematoma: Endovascular Embolization Combined with Drainage Surgery and Use of Urokinase.
Cysts
The urine urokinase concentration in end stage renal disease with acquired renal cyst.
Cysts
Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
Darier Disease
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Death, Sudden, Cardiac
Circadian fluctuations in the efficacy of thrombolysis with streptokinase.
Dehydration
Resolution of proteinuria secondary to bilateral renal vein thrombosis after treatment with systemic thrombolytic therapy.
Dementia
Excessive urokinase-type plasminogen activator activity in the euglobulin fraction of patients with Alzheimer-type dementia.
Dementia
The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.
Dementia, Vascular
Excessive urokinase-type plasminogen activator activity in the euglobulin fraction of patients with Alzheimer-type dementia.
Demyelinating Diseases
A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis.
Demyelinating Diseases
Nerve lesions induced by macrophage activation.
Dermatitis Herpetiformis
Enhanced expression of interstitial collagenase, stromelysin-1, and urokinase plasminogen activator in lesions of dermatitis herpetiformis.
Dermatitis Herpetiformis
Urokinase plasminogen activator is expressed by basal keratinocytes before interstitial collagenase, stromelysin-1, and laminin-5 in experimentally induced dermatitis herpetiformis lesions.
Diabetes Mellitus
Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Diabetes Mellitus
Deficiency of Urokinase Plasminogen Activator May Impair ? Cells Regeneration and Insulin Secretion in Type 2 Diabetes Mellitus.
Diabetes Mellitus
Distribution of C-->T and T-->C polymorphisms of the urokinase-type plasminogen activator gene in children with type 1 diabetes mellitus and insulin resistance.
Diabetes Mellitus
Insulin Treatment Forces Arteriogenesis in Diabetes Mellitus by Upregulation of the Early Growth Response-1 (Egr-1) Pathway in Mice.
Diabetes Mellitus
Low level of low-density lipoprotein cholesterol is related with increased hemorrhagic transformation after acute ischemic cerebral infarction.
Diabetes Mellitus
Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
Diabetes Mellitus
Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias.
Diabetes Mellitus
Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.
Diabetes Mellitus
Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus.
Diabetes Mellitus
Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.
Diabetes Mellitus
[Case of cholesterol crystal embolism occurring after treatment of cerebral infarction with urokinase]
Diabetes Mellitus
[Determination of efficacy of second application of Urokinase Medac in a diabetic foot syndrome].
Diabetes Mellitus
[Urinary urokinase and blood fibrinolytic activity in patients with diabetes mellitus]
Diabetes Mellitus, Experimental
[Histidase and urokinase activity in the blood and liver of the rat in alloxan diabetes and the effect of insulin on their activities]
Diabetes Mellitus, Type 1
Distribution of C-->T and T-->C polymorphisms of the urokinase-type plasminogen activator gene in children with type 1 diabetes mellitus and insulin resistance.
Diabetes Mellitus, Type 1
Plasma soluble urokinase plasminogen activator receptor (suPAR) level is associated with myocardial impairment assessed with advanced echocardiography in Type 1 Diabetes Patients with normal ejection fraction and without known heart disease or end stage renal disease.
Diabetes Mellitus, Type 1
Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
Diabetes Mellitus, Type 1
Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
Diabetes Mellitus, Type 2
Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Diabetes Mellitus, Type 2
Deficiency of Urokinase Plasminogen Activator May Impair ? Cells Regeneration and Insulin Secretion in Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
Diabetes Mellitus, Type 2
Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.
Diabetes Mellitus, Type 2
Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
Diabetes Mellitus, Type 2
Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.
Diabetes Mellitus, Type 2
Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status.
Diabetic Angiopathies
[Intra-arterial thrombolytic therapy of ischaemic complications of lower-limb diabetic angiopathy].
Diabetic Foot
Intermittent intravenous urokinase for critical limb ischemia in diabetic foot ulceration.
Diabetic Foot
The role of soluble urokinase plasminogen activator receptor (suPAR) in the diagnostics of diabetic foot infection.
Diabetic Foot
[Determination of efficacy of second application of Urokinase Medac in a diabetic foot syndrome].
Diabetic Foot
[Regional intraosseous thrombolytic therapy in comprehensive treatment of patients with diabetic foot syndrome].
Diabetic Nephropathies
Diabetic nephropathy is associated with increased urine excretion of proteases plasmin, prostasin and urokinase and activation of amiloride-sensitive current in collecting duct cells.
Diabetic Nephropathies
Effect of urokinase on preservation of renal function in patients with diabetic nephropathy.
Diabetic Nephropathies
Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
Diabetic Nephropathies
Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy.
Diabetic Nephropathies
RAGE and ?V?3-integrin are essential for suPAR signaling in podocytes.
Diabetic Nephropathies
Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Diabetic Nephropathies
Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes.
Diabetic Nephropathies
Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus.
Diabetic Nephropathies
Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
Diabetic Retinopathy
Diabetic Retinopathy in the Spontaneously Diabetic Torii Rat: Pathogenetic Mechanisms and Preventive Efficacy of Inhibiting the Urokinase-Type Plasminogen Activator Receptor System.
Diabetic Retinopathy
The Urokinase Receptor-Derived Peptide UPARANT Recovers Dysfunctional Electroretinogram and Blood-Retinal Barrier Leakage in a Rat Model of Diabetes.
Diabetic Retinopathy
Thrombosis and Hemorrhage in Diabetic Retinopathy: A Perspective from an Inflammatory Standpoint.
Diabetic Retinopathy
[Urokinase therapy in diabetic retinopathy (author's transl)]
Digestive System Diseases
[Diagnostic values of alkaline phosphatase, histidase and urokinase in the bile in children with hepatobiliary diseases]
Diphtheria
A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts.
Diphtheria
Contribution of plasminogen activator urokinase to in vitro cytotoxicity of diphtheria toxin.
Diphtheria
Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13.
Diphtheria
Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.
Diphtheria
Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice.
Diphtheria
Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
Diphtheria
Specific cleavage of diphtheria toxin by human urokinase.
Diphtheria
Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.
Diphtheria
Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.
Diphtheria
The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells.
Disorders of Excessive Somnolence
[FDG-PET in an amnestic and hypersomnic patient with bilateral paramedian thalamic infarction]
Disseminated Intravascular Coagulation
Beneficial effects of urokinase on lipopolysaccharide-induced disseminated intravascular coagulation in rats: focus on organ function and endothelin levels.
Disseminated Intravascular Coagulation
Danger of urokinase as an anticoagulant with left ventricular assist devices.
Disseminated Intravascular Coagulation
Detection of low molecular weight urokinase in plasma of patient with acute pancreatitis followed by disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation. Heparin, anticoagulant and urokinase in experimental nephritic in mice.
Disseminated Intravascular Coagulation
Effect of urokinase on disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
Disseminated Intravascular Coagulation
Fibrinolytic agents: a new approach to the treatment of adult respiratory distress syndrome.
Disseminated Intravascular Coagulation
Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis.
Disseminated Intravascular Coagulation
Localization of tissue plasminogen activator on experimental thrombi in rats.
Disseminated Intravascular Coagulation
Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target?
Disseminated Intravascular Coagulation
Plasmin-alpha 2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis.
Disseminated Intravascular Coagulation
Unclear Issues Regarding COVID-19.
Disseminated Intravascular Coagulation
[Disseminated intravascular coagulation induced by endotoxin in rabbits: effect of treatment with t-PA and urokinase]
Disseminated Intravascular Coagulation
[Therapy of consumption coagulopathy and hyperfibrinolysis with urokinase in a case of acute promyelocytic leukemia]
Disseminated Intravascular Coagulation
[Urokinase excretion and fibrinolysis in consumption coagulopathy and acute kidney failure]
Drug-Related Side Effects and Adverse Reactions
Urokinase does not upregulate the vascular endothelial cell-mediated inflammatory response.
Duodenal Ulcer
Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease.
Dyspnea
Randomised Controlled Trial of Urokinase versus Placebo for Non-draining Malignant Pleural Effusion.
Dyspnea
[Successful thrombolysis of a thrombosed mitral valve prosthesis]
Eclampsia
Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia.
Eclampsia
[Fibrinolysis in pregnancy toxemia]
Embolic Stroke
A case-control analysis of intra-arterial urokinase thrombolysis in acute cardioembolic stroke.
Embolic Stroke
A Combined Treatment with Taurine and Intra-arterial Thrombolysis in an Embolic Model of Stroke in Rats: Increased Neuroprotective Efficacy and Extended Therapeutic Time Window.
Embolic Stroke
Effect of intra-arterial tissue plasminogen activator and urokinase on autologous arterial emboli in the cerebral circulation of rabbits [corrected]
Embolic Stroke
Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate.
Embolic Stroke
Good clinical outcome in a patient with a large CT scan hypodensity treated with intra-arterial urokinase after an embolic stroke.
Embolic Stroke
Intraoperative urokinase infusion for embolic stroke during carotid endarterectomy.
Embolic Stroke
Selective and superselective infusion of urokinase for embolic stroke.
Embolic Stroke
Tirofiban combined with urokinase selective intra-arterial thrombolysis for the treatment of middle cerebral artery occlusion.
Embolism
A new "wonder" drug to dissolve clots. The results of urokinase therapy in acute myocardial infarction, pulmonary embolism and deep vein thrombosis.
Embolism
Carotid endarterectomy and intracranial thrombolysis: simultaneous and staged procedures in ischemic stroke.
Embolism
Central venous line thrombosis in premature infants: a case management and literature review.
Embolism
Combined modality of mechanical breakdown and intraembolus thrombolysis in failed systemic thrombolysis of subacute pulmonary embolism patients.
Embolism
Coronary embolism following aortic and mitral valve replacement: successful management with abciximab and urokinase.
Embolism
Cost-effectiveness of intra-arterial thrombolytic therapy.
Embolism
Effect of urokinase on fibrinolysis and fibrinogenolysis.
Embolism
Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism.
Embolism
Experimental pulmonary embolus in the rat: a new in vivo model to test thrombolytic drugs.
Embolism
Experimentally Induced Arterial Embolism by Hyaluronic Acid Injection: Clinicopathologic Observations and Treatment.
Embolism
Experimentally Induced Arterial Embolism by Hyaluronic Acid Injection: Clinicopathological Observations and Treatment.
Embolism
Fibrinolytic therapy for acute embolic stroke: intravenous, intracarotid, and intra-arterial local approaches.
Embolism
Fibrinolytic therapy for upper-extremity arterial occlusions.
Embolism
High-dose bolus injection of urokinase. Use during cardiopulmonary resuscitation for massive pulmonary embolism.
Embolism
History and physical examination in acute pulmonary embolism in patients without preexisting cardiac or pulmonary disease.
Embolism
Immediate postoperative thrombolytic therapy: an aggressive strategy for neurologic salvage when cerebral thromboembolism complicates carotid endarterectomy.
Embolism
Intraarterial therapy for acute ischemic stroke: investigation of prognostic factors.
Embolism
Intravenous Hyaluronidase with Urokinase as Treatment for Arterial Hyaluronic Acid Embolism.
Embolism
Intravenous Hyaluronidase with Urokinase as Treatment for Rabbit Retinal Artery Hyaluronic Acid Embolism.
Embolism
Lung endothelium targeting for pulmonary embolism thrombolysis.
Embolism
Management of acute superior mesenteric artery occlusion.
Embolism
Outcome in acute stroke with different intra-arterial infusion rate of urokinase on thrombolysis.
Embolism
Percutaneous management of emboli associated with hot tip laser-assisted angioplasty.
Embolism
Pulmonary embolus and Malassezia pulmonary infection related to urokinase therapy.
Embolism
Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan.
Embolism
Recanalization by mechanical embolus disruption during intra-arterial thrombolysis in the carotid territory.
Embolism
Renal artery embolus treated with urokinase perfusion.
Embolism
Reply: Intravenous Hyaluronidase with Urokinase as Treatment for Arterial Hyaluronic Acid Embolism.
Embolism
Role of urokinase in the superior mesenteric artery embolism.
Embolism
Safety and efficacy of urokinase during elective coronary angioplasty.
Embolism
Successful intra-arterial fibrinolysis of the anterior choroidal artery in the acute stage of internal carotid artery occlusion: case report.
Embolism
Successful intraarterial fragmentation and urokinase therapy in superior mesenteric artery embolisms.
Embolism
Superior mesenteric arterial embolism: a retrospective study of local thrombolytic treatment with urokinase in West China.
Embolism
Superior mesenteric arterial embolism: local fibrinolytic treatment with urokinase.
Embolism
Superior mesenteric artery embolism: treatment with intraarterial urokinase.
Embolism
Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus.
Embolism
Thrombolytic therapy for catheter-related thrombosis.
Embolism
Urokinase evaluated with the experimental radioactive embolus.
Embolism
Urokinase in pulnonary embolism.
Embolism
Urokinase resolution of impending paradoxic embolus in transit: evaluation by multiplane transesophageal echocardiography.
Embolism
Urokinase thrombolysis as initial therapy for acute and non-acute ischemic extremities.
Embolism
Urokinase treatment preserves endothelial and smooth muscle function in experimental acute arterial thrombosis.
Embolism
[A case of inferior vena cava thrombosis associated with cholelithiasis demonstrated by ultrasonic examination]
Embolism
[A case of renal artery embolism treated with urokinase]
Embolism
[Arterial infusion therapy in mesenteric artery embolisms. A report of two cases treated by infusion therapy using only urokinase]
Embolism
[Case of cholesterol crystal embolism occurring after treatment of cerebral infarction with urokinase]
Embolism
[Comparative assessment of efficacy of local thrombolysis with various fibrinolytics].
Embolism
[Drug therapy of pulmonary embolism]
Embolism
[Experience with intra-arterial thrombolysis in patients with acute stroke]
Embolism
[Intensive medical monitoring with transesophageal echocardiography in fulminant pulmonary embolism]
Embolism
[Intra-arterial infusion with urokinase for embolism of the superior mesenteric artery]
Embolism
[Intra-arterial perfusion with urokinase in embolism of the superior mesenteric artery]
Embolism
[Local thrombolysis in renal artery embolism]
Embolism
[Mechanical high speed analysis of acute thromboembolic occlusions of t he popliteal artery. Initial experiences with the Amplatz thrombectomy catheter]
Embolism
[Multicenter study of 2 urokinase protocols in severe pulmonary embolism. Research Group on Urokinase and Pulmonary Embolism]
Embolism
[Renal artery embolism treated with a continuous selective intra-arterial urokinase infusion therapy: a case report]
Embolism
[Successful thrombolysis of a fulminant lung embolism during cardiopulmonary resuscitation]
Embolism
[Systemic lysotherapy using recombinant tissue plasminogen activator for fulminant pulmonary embolism]
Embolism
[Thrombus fragmentation and local lysis in extensive pulmonary embolisms]
Embolism
[Treatment of a mesenteric artery embolism with local high-dosage urokinase administration]
Embolism, Air
Uncommon Occurrences of Air Embolism: Description of Cases and Review of the Literature.
Empyema
Community-acquired Pseudomonas aeruginosa pneumonia complicated with loculated empyema in an infant with selective IgA deficiency.
Empyema
Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema.
Empyema
Computed tomography-guided catheter drainage with urokinase and ozone in management of empyema.
Empyema
Empyema and effusion: outcome of image-guided small-bore catheter drainage.
Empyema
Fibrinolysis with Lower Dose Urokinase in Patients with Complicated Parapneumonic Effusion.
Empyema
Hyaluronic acid on the urokinase sustained release with a hydrogel system composed of poloxamer 407: HA/P407 hydrogel system for drug delivery.
Empyema
Initial treatment of septated parapneumonic empyema with drainage plus fibrinolytic agents is equally effective as video-assisted thoracoscopic surgery, and is suitable as first-line therapy.
Empyema
Intra-pleural fibrinolytic therapy vs. conservative management in the treatment of parapneumonic effusions and empyema.
Empyema
Intracavitary urokinase therapy as an adjunct to percutaneous drainage in a patient with a multiloculated empyema.
Empyema
Intrapleural alteplase in a patient with complicated pleural effusion.
Empyema
Intrapleural fibrinolytic treatment of multiloculated thoracic empyemas.
Empyema
Intrapleural urokinase in the management of parapneumonic empyema: a randomised controlled trial.
Empyema
Intrapleural urokinase in the treatment of complicated parapneumonic pleural effusions and empyema.
Empyema
Intrapleural urokinase treatment in children with complicated parapneumonic effusion.
Empyema
Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. A randomized, double-blind study.
Empyema
Intrapleural urokinase versus surgical management of childhood empyema.
Empyema
Less is best? The impact of urokinase as the first line management of empyema thoracis.
Empyema
Once-daily intrapleural urokinase treatment of complicated parapneumonic effusion in pediatric patients.
Empyema
Phase 1 trial of intrapleural LTI-01; single chain urokinase in complicated parapneumonic effusions or empyema.
Empyema
Randomised trial of intrapleural urokinase in the treatment of childhood empyema.
Empyema
Role of Intrapleural Urokinase in Empyema Thoracis.
Empyema
Role of routine computed tomography in paediatric pleural empyema.
Empyema
Single-chain urokinase in empyema induced by Pasturella multocida.
Empyema
The in vitro efficacy of varidase versus streptokinase or urokinase for liquefying thick purulent exudative material from loculated empyema.
Empyema
Treatment of loculated pleural effusion with intrapleural urokinase in children.
Empyema
Treatment of thoracic multiloculated empyemas with intracavitary urokinase: a prospective study.
Empyema
Urokinase and VATS are equally effective for septated empyema.
Empyema
Urokinase in the treatment of childhood empyema.
Empyema
Urokinase versus VATS for treatment of empyema: a randomized multicenter clinical trial.
Empyema
[Fibrinolysis with intracavitary urokinase in two cases of empyema drained percutaneously with computerized tomography]
Empyema
[Intrathoracic washing with urokinase was effective for empyema with atelectasis].
Empyema
[Successful treatment of thoracic drainage using urokinase for empyema in an elderly man].
Empyema
[Two fibrinopulurent empyema cases--treatment with early mini-thoracotomy and transcatheter urokinase instillation]
Empyema
[Usefulness of urokinase in multilocular pleural effusion]
Empyema, Pleural
Computed tomography-guided catheter drainage with urokinase and ozone in management of empyema.
Empyema, Pleural
Evaluation of a pediatric protocol of intrapleural urokinase for pleural empyema: A prospective study.
Empyema, Pleural
Intrapleural urokinase in the treatment of complicated parapneumonic pleural effusions and empyema.
Empyema, Pleural
Intrapleural urokinase therapy in a neonate with pleural empyema.
Empyema, Pleural
Once-daily intrapleural urokinase treatment of complicated parapneumonic effusion in pediatric patients.
Empyema, Pleural
The role of video-assisted thoracoscopic surgery in the treatment of parapneumonic empyema after the failure of fibrinolytics.
Empyema, Pleural
The use of urokinase for loculated thoracic empyema in children: a case report and review of the literature.
Empyema, Pleural
Use of urokinase in childhood pleural empyema.
Encephalitis
Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.
Encephalomyelitis, Autoimmune, Experimental
A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis.
Endocarditis
[Indications for the intra-arterial infusion of urokinase in the treatment of acute intestinal ischemia in patients with heart disease]
Endometrial Hyperplasia
Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Endometrial Neoplasms
A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study.
Endometrial Neoplasms
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Endometrial Neoplasms
Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Endometrial Neoplasms
Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators (u-PA, t-PA) in endometrial carcinoma.
Endometrial Neoplasms
Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.
Endometrial Neoplasms
Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies.
Endometrial Neoplasms
Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Endometrial Neoplasms
Sex steroids regulate the expression of plasminogen activator inhibitor-1 (PAI-1) and its mRNA in uterine endometrial cancer cell line Ishikawa.
Endometrial Neoplasms
The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer.
Endometrial Neoplasms
Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma.
Endometrial Neoplasms
Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer.
Endometrial Neoplasms
Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer.
Endometrial Neoplasms
Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients.
Endometriosis
Expression of angiogenic factors in endometriosis: relationship to fibrinolytic and metalloproteinase systems.
Endometriosis
Expression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis.
Endometriosis
Extracellular matrix remodelling in the endometrium and its possible relevance to the pathogenesis of endometriosis.
Endometriosis
Fibrinolytic factors in endometriotic tissue, endometrium, peritoneal fluid, and plasma from women with endometriosis and in endometrium and peritoneal fluid from healthy women.
Endometriosis
Genetic Variants in Fibrinolytic System-Related Genes in Infertile Women With and Without Endometriosis.
Endometriosis
In situ localization of mRNA for the fibrinolytic factors uPA, PAI-1 and uPAR in endometriotic and endometrial tissue.
Endometriosis
Melatonin protects against endometriosis via regulation of matrix metalloproteinase-3 and an apoptotic pathway.
Endometriosis
mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay.
Endometriosis
Soluble urokinase-type plasminogen activator receptor is over-expressed in uterine endometrium from women with endometriosis.
Endometriosis
Upregulation of CFTR in patients with endometriosis and its involvement in NF?B-uPAR dependent cell migration.
Endometriosis
Urokinase-type plasminogen activator and insulin-like growth factor-binding protein 3 mRNA expression in endometriotic lesions and eutopic endometrium: implications for the pathophysiology of endometriosis.
Endotoxemia
Concurrent upregulation of urokinase plasminogen activator receptor and CD11b during tuberculosis and experimental endotoxemia.
Endotoxemia
Endotoxin stimulates expression of the murine urokinase receptor gene in vivo.
Endotoxemia
Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia.
Endotoxemia
Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia.
Enterocolitis, Necrotizing
The importance of biomarkers in neonatology.
Eosinophilia
Changes to plasminogen activators and matrix metalloproteinase-9 in dogs with toxocarosis.
Epilepsy
Increased expression of urokinase-type plasminogen activator receptor in the frontal cortex of patients with intractable frontal lobe epilepsy.
Epilepsy
The relationship between levels of plasma-soluble urokinase plasminogen activator receptor (suPAR) and presence of migraine attack and aura.
Epilepsy
The role of the urokinase receptor in epilepsy, in disorders of language, cognition, communication and behavior, and in the central nervous system.
Epilepsy
Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.
Epilepsy
Urokinase-type plasminogen activator deficiency has little effect on seizure susceptibility and acquired epilepsy phenotype but reduces spontaneous exploration in mice.
Epilepsy
Urokinase-Type Plasminogen Activator Receptor Modulates Epileptogenesis in Mouse Model of Temporal Lobe Epilepsy.
Epilepsy, Frontal Lobe
Increased expression of urokinase-type plasminogen activator receptor in the frontal cortex of patients with intractable frontal lobe epilepsy.
Epilepsy, Temporal Lobe
Urokinase-Type Plasminogen Activator Receptor Modulates Epileptogenesis in Mouse Model of Temporal Lobe Epilepsy.
Epiretinal Membrane
Plasminogen activation in epiretinal membranes.
Epistaxis
[The analysis of plasma Urokinase-type plasminogen activator and Urokinase-type plasminogen activator receptor which unknown factor nosebleed patients]
Erysipelas
[Bier's occlusion. An unjustly neglected therapeutic possibility in resistant tissue defects of the extremities]
Esophageal Neoplasms
High expression of uPA related to p38MAPK in esophageal cancer indicates poor prognosis.
Esophageal Neoplasms
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.
Esophageal Squamous Cell Carcinoma
Altered expression of the urokinase receptor homologue, C4.4A, in invasive areas of human esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Differential expression of MMP and uPA systems and prognostic relevance of their expression in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma.
Essential Hypertension
Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease.
Exostoses
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Extranodal Extension
Urokinase-type plasminogen activator expression in human prostate carcinomas.
Eye Hemorrhage
[Treatment of traumatic hemophthalmos with intravitreal urokinase]
Eye Injuries, Penetrating
Effect of urokinase on posterior penetrating eye injuries.
Factor XII Deficiency
[Congenital deficiency of factor Xii and spontaenous venous thrombosis treated with urokinase]
Fatty Liver
Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.
Febrile Neutropenia
The diagnostic value of soluble urokinase plasminogen activator receptor compared with C-reactive protein and procalcitonin in children with febrile neutropenia.
Febrile Neutropenia
The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
Femoral Neuropathy
Femoral nerve palsy secondary to anticoagulant induced iliacus hematoma. A case report.
Fetal Diseases
[Myocardial infarction and thromboembolism during pregnancy]
Fetal Growth Retardation
Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: possible markers of placental function.
Fibrosarcoma
1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells.
Fibrosarcoma
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
Fibrosarcoma
Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation.
Fibrosarcoma
Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
Fibrosarcoma
Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Fibrosarcoma
Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines.
Fibrosarcoma
Enhanced expression of the urokinase-type plasminogen activator gene and reduced colony formation in soft agar by ectopic expression of PU.1 in HT1080 human fibrosarcoma cells.
Fibrosarcoma
External modulation of HT-1080 human fibrosarcoma cells improves urokinase production.
Fibrosarcoma
Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion.
Fibrosarcoma
Fiber-Reinforced Silk Composite for Enhanced Urokinase Production Using High-Density Perfusion Culture and Bioactive Molecule Supplementation.
Fibrosarcoma
Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
Fibrosarcoma
Inhibition of experimental metastasis by enzyme inhibitors from microorganisms and plants.
Fibrosarcoma
Integrated bioprocess for the production and isolation of urokinase from animal cell culture using supermacroporous cryogel matrices.
Fibrosarcoma
Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin.
Fibrosarcoma
Localization of urokinase to focal adhesions by human fibrosarcoma cells synthesizing recombinant vitronectin.
Fibrosarcoma
New-generation multicistronic expression platform: pTRIDENT vectors containing size-optimized IRES elements enable homing endonuclease-based cistron swapping into lentiviral expression vectors.
Fibrosarcoma
Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.
Fibrosarcoma
Plasminogen activators in nude mice xenotransplanted with human tumorigenic cells.
Fibrosarcoma
Regulation of urokinase plasminogen activator by epigallocatechin-3-gallate in human fibrosarcoma cells.
Fibrosarcoma
Seahorse-derived peptide suppresses invasive migration of HT1080 fibrosarcoma cells by competing with intracellular ?-enolase for plasminogen binding and inhibiting uPA-mediated activation of plasminogen.
Fibrosarcoma
Secreted proteases. Regulation of their activity and their possible role in metastasis.
Fibrosarcoma
Soluble urokinase receptor from fibrosarcoma HT-1080 cells.
Fibrosarcoma
Supermacroporous cryogel matrix for integrated protein isolation. Immobilized metal affinity chromatographic purification of urokinase from cell culture broth of a human kidney cell line.
Fibrosarcoma
Suppression of urokinase-type plasminogen activator mRNA levels in human fibrosarcoma cells and synovial fibroblasts by anti-inflammatory glucocorticoids.
Fibrosarcoma
The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.
Fibrosarcoma
Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Fibrosarcoma
Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines.
Fibrosarcoma
Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells.
Fibrosarcoma
Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components.
Foot Ulcer
The role of soluble urokinase plasminogen activator receptor (suPAR) in the diagnostics of diabetic foot infection.
Fragile X Syndrome
Urokinase plasminogen activator mediates changes in human astrocytes modeling fragile X syndrome.
Gallbladder Neoplasms
A MEK inhibitor (U0126) markedly inhibits direct liver invasion of orthotopically inoculated human gallbladder cancer cells in nude mice.
Gallbladder Neoplasms
Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid.
Gallbladder Neoplasms
Relationship between urokinase-type plasminogen activator receptor and vascular endothelial growth factor expression and metastasis of gallbladder cancer.
Gastrointestinal Hemorrhage
Recurrent gastrointestinal bleeding: use of thrombolysis with anticoagulation in diagnosis.
Gastrointestinal Neoplasms
Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers.
Gastrointestinal Neoplasms
Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers.
gelatinase b deficiency
Plasmin and matrix metalloproteinases in vascular remodeling.
Giant Cell Tumor of Bone
[Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone]
Giant Cell Tumors
Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
Giant Cell Tumors
[Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone]
Gingivitis
Salivary levels of MPO, MMP-8 and TIMP-1 are associated with gingival inflammation response patterns during experimental gingivitis.
Glaucoma
Intracameral urokinase for dissolution of fibrin or blood clots after glaucoma surgery.
Glaucoma
Tissue and urokinase plasminogen activators instigate the degeneration of retinal ganglion cells in a mouse model of glaucoma.
Glaucoma, Neovascular
Two cases of frosted branch angiitis with central retinal vein occlusion.
Glaucoma, Neovascular
[Two cases of frosted retinal angiitis with central retinal vein occlusion]
Glioblastoma
A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Glioblastoma
A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
Glioblastoma
A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
Glioblastoma
A novel role for the urokinase-type plasminogen activator receptor in apoptosis of malignant gliomas.
Glioblastoma
A nutrient mixture inhibits glioblastoma xenograft U-87 MG growth in male nude mice.
Glioblastoma
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin.
Glioblastoma
A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.
Glioblastoma
Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro.
Glioblastoma
Cisplatin resistant glioblastoma cells may have increased concentration of urokinase plasminogen activator and plasminogen activator inhibitor type 1.
Glioblastoma
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Glioblastoma
Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells.
Glioblastoma
Downregulation of urokinase-type plasminogen activator receptor (uPAR) induces caspase-mediated cell death in human glioblastoma cells.
Glioblastoma
Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B.
Glioblastoma
Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
Glioblastoma
Epidermal growth factor receptor-mediated regulation of urokinase plasminogen activator expression and glioblastoma invasion via C-SRC/MAPK/AP-1 signaling pathways.
Glioblastoma
Expression and cellular localization of low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor in human glioblastoma in vivo.
Glioblastoma
Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
Glioblastoma
Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13.
Glioblastoma
Improved positron emission tomography imaging of glioblastoma cancer using novel
Glioblastoma
Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors.
Glioblastoma
Intraventricular urokinase to treat a blocked ventriculoperitoneal shunt in a glioblastoma patient with leptomeningeal spread.
Glioblastoma
Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody.
Glioblastoma
Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Glioblastoma
Protein Kinase C-{alpha} Mediated Regulation of Low-Density Lipoprotein Receptor Related Protein and Urokinase Increases Astrocytoma Invasion.
Glioblastoma
Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.
Glioblastoma
Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines.
Glioblastoma
Sense p16 and antisense uPAR bicistronic construct inhibits angiogenesis and induces glioma cell death.
Glioblastoma
Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
Glioblastoma
Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.
Glioblastoma
Sphingosine-1-phosphate regulates glioblastoma cell invasiveness through the urokinase plasminogen activator system and CCN1/Cyr61.
Glioblastoma
Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells.
Glioblastoma
Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth.
Glioblastoma
Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.
Glioblastoma
Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.
Glioblastoma
The role of proteolysis in tumor invasiveness in glioblastoma and metastatic brain tumors.
Glioblastoma
The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres.
Glioblastoma
Transforming growth factor-beta 1 is a potent inducer of plasminogen activator inhibitor type-1 in human glioblastoma and carcinoma cell lines.
Glioblastoma
Tristetraprolin Inhibits the Growth of Human Glioma Cells through Downregulation of Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor mRNAs.
Glioblastoma
Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion.
Glioblastoma
Urokinase induces receptor mediated brain tumor cell migration and invasion.
Glioblastoma
Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells.
Glioblastoma
Urokinase plasminogen activator, uPAR, MMP-2, and MMP-9 in the C6-glioblastoma rat model.
Glioblastoma
Urokinase-targeted fusion by oncolytic Sendai virus eradicates orthotopic glioblastomas by pronounced synergy with interferon-? gene.
Glioblastoma
Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
Glioblastoma
[A plasminogen regulation system in brain tumors].
Glioma
A novel role for the urokinase-type plasminogen activator receptor in apoptosis of malignant gliomas.
Glioma
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin.
Glioma
Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth.
Glioma
Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas.
Glioma
Altered in vitro spreading and cytoskeletal organization in human glioma cells by downregulation of urokinase receptor.
Glioma
Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors.
Glioma
Co-depletion of cathepsin B and uPAR induces G0/G1 arrest in glioma via FOXO3a mediated p27 upregulation.
Glioma
Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate.
Glioma
Down-regulation of integrin alpha(v)beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes.
Glioma
Downregulation of uPARAP mediates cytoskeletal rearrangements and decreases invasion and migration properties in glioma cells.
Glioma
Ebselen abrogates TNFalpha induced pro-inflammatory response in glioblastoma.
Glioma
Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Glioma
Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Glioma
Epigallocatechin-3-gallate exhibits anti-tumor effect by perturbing redox homeostasis, modulating the release of pro-inflammatory mediators and decreasing the invasiveness of glioblastoma cells.
Glioma
Ets-1 transcription factor-mediated urokinase-type plasminogen activator expression and invasion in glioma cells stimulated by serum and basic fibroblast growth factors.
Glioma
Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade.
Glioma
Expression and localisation of urokinase-type plasminogen activator gene in gliomas.
Glioma
Expression and localization of urokinase-type plasminogen activator receptor in human gliomas.
Glioma
Expression and significance of urokinase type plasminogen activator gene in human brain gliomas.
Glioma
Expression and significance of urokinase-type plasminogen activator in human gliomas.
Glioma
Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis.
Glioma
Expression of dominant-negative form of Ets-1 suppresses fibronectin-stimulated cell adhesion and migration through down-regulation of integrin alpha5 expression in U251 glioma cell line.
Glioma
Expression of the constitutively activated RelA/NF-kappaB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion.
Glioma
Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression.
Glioma
Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
Glioma
High-molecular-weight serum protein complexes differentially promote cell migration and the focal adhesion localization of the urokinase receptor in human glioma cells.
Glioma
In vitro inhibition of human malignant brain tumour cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies.
Glioma
Increased expression of low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas.
Glioma
Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors.
Glioma
Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells.
Glioma
Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.
Glioma
Invasion of brain tissue by primary glioma: evidence for the involvement of urokinase-type plasminogen activator as an activator of type IV collagenase.
Glioma
Involvement of nitric oxide synthase in matrix metalloproteinase-9- and/or urokinase plasminogen activator receptor-mediated glioma cell migration.
Glioma
Killing Glioma 'Stem-like' Cells via Drug-Induced Relocation of Endosomal Urokinase Proteins.
Glioma
Mechanism of p27 upregulation induced by downregulation of cathepsin B and uPAR in glioma.
Glioma
Mis-trafficking of endosomal urokinase proteins triggers drug-induced glioma nonapoptotic cell death.
Glioma
Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells.
Glioma
Molecular changes during the genesis of human gliomas.
Glioma
Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Glioma
Prognostic role of urokinase-type plasminogen activator in human gliomas.
Glioma
Protease nexin 1 is expressed in the human placenta.
Glioma
Protease Nexin-1 affects the migration and invasion of C6 glioma cells through the regulation of urokinase Plasminogen Activator and Matrix Metalloproteinase-9/2.
Glioma
Regulation of DNA repair mechanism in human glioma xenograft cells both in vitro and in vivo in nude mice.
Glioma
Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines.
Glioma
Retraction: Down-regulation of integrin ?v?3 expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes.
Glioma
Retraction: Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.
Glioma
RNA interference-mediated simultaneous down-regulation of urokinase-type plasminogen activator receptor and cathepsin B induces caspase-8-mediated apoptosis in SNB19 human glioma cells.
Glioma
Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo.
Glioma
Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells.
Glioma
Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism.
Glioma
Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.
Glioma
Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences.
Glioma
Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth.
Glioma
Targeting of c-Met and Urokinase Expressing Human Glioma Cell Lines by Retrovirus Vector Displaying Single-Chain Variable Fragment Antibody.
Glioma
The mechanical and pharmacological regulation of glioblastoma cell migration in 3D matrices.
Glioma
The recombinant kringle domain of urokinase plasminogen activator inhibits in vivo malignant glioma growth.
Glioma
Tristetraprolin Inhibits the Growth of Human Glioma Cells through Downregulation of Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor mRNAs.
Glioma
Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor.
Glioma
uPAR and cathepsin B downregulation induces apoptosis by targeting calcineurin A to BAD via Bcl-2 in glioma.
Glioma
Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity.
Glioma
Use of intrathecal urokinase in repeated shunt and external ventricular drain blockage from high CSF protein due to an optic pathway glioma.
Glomerulonephritis
Clinical effect of urokinase on chronic glomerulonephritis (group study).
Glomerulonephritis
Clinical significance of serum and urinary soluble urokinase receptor (suPAR) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese.
Glomerulonephritis
Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.
Glomerulonephritis
Induction of urokinase receptor expression in nephrotoxic nephritis.
Glomerulonephritis
Levels of fibrinopeptide A (FPA) and fibrinopeptide B beta 15-42 (FPB beta) in urine and plasma after urokinase administration in patients with chronic glomerulonephritis.
Glomerulonephritis
mRNA expression of urokinase and plasminogen activator inhibitor-1 in human crescentic glomerulonephritis.
Glomerulonephritis
Plasminogen activator in nephrotic syndrome.
Glomerulonephritis
Prevention and treatment of experimental glomerulonephritis in mice by urokinase.
Glomerulonephritis
Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis.
Glomerulonephritis
Urinary UK, t-PA and urinary trypsin inhibitor in health and glomerular diseases.
Glomerulonephritis
Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis.
Glomerulonephritis
Vitamin D and Glomerulonephritis.
Glomerulonephritis
[A role of fibrin deposits in the development of rabbit Masugi nephritis and effect of urokinase on the experimental glomerulonephritis (author's transl)]
Glomerulonephritis
[A study on the urokinase treatment in patients with glomerulonephritis and nephrotic syndrome]
Glomerulonephritis
[Effect of urokinase therapy in patients with glomerulonephritis and nephrotic syndrome. Trial at multiple institutes in Japan]
Glomerulonephritis
[Fibrinolytic activity of the urine during chronic glomerulonephritis and amyloidosis]
Glomerulonephritis
[The levels of fibrinopeptide A and fibrinopeptide B beta in the urine from patients with chronic glomerulonephritis during urokinase therapy]
Glomerulonephritis
[Treatment of rapid progressive glomerulonephritis (RPGN) with pulse methylprednisolone (MP) and urokinase (UK): a renal rebiopsy study]
Glomerulonephritis
[Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis]
Glomerulonephritis, IGA
Defibrination of intraglomerular fibrin deposits by urokinase in patients with IgA nephropathy.
Glomerulonephritis, IGA
Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.
Glomerulonephritis, IGA
Effects of co-administration of urokinase and benazepril on severe IgA nephropathy.
Glomerulonephritis, IGA
In IgA Nephropathy, Glomerulosclerosis Is Associated with Increased Urinary CD80 Excretion and Urokinase-Type Plasminogen Activator Receptor-Positive Podocyturia.
Glomerulonephritis, IGA
Long-term effect of urokinase therapy in IgA nephropathy.
Glomerulonephritis, IGA
Pathological improvement of IgA nephropathy and Henoch-Schönlein purpura nephritis with urokinase therapy.
Glomerulonephritis, IGA
Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy.
Glomerulonephritis, IGA
Significant correlation between the immunofluorescence of alpha 2-plasmin inhibitor in glomeruli and the effects of urokinase therapy in patients with IgA nephropathy.
Glomerulonephritis, IGA
Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.
Glomerulonephritis, IGA
Urokinase-type plasminogen activator receptor in IgA nephropathy.
Glomerulonephritis, IGA
Vitamin D and Glomerulonephritis.
Glomerulonephritis, Membranous
Analysis of plasmin binding and urokinase activation of plasminogen bound to the Heymann nephritis autoantigen, gp330.
Glomerulonephritis, Membranous
Effect of the nephritogenic autoantibody of Heymann's nephritis on plasminogen-binding to gp330 and activation by urokinase.
Glomerulonephritis, Membranous
Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.
Glomerulonephritis, Membranous
Successful thrombolytic therapy in two patients with renal vein thrombosis.
Glomerulonephritis, Membranous
Urokinase gene 3'-UTR T/C polymorphism is associated with malignancy and ESRD in idiopathic membranous nephropathy.
Glomerulonephritis, Membranous
[A case of renal vein thrombosis and pulmonary embolism associated with diffuse membranous glomerulonephritis: the usefulness of low-molecular-weight heparin and urokinase therapy]
Glomerulosclerosis, Focal Segmental
1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria.
Glomerulosclerosis, Focal Segmental
A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease.
Glomerulosclerosis, Focal Segmental
Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria.
Glomerulosclerosis, Focal Segmental
Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?
Glomerulosclerosis, Focal Segmental
Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.
Glomerulosclerosis, Focal Segmental
CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
Glomerulosclerosis, Focal Segmental
Circulating mediators of focal segmental glomerulosclerosis: soluble urokinase plasminogen activator receptor in context.
Glomerulosclerosis, Focal Segmental
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
Glomerulosclerosis, Focal Segmental
Clinical significance of serum and urinary soluble urokinase receptor (suPAR) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese.
Glomerulosclerosis, Focal Segmental
Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.
Glomerulosclerosis, Focal Segmental
Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
Glomerulosclerosis, Focal Segmental
Elevated soluble urokinase receptors in focal segmental glomerulosclerosis: a role for IL-2?
Glomerulosclerosis, Focal Segmental
Erratum to: Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Glomerulosclerosis, Focal Segmental
Focal Segmental Glomerulosclerosis Recurrence: Soluble Urokinase Receptor Left Out?
Glomerulosclerosis, Focal Segmental
Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.
Glomerulosclerosis, Focal Segmental
Further Evidence that the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
Glomerulosclerosis, Focal Segmental
Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
Glomerulosclerosis, Focal Segmental
Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis.
Glomerulosclerosis, Focal Segmental
Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
Glomerulosclerosis, Focal Segmental
Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.
Glomerulosclerosis, Focal Segmental
Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.
Glomerulosclerosis, Focal Segmental
Protein A immunoadsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis.
Glomerulosclerosis, Focal Segmental
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte ?3-integrin Activation.
Glomerulosclerosis, Focal Segmental
Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis.
Glomerulosclerosis, Focal Segmental
Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome.
Glomerulosclerosis, Focal Segmental
Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.
Glomerulosclerosis, Focal Segmental
Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Glomerulosclerosis, Focal Segmental
Soluble Urokinase Receptor and Chronic Kidney Disease.
Glomerulosclerosis, Focal Segmental
Soluble urokinase receptor and focal segmental glomerulosclerosis.
Glomerulosclerosis, Focal Segmental
Soluble urokinase receptor in a toddler with focal segmental glomerulosclerosis.
Glomerulosclerosis, Focal Segmental
Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.
Glomerulosclerosis, Focal Segmental
Soluble Urokinase Receptor Levels in Secondary Focal Segmental Glomerulosclerosis.
Glomerulosclerosis, Focal Segmental
Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
Glomerulosclerosis, Focal Segmental
The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury.
Glomerulosclerosis, Focal Segmental
The clinical pattern of nephrotic syndrome in children has no effect on the concentration of soluble urokinase receptor (suPAR) in serum and urine.
Glomerulosclerosis, Focal Segmental
The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.
Glomerulosclerosis, Focal Segmental
uPAR isoform 2 forms a dimer and induces severe kidney disease in mice.
Glomerulosclerosis, Focal Segmental
Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
Glomerulosclerosis, Focal Segmental
Urine But Not Serum Soluble Urokinase Receptor (suPAR) May Identify Cases of Recurrent FSGS in Kidney Transplant Candidates.
Glomerulosclerosis, Focal Segmental
[Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome].
Glomerulosclerosis, Focal Segmental
[Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].
Granuloma
Detection of granuloma-associated plasminogen activator in experimental murine schistosomiasis.
Granuloma
Influence of hypercholesterolemia and cholesterol accumulation on rabbit carrageenan granuloma macrophage activation.
Granuloma
The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study.
Gray Platelet Syndrome
Advances in our understanding of the molecular basis of disorders of platelet function.
Guillain-Barre Syndrome
Role of the urokinase plasminogen activator system in patients with bacterial meningitis.
Hamartoma
[Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]
Hantavirus Infections
Plasma levels of soluble urokinase-type plasminogen activator receptor associate with the clinical severity of acute puumala hantavirus infection.
Hantavirus Infections
Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection.
Head and Neck Neoplasms
Invasion and metastasis.
Head and Neck Neoplasms
Overexpression of EMMPRIN Isoform 2 Is Associated with Head and Neck Cancer Metastasis.
Head and Neck Neoplasms
Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.
Hearing Loss, Sudden
[Observation on large doses of urokinase in treatment of sudden deafness]
Heart Arrest
Post-mortem administration of urokinase in canine lung transplantation from non-heart-beating donors.
Heart Arrest
[Effect of urokinase on cerebral perfusion in rabbits after cardiopulmonary resuscitation].
Heart Block
Binding of anti-SSA antibodies to apoptotic fetal cardiocytes stimulates urokinase plasminogen activator (uPA)/uPA receptor-dependent activation of TGF-? and potentiates fibrosis.
Heart Block
Role of the urokinase plasminogen activator receptor in mediating impaired efferocytosis of anti-SSA/Ro-bound apoptotic cardiocytes: Implications in the pathogenesis of congenital heart block.
Heart Defects, Congenital
Late complication of classic Fontan operation: giant right atrial thrombus and massive pulmonary thromboembolism.
Heart Diseases
Lysis of left ventricular thrombus with urokinase in a patient with alcohol heart disease.
Heart Diseases
Plasma soluble urokinase plasminogen activator receptor (suPAR) level is associated with myocardial impairment assessed with advanced echocardiography in Type 1 Diabetes Patients with normal ejection fraction and without known heart disease or end stage renal disease.
Heart Diseases
Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease.
Heart Diseases
[Indications for the intra-arterial infusion of urokinase in the treatment of acute intestinal ischemia in patients with heart disease]
Heart Failure
Abnormalities of pathways of fibrin turnover in the human pleural space.
Heart Failure
Circulating proteins as predictors of incident heart failure in the elderly.
Heart Failure
COVID-19 and pneumonia: a role for the uPA/uPAR system.
Heart Failure
Effect of vasoconstrictor coupling factor 6 on gene expression profile in human vascular endothelial cells: enhanced release of asymmetric dimethylarginine.
Heart Failure
ERK1/2 mediates the lipopolysaccharide-induced upregulation of FGF-2, uPA, MMP-2, MMP-9 and cellular migration in cardiac fibroblasts.
Heart Failure
Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation.
Heart Failure
Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells.
Heart Failure
Long-term outcome of patients with ST-segment elevation myocardial infarction treated with low-dose intracoronary thrombolysis during primary percutaneous coronary intervention: the 5-year results of the DISSOLUTION Trial.
Heart Failure
Plasmin and matrix metalloproteinases in vascular remodeling.
Heart Failure
Selective use of the intensive care unit after nonaortic arterial surgery.
Heart Failure
Serine proteases and cardiac function.
Heart Failure
Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure.
Heart Failure
Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure.
Heart Failure
Soluble urokinase-type plasminogen activator receptor strongly predicts global mortality in acute heart failure patients: insight from the STADE-HF registry.
Heart Failure
Thrombolytic therapy in fulminant pulmonary thromboembolism.
Heart Failure
[Conservative therapeutic approaches in terminal coronary heart disease. Chronic intermittent urokinase therapy]
Heart Failure
[Treatment by urokinase of myocardial infarction and threatened infarction. Randomised study of 120 cases]
Heart Rupture
Plasmin and matrix metalloproteinases in vascular remodeling.
Heart Rupture
Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes.
HELLP Syndrome
Placental expression of proteases and their inhibitors in patients with HELLP syndrome.
Hemangioblastoma
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Hemangioma
Increased secretion of urokinase-type plasminogen activator by human lung microvascular endothelial cells.
Hemangioma
The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study.
Hemangioma, Cavernous
A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470.
Hemangiosarcoma
Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors.
Hemangiosarcoma
The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study.
Hematologic Neoplasms
Circulating Levels of Urokinase-Type Plasminogen Activator Receptor and D-Dimer in Patients With Hematological Malignancies.
Hematologic Neoplasms
Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies.
Hematologic Neoplasms
The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
Hematologic Neoplasms
[The clinical value of soluble urokinase plasminogen activation receptor in febrile neutropenic patients with hematological malignancies after chemotherapy].
Hematoma, Subdural
Surviving the Largest Atypical Parasagittal Meningioma in a 2-Year-Old Child: A Case Report and a Brief Review of the Literature.
Hematoma, Subdural
The Effectiveness of Subdural Drains Using Urokinase after Burr Hole Evacuation of Subacute Subdural Hematoma in Elderly Patients: A Prelimilary Report.
Hematoma, Subdural
Treatment of a recurrent subdural hematoma using urokinase.
Hematoma, Subdural, Acute
Burr Hole Drainage with Urokinase Irrigation for the Treatment of Acute Subdural Hematoma: A Case Report.
Hematoma, Subdural, Acute
Delayed Operation of Acute Subdural Hematoma in Subacute Stage by Trephine Drainage using Urokinase.
Hematoma, Subdural, Chronic
An improved electronic twist-drill craniostomy procedure with post-operative urokinase instillation in treating chronic subdural hematoma.
Hematoma, Subdural, Chronic
Prediction Models for Recurrence of Chronic Subdural Hematoma in Patients Underwent Twist-Drill Craniostomy Combined With Urokinase Instillation.
Hematuria
Abberant sex habits leading to acute limb ischemia and hematuria.
Hematuria
Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.
Hematuria
Treatment of hematuria in a hemophiliac by epsilon aminocaproic acid with concomitant urokinase determination.
Hematuria
Urokinase, a scavenger of affected tubules in acute worsening during macroscopic hematuria of IgA nephropathy?
Hematuria
[Extensive cerebral venous thrombosis resistant to heparin: local fibrinolysis with urokinase]
Hematuria
[Hematuria due to increased urokinase activity. Its successful treatment with p-aminomethylbenzoic acid (PAMBA)]
Hematuria
[On the cure of renal hematuria by an inhibitor of fibrinolytic urokinase.]
Hematuria
[Treatment of hematuria in hemorrhagic diathesis by means of epsilon-aminocaproic acid with concomitant determination of urokinase]
Hemiplegia
Complex tumors of the glomus jugulare: criteria, treatment, and outcome.
Hemiplegia
[Successful treatment of thoracic drainage using urokinase for empyema in an elderly man].
Hemoglobinuria
A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria
Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria
Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity.
Hemoglobinuria
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Hemoglobinuria
Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes.
Hemoglobinuria
The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria
Thrombolytic therapy for inferior vena cava thrombosis in paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria
[Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria]
Hemoglobinuria, Paroxysmal
A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria, Paroxysmal
Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria, Paroxysmal
Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity.
Hemoglobinuria, Paroxysmal
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Hemoglobinuria, Paroxysmal
Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes.
Hemoglobinuria, Paroxysmal
The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria, Paroxysmal
Thrombolytic therapy for inferior vena cava thrombosis in paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria, Paroxysmal
[Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria]
Hemolytic-Uremic Syndrome
Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Endarterial urokinase in childhood hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
[Treatment of childhood hemolytic-uremic syndrome with urokinase. Cooperative controlled trial]
Hemophilia A
Platelet-delivered therapeutics.
Hemorrhagic Disorders
Superior mesenteric venous thrombosis treated by direct aspiration thrombectomy.
Hemorrhagic Disorders
[Treatment of hematuria in hemorrhagic diathesis by means of epsilon-aminocaproic acid with concomitant determination of urokinase]
Hemorrhagic Fever with Renal Syndrome
[Clinical significance of urokinase and anticoagulant activity of the urine in patients suffering from hemorrhagic fever with renal syndrome]
Hemorrhagic Fever, Crimean
The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever.
Hemothorax
Effectiveness of Delayed Intrapleural Alteplase Instillation for Infected Residual Traumatic Hemothorax. Case Report.
Hemothorax
Intrapleural Fibrinolytic Therapy for Residual Coagulated Hemothorax After Lung Surgery.
Hemothorax
Life-threatening hemothorax in a child following intrapleural administration of urokinase.
Hemothorax
Urokinase application for hemothorax in pulmonary mucormycosis.
Hepatic Encephalopathy
[Clinical application and efficacy of TIPS combined with AngioJet mechanical thrombectomy for liver cirrhosis with extensive portal vein thrombosis].
Hepatitis
A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.
Hepatitis
Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure.
Hepatitis
Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Hepatitis
Serine proteases of the fibrinolysis pathway are not involved in lethal hepatitis and fibrinogen breakdown induced by tumor necrosis factor.
Hepatitis B
Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes.
Hepatitis B
Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes.
Hepatitis B
Hepatitis B virus inhibits liver regeneration via epigenetic regulation of urokinase-type plasminogen activator.
Hepatitis B
Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA.
Hepatitis B
Over-expression of uPA increases risk of liver injury in pAAV-HBV transfected mice.
Hepatitis B
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.
Hepatitis B
Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology.
Hepatitis B, Chronic
Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Hepatitis B, Chronic
Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.
Hepatitis B, Chronic
Serum soluble urokinase-type plasminogen activator receptor and interferon-?-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B.
Hepatitis B, Chronic
[Detection of plasma urokinase-type plasminogen activator and its receptor in acute or chronic hepatitis B patients and its clinical significance.]
Hepatitis B, Chronic
[The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B]
Hepatitis C
Formulated Minimal-Length Synthetic Small Hairpin RNAs are Potent Inhibitors of Hepatitis C Virus in Mice with Humanized Livers.
Hepatitis C
Fragment-based drug discovery: opportunities for organic synthesis.
Hepatitis C
Practical Evaluation of a Mouse with Chimeric Human Liver Model for Hepatitis C Virus Infection Using an NS3-4A Protease Inhibitor.
Hepatitis C
Soluble urokinase plasminogen activator receptor in chronic hepatitis due to hepatitis C virus.
Hepatitis C
Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection.
Hepatitis C
Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Hepatitis C
Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology.
Hepatitis C, Chronic
Plasma and hepatic tissue levels of thrombomodulin, tissue factor, NFkappaB and nitric oxide in responders and nonresponders to IFNalpha therapy.
Hepatitis, Chronic
Soluble urokinase plasminogen activator receptor in chronic hepatitis due to hepatitis C virus.
Herpes Simplex
Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
Histiocytoma, Malignant Fibrous
Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
Histiocytosis, Langerhans-Cell
Cutaneous infiltrates of histiocytosis X contain plasminogen activator-bearing epidermotropic dendritic cells different from Langerhans cells.
HIV Infections
Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
Hodgkin Disease
Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and ?1 Integrin in Patients with Hodgkin's Lymphoma.
Hodgkin Disease
High-dose urokinase therapy for the lysis of a central venous catheter-related thrombus in a young patient with Hodgkin's disease.
Hodgkin Disease
[Value of the study of the activity of gamma-glutamyltransferase and urokinase for diagnosis of liver lesions in Hodgkin's disease]
Hyaline Membrane Disease
[Treatment of hyaline membrane disease with the plasminogen urokinase combination]
Hydatidiform Mole
Localization and significance of urokinase plasminogen activator and its receptor in placental tissue from intrauterine, ectopic and molar pregnancies.
Hydrocephalus
A study on the efficacy of intraventricular urokinase in the treatment of intraventricular haemorrhage.
Hydrocephalus
Citrobacter koseri meningitis: A neurosurgical condition?
Hydrocephalus
Efficacy and safety of intraventricular fibrinolytic therapy for post-intraventricular hemorrhagic hydrocephalus in extreme low birth weight infants: a preliminary clinical study.
Hydrocephalus
Heron-mouth neuroendoscopic sheath-assisted neuroendoscopy plays critical roles in treating hypertensive intraventricular hemorrhage.
Hydrocephalus
Intrathecal urokinase as a treatment for intraventricular hemorrhage in the preterm infant.
Hydrocephalus
Intraventricular administration of urokinase as a novel therapeutic approach for communicating hydrocephalus.
Hydrocephalus
Intraventricular urokinase for the treatment of posthemorrhagic hydrocephalus.
Hydrocephalus
Intraventricular urokinase to treat a blocked ventriculoperitoneal shunt in a glioblastoma patient with leptomeningeal spread.
Hydrocephalus
Lysis of intraventricular blood clot with urokinase in a canine model: Part 3. Effects of intraventricular urokinase on clot lysis and posthemorrhagic hydrocephalus.
Hydrocephalus
Treatment of intraventricular hemorrhage in the premature infant with urokinase. A preliminary report.
Hydrocephalus
Twist drill craniostomy for traumatic acute subdural hematoma in the elderly: case series and literature review.
Hydrocephalus
uPA alleviates kaolin-induced hydrocephalus by promoting the release and activation of hepatocyte growth factor in rats.
Hydrocephalus
Use of urokinase in the treatment of tuberculous meningitis hydrocephalus.
Hydronephrosis
[Renal and tissue fibrinolysis dysfunction in secondary pyelonephritis in children before and after the surgery]
Hypercholesterolemia
Influence of hypercholesterolemia and cholesterol accumulation on rabbit carrageenan granuloma macrophage activation.
Hyperemesis Gravidarum
Soluble urokinase-type plasminogen activator receptor (suPAR) and interleukin-6 levels in hyperemesis gravidarum.
Hyperemia
uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK.
Hyperglycemia
Factors predicting hemorrhagic complications after multimodal reperfusion therapy for acute ischemic stroke.
Hyperglycemia
Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid.
Hyperlipidemias
Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis.
Hypersensitivity
Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase.
Hypersensitivity
Intrapleural Fibrinolytic Therapy for Residual Coagulated Hemothorax After Lung Surgery.
Hypersensitivity
Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion.
Hypersensitivity
Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism.
Hypersensitivity
Streptokinase and urokinase in the treatment of pulmonary thromboemboli; from a national cooperative study.
Hypersensitivity
[An allergic reaction due to i.v. urokinase administration]
Hypersensitivity
[Cardiovascular pharmacology (XIII). The efficacy of different thrombolytic drugs in the treatment of acute myocardial infarct]
Hypersensitivity
[Comparison of clinical efficacy of thrombolytic drugs in patients with acute myocardial infarction]
Hypersensitivity
[Thrombolysis with Urokinase after anaphylaxis caused by streptokinase treatment (author's transl)]
Hypertension
Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Hypertension
Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis.
Hypertension
Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats.
Hypertension
Down-regulation of UBA6 exacerbates brain injury by inhibiting the activation of Notch signaling pathway to promote cerebral cell apoptosis in rat acute cerebral infarction model.
Hypertension
Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura.
Hypertension
Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: possible markers of placental function.
Hypertension
Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion.
Hypertension
Serine proteases and cardiac function.
Hypertension
Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years.
Hypertension
Statistical analysis of visual prognosis following stellate ganglion block treatment on patients with retinal vessel obstruction.
Hypertension
Whole-blood fibrinolytic activity in normal and hypertensive pregnancies and its relation to the placental concentration of urokinase inhibitor.
Hypertension
[Case of cholesterol crystal embolism occurring after treatment of cerebral infarction with urokinase]
Hypertension
[Treatment of great hematoma in brain hemorrhage with multi-point puncture and continuous irrigation-draining]
Hypertension, Portal
[Expression of plasminogen activator system components in the gastric mucosa in portal hypertensive gastropathy].
Hypertension, Pulmonary
Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice.
Hypertension, Pulmonary
Rapid reversal of canine thromboembolic pulmonary hypertension by bolus injection of the novel recombinant plasminogen activator BM 06.022.
Hypertension, Pulmonary
Successful treatment of peripartum massive pulmonary embolism with extracorporeal membrane oxygenation and catheter-directed pulmonary thrombolytic therapy.
Hypertension, Pulmonary
Use of thrombolytic drugs in non-coronary disorders.
Hypertension, Renovascular
Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease.
Hyperthyroidism
Tissue plasminogen activator (PA) and urokinase inhibitor in the tissue of neutral and hyperthyroid goitre.
Hyphema
Treatment of total hyphemas with urokinase.
Hypoalbuminemia
Resolution of protein-losing enteropathy with standard high molecular heparin and urokinase after Fontan repair in a patient with tricuspid atresia.
Hypotension
An autopsy case of vertebrobasilar dolichoectasia under hemodialysis due to autosomal dominant polycystic kidney disease.
Hypotension
Inhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia.
Hypotension
Therapeutic approach to acute pulmonary embolism.
Hypotension
Thrombolytic therapy with urokinase for pulmonary embolism in patients with stable hemodynamics.
Hypotension
Treatment of myocardial infarction: hypotensive effect of different thrombolytic agents.
Hypotension
uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK.
Hypotension
[Comparison of clinical efficacy of thrombolytic drugs in patients with acute myocardial infarction]
Hypoxia, Brain
Inhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia.
Idiopathic Pulmonary Fibrosis
Associations of Serological Biomarkers of sICAM-1, IL-1?, MIF, and su-PAR with 3-Month Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis
Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis
The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF.
Idiopathic Pulmonary Fibrosis
The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy.
IgA Vasculitis
Methylprednisolone pulse plus mizoribine in children with Henoch-Schoenlein purpura nephritis.
Infarction, Middle Cerebral Artery
A Combined Treatment with Taurine and Intra-arterial Thrombolysis in an Embolic Model of Stroke in Rats: Increased Neuroprotective Efficacy and Extended Therapeutic Time Window.
Infarction, Middle Cerebral Artery
Elevation of mRNA levels of tissue-type plasminogen activator and urokinase-type plasminogen activator in hippocampus and cerebral cortex following middle cerebral artery occlusion in rats.
Infarction, Middle Cerebral Artery
Evaluation of local intra-arterial fibrinolytic therapy for acute middle cerebral artery occlusion.
Infarction, Middle Cerebral Artery
Neanthes japonica (Iznka) fibrinolytic enzyme reduced cerebral infarction, cerebral edema and increased antioxidation in rat models of focal cerebral ischemia.
Infarction, Middle Cerebral Artery
Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan.
Infarction, Middle Cerebral Artery
Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion.
Infarction, Middle Cerebral Artery
Successful intra-arterial thrombolysis for acute ischemic stroke in the immediate postpartum period: case report.
Infarction, Middle Cerebral Artery
Tirofiban combined with urokinase selective intra-arterial thrombolysis for the treatment of middle cerebral artery occlusion.
Infarction, Middle Cerebral Artery
[Local therapeutic fibrinolysis in ischemic cerebrovascular insults: initial findings in 6 patients]
Infarction, Middle Cerebral Artery
[New methods of intensive therapy in stroke: hemicraniectomy in patients with complete middle cerebral artery infarction and treatment of intracerebral and intraventricular hemorrhage with urokinase]
Infections
1C.01: SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR AS A PROGNOSTIC MARKER OF ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN A BLACK POPULATION.
Infections
4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia.
Infections
A C to T polymorphism of urokinase plasminogen activator (P141L) is associated with Helicobacter pylori infection.
Infections
A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters.
Infections
A novel orally available small molecule that inhibits hepatitis B virus expression.
Infections
A prospective double-blind randomized trial of urokinase flushes to prevent bacteremia resulting from luminal colonization of subcutaneous central venous catheters.
Infections
A prospective randomized trial of urokinase as an adjuvant in the treatment of proven Hickman catheter sepsis.
Infections
A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages.
Infections
Advances in parenteral nutrition.
Infections
Antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA.
Infections
Application of the Ommaya reservoir in managing ventricular hemorrhage.
Infections
Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice.
Infections
Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas.
Infections
Cerebral amyloid angiopathy-related intracerebral hemorrhage: Feasibility and safety of bedside catheter hematoma evacuation with urokinase.
Infections
Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes.
Infections
Citrobacter koseri meningitis: A neurosurgical condition?
Infections
Clinical value of plasma soluble urokinase-type plasminogen activator receptor levels in term neonates with infection or sepsis: a prospective study.
Infections
Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection.
Infections
Coordinated expression of vascular endothelial growth factor A and urokinase-type plasminogen activator contributes to classical swine fever virus Shimen infection in macrophages.
Infections
Distinct Immune Imprints of Post-Liver Transplantation Hepatitis C Persist Despite Viral Clearance.
Infections
Effect of urokinase on the extracellular virulence properties of Pseudomonas aeruginosa and Burkholderia cepacia.
Infections
Effects of bacteria involved with the pathogenesis of infection-induced urolithiasis on the urokinase and sialidase (neuraminidase) activity.
Infections
Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome.
Infections
EMMPRIN (CD 147) is a central activator of extracellular matrix degradation by Chlamydia pneumoniae-infected monocytes. Implications for plaque rupture.
Infections
Evidence-based criteria for the choice and the clinical use of the most appropriate lock solutions for central venous catheters (excluding dialysis catheters): a GAVeCeLT consensus.
Infections
Exogenous rh-urokinase modifies inflammation and Pseudomonas aeruginosa infection in a rat chronic pulmonary infection model.
Infections
Granulocyte elastase, tumor necrosis factor-alpha and urokinase levels as prognostic markers in severe infection.
Infections
Griffithsin has antiviral activity against hepatitis C virus.
Infections
Helicobacter pylori induces plasminogen activator inhibitor 2 in gastric epithelial cells through nuclear factor-kappaB and RhoA: implications for invasion and apoptosis.
Infections
Helicobacter pylori interactions with plasminogen.
Infections
Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children.
Infections
Heron-mouth neuroendoscopic sheath-assisted neuroendoscopy plays critical roles in treating hypertensive intraventricular hemorrhage.
Infections
Hickman catheter for haemodialysis in paediatric patients.
Infections
High level synthesis and secretion of human urokinase using a late gene promoter of the Autographa californica nuclear polyhedrosis virus.
Infections
High pneumococcal DNA load, procalcitonin and suPAR levels correlate to severe disease development in patients with pneumococcal pneumonia.
Infections
Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure.
Infections
Intraperitoneal urokinase and oral rifampicin for persisting asymptomatic dialysate infection following acute coagulase-negative Staphylococcus peritonitis.
Infections
Intrapleural fibrinolytics combined with image-guided chest tube drainage for pleural infection.
Infections
Intrapleural use of urokinase and DNase in pleural infections managed with repeated thoracentesis: A comparative cohort study.
Infections
Intravenous catheter-related infections.
Infections
Laparoscopic implantation of the Tenckhoff catheter for the treatment of end-stage renal failure and congestive heart failure: experience with the pelvic fixation technique.
Infections
Late vascular occlusion of central lines in pediatric malignancies.
Infections
Levels of Soluble Urokinase Plasminogen Activator Receptor in Pediatric Lower Respiratory Tract Infections.
Infections
Long-term follow-up of upper extremity implanted venous access devices in oncology patients.
Infections
Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomized dose-response trial.
Infections
Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activator.
Infections
Manual Intrapleural Saline Flushing Plus Urokinase: A Potentially Useful Therapy for Complicated Parapneumonic Effusions and Empyemas.
Infections
Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury.
Infections
Osteopontin induces soluble urokinase-type plasminogen activator receptor production and release.
Infections
Plasma soluble urokinase plasminogen activator receptor in children with urinary tract infection.
Infections
Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia.
Infections
Practical Evaluation of a Mouse with Chimeric Human Liver Model for Hepatitis C Virus Infection Using an NS3-4A Protease Inhibitor.
Infections
Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies.
Infections
Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study.
Infections
Prospective randomized comparison of valved versus nonvalved peripherally inserted central vein catheters.
Infections
Pulmonary embolus and Malassezia pulmonary infection related to urokinase therapy.
Infections
Recruitment of Chlamydia pneumoniae-infected macrophages to the carotid artery wall in noninfected, nonatherosclerotic mice.
Infections
Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia.
Infections
Review and update of the use of urokinase in the prevention and management of CVAD-related complications in pediatric oncology patients.
Infections
Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias.
Infections
Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients.
Infections
Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.
Infections
Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection.
Infections
Serum soluble urokinase-type plasminogen activator receptor and interferon-?-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B.
Infections
Single-port laparoscopic insertion of peritoneal dialysis catheters in children.
Infections
Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.
Infections
Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia.
Infections
Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection.
Infections
Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection.
Infections
Soluble urokinase-type plasminogen activator receptor (suPAR) as new biomarker of the prosthetic joint infection: correlation with inflammatory cytokines.
Infections
Soluble urokinase-type plasminogen activator receptor (suPAR) in patients with acute pancreatitis (AP) - Progress in prediction of AP severity.
Infections
Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study.
Infections
Structural determination of group A Streptococcal surface dehydrogenase and characterization of its interaction with urokinase-type plasminogen activator receptor.
Infections
The effect of perirenal puncture and drainage with urokinase treatment of perirenal hematoma complicated by infection: Two cases' report.
Infections
The effect of Plasmodium falciparum infection on expression of monocyte surface molecules.
Infections
The fibrinolytic system in dissemination and matrix protein deposition during a mycobacterium infection.
Infections
The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis.
Infections
The role of serum soluble urokinase-type plasminogen activator receptor in stable chronic obstructive pulmonary disease.
Infections
The role of soluble urokinase plasminogen activator receptor (suPAR) in the diagnostics of diabetic foot infection.
Infections
The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection.
Infections
Thrombolytic therapy for central venous catheter occlusion.
Infections
Thrombolytic therapy in acute stroke.
Infections
Treatment of posthemorrhagic hydrocephalus in the preterm infant with a ventricular access device.
Infections
Treatment of severe intraventricular hemorrhage by intraventricular infusion of urokinase.
Infections
Urokinase enhances the growth of Pseudomonas spp. in vitro under nonshaking (oxygen limited) conditions.
Infections
Urokinase in the treatment of bacteremia and candidemia in patients with right atrial catheters.
Infections
Urokinase plasminogen activator and TGF-beta production in immunosuppressed patients with and without P. Jiroveci infection.
Infections
Urokinase plasminogen activator receptor (uPAR; CD87) expression on monocytic cells and T cells is modulated by HIV-1 infection.
Infections
Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection.
Infections
Urokinase-Type Plasminogen Activator Inhibits Efferocytosis of Neutrophils.
Infections
Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection.
Infections
Urokinase: a treatment for relapsing peritonitis due to coagulase-negative staphylococci.
Infections
Use of fibrinolytic agents to coat wire implants to decrease infection. An animal model.
Infections
Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study.
Infections
Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology.
Infections
Ventriculostomy and Infection: A 4-year-review in a local hospital.
Infections
[Cannulation of the internal jugular vein with 2 silastic catheters. A new method of vascular access for hemodialysis]
Infections
[Central venous access for hemodialysis: use and practice with the child in France]
Infections
[Effect of Zhibai Dihuang Pill on uPA of Uu-infection infertility patients].
Infections
[Use of central venous catheters implanted subcutaneously in children with neoplasms]
Infertility
Could the defects in the endometrial extracellular matrix during the implantation be a cause for impaired fertility?
Infertility
Functionally inactive protein C inhibitor in seminal plasma may be associated with infertility.
Infertility
Human seminal plasma fibrinolytic activity.
Infertility
[Urokinase-type plasminogen activator improves the reproductive function of male rats]
Infertility, Male
Clinical Efficacy of Prodom-Assisted Urokinase in the Treatment of Male Infertility Caused by Impaired Semen Liquefaction.
Infertility, Male
Tissue-specific inhibition of urokinase-type plasminogen activator expression in the testes of mice by inducible lentiviral RNA interference causes male infertility.
Infertility, Male
[Effects of urokinase-type plasminogen activator on chemotactic responses of spermatozoa in vitro]
Inflammatory Bowel Diseases
Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease.
Influenza, Human
Cleavage activation of human-adapted influenza virus subtypes by kallikrein-related peptidases 5 and 12.
Insulin Resistance
Association analyses of porcine SERPINE1 reveal sex-specific effects on muscling, growth, fat accretion and meat quality.
Insulin Resistance
Distribution of C-->T and T-->C polymorphisms of the urokinase-type plasminogen activator gene in children with type 1 diabetes mellitus and insulin resistance.
Insulin Resistance
Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity.
Intracranial Aneurysm
A Less Invasive Strategy for Ruptured Cerebral Aneurysms with Intracerebral Hematomas: Endovascular Coil Embolization Followed by Stereotactic Aspiration of Hematomas Using Urokinase.
Intracranial Aneurysm
Intra-arterial infusion of tirofiban and urokinase for thromboembolic complications during coil embolization of ruptured intracranial aneurysms.
Intracranial Aneurysm
[Intrathecal irrigation with urokinase in ruptured cerebral aneurysm cases. Basic study and clinical application]
Intracranial Embolism
Cerebral embolism associated with left ventricular assist device support and successful therapy with intraarterial urokinase.
Intracranial Embolism
Endovascular treatment of acute embolism of the major cerebral arteries. The value of balloon disruption of the embolus.
Intracranial Embolism
Intravenous thrombolysis for pure pontine infarcts caused by cardiac myxoma: a case report and literature review.
Intracranial Embolism
The thrombolytic effect of lumbrokinase is not as potent as urokinase in a rabbit cerebral embolism model.
Intracranial Hemorrhage, Hypertensive
Clinical study on the early application and ideal dosage of urokinase after surgery for hypertensive intracerebral hemorrhage.
Intracranial Hemorrhages
A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators.
Intracranial Hemorrhages
Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis.
Intracranial Hemorrhages
Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate.
Intracranial Hemorrhages
Free-hand bedside catheter evacuation of cerebellar hemorrhage.
Intracranial Hemorrhages
Initial angiographic appearance of intracranial vascular occlusions in acute stroke as a predictor of outcome of thrombolysis: initial experience.
Intracranial Hemorrhages
Intraarterial therapy for acute ischemic stroke: investigation of prognostic factors.
Intracranial Hemorrhages
Lysis of intraventricular blood clot with urokinase in a canine model: Part 2. In vivo safety study of intraventricular urokinase.
Intracranial Hemorrhages
Outcomes and Treatment Complications of Intravenous Urokinase Thrombolysis in Acute Ischemic Stroke in China.
Intracranial Hemorrhages
Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone--a randomized pilot trial (the PROMPT Study). Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis.
Intracranial Hemorrhages
The beneficial effect of intracarotid urokinase on acute stroke in a baboon model.
Intracranial Hemorrhages
[Effectiveness of urokinase used in combination with batroxobin (DF-521) in rat model of focal cerebral ischemia-reperfusion]
Intracranial Hemorrhages
[Endovascular embolization of cerebral arteriovenous malformation]
Intracranial Hemorrhages
[Individualized endovascular treatment of cerebral venous thrombosis: analysis of 168 patients]
Intracranial Hemorrhages
[Treatment of great hematoma in brain hemorrhage with multi-point puncture and continuous irrigation-draining]
Intracranial Hypertension
Superior sagittal sinus thrombus secondary to occult meningioma: a case report.
Intracranial Thrombosis
Changes of the levels of antithrombin III in patients with cerebrovascular diseases.
Intracranial Thrombosis
Oral urokinase: absorption, mechanisms of fibrinolytic enhancement and clinical effect on cerebral thrombosis.
Intracranial Thrombosis
Variations of alpha 2-plasmin inhibitor, antithrombin III, plasminogen in the serum of patients of cerebral thrombosis infused with urokinase.
Intracranial Thrombosis
[Experimental and clinical studies on oral urokinase and lysyl-plasminogen. Thrombolytic therapy for cerebral thrombosis]
Intracranial Thrombosis
[Thrombolytic therapy using urokinase in cerebral thrombosis (author's transl)]
Ischemic Attack, Transient
Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke.
Ischemic Stroke
A pilot study of a new thrombolytic agent for acute ischemic stroke in taiwan within a five-hour window.
Ischemic Stroke
Carotid endarterectomy and intracranial thrombolysis: simultaneous and staged procedures in ischemic stroke.
Ischemic Stroke
Case presentations of neuroradiologic interventions for acute cerebrovascular disease.
Ischemic Stroke
Clinical, Biochemical and Neuroimaging Parameters after Thrombolytic Therapy Predict Long-Term Stroke Outcome.
Ischemic Stroke
Combination of Polyethylene Glycol-Conjugated Urokinase Nanogels and Urokinase for Acute Ischemic Stroke Therapeutic Implications.
Ischemic Stroke
Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic stroke.
Ischemic Stroke
Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip.
Ischemic Stroke
Effect of one-shot intravenous 0.42 mega unit urokinase therapy in patients with acute ischemic stroke.
Ischemic Stroke
Effectiveness of intravenous r-tPA versus UK for acute ischaemic stroke: a nationwide prospective Chinese registry study.
Ischemic Stroke
Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate.
Ischemic Stroke
Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase.
Ischemic Stroke
Factors and outcomes associated with recanalization timing after thrombolysis.
Ischemic Stroke
Intra-Arterial Adjunctive Medications for Acute Ischemic Stroke During Mechanical Thrombectomy: A Meta-Analysis.
Ischemic Stroke
Intra-arterial adjuvant tirofiban after unsuccessful intra-arterial thrombolysis of acute ischemic stroke: preliminary experience in 16 patients.
Ischemic Stroke
Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke.
Ischemic Stroke
Intra-arterial thrombolysis in acute ischaemic stroke.
Ischemic Stroke
Intra-arterial thrombolysis of a distal internal carotid artery occlusion in an adolescent.
Ischemic Stroke
Intra-arterial urokinase for acute ischemic stroke: factors associated with complications.
Ischemic Stroke
Intra-carotid thrombolytic therapy in acute ischemic stroke of carotid arterial territory.
Ischemic Stroke
Intraarterial recombinant tissue plasminogen activator for ischemic stroke: an accelerating dosing regimen.
Ischemic Stroke
Intraarterial thrombolysis for treatment of acute stroke: experience in 26 patients with long-term follow-up.
Ischemic Stroke
Intraoperative high-dose regional urokinase infusion for cerebrovascular occlusion after carotid endarterectomy.
Ischemic Stroke
Intravenous glycoprotein IIb/IIIa inhibitor (tirofiban) followed by intra-arterial urokinase and mechanical thrombolysis in stroke.
Ischemic Stroke
Ischemic preconditioning as induction of ischemic tolerance after transient ischemic attacks in human brain: its clinical relevance.
Ischemic Stroke
Local intra-arterial thrombolysis in acute ischemic stroke.
Ischemic Stroke
Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan.
Ischemic Stroke
Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study.
Ischemic Stroke
Low-Dose Intra-Arterial Urokinase and Aggressive Mechanical Clot Disruption for Acute Ischemic Stroke after Failure of Intravenous Thrombolysis.
Ischemic Stroke
Low-dose tissue plasminogen activator is as effective as standard tissue plasminogen activator administration for the treatment of acute ischemic stroke.
Ischemic Stroke
Mechanical thrombolysis with adjuvant intraarterial urokinase for treatment of hyperacute ischemic stroke patients.
Ischemic Stroke
Neuroprotection by urokinase plasminogen activator in the hippocampus.
Ischemic Stroke
New grading system for angiographic evaluation of arterial occlusions and recanalization response to intra-arterial thrombolysis in acute ischemic stroke.
Ischemic Stroke
Outcome evaluation of intravenous infusion of urokinase for acute ischemic stroke.
Ischemic Stroke
Outcomes and Treatment Complications of Intravenous Urokinase Thrombolysis in Acute Ischemic Stroke in China.
Ischemic Stroke
Plasminogen activator inhibitor-1 promotes synaptogenesis and protects against A?(1-42)-induced neurotoxicity in primary cultured hippocampal neurons.
Ischemic Stroke
Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke.
Ischemic Stroke
Preliminary Efficacy Report of a Novel Thrombolytic Agent for Acute Ischaemic Stroke within a 5-Hour Window.
Ischemic Stroke
Rationale and design of a phase 3b, prospective, randomized, open label, blinded-endpoint, multicenter trial of the efficacy and safety of urokinase thrombolysis comparing with antiplatelet agents for patients with minor stroke.
Ischemic Stroke
Rescue therapy with local intra-arterial urokinase after poor clinical response with intravenous recombinant tissue plasminogen activator in acute ischaemic stroke.
Ischemic Stroke
Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke.
Ischemic Stroke
Safety and Angiographic Efficacy of Intra-Arterial Fibrinolytics as Adjunct to Mechanical Thrombectomy: Results from the INFINITY Registry.
Ischemic Stroke
Safety of High Doses of Urokinase and Reteplase for Acute Ischemic Stroke.
Ischemic Stroke
Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke.
Ischemic Stroke
Simple microwire and microcatheter mechanical thrombolysis with adjuvant intraarterial urokinase for treatment of hyperacute ischemic stroke patients.
Ischemic Stroke
Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
Ischemic Stroke
Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA.
Ischemic Stroke
Suppression of PKC-? attenuates TNF-?-evoked cerebral barrier breakdown via regulations of MMP-2 and plasminogen-plasmin system.
Ischemic Stroke
Symptomatic intracranial haemorrhage after intra-arterial thrombolysis in acute ischaemic stroke: assessment of 294 patients treated with urokinase.
Ischemic Stroke
The protective effect of polyethylene glycol-conjugated urokinase nanogels in rat models of ischemic stroke when administrated outside the usual time window.
Ischemic Stroke
Transgenic chickens expressing human urokinase-type plasminogen activator.
Ischemic Stroke
Urokinase Plasminogen Activator: A Potential Thrombolytic Agent for Ischaemic Stroke.
Ischemic Stroke
Urokinase-type plasminogen activator promotes dendritic spine recovery and improves neurological outcome following ischemic stroke.
Ischemic Stroke
Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke.
Ischemic Stroke
[Experimental thrombolysis of thromboembolisms in the middle cerebral artery circulatory area]
Jaw Cysts
Urokinase and its receptor in follicular and inflammatory cysts of the jaws.
Joint Diseases
Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis.
Joint Diseases
Significance of serine proteinase and matrix metalloproteinase systems in the destruction of human articular cartilage.
Joint Diseases
The urokinase-type plasminogen activator system and inflammatory joint diseases.
Joint Diseases
Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells.
Kallmann Syndrome
Cross-talk of anosmin-1, the protein implicated in X-linked Kallmann's syndrome, with heparan sulphate and urokinase-type plasminogen activator.
Keloid
Expression of urokinase-type plasminogen activator and its receptor in keloids.
Keloid
Increased plasminogen activator inhibitor-1 in keloid fibroblasts may account for their elevated collagen accumulation in fibrin gel cultures.
Keloid
Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts.
Keratitis, Herpetic
Analysis of fibronectin, plasminogen activators and plasminogen in tear fluid as markers of corneal damage and repair.
Kidney Calculi
Association of urokinase gene 3'-UTR polymorphism with calcium oxalate nephrolithiasis.
Kidney Calculi
[Calcium kidney stones. Diagnostic and preventive prospects]
Kidney Cortex Necrosis
Local infusion of urokinase and heparin into renal arteries in impending renal cortical necrosis.
Kidney Diseases
Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.
Kidney Diseases
Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children.
Kidney Diseases
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction.
Kidney Diseases
Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients.
Kidney Diseases
Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels.
Kidney Diseases
Non-immune cell-derived ICOS ligand functions as a renoprotective ?v?3 integrin-selective antagonist.
Kidney Diseases
RAGE and ?V?3-integrin are essential for suPAR signaling in podocytes.
Kidney Diseases
Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography.
Kidney Diseases
Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit.
Kidney Diseases
Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.
Kidney Diseases
Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.
Kidney Diseases
Soluble Urokinase Receptor and Acute Kidney Injury.
Kidney Diseases
Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.
Kidney Diseases
Successful therapy with tonsillectomy for severe ISKDC grade VI Henoch-Schönlein purpura nephritis and persistent nephrotic syndrome.
Kidney Diseases
The Associations of Plasma Biomarkers of Inflammation With Histopathologic Lesions, Kidney Disease Progression, and Mortality-The Boston Kidney Biopsy Cohort Study.
Kidney Diseases
The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis.
Kidney Diseases
Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
Kidney Diseases
[Studies on urokinase excretion in kidney diseases]
Kidney Diseases
[Urokinase activity and fibrinolysis in kidney diseases]
Kidney Diseases
[Urokinase excretion and fibrinolysis in infectious kidney diseases]
Kidney Diseases, Cystic
The urine urokinase concentration in end stage renal disease with acquired renal cyst.
Kidney Failure, Chronic
Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients.
Kidney Failure, Chronic
Coagulation, fibrinolysis and fibrinolysis inhibitors in haemodialysis patients: contribution of arteriovenous fistula.
Kidney Failure, Chronic
Fibrinolytic activity in end-stage renal disease.
Kidney Failure, Chronic
Plasma soluble urokinase plasminogen activator receptor (suPAR) level is associated with myocardial impairment assessed with advanced echocardiography in Type 1 Diabetes Patients with normal ejection fraction and without known heart disease or end stage renal disease.
Kidney Failure, Chronic
Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.
Kidney Failure, Chronic
Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.
Kidney Failure, Chronic
The urine urokinase concentration in end stage renal disease with acquired renal cyst.
Kidney Failure, Chronic
Urokinase gene 3'-UTR T/C polymorphism is associated with malignancy and ESRD in idiopathic membranous nephropathy.
Kidney Failure, Chronic
[Case of cholesterol crystal embolism occurring after treatment of cerebral infarction with urokinase]
Kidney Neoplasms
Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Kidney Neoplasms
Fibrinolysis-inhibitory activity of cultured human cancer cell lines.
Kidney Neoplasms
Immunological analysis of plasminogen activators from cultured human cancer cells.
Laryngeal Neoplasms
[Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms]
Leg Ulcer
Differential effects of acute and chronic wound fluids on urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and tissue-type plasminogen activator in cultured human keratinocytes and fibroblasts.
Leg Ulcer
Expression of tissue-type and urokinase-type plasminogen activator activities in chronic venous leg ulcers.
Leg Ulcer
Plasminogen activators, venous leg ulcers and reepithelialization.
Leg Ulcer
Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing.
Leg Ulcer
Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers.
Leg Ulcer
[Bier's occlusion. An unjustly neglected therapeutic possibility in resistant tissue defects of the extremities]
Leg Ulcer
[Retrograde intravenous perfusion: technique and different variants]
Leg Ulcer
[Urokinase in refractory lower leg ulcers: therapy with retrograde intravenous pressure infusion]
Leiomyoma
Insulin-like growth factors II exon 9 and E-cadherin-Pml I but not myeloperoxidase promoter-463, urokinase-ApaL I nor xeroderma pigmentosum polymorphisms are associated with higher susceptibility to leiomyoma.
Leiomyosarcoma
Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
Leukemia
A novel oncogenic role for urokinase receptor in leukemia cells: molecular sponge for oncosuppressor microRNAs.
Leukemia
Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients.
Leukemia
Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
Leukemia
Clinical and molecular features of papillary thyroid cancer in adolescents and young adults.
Leukemia
Design and testing of a packaged microfluidic cell for the multiplexed electrochemical detection of cancer markers.
Leukemia
Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
Leukemia
Expression and functional role of urokinase-type plasminogen activator receptor (UPA-R; CD87) in normal and acute leukemia cells.
Leukemia
Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue.
Leukemia
FDP D-dimer induces the secretion of interleukin-1, urokinase-type plasminogen activator, and plasminogen activator inhibitor-2 in a human promonocytic leukemia cell line.
Leukemia
Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor.
Leukemia
High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia.
Leukemia
Increase in the D-dimer levels during treatment in patients with acute myelogenous leukemia.
Leukemia
Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins ?M?2 and ?V?3.
Leukemia
Leukemia inhibitory factor promote trophoblast invasion via urokinase-type plasminogen activator receptor in preeclampsia.
Leukemia
Osteopontin ablation ameliorates muscular dystrophy by shifting macrophages to a pro-regenerative phenotype.
Leukemia
Plasma urokinase-type plasminogen activator in patients with leukemias.
Leukemia
Plasminogen activator and its enhancement in differentiating mouse Friend erythroleukemia cells.
Leukemia
Plasminogen activator inhibitor-2 in patients with monocytic leukemia.
Leukemia
Plasminogen activators and their inhibitors in leukemic cell homogenates.
Leukemia
Production of an active urokinase by leukemia cells: a novel distinction from cell lines of solid tumors.
Leukemia
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Leukemia
Regulation and secretion of plasminogen activators and their inhibitors in a human leukemic cell line (K562).
Leukemia
Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia.
Leukemia
Stimulated production of urokinase and plasminogen activator inhibitor-2 by the human promyelocytic leukemia cell line HL-60.
Leukemia
Studies on the changes of uPA system in a co-culture model of bone marrow stromal cells-leukemia cells.
Leukemia
Urinary trypsin inhibitor efficiently inhibits urokinase production in tumor necrosis factor-stimulated cells.
Leukemia
[Establishment of urokinase receptor gene antisense RNA transfer system and its application in leukemia research]
Leukemia
[Therapy of consumption coagulopathy and hyperfibrinolysis with urokinase in a case of acute promyelocytic leukemia]
Leukemia, Monocytic, Acute
Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins ?M?2 and ?V?3.
Leukemia, Myeloid
Transcriptional regulation of urokinase-type plasminogen activator receptor by cyclic AMP in PL-21 human myeloid leukemia cells: comparison with the regulation by phorbol myristate acetate.
Leukemia, Myeloid
Urokinase-type plasminogen-activator (upa), a protease with cytokine-like activity in human hl-60 leukemic-cell line.
Leukemia, Myeloid, Acute
Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients.
Leukemia, Myeloid, Acute
Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
Leukemia, Myeloid, Acute
Flow cytometry evaluation of urokinase-type plasminogen activator receptor (UPA-R) in acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
Leukemia, Myeloid, Acute
High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia.
Leukemia, Myeloid, Acute
Increase in the D-dimer levels during treatment in patients with acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
Leukemia, Myeloid, Acute
Matrix and serine protease expression during leukemic cell differentiation induced by aclacinomycin and all-trans-retinoic acid.
Leukemia, Myeloid, Acute
Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).
Leukemia, Myeloid, Acute
Plasminogen activators and their inhibitors in leukemic cell homogenates.
Leukemia, Myeloid, Acute
Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
Leukemia, Myeloid, Acute
The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
Leukemia, Promyelocytic, Acute
Plasminogen activators and their inhibitors in leukemic cell homogenates.
Leukemia, Promyelocytic, Acute
[Therapy of consumption coagulopathy and hyperfibrinolysis with urokinase in a case of acute promyelocytic leukemia]
Leukocytosis
Role of the urokinase plasminogen activator system in patients with bacterial meningitis.
Leukopenia
The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report.
Lichen Sclerosus et Atrophicus
Do plasminogen activators play a role in lichen sclerosus?
Lipodystrophy
Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls.
Lipodystrophy
Soluble Urokinase Plasminogen Activator Receptor (suPAR) is Associated with Metabolic Changes in HIV-1-Infected Africans: A Prospective Study.
Liver Abscess
Effect of intracavitary injection of urokinase in the experimentally induced early pyogenic liver abscess of the rabbit.
Liver Abscess, Pyogenic
Effect of intracavitary injection of urokinase in the experimentally induced early pyogenic liver abscess of the rabbit.
Liver Cirrhosis
Determination of plasma urokinase-type plasminogen activator antigen in patients with primary liver cancer: characterization as tumor-associated antigen and comparison with alpha-fetoprotein.
Liver Cirrhosis
Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis.
Liver Cirrhosis
Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.
Liver Cirrhosis
Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
Liver Cirrhosis
Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis.
Liver Cirrhosis
Human urokinase-type plasminogen activator gene-modified bone marrow-derived mesenchymal stem cells attenuate liver fibrosis in rats by down-regulating the Wnt signaling pathway.
Liver Cirrhosis
Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis.
Liver Cirrhosis
Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy.
Liver Cirrhosis
Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Liver Cirrhosis
Properties of urokinase type-plasminogen activator found in chest fluid.
Liver Cirrhosis
Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection.
Liver Cirrhosis
Transplantation of urokinase-type plasminogen activator gene-modified bone marrow-derived liver stem cells reduces liver fibrosis in rats.
Liver Cirrhosis
Urokinase antigen in plasma of patients with liver cirrhosis and hepatoma.
Liver Cirrhosis
Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF.
Liver Cirrhosis
[Effects of gene-transfected bone marrow-derived liver stem cell transplantation on accumulation of extracellular matrix in rats with liver fibrosis]
Liver Cirrhosis
[Effects of Qinggan Huoxue Recipe and its separated recipes on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 fibrinolytic system in rats with alcoholic liver fibrosis]
Liver Cirrhosis
[The plasma levels of urokinase plasminogen activator and plasminogen activator inhibitor-1 and the protein expressions of alpha-SMA and MMP-1 and TIMP-1 in patients with different grades of liver fibrosis]
Liver Cirrhosis
[The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B]
Liver Cirrhosis, Alcoholic
Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.
Liver Cirrhosis, Biliary
Improved effects of viral gene delivery of human uPA plus biliodigestive anastomosis induce recovery from experimental biliary cirrhosis.
Liver Cirrhosis, Experimental
Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissue.
Liver Cirrhosis, Experimental
Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF.
Liver Diseases
Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Liver Diseases
Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma.
Liver Diseases
Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.
Liver Diseases
Morphological and microarray analyses of human hepatocytes from xenogeneic host livers.
Liver Diseases
Over-expression of uPA increases risk of liver injury in pAAV-HBV transfected mice.
Liver Diseases
Propagation of Human Hepatocytes in uPA/SCID Mice: Producing Chimeric Mice with Humanized Liver.
Liver Diseases
Serum soluble urokinase plasminogen activator receptor in alcoholics: relation to liver disease severity, fibrogenesis and alcohol use.
Liver Diseases
Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.
Liver Diseases
Soluble Urokinase Receptor and Liver Disease.
Liver Diseases
Tissue-type plasminogen activator deficiency exacerbates cholestatic liver injury in mice.
Liver Diseases
Urokinase antigen in plasma of patients with liver cirrhosis and hepatoma.
Liver Diseases
[Urokinase in liver diseases]
Liver Failure
A fatal case of Behcet's disease.
Liver Failure
Generation of hybrid hepatocytes by cell fusion from monkey embryoid body cells in the injured mouse liver.
Liver Failure
Near completely humanized liver in mice shows human-type metabolic responses to drugs.
Liver Failure, Acute
Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure.
Liver Neoplasms
Determination of plasma urokinase-type plasminogen activator antigen in patients with primary liver cancer: characterization as tumor-associated antigen and comparison with alpha-fetoprotein.
Liver Neoplasms
Plumbagin inhibits invasion and migration of liver cancer HepG2 cells by decreasing productions of matrix metalloproteinase-2 and urokinase- plasminogen activator.
Liver Neoplasms
Some pyrazole and pyrazolo[3,4-d]pyrimidine derivatives: synthesis and anticancer evaluation.
Liver Neoplasms
Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer.
Liver Neoplasms
Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.
Lung Diseases
Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome.
Lung Diseases
Developmental expression of plasminogen activator inhibitor type 1 by human alveolar macrophages. Possible role in lung injury.
Lung Diseases, Interstitial
Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis.
Lung Diseases, Interstitial
Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs.
Lung Injury
A urokinase receptor mRNA binding protein from rabbit lung fibroblasts and mesothelial cells.
Lung Injury
Association between urokinase haplotypes and outcome from infection-associated acute lung injury.
Lung Injury
Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice.
Lung Injury
Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells.
Lung Injury
Induction of Tissue Factor by Urokinase in Lung Epithelial Cells and in the Lungs.
Lung Injury
Involvement of urokinase in cigarette smoke extract-induced epithelial-mesenchymal transition in human small airway epithelial cells.
Lung Injury
p53 and miR-34a Feedback Promotes Lung Epithelial Injury and Pulmonary Fibrosis.
Lung Injury
Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin.
Lung Injury
Regulation of lung injury and fibrosis by p53-mediated changes in urokinase and plasminogen activator inhibitor-1.
Lung Injury
Role of p53-fibrinolytic system cross-talk in the regulation of quartz-induced lung injury.
Lung Injury
Role of the urokinase-fibrinolytic system in epithelial-mesenchymal transition during lung injury.
Lung Injury
The Contribution of the Urokinase Plasminogen Activator and the Urokinase Receptor to Pleural and Parenchymal Lung Injury and Repair: A Narrative Review.
Lung Injury
The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system.
Lung Injury
Urokinase Plasminogen Activator Receptor-Deficient Mice Demonstrate Reduced Hyperoxia-Induced Lung Injury.
Lung Injury
[Experimental bleomycin lung injury and preventive effects of urokinase]
Lung Neoplasms
Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines.
Lung Neoplasms
Aeroallergen Der p 2 promotes motility of human non-small cell lung cancer cells via toll-like receptor-mediated up-regulation of urokinase-type plasminogen activator and integrin/focal adhesion kinase signaling.
Lung Neoplasms
Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition.
Lung Neoplasms
Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer.
Lung Neoplasms
Camptothecin induces urokinase-type plasminogen activator gene-expression in human RC-K8 malignant lymphoma and H69 small cell lung cancer cells.
Lung Neoplasms
Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting and in situ hybridization.
Lung Neoplasms
Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells.
Lung Neoplasms
Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients.
Lung Neoplasms
Detection of cathepsin B, plasminogen activators and plasminogen activator inhibitor in human non-small lung cancer cell lines.
Lung Neoplasms
Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.
Lung Neoplasms
Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.
Lung Neoplasms
ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts.
Lung Neoplasms
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Lung Neoplasms
Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma.
Lung Neoplasms
Fibrinolysis-inhibitory activity of cultured human cancer cell lines.
Lung Neoplasms
G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells.
Lung Neoplasms
Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells.
Lung Neoplasms
Graphene nanosheets as an electric mediator for ultrafast sensing of urokinase plasminogen activator receptor-A biomarker of cancer.
Lung Neoplasms
Immunological analysis of plasminogen activators from cultured human cancer cells.
Lung Neoplasms
Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Lung Neoplasms
Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients.
Lung Neoplasms
Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells.
Lung Neoplasms
Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells.
Lung Neoplasms
Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model.
Lung Neoplasms
Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.
Lung Neoplasms
Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.
Lung Neoplasms
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Lung Neoplasms
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Lung Neoplasms
Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer.
Lung Neoplasms
Peonidin 3-glucoside inhibits lung cancer metastasis by downregulation of proteinases activities and MAPK pathway.
Lung Neoplasms
Peroxiredoxin 6 promotes lung cancer cell invasion by inducing urokinase-type plasminogen activator via p38 kinase, phosphoinositide 3-kinase, and Akt.
Lung Neoplasms
Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro.
Lung Neoplasms
Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
Lung Neoplasms
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
Lung Neoplasms
Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer.
Lung Neoplasms
Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
Lung Neoplasms
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Lung Neoplasms
Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Lung Neoplasms
Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer.
Lung Neoplasms
Prognostic value of urokinase plasminogen activator system in non-small cell lung cancer: A systematic review and meta-analysis.
Lung Neoplasms
Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival.
Lung Neoplasms
Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with {beta}1 integrins.
Lung Neoplasms
Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis.
Lung Neoplasms
Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.
Lung Neoplasms
Subpopulations of uPAR(+) contribute to vasculogenic mimicry and metastasis in large cell lung cancer.
Lung Neoplasms
Surface ?-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target.
Lung Neoplasms
The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC).
Lung Neoplasms
The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.
Lung Neoplasms
The effect of TNP-470 on cell proliferation and urokinase-type plasminogen activator and its inhibitor in human lung cancer cell lines.
Lung Neoplasms
The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
Lung Neoplasms
The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group.
Lung Neoplasms
Transcriptional regulation of urokinase receptor in high- (95D) and low-metastatic (95C) human lung cancer cells.
Lung Neoplasms
Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer.
Lung Neoplasms
Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment.
Lung Neoplasms
Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene.
Lung Neoplasms
Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors.
Lung Neoplasms
Urokinase combination chemotherapy in small cell lung cancer. A phase II study.
Lung Neoplasms
Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Lung Neoplasms
Urokinase plasminogen activator receptor induced non-small cell lung cancer invasion and metastasis requires NHE1 transporter expression and transport activity.
Lung Neoplasms
Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis.
Lung Neoplasms
Urokinase receptors in lung cancer and normal lung.
Lung Neoplasms
[Biological function of fusion protein ATF-PAI2CD]
Lung Neoplasms
[Clinical evaluation of various antineoplastic agents combined with urokinase--a comparison between urokinase from tissue culture (TCUK) and urine-derived urokinase (UUK)]
Lung Neoplasms
[Effects of MnSOD silence on in vitro tumorigenicity in NCI-H446 cells].
Lung Neoplasms
[Increase of cellular fibrinolysis in human lung cancer cell line by radiation: relationship between urokinase-type plasminogen activator (uPA) and metastasis and invasion]
Lung Neoplasms
[Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer]
Lung Neoplasms
[Urokinase plasminogen activator /U-PA/in blood of patients with lung cancer]
Lupus Erythematosus, Systemic
Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Systemic Lupus Erythematosus Patients.
Lupus Erythematosus, Systemic
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
[Thrombolytic therapy with urokinase in two systemic lupus erythematosus patients with deep vein thrombosis]
Lupus Nephritis
Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model.
Lupus Nephritis
Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: a large cohort study from China.
Lupus Nephritis
Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity.
Lupus Nephritis
Vitamin D and Glomerulonephritis.
Lupus Nephritis
[The functional activity of plasminogen activators in the blood plasma and urine of patients with lupus nephritis]
Lyme Disease
Binding of human plasminogen and urokinase-type plasminogen activator to the Lyme disease spirochete, Borrelia burgdorferi.
Lyme Disease
The Urokinase Receptor (uPAR) Facilitates Clearance of Borrelia burgdorferi.
Lyme Disease
The urokinase receptor (uPAR) facilitates clearance of Borrelia burgdorferi.
Lymphatic Metastasis
Antigen expression associated with lymph node metastasis in gastric adenocarcinomas.
Lymphatic Metastasis
Clinical significance of urokinase-type plasminogen activator (uPA) in invasive cervical cancer of the uterus.
Lymphatic Metastasis
Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer.
Lymphatic Metastasis
Expression of HLA-DR and urokinase-type plasminogen activator in stage IV gastric cancer.
Lymphatic Metastasis
Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
Lymphatic Metastasis
High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast.
Lymphatic Metastasis
Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor.
Lymphatic Metastasis
Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
Lymphatic Metastasis
Isolated splenic metastasis of sigmoid colon cancer: a case report.
Lymphatic Metastasis
Plasminogen Activation System in Rectal Adenocarcinoma.
Lymphatic Metastasis
Sentinel Lymph Node-Targeted Therapy by Oncolytic Sendai Virus Suppresses Micrometastasis of Head and Neck Squamous Cell Carcinoma in an Orthotopic Nude Mouse Model.
Lymphatic Metastasis
Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.
Lymphatic Metastasis
Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients.
Lymphatic Metastasis
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
Lymphatic Metastasis
[Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer]
Lymphoma
Amurubicinol-induced eotaxin-3 expression in human NCI-H69 small cell lung carcinoma cells.
Lymphoma
Camptothecin induces urokinase-type plasminogen activator gene-expression in human RC-K8 malignant lymphoma and H69 small cell lung cancer cells.
Lymphoma
Down-regulation of urokinase secretion from a human lymphoma cell line RC-K8 by dexamethasone without inducing plasminogen activator inhibitors.
Lymphoma
Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue.
Lymphoma
Induction of urokinase-type plasminogen activator by the anthracycline antibiotic in human RC-K8 lymphoma and H69 lung-carcinoma cells.
Lymphoma
Inhibitory effect of a synthetic prostacyclin analogue, beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells.
Lymphoma
Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells.
Lymphoma
Modulation of urokinase-type plasminogen activator gene expression by inflammatory cytokines in human pre-B lymphoma cell line RC-K8.
Lymphoma
Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells.
Lymphoma
Plasminogen activator inhibitor-2 in patients with monocytic leukemia.
Lymphoma
Protein kinase activity-dependent inhibition of urokinase-type plasminogen activator gene transcription by cyclic AMP in human pre-B lymphoma cell line RC-K8.
Lymphoma
Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
Lymphoma, Non-Hodgkin
Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Successful treatment of veno-occlusive disease of the liver with urokinase in a patient with non-Hodgkin's lymphoma.
Macular Degeneration
Increased soluble urokinase plasminogen activator receptor (suPAR) levels in neovascular age-related macular degeneration: a role for inflammation in the pathogenesis of the disease?
Macular Degeneration
Inhibitors of the proteolytic activity of urokinase type plasminogen activator.
Malaria
Correlation of biomarkers for parasite burden and immune activation with acute kidney injury in severe falciparum malaria.
Malaria
Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice.
Malaria
Elevated plasma urokinase receptor predicts low birth weight in maternal malaria.
Malaria
Host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes.
Malaria
Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome.
Malaria
Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection.
Malaria, Cerebral
Lesion associated expression of urokinase-type plasminogen activator receptor (uPAR, CD87) in human cerebral malaria.
Malaria, Falciparum
Host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes.
Malaria, Falciparum
Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection.
Measles
Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
Measles
Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.
Measles
Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Medulloblastoma
Nuclear Translocation of Hand-1 Acts as a Molecular Switch to Regulate Vascular Radiosensitivity in Medulloblastoma Tumors: The Protein uPAR Is a Cytoplasmic Sequestration Factor for Hand-1.
Medulloblastoma
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Medulloblastoma
Urokinase-type plasminogen activator receptor (uPAR)-mediated regulation of WNT/?-catenin signaling is enhanced in irradiated medulloblastoma cells.
Medulloblastoma
[Expression and significance of urokinase-type plasminogen activator in medulloblastoma]
Melanoma
Activation of pro-urokinase by the human T cell-associated serine proteinase HuTSP-1.
Melanoma
Alterations in endothelial cell proteinase and inhibitor polarized secretion following treatment with interleukin-1, phorbol ester, and human melanoma cell conditioned medium.
Melanoma
Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice.
Melanoma
Autotaxin stimulates urokinase-type plasminogen activator expression through phosphoinositide 3-kinase-Akt-nuclear [corrected] factor kappa B signaling cascade in human melanoma cells.
Melanoma
Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.
Melanoma
Cambodian Phellinus linteus inhibits experimental metastasis of melanoma cells in mice via regulation of urokinase type plasminogen activator.
Melanoma
Characterization of plasminogen activator produced by an established cell line from human ovary.
Melanoma
Clearance of a novel recombinant tissue plasminogen activator in rabbits.
Melanoma
Co-localization of CD44 and urokinase-type plasminogen activator on the surface of human melanoma cells.
Melanoma
Comparative electrophoretic analysis of human and porcine plasminogen activators in SDS-polyacrylamide gels containing plasminogen and casein.
Melanoma
Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
Melanoma
Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
Melanoma
Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
Melanoma
Correlated suppression by 5-bromodeoxyuridine of tumorigenicity and plasminogen activator in mouse melanoma cells.
Melanoma
Cytokine-dependent invasiveness in B16 murine melanoma cells: role of uPA system and MMP-9.
Melanoma
De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation.
Melanoma
Decoy molecules based on PNA-DNA chimeras and targeting Sp1 transcription factors inhibit the activity of urokinase-type plasminogen activator receptor (uPAR) promoter.
Melanoma
Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression.
Melanoma
Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates.
Melanoma
Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro.
Melanoma
Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor.
Melanoma
Differentiation and the tumorigenic and metastatic phenotype of murine melanoma cells.
Melanoma
Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines.
Melanoma
EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.
Melanoma
Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.
Melanoma
Growth inhibition of vascular smooth muscle cells derived from urokinase receptor (u-PAR)-deficient mice in the presence of carcinoma cells.
Melanoma
High tPA-expression in primary melanoma of the limb correlates with good prognosis.
Melanoma
Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
Melanoma
Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor.
Melanoma
Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis.
Melanoma
Immunological characterisation of plasminogen activators in the human vessel wall.
Melanoma
Immunological characterization of plasminogen activators in human mixed saliva.
Melanoma
Immunological comparison between human and rat plasminogen activators in blood and the vessel wall.
Melanoma
Importance of intramolecular interactions in the control of the fibrin affinity and activation of human plasminogen.
Melanoma
In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
Melanoma
Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: radiation-induced increase in fraction of hypoxic cells and hypoxia-induced up-regulation of urokinase-type plasminogen activator receptor.
Melanoma
Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Melanoma
Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.
Melanoma
Interleukin 1 preferentially stimulates the production of tissue-type plasminogen activator by human articular chondrocytes.
Melanoma
Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.
Melanoma
Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.
Melanoma
Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR.
Melanoma
Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
Melanoma
Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor.
Melanoma
Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.
Melanoma
Modulation of the urokinase-type plasminogen activator receptor by the beta6 integrin subunit.
Melanoma
Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton.
Melanoma
Molecular species of plasminogen activators secreted by normal and neoplastic human cells.
Melanoma
New approaches to thrombolytic therapy.
Melanoma
New type of plasminogen activator produced by an established cell line from human ovary.
Melanoma
Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
Melanoma
Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice.
Melanoma
Plasminogen activation in melanocytic neoplasia.
Melanoma
Plasminogen activators in human malignant melanoma.
Melanoma
Plasminogen activators in nude mice xenotransplanted with human tumorigenic cells.
Melanoma
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
Melanoma
Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma.
Melanoma
Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.
Melanoma
Purification and properties of a plasminogen activator from cultured rat prostate adenocarcinoma cells.
Melanoma
Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3.
Melanoma
Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes.
Melanoma
Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes.
Melanoma
Secreted proteases. Regulation of their activity and their possible role in metastasis.
Melanoma
Serine enzymes released by cultured neoplastic cells.
Melanoma
Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest PAI-1 immunoassay evaluated.
Melanoma
Spitz naevi may express components of the plasminogen activation system.
Melanoma
Suppression of type I collagenase expression by antisense RNA in melanoma cells results in reduced synthesis of the urokinase-type plasminogen activator receptor.
Melanoma
Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.
Melanoma
Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions.
Melanoma
The plasminogen activation system in melanoma cell lines and in melanocytic lesions.
Melanoma
Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
Melanoma
uPAR controls vasculogenic mimicry ability expressed by drug-resistant melanoma cells.
Melanoma
uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients.
Melanoma
Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells.
Melanoma
Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Melanoma, Experimental
Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: lack of association with in vitro invasion.
Melanoma, Experimental
Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.
Melioidosis
Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis.
Meningioma
Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas.
Meningioma
Immunohistochemical expression of Ets-1 transcription factor and the urokinase-type plasminogen activator is correlated with the malignant and invasive potential in meningiomas.
Meningioma
Radiation-induced hypomethylation triggers urokinase plasminogen activator transcription in meningioma cells.
Meningioma
RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.
Meningioma
RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth.
Meningioma
uPAR and cathepsin B shRNA impedes TGF-?1-driven proliferation and invasion of meningioma cells in a XIAP-dependent pathway.
Meningioma
[A plasminogen regulation system in brain tumors].
Meningitis
Biochemical and pathological evaluation of albendazole/thalidomide co-therapy against eosinophilic meningitis or meningoencephalitis induced by Angiostrongylus cantonensis.
Meningitis
Cerebrospinal fluid u-plasminogen activator and matrix metalloproteinase-9 levels in human eosinophilic meningitis associated with angiostrongyliasis.
Meningitis
Comparative efficacies of albendazole and the Chinese herbal medicine long-dan-xie-gan-tan, used alone or in combination, in the treatment of experimental eosinophilic meningitis induced by Angiostrongylus cantonensis.
Meningitis
Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome.
Meningitis
Elevation of plasminogen activators in cerebrospinal fluid of mice with eosinophilic meningitis caused by Angiostrongylus cantonensis.
Meningitis
Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome.
Meningitis
Treatment of intraventricular hemorrhage using urokinase.
Meningitis, Bacterial
Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome.
Meningitis, Bacterial
Role of the urokinase plasminogen activator system in patients with bacterial meningitis.
Meningitis, Pneumococcal
Urokinase-type plasminogen activator receptor regulates leukocyte recruitment during experimental pneumococcal meningitis.
Mesenteric Ischemia
Mesenteric venous thrombosis treated with urokinase via the superior mesenteric artery.
Mesenteric Ischemia
Transradial approach for transcatheter selective superior mesenteric artery urokinase infusion therapy in patients with acute extensive portal and superior mesenteric vein thrombosis.
Mesenteric Ischemia
Treatment of acute mesenteric venous thrombosis with transjugular intramesenteric urokinase infusion.
Mesenteric Ischemia
Urokinase therapy in mesenteric venous thrombosis: a case study.
Mesenteric Ischemia
Vasodilation, fibrinolysis, and thrombolysis with intraarterial infusion of urokinase in the canine superior mesenteric artery.
Mesenteric Ischemia
[A case of acute portal and mesenteric venous thrombosis treated with urokinase via superior mesenteric artery]
Mesenteric Ischemia
[Mesenteric ischemia diagnosed with Doppler ultrasonography and successfully treated with intra-arterial urokinase]
Mesenteric Ischemia
[Portal and superior mesenteric venous thrombosis treated with urokinase infusion via superior mesenteric artery]
Mesenteric Ischemia
[Transradial approach for transcatheter selective superior mesenteric artery urokinase infusion therapy in patients with acute extensive portal and superior mesenteric vein thrombosis].
Mesothelioma
A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells.
Mesothelioma
BioKnife, a uPA Activity-dependent Oncolytic Sendai Virus, Eliminates Pleural Spread of Malignant Mesothelioma via Simultaneous Stimulation of uPA Expression.
Mesothelioma
Intrapleural Urokinase Directly Under Medical Thoracoscopy for the Diagnosis of Malignant Pleural Mesothelioma With Severe Multiloculated Pleural Effusions.
Mesothelioma
Intrapleural urokinase directly under medical thoracoscopy for the diagnosis of tuberculous pleurisy.
Mesothelioma
Posttranscriptional regulation of urokinase receptor gene expression in human lung carcinoma and mesothelioma cells in vitro.
Mesothelioma
Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells.
Mesothelioma
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Mesothelioma
The Urokinase Receptor Supports Tumorigenesis of Human Malignant Pleural Mesothelioma Cells.
Mesothelioma, Malignant
A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells.
Mesothelioma, Malignant
BioKnife, a uPA Activity-dependent Oncolytic Sendai Virus, Eliminates Pleural Spread of Malignant Mesothelioma via Simultaneous Stimulation of uPA Expression.
Mesothelioma, Malignant
Intrapleural Urokinase Directly Under Medical Thoracoscopy for the Diagnosis of Malignant Pleural Mesothelioma With Severe Multiloculated Pleural Effusions.
Mesothelioma, Malignant
Intrapleural urokinase directly under medical thoracoscopy for the diagnosis of tuberculous pleurisy.
Mesothelioma, Malignant
The Urokinase Receptor Supports Tumorigenesis of Human Malignant Pleural Mesothelioma Cells.
Mesothelioma, Malignant
Urinary trypsin inhibitor suppresses migration of malignant mesothelioma.
Mesothelioma, Malignant
Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis.
Mesothelioma, Malignant
Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma.
Metabolic Syndrome
Association among Fibrinolytic Proteins, Metabolic Syndrome Components, Insulin Secretion, and Resistance in Schoolchildren.
Migraine Disorders
The relationship between levels of plasma-soluble urokinase plasminogen activator receptor (suPAR) and presence of migraine attack and aura.
MINOCA
Increased Inflammatory Activity in Patients 3 Months after Myocardial Infarction with Nonobstructive Coronary Arteries.
Mitral Valve Prolapse
Association between urokinase-plasminogen activator gene T4065C polymorphism and risk of mitral valve prolapse.
Mitral Valve Stenosis
[Case of mitral stenosis with regression and elimination of left atrial thrombus after combined therapy of urokinase, dipyridamole and aspirin]
Mouth Neoplasms
Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - ?1 (TGF-?1) and potential effects on migration and invasion.
Mouth Neoplasms
Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator.
Mouth Neoplasms
Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor.
Mouth Neoplasms
Plasminogen activation system in oral cancer: Relevance in prognosis and therapy (Review).
Mouth Neoplasms
RNAi-mediated downregulation of urokinase plasminogen activator receptor inhibits proliferation, adhesion, migration and invasion in oral cancer cells.
Mouth Neoplasms
Urokinase gene 3'-UTR T/C polymorphism is associated with oral cancer.
Mouth Neoplasms
Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.
Mouth Neoplasms
[Effect of hypoxia on the expression of urokinase-type plasminogen activator in human tongue squamous cell carcinoma cells (Tca8113)]
Mucocutaneous Lymph Node Syndrome
Intracoronary urokinase and post-thrombolytic regimen in an infant with Kawasaki disease and acute myocardial infarction.
Mucocutaneous Lymph Node Syndrome
Intracoronary urokinase in Kawasaki disease: treatment and prevention of myocardial infarction.
Mucocutaneous Lymph Node Syndrome
Low-dose i.v. urokinase for coronary thrombosis in Kawasaki disease.
Mucocutaneous Lymph Node Syndrome
Management of myocardial infarction in children with Kawasaki disease.
Mucocutaneous Lymph Node Syndrome
[Clinical analysis of intravenous urokinase treatment of 10 cases with Kawasaki disease complicated with thrombus in coronary aneurysm]
Mucormycosis
Urokinase application for hemothorax in pulmonary mucormycosis.
Multiple Endocrine Neoplasia Type 2a
[Systemic fibrinolysis following resuscitation or temporary electrostimulation]
Multiple Endocrine Neoplasia Type 2b
Intracoronary urokinase as an adjunct to percutaneous transluminal coronary angioplasty in patients with complex coronary narrowings or angioplasty-induced complications.
Multiple Myeloma
Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis.
Multiple Myeloma
Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression.
Multiple Myeloma
Bone Marrow Urokinase Plasminogen Activator Receptor Levels are Associated with the Progress of Multiple Myeloma.
Multiple Myeloma
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction.
Multiple Myeloma
Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
Multiple Myeloma
[Detection and clinical significance of plasma urokinase-type plasminogen activator and its soluble receptor in patients with multiple myeloma]
Multiple Sclerosis
Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis.
Multiple Sclerosis
Inhibitors of urokinase type plasminogen activator and cytostatic activity from crude plants extracts.
Multiple Sclerosis
Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system.
Multiple Sclerosis
Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage.
Multiple Sclerosis
Role of cytoskeletal elements in expression of monocyte urokinase plasminogen activator receptor, activation-associated antigen Mo3.
Multiple Sclerosis, Relapsing-Remitting
Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1).
Muscle Spasticity
Case presentations of neuroradiologic interventions for acute cerebrovascular disease.
Muscle Weakness
Kidney function estimates using cystatin C versus creatinine: Impact on medication prescribing in acutely hospitalized elderly patients.
Muscular Dystrophy, Duchenne
Cell invasion is affected by differential expression of the urokinase plasminogen activator/urokinase plasminogen activator receptor system in muscle satellite cells from normal and dystrophic patients.
Muscular Dystrophy, Duchenne
Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system.
Myasthenia Gravis
Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study.
Myeloproliferative Disorders
Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism.
Myocardial Infarction
A clinicopathologic study of patients with hemorrhagic myocardial infarction treated with selective coronary thrombolysis with urokinase.
Myocardial Infarction
A comparative study on the effects of low dose of tPA and different regimens of intravenous urokinase in acute myocardial infarction.
Myocardial Infarction
A Double-Blind Multicenter Comparison of the Efficacy and Safety of Saruplase and Urokinase in the Treatment of Acute Myocardial Infarction: Report of the SUTAMI Study Group.
Myocardial Infarction
A new "wonder" drug to dissolve clots. The results of urokinase therapy in acute myocardial infarction, pulmonary embolism and deep vein thrombosis.
Myocardial Infarction
A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial.
Myocardial Infarction
A white flapping structure in the coronary artery lumen observed by angioscopy after coronary thrombolysis--is this the "ruptured atheroma" that initiated the acute myocardial infarction?
Myocardial Infarction
Accelerated ST-segment reduction after thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) compared to urokinase.
Myocardial Infarction
Acute myocardial infarction complicating recanalization of aortocoronary bypass grafts with urokinase therapy.
Myocardial Infarction
Acute myocardial infarction complicating urokinase infusion for total saphenous vein graft occlusion.
Myocardial Infarction
Acute myocardial infarction in a patient with essential thrombocythemia: successful treatment with percutaneous transluminal coronary recanalization.
Myocardial Infarction
Adjunctive abciximab improves outcomes during recanalization of totally occluded saphenous vein grafts using transluminal extraction atherectomy.
Myocardial Infarction
Angina preceding myocardial infarction and residual coronary narrowing after intracoronary thrombolysis.
Myocardial Infarction
Angiographic features in the infarct-related artery after intracoronary urokinase followed by prolonged anticoagulation. Role of ruptured atheromatous plaque and adherent thrombus in acute myocardial infarction in vivo.
Myocardial Infarction
Angiographic features of the coronary arteries during intracoronary thrombolysis.
Myocardial Infarction
Angiographic study of mutant tissue-type plasminogen activator versus urokinase for acute myocardial infarction.
Myocardial Infarction
Augmented plasma protein C activity after coronary thrombolysis with urokinase in patients with acute myocardial infarction.
Myocardial Infarction
Biochemical evaluation of low dose of urokinase in acute myocardial infarction. A double-blind study.
Myocardial Infarction
Bleeding after thrombolysis in acute myocardial infarction.
Myocardial Infarction
Cardiac rupture complicating hemorrhagic infarction after intracoronary thrombolysis.
Myocardial Infarction
Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.
Myocardial Infarction
Circadian fluctuations in the efficacy of thrombolysis with streptokinase.
Myocardial Infarction
Clinical characteristics of myocardial infarction following Kawasaki disease: report of 11 cases.
Myocardial Infarction
Clinical experience with urokinase in intracoronary thrombolysis.
Myocardial Infarction
Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
Myocardial Infarction
Clinical significance of early myocardial 99mTc-pyrophosphate uptake in patients with acute myocardial infarction.
Myocardial Infarction
Clinical study on the thrombolytic effect with different doses of urokinase in acute myocardial infarction. The Collaborative Research Group on Thrombolysis.
Myocardial Infarction
Clinical use of streptokinase and urokinase therapy for acute myocardial infarction.
Myocardial Infarction
Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
Myocardial Infarction
Comparative efficacy of thrombolytic therapy for acute myocardial infarction in patients with and without chronic preinfarction angina.
Myocardial Infarction
Comparative tolerability profiles of thrombolytic agents. A review.
Myocardial Infarction
Comparison of catalytic activity and mass concentration of serum creatine kinase MB isoenzyme in the detection of coronary reperfusion in acute myocardial infarction after therapeutic thrombolysis.
Myocardial Infarction
Comparison of double bolus urokinase versus front-loaded alteplase regimen for acute myocardial infarction. Thrombolysis in Myocardial Infarction in Korea (TIMIKO) study group.
Myocardial Infarction
Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction. Urochinasi per via Sistemica nell'Infarto Miocardico (USIM) Collaborative Group.
Myocardial Infarction
Comparison of the Pharmacokinetics and Effects on the Hemostatic System of Saruplase and Urokinase in Patients with Acute Myocardial Infarction.
Myocardial Infarction
Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo.
Myocardial Infarction
Controlled trial of urokinase in myocardial infarction. A European Collaborative Study.
Myocardial Infarction
Coronary angiographic findings in infarct-related arteries following 1 month of medical treatment.
Myocardial Infarction
Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction.
Myocardial Infarction
Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
Myocardial Infarction
Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase.
Myocardial Infarction
Coronary thrombolysis in man with pro-urokinase: improved efficacy with low dose urokinase.
Myocardial Infarction
Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.
Myocardial Infarction
Coronary thrombolysis with intravenous urokinase in patients with acute myocardial infarction.
Myocardial Infarction
Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction.
Myocardial Infarction
Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
Myocardial Infarction
Coronary thrombolysis with urokinase infusion in acute myocardial infarction: multicenter study in Japan.
Myocardial Infarction
Defibrotide versus heparin in the prevention of coronary reocclusion after thrombolysis in acute myocardial infarction.
Myocardial Infarction
Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Addition to High-Sensitivity Troponin I in Early Diagnosis of Acute Myocardial Infarction.
Myocardial Infarction
Dipyridamole echocardiography test. A new tool for detecting jeopardized myocardium after thrombolytic therapy.
Myocardial Infarction
Dose of urokinase for intracoronary thrombolysis in patients with acute myocardial infarction.
Myocardial Infarction
Economic assessment of rheolytic thrombectomy versus intracoronary urokinase for treatment of extensive intracoronary thrombus: Results from a randomized clinical trial.
Myocardial Infarction
Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction.
Myocardial Infarction
Effects of coronary artery reperfusion on relation between creatine kinase-MB release and infarct size estimated by myocardial emission tomography with thallium-201 in man.
Myocardial Infarction
Effects of intracoronary thrombolysis therapy on left ventricular function after acute myocardial infarction.
Myocardial Infarction
Effects of intracoronary urokinase during acute myocardial infarction.
Myocardial Infarction
Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction.
Myocardial Infarction
Effects of lipoprotein(a) on thrombolysis.
Myocardial Infarction
Effects of patency of infarct-related coronary artery on acute outcome in acute myocardial infarction patients undergoing urokinase therapy. Collaborative Research Group on Thrombolysis.
Myocardial Infarction
Effects of percutaneous transluminal coronary angioplasty: intracoronary thrombolysis with urokinase in acute myocardial infarction.
Myocardial Infarction
Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function. The TAMI Investigators. Thrombolysis and Angioplasty in Acute Myocardial Infarction.
Myocardial Infarction
Efficacy of intracoronary and intravenous urokinase in acute myocardial infarction.
Myocardial Infarction
Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction.
Myocardial Infarction
Emerging technologies in therapeutic ultrasound: thermal ablation to gene delivery.
Myocardial Infarction
ERK1/2 mediates the lipopolysaccharide-induced upregulation of FGF-2, uPA, MMP-2, MMP-9 and cellular migration in cardiac fibroblasts.
Myocardial Infarction
Evaluation of the patency rate of infarct-related artery after intravenous urokinase in acute myocardial infarction by 90 minutes angiography. Collaborative Group of Clinical Trial for Urokinase Therapy.
Myocardial Infarction
Experiences in intravenous urokinase treatment of 100 acute myocardial infarction patients]
Myocardial Infarction
Feasibility of urokinase in the treatment of acute myocardial infarction.
Myocardial Infarction
Febrile reaction associated with urokinase.
Myocardial Infarction
Femoral nerve palsy secondary to anticoagulant induced iliacus hematoma. A case report.
Myocardial Infarction
Fiber-Reinforced Silk Composite for Enhanced Urokinase Production Using High-Density Perfusion Culture and Bioactive Molecule Supplementation.
Myocardial Infarction
Fibrinolytic effects of pro-urokinase combined with low-dose urokinase compared to high-dose urokinase in patients with acute myocardial infarction.
Myocardial Infarction
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Myocardial Infarction
Fibrinolytic therapy urokinase for myocardial infarction.
Myocardial Infarction
Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction.
Myocardial Infarction
Hemostatic changes after thrombolytic therapy with saruplase (unglycosylated single-chain urokinase-type plasminogen activator) and urokinase (two-chain urokinase-type plasminogen activator).
Myocardial Infarction
High-dose intra-arterial urokinase for the treatment of hepatic artery thrombosis in liver transplantation.
Myocardial Infarction
HTUPA as a new thrombolytic agent for acute myocardial infarction: A multicenter, randomized study.
Myocardial Infarction
Human fibrinogen heterogeneity. A study of limited fibrinogen degradation.
Myocardial Infarction
Improved prognosis after coronary thrombolysis with urokinase in acute myocardial infarction.
Myocardial Infarction
Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase.
Myocardial Infarction
Indications for and limitations of coronary thrombolysis.
Myocardial Infarction
Influence of different start time of urokinase therapy after acute myocardial infarction efficacy of thrombolysis. The Collaborative Research Group on Thrombolysis.
Myocardial Infarction
Influence of the plasminogen activator system on necrosis in acute myocardial infarction: analysis of urokinase- and urokinase receptor-knockout mouse models.
Myocardial Infarction
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.
Myocardial Infarction
Intracoronary thrombolysis in patients with acute myocardial infarction: comparison of the efficacy of urokinase with streptokinase.
Myocardial Infarction
Intracoronary thrombolysis with urokinase in acute myocardial infarction. Effects on reperfusion and left ventricular wall motion.
Myocardial Infarction
Intracoronary urokinase and post-thrombolytic regimen in an infant with Kawasaki disease and acute myocardial infarction.
Myocardial Infarction
Intracoronary urokinase in acute myocardial infarction: prevalence of total coronary occlusion during the early hours, effects on myocardial infarct size and left ventricular function, and outcome of residual coronary stenosis.
Myocardial Infarction
Intracoronary urokinase in Kawasaki disease: treatment and prevention of myocardial infarction.
Myocardial Infarction
Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).
Myocardial Infarction
Intravenous recombinant tissue-type plasminogen activator (rt-PA) and urokinase (UK) in patients with evolving myocardial infarction--a multicenter double-blind, randomized trial in Japan.
Myocardial Infarction
Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
Myocardial Infarction
Intravenous urokinase in acute myocardial infarction.
Myocardial Infarction
Isoforms of creatine kinase isoenzymes in serum in acute myocardial infarction after intracoronary thrombolysis.
Myocardial Infarction
Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction.
Myocardial Infarction
Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate.
Myocardial Infarction
Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells.
Myocardial Infarction
Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study.
Myocardial Infarction
Long-term outcome of patients with ST-segment elevation myocardial infarction treated with low-dose intracoronary thrombolysis during primary percutaneous coronary intervention: the 5-year results of the DISSOLUTION Trial.
Myocardial Infarction
Long-term prognosis after thrombolytic therapy for acute myocardial infarction.
Myocardial Infarction
Low dose urokinase preactivated natural prourokinase for thrombolysis in acute myocardial infarction.
Myocardial Infarction
Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion.
Myocardial Infarction
Lysis of left ventricular thrombi with urokinase.
Myocardial Infarction
Lysis of mobile left ventricular thrombi during acute myocardial infarction with urokinase.
Myocardial Infarction
Management of myocardial infarction in children with Kawasaki disease.
Myocardial Infarction
Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study.
Myocardial Infarction
Multicenter clinical trial of thrombolytic therapy in 1,406 patients with acute myocardial infarction. Collaborative Group of Clinical Trial for Urokinase Therapy.
Myocardial Infarction
Multicenter dose-finding trial for thrombolysis with urokinase preactivated pro-urokinase (TCL 598) in acute myocardial infarction. German Preactivated Pro-Urokinase Study Group.
Myocardial Infarction
Multiple coronary artery aneurysms in an adult associated with extensive thrombus formation resulting in acute myocardial infarction: successful treatment with intracoronary urokinase, intravenous heparin, and oral anticoagulation.
Myocardial Infarction
Myocardial Infarction: Symptoms and Treatments.
Myocardial Infarction
Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice.
Myocardial Infarction
Peaking time of creatine-kinase MB in patients treated with urokinase or conventionally during acute myocardial infarction: is it really a clue to reperfusion?
Myocardial Infarction
Percutaneous transluminal coronary angioplasty, alone or in combination with urokinase therapy, during acute myocardial infarction.
Myocardial Infarction
Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction.
Myocardial Infarction
Plasmin and matrix metalloproteinases in vascular remodeling.
Myocardial Infarction
Platelet aggregation and thromboxane B2 release in patients with acute myocardial infarction--their relation to coronary patency.
Myocardial Infarction
Platelet-dependent thrombin generation after in vitro fibrinolytic treatment.
Myocardial Infarction
Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction.
Myocardial Infarction
Prevention of an early re-occlusion after thrombolytic therapy of acute myocardial infarction by ketanserin.
Myocardial Infarction
Procoagulant effects of thrombolytic therapy in acute myocardial infarction.
Myocardial Infarction
Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction.
Myocardial Infarction
Quantitation of infarct size in man by means of plasma enzyme levels.
Myocardial Infarction
Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group.
Myocardial Infarction
Randomized comparison of intracoronary tirofiban versus urokinase as an adjunct to primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: results of the ICTUS-AMI trial.
Myocardial Infarction
Randomized double-blind trial of intracoronary urokinase for acute myocardial infarction: multicenter study.
Myocardial Infarction
Randomized trial of thrombolysis versus heparin in unstable angina.
Myocardial Infarction
Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.
Myocardial Infarction
Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used.
Myocardial Infarction
Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.
Myocardial Infarction
Relationship between preinfarction angina and time interval to reperfusion with thrombolytic therapy in acute myocardial infarction.
Myocardial Infarction
Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Myocardial Infarction
Report on the use of urokinase in acute myocardial infarction.
Myocardial Infarction
Results of high dose intravenous urokinase for acute myocardial infarction.
Myocardial Infarction
Ruptured arteriovenous malformation complicating thrombolytic therapy with tissue plasminogen activator.
Myocardial Infarction
Saruplase is a safe and effective thrombolytic agent; observations in 1,698 patients: results of the PASS study. Practical Applications of Saruplase Study.
Myocardial Infarction
Serum enzymes in acute myocardial infarction after intracoronary thrombolysis.
Myocardial Infarction
Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.
Myocardial Infarction
Soluble urokinase plasminogen activator receptor in one-year prediction of major adverse cardiac events in patients after first myocardial infarction treated with primary percutaneous coronary intervention.
Myocardial Infarction
Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction.
Myocardial Infarction
Spontaneous splenic rupture associated with thrombolytic therapy and/or concomitant heparin anticoagulation.
Myocardial Infarction
Successful surgical repair of left ventricular rupture after acute myocardial infarction.
Myocardial Infarction
SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease.
Myocardial Infarction
Systolic left ventricular function after reperfusion therapy for acute myocardial infarction. Analysis of determinants of improvement. The TAMI Study Group.
Myocardial Infarction
The co-operative action of hyaluronidase and urokinase on the isoproterenol-induced myocardial infarction in rats.
Myocardial Infarction
The feasibility of urokinase therapy in acute myocardial infarction.
Myocardial Infarction
The impact of thrombolytic therapy on hospital mortality from acute myocardial infarction in the Chinese in Hong Kong.
Myocardial Infarction
The intracoronary administration of urokinase following direct PTCA for acute myocardial infarction reduces early restenosis.
Myocardial Infarction
The role of macrophage-derived urokinase plasminogen activator in myocardial infarct repair Urokinase attenuates ventricular remodeling.
Myocardial Infarction
The role of the low-density lipoprotein receptor-related protein (LRP) in the plasma clearance and liver uptake of recombinant single-chain urokinase-type plasminogen activator in rats.
Myocardial Infarction
The use of urokinase in acute myocardial infarction: report of two cases.
Myocardial Infarction
Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
Myocardial Infarction
Thrombolytic Therapy for Acute Myocardial Infarction : A Review.
Myocardial Infarction
Thrombolytic therapy in acute myocardial infarction. A perspective.
Myocardial Infarction
Thrombolytic therapy with urokinase reduces increased circulating endothelial adhesion molecules in acute myocardial infarction.
Myocardial Infarction
Thrombolytic therapy: overview of results in major vascular occlusions.
Myocardial Infarction
Thrombolytic therapy: then and now.
Myocardial Infarction
Treatment of acute myocardial infarction with prolonged intracoronary urokinase delivery through intracoronary infusion catheter.
Myocardial Infarction
Treatment of myocardial infarction: hypotensive effect of different thrombolytic agents.
Myocardial Infarction
uPA, uPAR and TGF?? expression during early and late post myocardial infarction period in rat myocardium.
Myocardial Infarction
Urokinase plus heparin versus aspirin in unstable angina and non-Q-wave myocardial infarction.
Myocardial Infarction
Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction.
Myocardial Infarction
Urokinase therapy in the early stage of acute myocardial infarction.
Myocardial Infarction
Urokinase versus heparin in acute myocardial infarction: no difference?
Myocardial Infarction
Use of thrombolytic drugs in non-coronary disorders.
Myocardial Infarction
Use of urokinase in acute myocardial infarction.
Myocardial Infarction
Usefulness of coronary artery bypass graft surgery or percutaneous transluminal angioplasty after thrombolytic therapy.
Myocardial Infarction
Usefulness of Local Delivery of Thrombolytics Before Thrombectomy in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (the Delivery of Thrombolytics Before Thrombectomy in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention [DISSOLUTION] Randomized Trial).
Myocardial Infarction
Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention.
Myocardial Infarction
[1st results in thrombolitic treatment with urokinase in myocardial infarct and premonitory syndromes]
Myocardial Infarction
[A case of successful prevention of recurrent acute myocardial infarction by emergency aorto-coronary bypass grafting after PTCR and a high intravenous dose of urokinase]
Myocardial Infarction
[A double-blind comparative study of intracoronary administration of GE-0943 and urokinase: multicenter study]
Myocardial Infarction
[A study of a systemic fibrinolytic treatment of acute myocardial infarction. The effect of a moderate dose infusion of urokinase]
Myocardial Infarction
[Accelerated thrombolysis by liposomal-encapsulated urokinase in a canine model of acute myocardial infarction]
Myocardial Infarction
[An allergic reaction due to i.v. urokinase administration]
Myocardial Infarction
[Analysis of factors correlated to death and reinfarction in patients with acute myocardial infarction]
Myocardial Infarction
[Analysis of segmental kinetics of the left ventricle after intravenous administration of urokinase in the acute phase of myocardial infarction]
Myocardial Infarction
[Calcitonin gene-related peptide and thrombolysis]
Myocardial Infarction
[Clinical analysis of early stage thrombolytic therapy with venous urokinase for acute myocardial infarction in 24 cases]
Myocardial Infarction
[Coronary arteriographic findings during early hours of acute myocardial infarction: response to intracoronary injection of nitrates and urokinase (author's transl)]
Myocardial Infarction
[Coronary thrombolysis in acute myocardial infarction]
Myocardial Infarction
[Effects of intravenous urokinase infusion in acute myocardial infarction]
Myocardial Infarction
[Electro-mechanical dissociation concomitant with myocardial reperfusion in the acute phase of myocardial infarction]
Myocardial Infarction
[Elements of choice of thrombolytic agents in myocardial infarction]
Myocardial Infarction
[Emergency percutaneous transluminal coronary angioplasty for acute myocardial infarction]
Myocardial Infarction
[Evaluation of coronary reperfusion for acute myocardial infarction by emission CT using technetium-99m pyrophosphate]
Myocardial Infarction
[Fibrinolytic therapy in acute myocardial infarction. Coronarographic evaluation of short-term results]
Myocardial Infarction
[Fibrinolytic treatment of acute myocardial infarction (author's transl)]
Myocardial Infarction
[Hemodynamic effects of diltiazem in the subacute stage of myocardial infarct treated by thrombolysis]
Myocardial Infarction
[Incidence of residual thrombi following successful thrombolytic therapy in acute myocardial infarct and their significance for the rate of early re-occlusion. A report of a multicenter dose-finding study for thrombolytic therapy with urokinase preactivated natural prourokinase (TCL 598)]
Myocardial Infarction
[Intracoronary thrombolysis using urokinase in acute myocardial infarct]
Myocardial Infarction
[Intracoronary thrombolysis]
Myocardial Infarction
[Intracoronary thrombolytic therapy in Kawasaki disease and the usefulness of two-dimensional echocardiography in detecting intracoronary thrombi]
Myocardial Infarction
[Intracoronary thrombolytic treatment with urokinase in myocardial infarct: clinical angiographic findings and effects on left ventricular function]
Myocardial Infarction
[Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)]
Myocardial Infarction
[Intravenous short-term coronary thrombolysis by a high-dose urokinase in aged patients with acute myocardial infarction]
Myocardial Infarction
[Intravenous thrombolysis by urokinase in acute myocardial infarction]
Myocardial Infarction
[Intravenous thrombolysis with domestic urokinase in 40 cases of acute myocardial infarction]
Myocardial Infarction
[Kawasaki disease: new and important problems in cardiology]
Myocardial Infarction
[Lysis treatment of left ventricular thrombi. Acute and long-term results]
Myocardial Infarction
[Moderate doses of urokinase (UK) in the treatment of myocardial infarct and pulmonary embolism]
Myocardial Infarction
[Percutaneous transluminal coronary angioplasty in patients over 75 years old with acute myocardial infarct or unstable angina pectoris]
Myocardial Infarction
[Possibilities of early diagnosis of thromboembolic complications in myocardial infarct by means of biochemical methods]
Myocardial Infarction
[Results of local intracoronary fibrinolysis in acute myocardial infarct and the effects of reperfusion on the function of the left ventricle]
Myocardial Infarction
[Role of urokinase in the acute phase of myocardial infarction]
Myocardial Infarction
[Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy]
Myocardial Infarction
[Serial changes in hemostatic molecular markers after urokinase therapy of acute myocardial infarction]
Myocardial Infarction
[Short- and long-term mortality of intracoronary urokinase in acute myocardial infarction]
Myocardial Infarction
[Study on defibrinogenasing enhancing the thrombolytic effect of urokinase on acute myocardial infarction]
Myocardial Infarction
[Study on effect of shenmai injection in protecting myocardium against ischemia-reperfusion injury in thrombolytic therapy with urokinase for acute myocardial infarction patients evaluated by 99mTc-MIBI myocardial imaging]
Myocardial Infarction
[Systemic fibrinolysis following resuscitation or temporary electrostimulation]
Myocardial Infarction
[The course of residual stenosis after intracoronary thrombolysis]
Myocardial Infarction
[The dose of intracoronary urokinase infusion in acute myocardial infarct]
Myocardial Infarction
[The effects of coronary thrombolysis on the short- and long-term mortality in acute myocardial infarction]
Myocardial Infarction
[The effects of intravenous urokinase administration in patients with acute myocardial infarction]
Myocardial Infarction
[The evaluation of the therapeutic effect on acute myocardial infarction by radioisotope method--assessment of the intravenous injection of urokinase and comparison with the results of PTCR + PTCA]
Myocardial Infarction
[The evaluation of thrombolytic effect of snake venom antithrombus enzyme in treatment of acute myocardial infarction]
Myocardial Infarction
[The kinetics of plasma coagulation fibrinolysis levels in acute myocardial infarction before and after treatment with intravenous urokinase]
Myocardial Infarction
[The thrombolysis treatment of acute myocardial infarct at the site of the emergency. A randomized double-blind study]
Myocardial Infarction
[Thrombolytic effect of a moderate dose of urokinase in acute myocardial infarction]
Myocardial Infarction
[Treatment by urokinase of myocardial infarction and threatened infarction. Randomised study of 120 cases]
Myocardial Infarction
[Treatment of acute myocardial infarct by intracoronary thrombolysis and aortocoronary bypass]
Myocardial Infarction
[Treatment of acute myocardial infarction by thrombolytic therapy with large dosage of urokinase]
Myocardial Infarction
[Urokinase treatment of threatened and acute myocardial infarct]
Myocardial Infarction
[Use of urokinase in acute myocardial infarction]
Myocardial Infarction
[Usefulness and safety of intravenous thrombolytic therapy for elderly patients with acute myocardial infarction: relationship with cardiac rupture]
Myocardial Ischemia
Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomized dose-response trial.
Myocardial Ischemia
Treatment of acute myocardial infarction with prolonged intracoronary urokinase delivery through intracoronary infusion catheter.
Myocardial Ischemia
[Symptomatic therapy refractory myocardial ischemia in coronary heart disease. Chronic intermittent urokinase therapy and invasive therapeutic measures]
Myocarditis
Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis.
Myoma
The relationship between urokinase plasminogen activator/plasminogen activator inhibitor type-1 expression in myoma/myometrium and mechanism of uterine artery occlusion by laparoscopy for uterine myoma treatment.
Myositis
Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.
Myxoma
Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor.
Nasopharyngeal Carcinoma
Hispolon suppresses migration and invasion of human nasopharyngeal carcinoma cells by inhibiting the urokinase-plasminogen activator through modulation of the Akt signaling pathway.
Nasopharyngeal Carcinoma
Measurement of urokinase-type plasminogen activator activity in sera of nasopharyngeal carcinoma patients by an immunocapture assay.
Nasopharyngeal Carcinoma
The concentration of u-PA and PAI-1 antigen in tissue extracts of nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.
Neonatal Sepsis
The importance of biomarkers in neonatology.
Neoplasm Metastasis
(-)-Epigallocatechin gallate derivatives reduce the expression of both urokinase plasminogen activator and plasminogen activator inhibitor-1 to inhibit migration, adhesion, and invasion of MDA-MB-231 cells.
Neoplasm Metastasis
(4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
Neoplasm Metastasis
(±)Equol inhibits invasion in prostate cancer DU145 cells possibly via down-regulation of matrix metalloproteinase-9, matrix metalloproteinase-2 and urokinase-type plasminogen activator by antioxidant activity.
Neoplasm Metastasis
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
Neoplasm Metastasis
A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis.
Neoplasm Metastasis
A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts.
Neoplasm Metastasis
A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines.
Neoplasm Metastasis
A highly polymorphic CA/GT repeat in intron 3 of the human urokinase receptor gene (PLAUR).
Neoplasm Metastasis
A human monoclonal antibody scFv to urokinase plasminogen activator.
Neoplasm Metastasis
A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.
Neoplasm Metastasis
A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer.
Neoplasm Metastasis
A new prognostic strategy for gastric carcinoma: mRNA expression of tumor growth-related factors in endoscopic biopsy specimens.
Neoplasm Metastasis
A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
Neoplasm Metastasis
A novel model for metastasis suppression involving regulation of nuclear precursor messenger-RNA stability.
Neoplasm Metastasis
A novel peptide blocking cancer cell invasion by structure-based drug design.
Neoplasm Metastasis
A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site.
Neoplasm Metastasis
A pharmacological analysis of the cholinergic regulation of urokinase-type plasminogen activator secretion in the human colon cancer cell line, HT-29.
Neoplasm Metastasis
A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development.
Neoplasm Metastasis
A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix.
Neoplasm Metastasis
A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation.
Neoplasm Metastasis
A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis.
Neoplasm Metastasis
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
Neoplasm Metastasis
Activation of the anti-cancer agent upamostat by the mARC enzyme system.
Neoplasm Metastasis
Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
Neoplasm Metastasis
Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Neoplasm Metastasis
Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines.
Neoplasm Metastasis
Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I).
Neoplasm Metastasis
Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression.
Neoplasm Metastasis
Amplification of the Urokinase-Type Plasminogen Activator Receptor (uPAR) Gene in Ductal Pancreatic Carcinomas Identifies a Clinically High-Risk Group.
Neoplasm Metastasis
Amplification of urokinase gene in prostate cancer.
Neoplasm Metastasis
An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.
Neoplasm Metastasis
An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Neoplasm Metastasis
Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.
Neoplasm Metastasis
Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells.
Neoplasm Metastasis
Anti-Invasion Effect of Crebanine and O-methylbulbocapnine from Stephania venosa via Down-Regulated MMPs and uPA.
Neoplasm Metastasis
Anti-invasive activity of synthetic serine protease inhibitors and its combined effect with a matrix metalloproteinase inhibitor.
Neoplasm Metastasis
Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: An orally active anti-cancer drug waiting for its call-of-duty?
Neoplasm Metastasis
Antigen expression associated with lymph node metastasis in gastric adenocarcinomas.
Neoplasm Metastasis
Antimetastatic Potential of Quercetin Analogues with Improved Pharmacokinetic Profile: Pharmacoinformatic Preliminary Study.
Neoplasm Metastasis
Antimetastatic Potentials of Phyllanthusurinaria L on A549 and Lewis Lung Carcinoma Cells via Repression of Matrix-Degrading Proteases.
Neoplasm Metastasis
Antimetastatic role of Smad4 signaling in colorectal cancer.
Neoplasm Metastasis
Antiprotease and antimetastatic activity of ursolic acid isolated from Salvia officinalis.
Neoplasm Metastasis
Antisense inhibition of urokinase: effect on malignancy in a human osteosarcoma cell line.
Neoplasm Metastasis
Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice.
Neoplasm Metastasis
Antitumor effects of the novel quinazolinone MJ-33: Inhibition of metastasis through the MAPK, AKT, NF-?B and AP-1 signaling pathways in DU145 human prostate cancer cells.
Neoplasm Metastasis
Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor.
Neoplasm Metastasis
Apigenin Suppresses the IL-1?-Induced Expression of the Urokinase-Type Plasminogen Activator Receptor by Inhibiting MAPK-Mediated AP-1 and NF-?B Signaling in Human Bladder Cancer T24 Cells.
Neoplasm Metastasis
Aspirin inhibits highly invasive prostate cancer cells.
Neoplasm Metastasis
Assessment of the interaction between urokinase and reactive site mutants of protein C inhibitor.
Neoplasm Metastasis
Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer.
Neoplasm Metastasis
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Neoplasm Metastasis
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Neoplasm Metastasis
Autotaxin stimulates urokinase-type plasminogen activator expression through phosphoinositide 3-kinase-Akt-nuclear [corrected] factor kappa B signaling cascade in human melanoma cells.
Neoplasm Metastasis
Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9.
Neoplasm Metastasis
Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence.
Neoplasm Metastasis
Binding site of amiloride to urokinase plasminogen activator depends on species.
Neoplasm Metastasis
Bioconjugatable azo-based dark-quencher dyes: synthesis and application to protease-activatable far-red fluorescent probes.
Neoplasm Metastasis
Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
Neoplasm Metastasis
Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse.
Neoplasm Metastasis
Calcitonin inhibits invasion of breast cancer cells: Involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Neoplasm Metastasis
Cambodian Phellinus linteus inhibits experimental metastasis of melanoma cells in mice via regulation of urokinase type plasminogen activator.
Neoplasm Metastasis
Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting and in situ hybridization.
Neoplasm Metastasis
Cancer invasion and metastasis: changing views.
Neoplasm Metastasis
Cancer metastasis: biological and clinical aspects.
Neoplasm Metastasis
Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment.
Neoplasm Metastasis
Caveolin-1-dependent and -independent uPAR signaling pathways contribute to ganglioside GT1b induced early apoptosis in A549 lung cancer cells.
Neoplasm Metastasis
cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Neoplasm Metastasis
Cell surface expression of urokinase receptor in normal mammary epithelial cells and breast cancer cell lines.
Neoplasm Metastasis
Cellular mechanisms of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MAPK signaling in hepatocellular carcinoma.
Neoplasm Metastasis
Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity.
Neoplasm Metastasis
Characterization of downstream Ras signals that induce alternative protease-dependent invasive phenotypes.
Neoplasm Metastasis
Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma.
Neoplasm Metastasis
Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.
Neoplasm Metastasis
Characterization of morphogenetic and invasive abilities of human mammary epithelial cells: correlation with variations of urokinase-type plasminogen activator activity and type-1 plasminogen activator inhibitor level.
Neoplasm Metastasis
Characterization of protease expression in human prostate-cancer cell-lines.
Neoplasm Metastasis
Characterization of the interaction between heterodimeric ?v?6 integrin and urokinase plasminogen activator receptor (uPAR) using functional proteomics.
Neoplasm Metastasis
Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
Neoplasm Metastasis
Chromosomal localization of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes: implications in colorectal cancer.
Neoplasm Metastasis
Circulating Levels of Urokinase-Type Plasminogen Activator Receptor and D-Dimer in Patients With Hematological Malignancies.
Neoplasm Metastasis
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Neoplasm Metastasis
Clinical significance of the uPA system in gastric cancer with peritoneal metastasis.
Neoplasm Metastasis
Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
Neoplasm Metastasis
Clinical significance of urokinase-type plasminogen activator (uPA) in invasive cervical cancer of the uterus.
Neoplasm Metastasis
Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma.
Neoplasm Metastasis
Clinicopathologic significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogenous metastasis.
Neoplasm Metastasis
Clotting factors in tumour tissue: implications for cancer therapy.
Neoplasm Metastasis
Clustering of murine lung metastases reflects fractal nonuniformity in regional lung blood flow.
Neoplasm Metastasis
Co-expression of uPAR and CXCR4 promotes tumor growth and metastasis in small cell lung cancer.
Neoplasm Metastasis
Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.
Neoplasm Metastasis
Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Neoplasm Metastasis
Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma.
Neoplasm Metastasis
Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Neoplasm Metastasis
Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma.
Neoplasm Metastasis
Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.
Neoplasm Metastasis
Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
Neoplasm Metastasis
Correlation between expression of urokinase-type plasminogen activator receptor and metastasis in gastric carcinoma.
Neoplasm Metastasis
Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.
Neoplasm Metastasis
CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases.
Neoplasm Metastasis
CSF levels of growth factors and plasminogen activators in leptomeningeal metastases.
Neoplasm Metastasis
Cysteine and serine proteases in gastric cancer.
Neoplasm Metastasis
Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase-induced tyrosine phosphorylation.
Neoplasm Metastasis
Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness.
Neoplasm Metastasis
Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor.
Neoplasm Metastasis
Detecting in vivo urokinase plasminogen activator activity with a catalyCEST MRI contrast agent.
Neoplasm Metastasis
Detection of cathepsin B, plasminogen activators and plasminogen activator inhibitor in human non-small lung cancer cell lines.
Neoplasm Metastasis
Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
Neoplasm Metastasis
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Neoplasm Metastasis
Dexamethasone plus Somatostatin-analog Manipulation as Bone Metastasis Microenvironment-targeting Therapy for the Treatment of Castration-resistant Prostate Cancer: A Meta-analysis of Uncontrolled Studies.
Neoplasm Metastasis
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.
Neoplasm Metastasis
Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice.
Neoplasm Metastasis
Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of Plasminogen Activator Inhibitor Type 2 (PAI-2) forms.
Neoplasm Metastasis
Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Neoplasm Metastasis
Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma.
Neoplasm Metastasis
Dihydromyricetin suppresses cell metastasis in human osteosarcoma through SP-1- and NF-?B-modulated urokinase plasminogen activator inhibition.
Neoplasm Metastasis
Direct evidence of the importance of vitronectin and its interaction with the urokinase receptor in tumor growth.
Neoplasm Metastasis
Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.
Neoplasm Metastasis
Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
Neoplasm Metastasis
Docosahexaenoic Acid Downregulates EGF-Induced Urokinase Plasminogen Activator and Matrix Metalloproteinase 9 Expression by Inactivating EGFR/ErbB2 Signaling in SK-BR3 Breast Cancer Cells.
Neoplasm Metastasis
Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.
Neoplasm Metastasis
Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells.
Neoplasm Metastasis
Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145.
Neoplasm Metastasis
Downregulation of Extracellular Matrix Metalloproteinase Inducer by scFv-M6-1B9 Intrabody Suppresses Cervical Cancer Invasion Through Inhibition of Urokinase-Type Plasminogen Activator.
Neoplasm Metastasis
Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer.
Neoplasm Metastasis
Downregulation of SPINK13 Promotes Metastasis by Regulating uPA in Ovarian Cancer Cells.
Neoplasm Metastasis
Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells.
Neoplasm Metastasis
Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B.
Neoplasm Metastasis
Effect of urokinase on growth and metastases of rabbit V2 carcinoma.
Neoplasm Metastasis
Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis.
Neoplasm Metastasis
Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases.
Neoplasm Metastasis
Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.
Neoplasm Metastasis
Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice.
Neoplasm Metastasis
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
Neoplasm Metastasis
Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Neoplasm Metastasis
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
Neoplasm Metastasis
Enhanced spontaneous metastasis in bikunin-deficient mice.
Neoplasm Metastasis
Enterolactone Suppresses Proliferation, Migration and Metastasis of MDA-MB-231 Breast Cancer Cells Through Inhibition of uPA Induced Plasmin Activation and MMPs-Mediated ECM Remodeling
Neoplasm Metastasis
Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator.
Neoplasm Metastasis
Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
Neoplasm Metastasis
ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation.
Neoplasm Metastasis
Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma.
Neoplasm Metastasis
Evolving role of uPA/uPAR system in human cancers.
Neoplasm Metastasis
Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma.
Neoplasm Metastasis
Explaining urokinase type plasminogen activator inhibition by amino-5-hydroxybenzimidazole and two naphthamidine-based compounds through quantum biochemistry.
Neoplasm Metastasis
Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Neoplasm Metastasis
Expression and purification of recombinant ATF-mellitin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris.
Neoplasm Metastasis
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Neoplasm Metastasis
Expression of C4.4A, a structural uPAR homolog, reflects squamous epithelial differentiation in the adult mouse and during embryogenesis.
Neoplasm Metastasis
Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer.
Neoplasm Metastasis
Expression of HLA-DR and urokinase-type plasminogen activator in stage IV gastric cancer.
Neoplasm Metastasis
Expression of MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical intraepithelial neoplasia.
Neoplasm Metastasis
Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.
Neoplasm Metastasis
Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Neoplasm Metastasis
Expression of urokinase-type plasminogen activator in an experimental model of hepatocarcinoma.
Neoplasm Metastasis
Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms.
Neoplasm Metastasis
Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
Neoplasm Metastasis
Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma.
Neoplasm Metastasis
Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma.
Neoplasm Metastasis
Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
Neoplasm Metastasis
Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Neoplasm Metastasis
Expression of urokinase-type plasminogen-activator in various human thyroid tissues.
Neoplasm Metastasis
Expression, Purification, and Biological Characterization of The Amino-Terminal Fragment of Urokinase in Pichia pastoris.
Neoplasm Metastasis
Expression, subcellular distribution and plasma membrane binding of cathepsin B and gelatinases in bone metastatic tissue.
Neoplasm Metastasis
Extending preclinical models of skeletal manifestations of malignancy to the clinical setting.
Neoplasm Metastasis
Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis.
Neoplasm Metastasis
Extracellular signal-regulated kinase and AP-1 pathways are involved in reactive oxygen species-induced urokinase plasminogen activator receptor expression in human gastric cancer cells.
Neoplasm Metastasis
FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions.
Neoplasm Metastasis
Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules.
Neoplasm Metastasis
Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells.
Neoplasm Metastasis
Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications.
Neoplasm Metastasis
Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma.
Neoplasm Metastasis
First-in-human uPAR PET: Imaging of Cancer Aggressiveness.
Neoplasm Metastasis
Flavokawain B inhibits growth of human squamous carcinoma cells: Involvement of apoptosis and cell cycle dysregulation in vitro and in vivo.
Neoplasm Metastasis
FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis via Upregulation of Expression of the Urokinase Plasminogen Activator System.
Neoplasm Metastasis
Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.
Neoplasm Metastasis
Gene expression in cancer cells is influenced by contact with bone cells in a novel coculture system that models bone metastasis.
Neoplasm Metastasis
Genetic down-regulation of phosphoinositide 3-kinase by bikunin correlates with suppression of invasion and metastasis in human ovarian cancer HRA cells.
Neoplasm Metastasis
Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.
Neoplasm Metastasis
Growth inhibition of MDA-MB-231 cell line by peptides designed based on uPA.
Neoplasm Metastasis
Growth of a human carcinoma (HEp3) in nude mice: rapid and efficient metastasis.
Neoplasm Metastasis
Guanidinobenzoatase and UPA in high-grade human astrocytomas and after xenografting cell suspensions into the rat cerebral cortex: proteases for metastasis and disease progression.
Neoplasm Metastasis
Heat shock proteins HSP70 and MRJ cooperatively regulate cell adhesion and migration through urokinase receptor.
Neoplasm Metastasis
Helicobacter pylori infection stimulates plasminogen activator inhibitor 1 production by gastric epithelial cells.
Neoplasm Metastasis
Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer.
Neoplasm Metastasis
Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase.
Neoplasm Metastasis
Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.
Neoplasm Metastasis
High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast.
Neoplasm Metastasis
High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.
Neoplasm Metastasis
High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
Neoplasm Metastasis
High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma.
Neoplasm Metastasis
High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
Neoplasm Metastasis
Hispolon suppresses SK-Hep1 human hepatoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen activator through the PI3K/Akt and ERK signaling pathways.
Neoplasm Metastasis
Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases.
Neoplasm Metastasis
Host protein C inhibitor inhibits tumor growth, but promotes tumor metastasis, which is closely correlated with hypercoagulability.
Neoplasm Metastasis
Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor.
Neoplasm Metastasis
Icariside II from Epimedium koreanum inhibits hypoxia-inducible factor-1alpha in human osteosarcoma cells.
Neoplasm Metastasis
IL-1 beta induces urokinase-plasminogen activator expression and cell migration through PKC alpha, JNK1/2, and NF-kappaB in A549 cells.
Neoplasm Metastasis
Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop.
Neoplasm Metastasis
Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
Neoplasm Metastasis
In vitro and in vivo antimetastatic effects of Terminalia catappa L. leaves on lung cancer cells.
Neoplasm Metastasis
In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
Neoplasm Metastasis
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Neoplasm Metastasis
Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas.
Neoplasm Metastasis
Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis.
Neoplasm Metastasis
Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
Neoplasm Metastasis
Increased surgical stress promotes tumor metastasis.
Neoplasm Metastasis
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
Neoplasm Metastasis
Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase.
Neoplasm Metastasis
Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Neoplasm Metastasis
Induction of urokinase-type plasminogen activator by lipopolysaccharide in PC-3 human prostatic cancer cells.
Neoplasm Metastasis
Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy.
Neoplasm Metastasis
Influence of drinking green tea on breast cancer malignancy among Japanese patients.
Neoplasm Metastasis
Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue.
Neoplasm Metastasis
Inhibiting tissue invasion and metastasis as targets for cancer therapy.
Neoplasm Metastasis
Inhibition of colon cancer metastasis by a 3'- end antisense urokinase receptor mRNA in a nude mouse model.
Neoplasm Metastasis
Inhibition of fibrinolysis by a synthetic urokinase inhibitor enhances lung colonization of metastatic murine mammary tumor cells.
Neoplasm Metastasis
Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator.
Neoplasm Metastasis
Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor.
Neoplasm Metastasis
Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model.
Neoplasm Metastasis
Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.
Neoplasm Metastasis
Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells.
Neoplasm Metastasis
Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.
Neoplasm Metastasis
Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
Neoplasm Metastasis
Inhibition of Tumor Growth and Metastasis by ATF-Fc, an Engineered Antibody: Targeting Urokinase Receptor.
Neoplasm Metastasis
Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.
Neoplasm Metastasis
Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model.
Neoplasm Metastasis
Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, WXC-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases.
Neoplasm Metastasis
Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells.
Neoplasm Metastasis
Inhibitors of the protease domain of urokinase-type plasminogen activator.
Neoplasm Metastasis
Inhibitors of urokinase type plasminogen activator and cytostatic activity from crude plants extracts.
Neoplasm Metastasis
Inhibitory effect of a synthetic prostacyclin analogue, beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells.
Neoplasm Metastasis
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Neoplasm Metastasis
Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells.
Neoplasm Metastasis
Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Neoplasm Metastasis
Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer.
Neoplasm Metastasis
Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.
Neoplasm Metastasis
Intrabronchial orthotopic propagation of human lung adenocarcinoma--characterizations of tumorigenicity, invasion and metastasis.
Neoplasm Metastasis
Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Neoplasm Metastasis
Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
Neoplasm Metastasis
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.
Neoplasm Metastasis
Invasion-Metastasis by Hepatocyte Growth Factor/c-Met Signaling Concomitant with Induction of Urokinase Plasminogen Activator in Human Pancreatic Cancer: Role as Therapeutic Target.
Neoplasm Metastasis
Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4.
Neoplasm Metastasis
Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells.
Neoplasm Metastasis
Is inhibition process better described with MD(QM/MM) simulations? The case of urokinase type plasminogen activator inhibitors.
Neoplasm Metastasis
Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
Neoplasm Metastasis
Is urokinase gene 3'-UTR polymorphism associated with prostate cancer?
Neoplasm Metastasis
Isolated splenic metastasis of sigmoid colon cancer: a case report.
Neoplasm Metastasis
JNK Suppression is Essential for 17beta-Estradiol Inhibits Prostaglandin E2-Induced uPA and MMP-9 Expressions and Cell Migration in Human LoVo Colon Cancer Cells.
Neoplasm Metastasis
Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
Neoplasm Metastasis
Korean Red Ginseng Suppresses Metastasis of Human Hepatoma SK-Hep1 Cells by Inhibiting Matrix Metalloproteinase-2/-9 and Urokinase Plasminogen Activator.
Neoplasm Metastasis
Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma.
Neoplasm Metastasis
Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array.
Neoplasm Metastasis
Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
Neoplasm Metastasis
LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system.
Neoplasm Metastasis
Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.
Neoplasm Metastasis
Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.
Neoplasm Metastasis
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Neoplasm Metastasis
Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.
Neoplasm Metastasis
Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis.
Neoplasm Metastasis
Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer.
Neoplasm Metastasis
Mechanisms of cancer prevention by green and black tea polyphenols.
Neoplasm Metastasis
Met-HGF/SF: tumorigenesis, invasion and metastasis.
Neoplasm Metastasis
Metastatic effect of LY-6K gene in breast cancer cells.
Neoplasm Metastasis
Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo.
Neoplasm Metastasis
MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.
Neoplasm Metastasis
Mistletoe Extract Targets the STAT3-FOXM1 Pathway to Induce Apoptosis and Inhibits Metastasis in Breast Cancer Cells.
Neoplasm Metastasis
Modulation of growth and urokinase secretion by vasopressin and closely related nonapeptides in metastatic mouse mammary tumor cells.
Neoplasm Metastasis
Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines.
Neoplasm Metastasis
Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human glioblastoma cell lines.
Neoplasm Metastasis
Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.
Neoplasm Metastasis
Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Neoplasm Metastasis
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Neoplasm Metastasis
MRTF-A and STAT3 promote MDA-MB-231 cell migration via hypermethylating BRSM1.
Neoplasm Metastasis
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Neoplasm Metastasis
Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis.
Neoplasm Metastasis
Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
Neoplasm Metastasis
N-Alkylisatin-Loaded Liposomes Target the Urokinase Plasminogen Activator System in Breast Cancer.
Neoplasm Metastasis
N-WASP activation by a beta1-integrin-dependent mechanism supports PI3K-independent chemotaxis stimulated by urokinase-type plasminogen activator.
Neoplasm Metastasis
New ELISA for quantitation of human urokinase receptor (CD87) in cancer.
Neoplasm Metastasis
NF-kappaB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1alpha.
Neoplasm Metastasis
NFkappaB-dependent regulation of urokinase plasminogen activator by proanthocyanidin-rich grape seed extract: effect on invasion by prostate cancer cells.
Neoplasm Metastasis
Nimbolide inhibits invasion and migration, and down-regulates uPAR chemokine gene expression, in two breast cancer cell lines.
Neoplasm Metastasis
Novel protein interactors of urokinase-type plasminogen activator receptor.
Neoplasm Metastasis
Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo.
Neoplasm Metastasis
One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.
Neoplasm Metastasis
Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer.
Neoplasm Metastasis
Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells.
Neoplasm Metastasis
Overexpression of c-met Protein in Gastric Cancer and Role of uPAR as a Therapeutic Target.
Neoplasm Metastasis
Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma.
Neoplasm Metastasis
Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
Neoplasm Metastasis
Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis.
Neoplasm Metastasis
Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis.
Neoplasm Metastasis
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
Neoplasm Metastasis
P38 MAPK pathway is involved in the urokinase plasminogen activator expression in human gastric SNU-638 cells.
Neoplasm Metastasis
p38? MAPK Mediates 17?-Estradiol Inhibition of MMP-2 and -9 Expression and Cell Migration in Human LoVo Colon Cancer Cells.
Neoplasm Metastasis
PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
Neoplasm Metastasis
PAI-1 and functional blockade of SNAI1 in breast cancer cell migration.
Neoplasm Metastasis
Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas.
Neoplasm Metastasis
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Neoplasm Metastasis
Plasminogen Activation System in Rectal Adenocarcinoma.
Neoplasm Metastasis
Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Neoplasm Metastasis
Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells.
Neoplasm Metastasis
Plasminogen activator inhibitor 2 (PAI-2) is not inactivated by exposure to oxidants which can be released from activated neutrophils.
Neoplasm Metastasis
Plasminogen activator inhibitor type 2 in breast cancer.
Neoplasm Metastasis
Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Neoplasm Metastasis
Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis.
Neoplasm Metastasis
Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.
Neoplasm Metastasis
Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine.
Neoplasm Metastasis
Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer.
Neoplasm Metastasis
Plasminogen binding and cancer: promises and pitfalls.
Neoplasm Metastasis
PLOD3 promotes lung metastasis via regulation of STAT3.
Neoplasm Metastasis
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.
Neoplasm Metastasis
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Neoplasm Metastasis
Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma.
Neoplasm Metastasis
Preclinical evaluation of [(111) In]MICA-401, an activity-based probe for SPECT imaging of in vivo uPA activity.
Neoplasm Metastasis
Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy.
Neoplasm Metastasis
Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Neoplasm Metastasis
Prevention of metastasis by inhibition of the urokinase receptor.
Neoplasm Metastasis
Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA).
Neoplasm Metastasis
Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
Neoplasm Metastasis
Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.
Neoplasm Metastasis
Production of a urokinase plasminogen activator-IgG fusion protein (uPA-IgG) in the baculovirus expression system.
Neoplasm Metastasis
Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Neoplasm Metastasis
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Neoplasm Metastasis
Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma.
Neoplasm Metastasis
Prognostic role of urokinase-type plasminogen activator in human gliomas.
Neoplasm Metastasis
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Neoplasm Metastasis
Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
Neoplasm Metastasis
Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.
Neoplasm Metastasis
Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Neoplasm Metastasis
Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma.
Neoplasm Metastasis
Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.
Neoplasm Metastasis
Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer.
Neoplasm Metastasis
Prognostic value of urokinase-type plasminogen activators in gastric-cancer.
Neoplasm Metastasis
Prostate cancer cells show elevated urokinase receptor in a mouse model of metastasis.
Neoplasm Metastasis
Prostate-specific antigen activates single-chain urokinase-type plasminogen activator.
Neoplasm Metastasis
Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion.
Neoplasm Metastasis
Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1.
Neoplasm Metastasis
Protease nexin-1 expression is altered in human breast cancer.
Neoplasm Metastasis
Proteases as prognostic markers in cancer.
Neoplasm Metastasis
Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue.
Neoplasm Metastasis
Protein kinase C is inhibited by bisphosphonates in prostate cancer PC-3 cells.
Neoplasm Metastasis
Proteolytic enzymes in proliferation and neoplastic metastases formation.
Neoplasm Metastasis
Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy.
Neoplasm Metastasis
Quercetin Has Antimetastatic Effects on Gastric Cancer Cells via the Interruption of uPA/uPAR Function by Modulating NF-?b, PKC-?, ERK1/2, and AMPK?.
Neoplasm Metastasis
Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3).
Neoplasm Metastasis
Rapid detection of urokinase plasminogen activator using flexible paper-based graphene-gold platform.
Neoplasm Metastasis
Rapid identification of urokinase plasminogen activator inhibitors from Traditional Chinese Medicines based on ultrafiltration, LC-MS and in silico docking.
Neoplasm Metastasis
Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite.
Neoplasm Metastasis
Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice.
Neoplasm Metastasis
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Neoplasm Metastasis
Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Neoplasm Metastasis
Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines.
Neoplasm Metastasis
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Neoplasm Metastasis
Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo.
Neoplasm Metastasis
Regulation of Urokinase Production by Androgens in Human Prostate Cancer Cells: Effect on Tumor Growth and Metastases in Vivo1.
Neoplasm Metastasis
Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells.
Neoplasm Metastasis
Relationship between urokinase plasminogen activator receptor (uPAR) and the invasion of human prenatal hair follicle.
Neoplasm Metastasis
Relationship between urokinase-type plasminogen activator receptor and vascular endothelial growth factor expression and metastasis of gallbladder cancer.
Neoplasm Metastasis
Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer.
Neoplasm Metastasis
Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival.
Neoplasm Metastasis
Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Neoplasm Metastasis
Retraction: Small Interfering RNA-Directed Reversal of Urokinase Plasminogen Activator Demethylation Inhibits Prostate Tumor Growth and Metastasis.
Neoplasm Metastasis
Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis.
Neoplasm Metastasis
Revisiting the biological roles of PAI2 (SERPINB2) in cancer.
Neoplasm Metastasis
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Neoplasm Metastasis
RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo.
Neoplasm Metastasis
RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.
Neoplasm Metastasis
RNAi-mediated downregulation of urokinase plasminogen activator receptor inhibits proliferation, adhesion, migration and invasion in oral cancer cells.
Neoplasm Metastasis
ROC1 promotes the malignant progression of bladder cancer by regulating p-I?B?/NF-?B signaling.
Neoplasm Metastasis
Role of epigenetics in cancer initiation and progression.
Neoplasm Metastasis
Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
Neoplasm Metastasis
Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies.
Neoplasm Metastasis
Role of urokinase in colorectal neoplasia.
Neoplasm Metastasis
Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Neoplasm Metastasis
Role of urokinase-type plasminogen activator and inhibitory effect of protease inhibitor in invasion and metastasis of pancreatic cancer.
Neoplasm Metastasis
Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221.
Neoplasm Metastasis
Secretion of urokinase and metalloproteinase-9 induced by staurosporine is dependent on a tyrosine kinase pathway in mammary tumor cells.
Neoplasm Metastasis
Selection criteria for epirubicin-based adjuvant chemotherapy in node-negative breast cancer.
Neoplasm Metastasis
Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis.
Neoplasm Metastasis
Sentinel Lymph Node-Targeted Therapy by Oncolytic Sendai Virus Suppresses Micrometastasis of Head and Neck Squamous Cell Carcinoma in an Orthotopic Nude Mouse Model.
Neoplasm Metastasis
Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers.
Neoplasm Metastasis
Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases.
Neoplasm Metastasis
Sex steroids regulate the expression of plasminogen activator inhibitor-1 (PAI-1) and its mRNA in uterine endometrial cancer cell line Ishikawa.
Neoplasm Metastasis
Significant association of urokinase plasminogen activator Pro141Leu with serum lipid profiles in a Japanese population.
Neoplasm Metastasis
Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.
Neoplasm Metastasis
siRNA-mediated downregulation of MMP-9 and uPAR in combination with radiation induces G2/M cell-cycle arrest in Medulloblastoma.
Neoplasm Metastasis
Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis.
Neoplasm Metastasis
Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
Neoplasm Metastasis
Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.
Neoplasm Metastasis
Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.
Neoplasm Metastasis
Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.
Neoplasm Metastasis
SPRY1 promotes the degradation of uPAR and inhibits uPAR-mediated cell adhesion and proliferation.
Neoplasm Metastasis
Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer.
Neoplasm Metastasis
Stromal cell-derived factor-1/CXC receptor 4 and b1 integrin interaction regulates urokinase-type plasminogen activator expression in human colorectal cancer cells.
Neoplasm Metastasis
Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect.
Neoplasm Metastasis
Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions.
Neoplasm Metastasis
Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
Neoplasm Metastasis
Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
Neoplasm Metastasis
Structure of human urokinase plasminogen activator in complex with its receptor.
Neoplasm Metastasis
Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis.
Neoplasm Metastasis
Structure-based design, synthesis and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors.
Neoplasm Metastasis
Studies of possible mechanisms for the effect of urokinase therapy in small cell carcinoma of the lung.
Neoplasm Metastasis
Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin.
Neoplasm Metastasis
Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor.
Neoplasm Metastasis
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Neoplasm Metastasis
Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428.
Neoplasm Metastasis
Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.
Neoplasm Metastasis
Suppression of urokinase expression and tumor metastasis by bikunin overexpression [mini-review].
Neoplasm Metastasis
Suppression of Urokinase-Type Plasminogen Activator Receptor by Docosahexaenoic Acid Mediated by Heme Oxygenase-1 in 12-O-Tetradecanoylphorbol-13-Acetate-Induced Human Endothelial Cells.
Neoplasm Metastasis
Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.
Neoplasm Metastasis
Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Neoplasm Metastasis
Synthetic urokinase inhibitors as potential anti-invasive drugs.
Neoplasm Metastasis
Targeting Multiple Conformations Leads to Small Molecule Inhibitors of the uPARuPA Protein-Protein Interaction that Block Cancer Cell Invasion.
Neoplasm Metastasis
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Neoplasm Metastasis
Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.
Neoplasm Metastasis
Targeting uPA/uPAR in prostate cancer.
Neoplasm Metastasis
Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
Neoplasm Metastasis
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Neoplasm Metastasis
Terminalia catappa attenuates urokinase-type plasminogen activator expression through Erk pathways in Hepatocellular carcinoma.
Neoplasm Metastasis
Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions.
Neoplasm Metastasis
The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.
Neoplasm Metastasis
The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer.
Neoplasm Metastasis
The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer.
Neoplasm Metastasis
The effect of essential fatty acids on growth and urokinase-type plasminogen activator production in human prostate DU-145 cells.
Neoplasm Metastasis
The effect of gamma-linolenic acid and eicosapentaenoic acid on urokinase activity.
Neoplasm Metastasis
The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor.
Neoplasm Metastasis
The expression of urokinase type plasminogen activator is a novel prognostic factor in dukes B and C colorectal cancer.
Neoplasm Metastasis
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
Neoplasm Metastasis
The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice.
Neoplasm Metastasis
The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
Neoplasm Metastasis
The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line.
Neoplasm Metastasis
The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase.
Neoplasm Metastasis
The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target.
Neoplasm Metastasis
The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.
Neoplasm Metastasis
The pharmacological pathways of GnRH mediating the inhibition of mammary tumours: implications in humans and domestic animals.
Neoplasm Metastasis
The plasminogen activator inhibitor "paradox" in cancer.
Neoplasm Metastasis
The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer.
Neoplasm Metastasis
The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
Neoplasm Metastasis
The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor.
Neoplasm Metastasis
The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes.
Neoplasm Metastasis
The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.
Neoplasm Metastasis
The role of proteolytic enzymes in cancer invasion and metastasis.
Neoplasm Metastasis
The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.
Neoplasm Metastasis
The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.
Neoplasm Metastasis
The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products.
Neoplasm Metastasis
The uPA/uPA receptor system as a target for tumor therapy.
Neoplasm Metastasis
The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Neoplasm Metastasis
The urokinase plasminogen activator binding to its receptor: a quantum biochemistry description within an in/homogeneous dielectric function framework with application to uPA-uPAR peptide inhibitors.
Neoplasm Metastasis
The urokinase plasminogen activator receptor as a gene therapy target for cancer.
Neoplasm Metastasis
The urokinase plasminogen activator system in breast cancer invasion and metastasis.
Neoplasm Metastasis
The urokinase plasminogen activator system in cancer: a putative therapeutic target?
Neoplasm Metastasis
The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis.
Neoplasm Metastasis
The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.
Neoplasm Metastasis
The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?
Neoplasm Metastasis
The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction.
Neoplasm Metastasis
The urokinase receptor as an entertainer of signal transduction.
Neoplasm Metastasis
The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.
Neoplasm Metastasis
The urokinase-system--role of cell proliferation and apoptosis.
Neoplasm Metastasis
The urokinase-type plasminogen activator system in cancer metastasis: a review.
Neoplasm Metastasis
The urokinase-type plasminogen activator system in prostate cancer metastasis.
Neoplasm Metastasis
The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group.
Neoplasm Metastasis
Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator.
Neoplasm Metastasis
Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Neoplasm Metastasis
Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
Neoplasm Metastasis
Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells.
Neoplasm Metastasis
Transcriptional complexity and roles of Fra-1/AP-1 at the uPA/Plau locus in aggressive breast cancer.
Neoplasm Metastasis
Transcriptional regulation of the urokinase receptor (u-PAR)--a central molecule of invasion and metastasis.
Neoplasm Metastasis
Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.
Neoplasm Metastasis
Transforming growth factor-beta1-dependent activation of Smad2/3 and up-regulation of PAI-1 expression is negatively regulated by Src in SKOV-3 human ovarian cancer cells.
Neoplasm Metastasis
Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells.
Neoplasm Metastasis
Translational research on u-PAR.
Neoplasm Metastasis
Tspan9 inhibits the proliferation, migration and invasion of human gastric cancer SGC7901 cells via the ERK1/2 pathway.
Neoplasm Metastasis
Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
Neoplasm Metastasis
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Neoplasm Metastasis
Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
Neoplasm Metastasis
Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment.
Neoplasm Metastasis
Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma.
Neoplasm Metastasis
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
Neoplasm Metastasis
uPA receptor expression in benign and malignant thyroid tumors.
Neoplasm Metastasis
uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
Neoplasm Metastasis
uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions.
Neoplasm Metastasis
uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.
Neoplasm Metastasis
uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line.
Neoplasm Metastasis
uPAR induces expression of transforming growth factor ? and interleukin-4 in cancer cells to promote tumor-permissive conditioning of macrophages.
Neoplasm Metastasis
uPAR peptide antagonist alters regulation of MAP kinases and Bcl-2 family members in favor of apoptosis in MDA-MB-231 cell line.
Neoplasm Metastasis
uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery.
Neoplasm Metastasis
Upregulation of C4.4A expression during progression of melanoma.
Neoplasm Metastasis
Upregulation of circulating cytokeratin 20, urokinase plasminogen activator and C-reactive protein is associated with poor prognosis in gastric cancer.
Neoplasm Metastasis
Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines.
Neoplasm Metastasis
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Neoplasm Metastasis
Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells.
Neoplasm Metastasis
Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
Neoplasm Metastasis
Urokinase induces stromal cell-derived factor-1 expression in human hepatocellular carcinoma cells.
Neoplasm Metastasis
Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo.
Neoplasm Metastasis
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.
Neoplasm Metastasis
Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.
Neoplasm Metastasis
Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer.
Neoplasm Metastasis
Urokinase plasminogen activator in ovarian cancer.
Neoplasm Metastasis
Urokinase plasminogen activator predicts poor prognosis in hepatocellular carcinoma.
Neoplasm Metastasis
Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.
Neoplasm Metastasis
Urokinase Plasminogen Activator Receptor (uPAR): A Potential Indicator of Invasion for In Situ Breast Cancer.
Neoplasm Metastasis
Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy.
Neoplasm Metastasis
Urokinase plasminogen activator receptor induced non-small cell lung cancer invasion and metastasis requires NHE1 transporter expression and transport activity.
Neoplasm Metastasis
Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Neoplasm Metastasis
Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Neoplasm Metastasis
Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease.
Neoplasm Metastasis
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
Neoplasm Metastasis
Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
Neoplasm Metastasis
Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.
Neoplasm Metastasis
Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
Neoplasm Metastasis
Urokinase receptor deficiency results in EGFR-mediated failure to transmit signals for cell survival and neurite formation in mouse neuroblastoma cells.
Neoplasm Metastasis
Urokinase receptor expression is upregulated by cell culture sparsity in breast cancer cell line BT-20.
Neoplasm Metastasis
Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
Neoplasm Metastasis
Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells.
Neoplasm Metastasis
Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer.
Neoplasm Metastasis
Urokinase type plasminogen activator receptor expression in colorectal neoplasms.
Neoplasm Metastasis
Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
Neoplasm Metastasis
Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec.
Neoplasm Metastasis
Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
Neoplasm Metastasis
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.
Neoplasm Metastasis
Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo.
Neoplasm Metastasis
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Neoplasm Metastasis
Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
Neoplasm Metastasis
Urokinase-type plasminogen activator activity increases during the growth of two murine mammary adenocarcinomas with different metastasizing abilities.
Neoplasm Metastasis
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Neoplasm Metastasis
Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
Neoplasm Metastasis
Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.
Neoplasm Metastasis
Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Neoplasm Metastasis
Urokinase-type Plasminogen Activator and Plasminogen-activator-inhibitor Type 1 Predict Metastases in Good Prognosis Breast Cancer Patients.
Neoplasm Metastasis
Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas.
Neoplasm Metastasis
Urokinase-type plasminogen activator in carcinomatous pleural fluid.
Neoplasm Metastasis
Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.
Neoplasm Metastasis
Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications.
Neoplasm Metastasis
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
Neoplasm Metastasis
Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
Neoplasm Metastasis
Urokinase-type plasminogen activator receptor (uPAR)-mediated regulation of WNT/?-catenin signaling is enhanced in irradiated medulloblastoma cells.
Neoplasm Metastasis
Urokinase-type plasminogen activator receptor expression in adenoid cystic carcinoma of the skull base.
Neoplasm Metastasis
Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
Neoplasm Metastasis
Urokinase-type plasminogen activator receptor inhibits apoptosis in triple-negative breast cancer through miR-17/20a suppression of death receptors 4 and 5.
Neoplasm Metastasis
Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.
Neoplasm Metastasis
Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models.
Neoplasm Metastasis
Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients.
Neoplasm Metastasis
Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
Neoplasm Metastasis
Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases.
Neoplasm Metastasis
Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers.
Neoplasm Metastasis
Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-beta(1) (TGF beta(1)) compared with factor(s) released by human epithelial-carcinoma cells.
Neoplasm Metastasis
Uterine fibrinolytic enzymes in endometrial cancer.
Neoplasm Metastasis
Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.
Neoplasm Metastasis
Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator.
Neoplasm Metastasis
Virtual Screening Targeting the Urokinase Receptor, Biochemical and Cell-Based Studies, Synthesis, Pharmacokinetic Characterization, and Effect on Breast Tumor Metastasis.
Neoplasm Metastasis
[A plasminogen regulation system in brain tumors].
Neoplasm Metastasis
[Antisense inhibition of urokinase in a human osteosarcoma cell line]
Neoplasm Metastasis
[Antisense RNA for urokinase receptor inhibits the invasiveness and metastasis of lung carcinoma]
Neoplasm Metastasis
[Assay and detection methods for urokinase-type plasminogen activator and its related-factors]
Neoplasm Metastasis
[Cell phenotype determines PAI-1 antiproliferative effect - suppressed proliferation of the lung cancer but not prostate cancer cells]
Neoplasm Metastasis
[Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer]
Neoplasm Metastasis
[Effect of hypoxia on the expression of urokinase-type plasminogen activator in human tongue squamous cell carcinoma cells (Tca8113)]
Neoplasm Metastasis
[Establishment of urokinase receptor gene antisense RNA transfer system and its application in leukemia research]
Neoplasm Metastasis
[Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer]
Neoplasm Metastasis
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
Neoplasm Metastasis
[Increase of cellular fibrinolysis in human lung cancer cell line by radiation: relationship between urokinase-type plasminogen activator (uPA) and metastasis and invasion]
Neoplasm Metastasis
[Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer]
Neoplasm Metastasis
[Inhibitory effect of FOY-305 on liver metastasis of the pancreatic cancer]
Neoplasm Metastasis
[Multiple emboli from a cardiac metastasis of a renal-cell carcinoma]
Neoplasm Metastasis
[Prognostic role of cisteine and serin proteases in gastriC cancer]
Neoplasm Metastasis
[Significance in gene expression of matrix metalloproteinase-9, urokinase-type plasminogen activator and tissue inhibitor of metalloproteinase for metastases of gastric and/or colo-rectal cancer]
Neoplasm Metastasis
[Significance of urokinase and its inhibitors in the invasiveness and metastasing of malignant tumors].
Neoplasm Metastasis
[Study on cases of D dimer values were dissociated from FDP-E]
Neoplasm Metastasis
[The clinical prospects for the study of the plasminogen activation system in breast cancer]
Neoplasm Metastasis
[The expression of urokinase-type plasminogen activator in oral squamous cell carcinoma]
Neoplasm Metastasis
[The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer]
Neoplasm Metastasis
[Urokinase plasminogen activator /U-PA/in blood of patients with lung cancer]
Neoplasm Metastasis
[Urokinase-type plasminogen activator as a predictor for lymph nodes metastasis of uterine cervical cancer]
Neoplasm Micrometastasis
T1 breast cancer: identification of patients at low risk of axillary lymph node metastases.
Neoplasm Micrometastasis
Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma.
Neoplasm, Residual
Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
Neoplasm, Residual
The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?
Neoplasm, Residual
Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.
Neoplasms
(4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
Neoplasms
(68)Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Neoplasms
1C.01: SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR AS A PROGNOSTIC MARKER OF ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN A BLACK POPULATION.
Neoplasms
2,3,7,8-Tetrachlorodibenzo-p-dioxin increases mRNA levels for interleukin-1beta, urokinase plasminogen activator, and tumor necrosis factor-alpha in human uterine endometrial adenocarcinoma RL95-2 cells.
Neoplasms
3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
Neoplasms
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
Neoplasms
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
Neoplasms
68Ga-labeled HBED-CC variant of uPAR targeting peptide AE105 compared with 68Ga-NODAGA-AE105.
Neoplasms
A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification.
Neoplasms
A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis.
Neoplasms
A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.
Neoplasms
A bisanthracycline (WP631) represses uPAR gene expression and cell migration of RKO colon cancer cells by interfering with transcription factor binding to a chromatin-accessible -148/-124 promoter region.
Neoplasms
A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Neoplasms
A C to T polymorphism of urokinase plasminogen activator (P141L) is associated with Helicobacter pylori infection.
Neoplasms
A C/T polymorphism in the urokinase-type plasminogen activator gene in colorectal cancer.
Neoplasms
A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors.
Neoplasms
A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
Neoplasms
A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts.
Neoplasms
A Fluorescent Carbon Nanotube Sensor Detects the Metastatic Prostate Cancer Biomarker uPA.
Neoplasms
A functional proteomics screen of proteases in colorectal carcinoma.
Neoplasms
A gene expression signature that distinguishes desmoid tumours from nodular fasciitis.
Neoplasms
A highly polymorphic CA/GT repeat in intron 3 of the human urokinase receptor gene (PLAUR).
Neoplasms
A highly potential cleavable linker for tumor targeting antibody-chemokines.
Neoplasms
A human monoclonal antibody scFv to urokinase plasminogen activator.
Neoplasms
A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Neoplasms
A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.
Neoplasms
A labile repressor acts through the NFkB-like binding sites of the human urokinase gene.
Neoplasms
A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer.
Neoplasms
A Multiscale Mathematical Model of Tumour Invasive Growth.
Neoplasms
A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer.
Neoplasms
A new tagging system for production of recombinant proteins in Drosophila S2 cells using the third domain of the urokinase receptor.
Neoplasms
A nomogram to predict individual prognosis in node-negative breast carcinoma.
Neoplasms
A novel oncogenic role for urokinase receptor in leukemia cells: molecular sponge for oncosuppressor microRNAs.
Neoplasms
A novel peptide blocking cancer cell invasion by structure-based drug design.
Neoplasms
A novel tumor targeting drug carrier for optical imaging and therapy.
Neoplasms
A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site.
Neoplasms
A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin.
Neoplasms
A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo.
Neoplasms
A personalized approach to cancer treatment: how biomarkers can help.
Neoplasms
A pharmacological analysis of the cholinergic regulation of urokinase-type plasminogen activator secretion in the human colon cancer cell line, HT-29.
Neoplasms
A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development.
Neoplasms
A prospective audit evaluating use of urokinase in oncology patients with occluded central venous access devices.
Neoplasms
A prospective double-blind randomized trial of urokinase flushes to prevent bacteremia resulting from luminal colonization of subcutaneous central venous catheters.
Neoplasms
A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue.
Neoplasms
A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth.
Neoplasms
A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix.
Neoplasms
A site for direct integrin ?v?6·uPAR interaction from structural modelling and docking.
Neoplasms
A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway.
Neoplasms
A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells.
Neoplasms
A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation.
Neoplasms
A suppressive role of mitogen inducible gene-2 in mesenchymal cancer cell invasion.
Neoplasms
A suppressor of multiple extracellular matrix-degrading proteases and cancer metastasis.
Neoplasms
A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.
Neoplasms
A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial.
Neoplasms
A8, an anti-uPA agonistic antibody, promotes metastasis of cancer cells via ERK pathway.
Neoplasms
Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
Neoplasms
Ab initio molecular simulations for proposing novel peptide inhibitors blocking the ligand-binding pocket of urokinase receptor.
Neoplasms
Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease.
Neoplasms
Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung.
Neoplasms
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.
Neoplasms
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
Neoplasms
Activation of CD95L fusion protein prodrugs by tumor-associated proteases.
Neoplasms
Activation of cultured rat hepatic stellate cells by tumoral hepatocytes.
Neoplasms
Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.
Neoplasms
Activation of the acute inflammatory phase response in idiopathic nephrotic syndrome: association with clinicopathological phenotypes and with response to corticosteroids.
Neoplasms
Activation of the anti-cancer agent upamostat by the mARC enzyme system.
Neoplasms
Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.
Neoplasms
Activation of uPAR is required for cigarette smoke extract-induced epithelial-mesenchymal transition in lung epithelial cells.
Neoplasms
Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
Neoplasms
Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.
Neoplasms
Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Neoplasms
Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth.
Neoplasms
Adenovirus E1A orchestrates the urokinase-plasminogen activator system and upregulates PAI-2 expression, supporting a tumor suppressor effect.
Neoplasms
Adenovirus E1A represses protease gene expression and inhibits metastasis of human tumor cells.
Neoplasms
Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines.
Neoplasms
Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth.
Neoplasms
Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas.
Neoplasms
Adjuvant Chemotherapy in Node-negative Breast Cancer: UPA/PAI-1 Determinations for 163 Cases.
Neoplasms
Adjuvant treatment for complement activation increases the effectiveness of photodynamic therapy of solid tumors.
Neoplasms
Alteration of the Methylation Status of Tumor-Promoting Genes Decreases Prostate Cancer Cell Invasiveness and Tumorigenesis In vitro and In vivo.
Neoplasms
Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
Neoplasms
Altered in vitro spreading and cytoskeletal organization in human glioma cells by downregulation of urokinase receptor.
Neoplasms
Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion.
Neoplasms
Amine-functionalized lanthanide-doped zirconia nanoparticles: optical spectroscopy, time-resolved fluorescence resonance energy transfer biodetection, and targeted imaging.
Neoplasms
Amino-Terminal Fragment of Urokinase Inhibits Tumor Cell Invasion In Vitro and In Vivo: Respective Contribution of the Urokinase Plasminogen Activator Receptor-Dependent or -Independent Pathway.
Neoplasms
Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Neoplasms
Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors.
Neoplasms
Amplification of the Urokinase-Type Plasminogen Activator Receptor (uPAR) Gene in Ductal Pancreatic Carcinomas Identifies a Clinically High-Risk Group.
Neoplasms
Amplification of urokinase gene in prostate cancer.
Neoplasms
Amurubicinol-induced eotaxin-3 expression in human NCI-H69 small cell lung carcinoma cells.
Neoplasms
An anti-urokinase plasminogen activator receptor (uPAR) antibody: crystal structure and binding epitope.
Neoplasms
An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.
Neoplasms
An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Neoplasms
An increase in plasminogen activator mRNA occurs at an early stage in ethylnitrosourea-induced transformation of rat brain cells.
Neoplasms
An inhibitor of urokinase and tissue plasminogen activators in Dunning R3327H prostate tumors of rats treated with D-Trp6-LH-RH.
Neoplasms
An orthotopic floor-of-mouth cancer model allows quantification of tumor invasion.
Neoplasms
Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator.
Neoplasms
Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.
Neoplasms
Anthrax toxin: structures, functions and tumour targeting.
Neoplasms
Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells.
Neoplasms
Anti-angiogenic effects of mangiferin and mechanism of action in metastatic melanoma.
Neoplasms
Anti-Invasion Effect of Crebanine and O-methylbulbocapnine from Stephania venosa via Down-Regulated MMPs and uPA.
Neoplasms
Anti-invasive activity of synthetic serine protease inhibitors and its combined effect with a matrix metalloproteinase inhibitor.
Neoplasms
Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: An orally active anti-cancer drug waiting for its call-of-duty?
Neoplasms
Antibiotic lock with vancomycin and urokinase can successfully treat colonized central venous catheters in pediatric cancer patients.
Neoplasms
Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging.
Neoplasms
Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer.
Neoplasms
Anticancer evaluation of some newly synthesized N-nicotinonitrile derivative.
Neoplasms
Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Neoplasms
Antigen levels of urokinase-type plasminogen activator receptor and its gene polymorphism related to microvessel density in colorectal cancer.
Neoplasms
Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates.
Neoplasms
Antimetastatic Potential of Quercetin Analogues with Improved Pharmacokinetic Profile: Pharmacoinformatic Preliminary Study.
Neoplasms
Antimetastatic Potentials of Phyllanthusurinaria L on A549 and Lewis Lung Carcinoma Cells via Repression of Matrix-Degrading Proteases.
Neoplasms
Antimetastatic role of Smad4 signaling in colorectal cancer.
Neoplasms
Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR).
Neoplasms
Antiprotease and antimetastatic activity of ursolic acid isolated from Salvia officinalis.
Neoplasms
Antiprotease therapy in cancer: hot or not?
Neoplasms
Antisense inhibition of urokinase: effect on malignancy in a human osteosarcoma cell line.
Neoplasms
Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors.
Neoplasms
Antisense oligonucleotides against the urokinase receptor: a therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer.
Neoplasms
Antitumor activity of the type 1 plasminogen activator inhibitor and cytotoxic conjugate in vitro.
Neoplasms
Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer.
Neoplasms
Antitumor effect and mechanism of action of a tumor-targeting recombinant human tumor necrosis factor-? fusion protein mediated by urokinase.
Neoplasms
Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-?B, on glioblastoma.
Neoplasms
Antitumor effects of Mucin 1/sec involves the modulation of urokinase-type plasminogen activator and signal transducer and activator of transcription 1 expression in tumor cells.
Neoplasms
Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor.
Neoplasms
Apigenin Suppresses the IL-1?-Induced Expression of the Urokinase-Type Plasminogen Activator Receptor by Inhibiting MAPK-Mediated AP-1 and NF-?B Signaling in Human Bladder Cancer T24 Cells.
Neoplasms
Apoptosis Induced by Knockdown of uPAR and MMP-9 is Mediated by Inactivation of EGFR/STAT3 Signaling in Medulloblastoma.
Neoplasms
Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
Neoplasms
Aspirin inhibits highly invasive prostate cancer cells.
Neoplasms
Assessment of breast cancer surgical margins with multimodal optical microscopy: A feasibility clinical study.
Neoplasms
Assessment of Complication Types and Rates Related to Diagnostic Angiography and Interventional N euroradiologic Procedures. A Four Year Review (1993-1996).
Neoplasms
Assessment of the interaction between urokinase and reactive site mutants of protein C inhibitor.
Neoplasms
Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis.
Neoplasms
Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer.
Neoplasms
Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Neoplasms
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Neoplasms
Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Neoplasms
Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer.
Neoplasms
Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Neoplasms
Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial.
Neoplasms
Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer.
Neoplasms
Autotaxin stimulates urokinase-type plasminogen activator expression through phosphoinositide 3-kinase-Akt-nuclear [corrected] factor kappa B signaling cascade in human melanoma cells.
Neoplasms
Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system.
Neoplasms
bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1/ERK2 activity.
Neoplasms
Benzodiazepine-Associated Carcinogenesis: Focus on Lorazepam-Associated Cancer Biomarker Changes in Overweight Individuals.
Neoplasms
Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9.
Neoplasms
Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Neoplasms
Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence.
Neoplasms
Binding of urokinase-type plasminogen activator receptor (uPAR) to the mannose 6-phosphate/insulin-like growth factor II receptor: contrasting interactions of full-length and soluble forms of uPAR.
Neoplasms
Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility.
Neoplasms
Binding site of amiloride to urokinase plasminogen activator depends on species.
Neoplasms
Biochemical and pathological evaluation of albendazole/thalidomide co-therapy against eosinophilic meningitis or meningoencephalitis induced by Angiostrongylus cantonensis.
Neoplasms
Biochemical markers as a predictor for lymph-node involvement in patients with cervical-cancer of the uterus.
Neoplasms
Bioconjugatable azo-based dark-quencher dyes: synthesis and application to protease-activatable far-red fluorescent probes.
Neoplasms
Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
Neoplasms
Biological implications of growth factors on the mechanism of invasion in gynecological tumor cells.
Neoplasms
Biological significance of tissue plasminogen activator content in brain tumors.
Neoplasms
Bioluminescence Imaging of Urokinase-Type Plasminogen Activator Activity in Vitro and in Tumors.
Neoplasms
Biomarker profile in stable Fontan patients.
Neoplasms
Biomarkers for predicting outcomes in chronic kidney disease.
Neoplasms
Biomarkers of blood cadmium and incidence of cardiovascular events in non-smokers: results from a population-based proteomics study.
Neoplasms
Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.
Neoplasms
Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma.
Neoplasms
Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors.
Neoplasms
Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas.
Neoplasms
Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin.
Neoplasms
Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells.
Neoplasms
Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma.
Neoplasms
Boosting the sensitivity of ligand-protein screening by NMR of long-lived states.
Neoplasms
Borrelia burgdorferi and other bacterial products induce expression and release of the urokinase receptor (CD87).
Neoplasms
Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia.
Neoplasms
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Neoplasms
Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
Neoplasms
Butyrate is a potent inhibitor of urokinase secretion by normal colonic epithelium in vitro.
Neoplasms
Calcitonin stimulates the secretion of urokinase-type plasminogen activator from prostate cancer cells: its possible implications on tumor cell invasion.
Neoplasms
Cambodian Phellinus linteus inhibits experimental metastasis of melanoma cells in mice via regulation of urokinase type plasminogen activator.
Neoplasms
Can linoleic acid and gamma-linolenic acid be important in cancer treatment?
Neoplasms
Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.
Neoplasms
Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting and in situ hybridization.
Neoplasms
Cancer cells release a covalent complex containing disulfide-linked domains from urinary plasminogen activator, neural cell adhesion molecule, and haptoglobin alpha and beta chains.
Neoplasms
Cancer invasion and metastasis: changing views.
Neoplasms
Cancer metastasis: biological and clinical aspects.
Neoplasms
Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Neoplasms
Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin.
Neoplasms
Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo.
Neoplasms
Carotenoids in Cancer Metastasis-Status Quo and Outlook.
Neoplasms
Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma.
Neoplasms
Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
Neoplasms
Caveolin-1-dependent and -independent uPAR signaling pathways contribute to ganglioside GT1b induced early apoptosis in A549 lung cancer cells.
Neoplasms
CD87-positive tumor cells in bone marrow aspirates identified by confocal laser scanning fluorescence microscopy.
Neoplasms
cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Neoplasms
CEA, EpCAM, ?v?6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy.
Neoplasms
Cell biologic factors and cancer spread.
Neoplasms
Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours.
Neoplasms
Cell surface expression of urokinase receptor in normal mammary epithelial cells and breast cancer cell lines.
Neoplasms
Cellular and extracellular plasminogen activator and inhibitor in an experimental tumour.
Neoplasms
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Neoplasms
Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer.
Neoplasms
Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
Neoplasms
Cellular mechanisms of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MAPK signaling in hepatocellular carcinoma.
Neoplasms
Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients.
Neoplasms
CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer.
Neoplasms
Challenges for drug discovery - a case study of urokinase receptor inhibition.
Neoplasms
Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Neoplasms
Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.
Neoplasms
Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures.
Neoplasms
Characterisation of a Novel Fc Conjugate of Macrophage Colony-stimulating Factor.
Neoplasms
Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells.
Neoplasms
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Neoplasms
Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals.
Neoplasms
Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma.
Neoplasms
Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.
Neoplasms
Characterization of the interaction between heterodimeric ?v?6 integrin and urokinase plasminogen activator receptor (uPAR) using functional proteomics.
Neoplasms
Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
Neoplasms
CHK1 and RAD51 activation after DNA damage is regulated via urokinase receptor/TLR4 signaling.
Neoplasms
Chromosomal localization of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes: implications in colorectal cancer.
Neoplasms
Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder.
Neoplasms
Circulating intact and cleaved forms of the urokinase-type plasminogen activator receptor: biological variation, reference intervals and clinical useful cut-points.
Neoplasms
Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.
Neoplasms
Circulating proteins as predictors of incident heart failure in the elderly.
Neoplasms
Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
Neoplasms
Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - ?1 (TGF-?1) and potential effects on migration and invasion.
Neoplasms
Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
Neoplasms
Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway.
Neoplasms
Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients.
Neoplasms
Clinical features and prognostic factors in Covid-19: A prospective cohort study.
Neoplasms
Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients.
Neoplasms
Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer.
Neoplasms
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Neoplasms
Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer.
Neoplasms
Clinical significance of plasma tissue factor pathway and urokinase-type plasminogen activator system in cancer patients.
Neoplasms
Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients.
Neoplasms
Clinical significance of the uPA system in gastric cancer with peritoneal metastasis.
Neoplasms
Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
Neoplasms
Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer.
Neoplasms
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Neoplasms
Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
Neoplasms
Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
Neoplasms
Clinicopathological significance of urokinase-type plasminogen activator genotypes in gastric cancer.
Neoplasms
Clotting factors in tumour tissue: implications for cancer therapy.
Neoplasms
Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.
Neoplasms
Co-expression of uPAR and CXCR4 promotes tumor growth and metastasis in small cell lung cancer.
Neoplasms
Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues.
Neoplasms
Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression.
Neoplasms
Colonic epithelial cell activation and the paradoxical effects of butyrate.
Neoplasms
Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma.
Neoplasms
Combined histomorphologic and immunohistochemical phenotype to predict the presence of vascular invasion in colon cancer.
Neoplasms
Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Neoplasms
Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma.
Neoplasms
Commentary: targeting colorectal cancer through molecular biology.
Neoplasms
Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis.
Neoplasms
Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells.
Neoplasms
Comparison of anti-invasive activity of parthenolide and 3-isopropyl-2-methyl-4-methyleneisoxazolidin-5-one (MZ-6)--a new compound with ?-methylene-?-lactone motif--on two breast cancer cell lines.
Neoplasms
Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate.
Neoplasms
Comparison of intraperitoneal anti-adhesive polysaccharides derived from Phellinus mushrooms in a rat peritonitis model.
Neoplasms
Comparison of the effects of auranofin and retinoic acid on plasminogen activator activity of peritoneal macrophages and Lewis lung carcinoma cells.
Neoplasms
Comparison of the tumor associated proteases cathepsin D (CATH D) and urokinase-type plasminogen activator (uPA) in cytosols of human breast cancer patients.
Neoplasms
Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
Neoplasms
Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.
Neoplasms
Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
Neoplasms
Computational Approaches and Analysis for a Spatio-Structural-Temporal Invasive Carcinoma Model.
Neoplasms
Computer aided identification of small molecules disrupting uPAR/alpha5beta1--integrin interaction: a new paradigm for metastasis prevention.
Neoplasms
Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment.
Neoplasms
Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines.
Neoplasms
Construction of Urokinase-Type Plasminogen Activator Receptor-Targeted Heterostructures for Efficient Photothermal Chemotherapy against Cervical Cancer To Achieve Simultaneous Anticancer and Antiangiogenesis.
Neoplasms
Content and characterization of plasminogen activators in human lung tumors and normal lung tissue.
Neoplasms
Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
Neoplasms
Controlled release of PEG chain from gold nanorods: targeted delivery to tumor.
Neoplasms
Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness.
Neoplasms
Coordinate inhibition of plasminogen activator and tumor growth by hydrocortisone in mouse mammary carcinoma.
Neoplasms
Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results.
Neoplasms
Correction: Targeting Tumor Cell Invasion and Dissemination In Vivo by an Aptamer that Inhibits Urokinase-type Plasminogen Activator through a Novel Multifunctional Mechanism.
Neoplasms
Correlates for disease progression and prognosis during concurrent HIV/TB infection.
Neoplasms
Correlation between tumor proliferation and tumor tissue level of urokinase-type plasminogen activator.
Neoplasms
Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells.
Neoplasms
Correlation of tissue and blood plasminogen activation system in breast cancer.
Neoplasms
Correlation of tumor plasminogen activator with peritumoral cerebral edema. A CT and biochemical study.
Neoplasms
Crebanine, an aporphine alkaloid, sensitizes TNF-?-induced apoptosis and suppressed invasion of human lung adenocarcinoma cells A549 by blocking NF-?B-regulated gene products.
Neoplasms
Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
Neoplasms
Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.
Neoplasms
CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases.
Neoplasms
Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA.
Neoplasms
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Neoplasms
Cyclooxygenase-2 alters transforming growth factor-beta 1 response during intestinal tumorigenesis.
Neoplasms
Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.
Neoplasms
Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
Neoplasms
Cysteine and serine proteases in gastric cancer.
Neoplasms
Cysteine peptidases and their inhibitors in breast and genital cancer.
Neoplasms
Cytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro.
Neoplasms
Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.
Neoplasms
Decoy molecules based on PNA-DNA chimeras and targeting Sp1 transcription factors inhibit the activity of urokinase-type plasminogen activator receptor (uPAR) promoter.
Neoplasms
Decreased expression of intercellular adhesion molecule-1 (ICAM-1) and urokinase-type plasminogen activator receptor (uPAR) is associated with tumor cell spreading in vivo.
Neoplasms
Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1).
Neoplasms
Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase-induced tyrosine phosphorylation.
Neoplasms
Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
Neoplasms
Deficiency of plasminogen activator inhibitor-2 results in accelerated tumor growth.
Neoplasms
Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma.
Neoplasms
Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.
Neoplasms
Demonstration of a possible link between high grade malignancy in dimethylbenz[a]anthracene-induced rat mammary carcinoma and increased urokinase plasminogen activator content.
Neoplasms
Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization.
Neoplasms
Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness.
Neoplasms
Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer.
Neoplasms
Deregulated activation of matriptase in breast cancer cells.
Neoplasms
Deregulated Expression of Urokinase and its Inhibitor Type 1 in Prostate Cancer Cells: Role of Epigenetic Mechanisms.
Neoplasms
Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype.
Neoplasms
Design and testing of a packaged microfluidic cell for the multiplexed electrochemical detection of cancer markers.
Neoplasms
Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents.
Neoplasms
Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive near-infrared reporter.
Neoplasms
Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor.
Neoplasms
Designing tracers for PET imaging of the urokinase-type plasminogen activator receptor from a cyclic uPA-derived peptide: first in vitro evaluations.
Neoplasms
Detecting in vivo urokinase plasminogen activator activity with a catalyCEST MRI contrast agent.
Neoplasms
Detection of in vivo enzyme activity with CatalyCEST MRI.
Neoplasms
Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
Neoplasms
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Neoplasms
Detection of soluble urokinase receptor by immunoradiometric assay and its application in tumor patients.
Neoplasms
Detection of the plasmin system in human mammary pathology using immunofluorescence.
Neoplasms
Detection of the receptor for the human urokinase-type plasminogen activator using fluoresceinated uPA.
Neoplasms
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
Neoplasms
Development of AE147 Peptide-Conjugated Nanocarriers for Targeting uPAR-Overexpressing Cancer Cells.
Neoplasms
Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners.
Neoplasms
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.
Neoplasms
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Neoplasms
Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: lack of association with in vitro invasion.
Neoplasms
Differential effect of radiation on endothelial cell function in rectal cancer and normal rectum.
Neoplasms
Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblasts.
Neoplasms
Differential expression levels of urokinase-type plasminogen activator and cathepsin D in locally advanced laryngeal squamous cell carcinoma: clinical implications.
Neoplasms
Differential expression of angiogenic cytokines by cell lines and primary cultures of human prostate cancer.
Neoplasms
Differential expression of c-jun and c-fos mRNAs in squamous cell carcinoma of the head and neck: associations with uPA, gelatinase B, and matrilysin mRNAs.
Neoplasms
Differential expression of genes by tumor cells of a low or a high malignancy phenotype: The case of murine and human Ly-6 proteins.
Neoplasms
Differential expression of genes by tumor cells of a low or a high malignancy phenotype: the case of murine and human Ly-6 proteins.
Neoplasms
Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
Neoplasms
Differential expression of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse skin after exposure to a tumor-promoting phorbol ester.
Neoplasms
Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Neoplasms
Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer.
Neoplasms
Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
Neoplasms
Differential regulation of plasminogen activators by epidermal growth factor in normal and neoplastic human urothelium.
Neoplasms
Differential roles of uPAR in peritoneal ovarian carcinomatosis.
Neoplasms
Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma.
Neoplasms
Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
Neoplasms
Direct evidence of the importance of vitronectin and its interaction with the urokinase receptor in tumor growth.
Neoplasms
Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase.
Neoplasms
Directed migration of murine and human tumor cells to collagenases and other proteases.
Neoplasms
Discovering novel ligands for macromolecules using X-ray crystallographic screening.
Neoplasms
Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
Neoplasms
Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.
Neoplasms
Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip.
Neoplasms
Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion.
Neoplasms
Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
Neoplasms
Distinct Immune Imprints of Post-Liver Transplantation Hepatitis C Persist Despite Viral Clearance.
Neoplasms
DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients.
Neoplasms
Do plasminogen activators play a role in lichen sclerosus?
Neoplasms
Docosahexaenoic Acid Downregulates EGF-Induced Urokinase Plasminogen Activator and Matrix Metalloproteinase 9 Expression by Inactivating EGFR/ErbB2 Signaling in SK-BR3 Breast Cancer Cells.
Neoplasms
Docosahexaenoic Acid Inhibits Tumor Promoter-Induced Urokinase-Type Plasminogen Activator Receptor by Suppressing PKC?- and MAPKs-Mediated Pathways in ECV304 Human Endothelial Cells.
Neoplasms
Does plasma urokinase antigen reflect tumor urokinase in prostatic carcinoma?
Neoplasms
Down regulation of u-PA by a nutrient mixture in hemangioma (EOMA) cells by inducing caspase-dependent apoptosis.
Neoplasms
Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation.
Neoplasms
Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells.
Neoplasms
Downregulation of angiogenic factors in Ewing tumor xenografts by the combination of human interferon-alpha or interferon-beta with ifosfamide.
Neoplasms
Downregulation of Extracellular Matrix Metalloproteinase Inducer by scFv-M6-1B9 Intrabody Suppresses Cervical Cancer Invasion Through Inhibition of Urokinase-Type Plasminogen Activator.
Neoplasms
Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer.
Neoplasms
Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
Neoplasms
Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells.
Neoplasms
Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma.
Neoplasms
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Neoplasms
Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells.
Neoplasms
Downregulation of urokinase-type plasminogen activator receptor (uPAR) induces caspase-mediated cell death in human glioblastoma cells.
Neoplasms
DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression.
Neoplasms
Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B.
Neoplasms
DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Neoplasms
Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo.
Neoplasms
Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
Neoplasms
E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma.
Neoplasms
Early detection of pancreatic cancers in liquid biopsies by ultrasensitive fluorescence nanobiosensors.
Neoplasms
Early events of metastasis in the microcirculation involve changes in gene expression of cancer cells. Tracking mRNA levels of metastasizing cancer cells in the chick embryo chorioallantoic membrane.
Neoplasms
Effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) on the liver metastasis of colon 26-L5 carcinoma cells.
Neoplasms
Effect of antisense inhibition of Urokinase receptor on malignancy.
Neoplasms
Effect of bFGF on invasion of ovarian cancer cells through the regulation of Ets-1 and urokinase-type plasminogen activator.
Neoplasms
Effect of body-weight loading onto the articular cartilage on the occurrence of quinolone-induced chondrotoxicity in juvenile rats.
Neoplasms
Effect of bone resorbing factors on u-PA and its specific receptor in osteosarcoma cell line.
Neoplasms
Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion.
Neoplasms
Effect of TGF-beta 1 and TNF-alpha on the plasminogen system of rat proximal tubular epithelial cells.
Neoplasms
Effect of transforming growth factor-beta on plasminogen activator production of cultured human uveal melanoma cells.
Neoplasms
Effect of urokinase on growth and metastases of rabbit V2 carcinoma.
Neoplasms
Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis.
Neoplasms
Effects of 1 year of exercise training versus combined exercise training and weight loss on body composition, low-grade inflammation and lipids in overweight patients with coronary artery disease: a randomized trial.
Neoplasms
Effects of a highly controlled carbohydrate-reduced high-protein diet on markers of oxidatively generated nucleic acid modifications and inflammation in weight stable participants with type 2 diabetes; a randomized controlled trial.
Neoplasms
Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases.
Neoplasms
Effects of Coriandrum sativum on Migration and Invasion Abilities of Cancer Cells.
Neoplasms
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Neoplasms
Effects of in vivo culture of murine mammary adenocarcinoma cells on tumor and metastatic growth.
Neoplasms
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
Neoplasms
Effects of macrophage-colony stimulating factor on human monocytes: induction of expression of urokinase-type plasminogen activator, but not of secreted prostaglandin E2, interleukin-6, interleukin-1, or tumor necrosis factor-alpha.
Neoplasms
Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes.
Neoplasms
Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Neoplasms
Effects of sex steroids and growth factors on invasive activity and 5'-deoxy-5-fluorouridine sensitivity in ovarian adenocarcinoma OMC-3 cells.
Neoplasms
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Neoplasms
Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.
Neoplasms
Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice.
Neoplasms
Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells.
Neoplasms
Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin.
Neoplasms
EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases.
Neoplasms
EGFR and ?v?6 as Promising Targets for Molecular Imaging of Cutaneous and Mucosal Squamous Cell Carcinoma of the Head and Neck Region.
Neoplasms
Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA).
Neoplasms
Electroanalysis of pM-levels of urokinase plasminogen activator in serum by phosphorothioated RNA aptamer.
Neoplasms
Elevated cell proliferation and VEGF production by high-glucose conditions in Müller cells involve XIAP.
Neoplasms
Elevated levels of angiostatin in effusions from patients with malignant disease.
Neoplasms
Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection.
Neoplasms
Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients: still looking for a marker of treatment efficacy.
Neoplasms
Elevated levels of urokinase-type plasminogen activator and its receptor during tumor growth in vivo.
Neoplasms
Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.
Neoplasms
Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.
Neoplasms
Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis.
Neoplasms
Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Neoplasms
Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer.
Neoplasms
Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor.
Neoplasms
ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients.
Neoplasms
Elucidation of the Contribution of Active Site and Exosite Interactions to Affinity and Specificity of Peptidylic Serine Protease Inhibitors, using Non-natural Arginine Analogs.
Neoplasms
EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression.
Neoplasms
Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes.
Neoplasms
Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma.
Neoplasms
Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating alpha(v)beta5 vitronectin receptor cell surface expression.
Neoplasms
Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography.
Neoplasms
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
Neoplasms
Enhanced spontaneous metastasis in bikunin-deficient mice.
Neoplasms
Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Neoplasms
Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness.
Neoplasms
Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue.
Neoplasms
Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells.
Neoplasms
Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Neoplasms
Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications.
Neoplasms
Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application?
Neoplasms
Epidermal growth factor receptor-mediated regulation of urokinase plasminogen activator expression and glioblastoma invasion via C-SRC/MAPK/AP-1 signaling pathways.
Neoplasms
Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator.
Neoplasms
Epigenetic modification of transgenes under the control of the mouse mammary tumor virus LTR: tissue-dependent influence on transcription of the transgenes.
Neoplasms
Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.
Neoplasms
Epigenetic upregulation of urokinase plasminogen activator promotes the tropism of mesenchymal stem cells for tumor cells.
Neoplasms
Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
Neoplasms
ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation.
Neoplasms
Estimating the Roles of Protonation and Electronic Polarization in Absolute Binding Affinity Simulations.
Neoplasms
Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: correlation with clinical outcome of anti-estrogen therapy.
Neoplasms
Ets-1 positively regulates expression of urokinase-type plasminogen activator (uPA) and invasiveness of astrocytic tumors.
Neoplasms
Evaluating the value of uPAR of serum and tissue on patients with cervical cancer.
Neoplasms
Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX(®), clinicopathological markers and tumor cell dissemination in the blood and bone marrow.
Neoplasms
Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Neoplasms
Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma.
Neoplasms
Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Neoplasms
Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer.
Neoplasms
Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and ?1 Integrin in Patients with Hodgkin's Lymphoma.
Neoplasms
Evidence for the clinical use of tumour markers.
Neoplasms
Evolving role of uPA/uPAR system in human cancers.
Neoplasms
Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma.
Neoplasms
Explaining urokinase type plasminogen activator inhibition by amino-5-hydroxybenzimidazole and two naphthamidine-based compounds through quantum biochemistry.
Neoplasms
Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study.
Neoplasms
Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma.
Neoplasms
Expression and localisation of urokinase-type plasminogen activator gene in gliomas.
Neoplasms
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Neoplasms
Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.
Neoplasms
Expression and localization of urokinase-type plasminogen activator receptor in human gliomas.
Neoplasms
Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Neoplasms
Expression and purification of recombinant ATF-mellitin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris.
Neoplasms
Expression of a novel factor, com1, in early tumor progression of breast cancer.
Neoplasms
Expression of a urokinase-type plasminogen activator during tumor growth leads to angiogenesis via galanin activation in tumor-bearing mice.
Neoplasms
Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis.
Neoplasms
Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.
Neoplasms
Expression of C4.4A, a structural uPAR homolog, reflects squamous epithelial differentiation in the adult mouse and during embryogenesis.
Neoplasms
Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer.
Neoplasms
Expression of integrins, degradative enzymes and their inhibitors in uveal melanoma: differences between in vitro and in vivo expression.
Neoplasms
Expression of MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical intraepithelial neoplasia.
Neoplasms
Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
Neoplasms
Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Neoplasms
Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
Neoplasms
Expression of plasminogen activators in basal cell carcinoma.
Neoplasms
Expression of the constitutively activated RelA/NF-kappaB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion.
Neoplasms
Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: purification of the recombinant proteins and generation of polyclonal antibodies in chicken.
Neoplasms
Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Neoplasms
Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression.
Neoplasms
Expression of the urokinase-type plasminogen activator receptor in human articular chondrocytes: association with caveolin and beta 1-integrin.
Neoplasms
Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion.
Neoplasms
Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study.
Neoplasms
Expression of urokinase plasminogen activator (uPA) in the leukocytes and tissues of patients with benign and malignant breast lesions.
Neoplasms
Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Neoplasms
Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers.
Neoplasms
Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells.
Neoplasms
Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis.
Neoplasms
Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
Neoplasms
Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors.
Neoplasms
Expression of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of the oral tongue.
Neoplasms
Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms.
Neoplasms
Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
Neoplasms
Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma.
Neoplasms
Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma.
Neoplasms
Expression of urokinase-type plasminogen activator receptor is increased during epileptogenesis in the rat hippocampus.
Neoplasms
Expression of urokinase-type plasminogen activator, its receptor and type-1 plasminogen activator inhibitor is differently regulated by inhibitors of protein synthesis in human cancer cell lines.
Neoplasms
Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
Neoplasms
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Neoplasms
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma.
Neoplasms
Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Neoplasms
Expression of urokinase-type plasminogen-activator (upa) and its receptor (upar) in human ovarian-cancer cells and in-vitro invasion capacity.
Neoplasms
Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: role of oxygenation status and tumour size.
Neoplasms
Expression, Purification, and Biological Characterization of The Amino-Terminal Fragment of Urokinase in Pichia pastoris.
Neoplasms
Extending preclinical models of skeletal manifestations of malignancy to the clinical setting.
Neoplasms
Extracellular collagenases and the endocytic receptor, urokinase plasminogen activator receptor-associated protein/Endo180, cooperate in fibroblast-mediated collagen degradation.
Neoplasms
Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis.
Neoplasms
Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Neoplasms
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor.
Neoplasms
Extracellular signal-regulated kinase and AP-1 pathways are involved in reactive oxygen species-induced urokinase plasminogen activator receptor expression in human gastric cancer cells.
Neoplasms
FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions.
Neoplasms
Fecal diglycerides as selective endogenous mitogens for premalignant and malignant human colonic epithelial cells.
Neoplasms
Fibrin and Fibrinolysis in Cancer.
Neoplasms
Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells.
Neoplasms
Fibrinogen-fibrin transformation in situ in renal cell carcinoma.
Neoplasms
Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
Neoplasms
Fibrinolysis-inhibitory activity of cultured human cancer cell lines.
Neoplasms
Fibrinolytic activity in human malignant tumors.
Neoplasms
Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
Neoplasms
Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications.
Neoplasms
Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma.
Neoplasms
First-in-human uPAR PET: Imaging of Cancer Aggressiveness.
Neoplasms
Flavokawain B inhibits growth of human squamous carcinoma cells: Involvement of apoptosis and cell cycle dysregulation in vitro and in vivo.
Neoplasms
Flow cytofluorometry in tumour cell receptor analysis. Survey of the literature and recent developments concerning the urokinase-type plasminogen activator (uPA).
Neoplasms
Fluorescent probes as tools to assess the receptor for the urokinase-type plasminogen activator on tumor cells.
Neoplasms
Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Neoplasms
Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.
Neoplasms
Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.
Neoplasms
Functional structure of the somatomedin B domain of vitronectin.
Neoplasms
Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors.
Neoplasms
Ganoderma lucidum: A rational pharmacological approach to surmount cancer.
Neoplasms
Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.
Neoplasms
Gelsolin-Cu/ZnSOD interaction alters intracellular reactive oxygen species levels to promote cancer cell invasion.
Neoplasms
Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs).
Neoplasms
Gene expression patterns associated with the metastatic phenotype in rodent and human tumors.
Neoplasms
Gene transfer of a soluble IL-1 type 2 receptor-Ig fusion protein improves cardiac allograft survival in rats.
Neoplasms
Generation of antibodies to the urokinase receptor (uPAR) by DNA immunization of uPAR knockout mice: membrane-bound uPAR is not required for an antibody response.
Neoplasms
Generation of high-affinity rabbit polyclonal antibodies to the murine urokinase receptor using DNA immunization.
Neoplasms
Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies.
Neoplasms
Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.
Neoplasms
Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia.
Neoplasms
Genistein reduces tumor necrosis factor alpha-induced plasminogen activator inhibitor-1 transcription but not urokinase expression in human endothelial cells.
Neoplasms
Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels.
Neoplasms
Germinated Brown Rice Attenuates Atherosclerosis and Vascular Inflammation in Low-Density Lipoprotein Receptor-Knockout Mice.
Neoplasms
Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
Neoplasms
GPI-specific phospholipase D mRNA expression in tumor cells of different malignancy.
Neoplasms
Granulocyte elastase, tumor necrosis factor-alpha and urokinase levels as prognostic markers in severe infection.
Neoplasms
Grape seed extract suppresses MDA-MB231 breast cancer cell migration and invasion.
Neoplasms
Graphene nanosheets as an electric mediator for ultrafast sensing of urokinase plasminogen activator receptor-A biomarker of cancer.
Neoplasms
Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.
Neoplasms
Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.
Neoplasms
Growth inhibition of MDA-MB-231 cell line by peptides designed based on uPA.
Neoplasms
Growth of a human carcinoma (HEp3) in nude mice: rapid and efficient metastasis.
Neoplasms
Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme.
Neoplasms
Heat shock proteins HSP70 and MRJ cooperatively regulate cell adhesion and migration through urokinase receptor.
Neoplasms
Helicobacter pylori Colonization Drives Urokinase Receptor (uPAR) Expression in Murine Gastric Epithelium During Early Pathogenesis.
Neoplasms
Helicobacter pylori infection stimulates plasminogen activator inhibitor 1 production by gastric epithelial cells.
Neoplasms
Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors.
Neoplasms
Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer.
Neoplasms
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Neoplasms
HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer.
Neoplasms
Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase.
Neoplasms
Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.
Neoplasms
Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.
Neoplasms
Heterogeneous distribution of macrophages, tumour necrosis factor alpha, tissue factor and fibrinolytic regulators in atherosclerotic vessels.
Neoplasms
High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma.
Neoplasms
High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Neoplasms
High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
Neoplasms
High levels of cathepsin B predict poor outcome in patients with breast cancer.
Neoplasms
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Neoplasms
High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
Neoplasms
High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer.
Neoplasms
High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma.
Neoplasms
High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer.
Neoplasms
High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
Neoplasms
High-affinity urokinase receptor antagonists identified with bacteriophage peptide display.
Neoplasms
HMG-CoA reductase inhibitors reduce matrix metalloproteinase-9 activity in human varicose veins.
Neoplasms
Homocysteine inhibits the proliferation and invasive potential of HT-1080 human fibrosarcoma cells.
Neoplasms
Host protein C inhibitor inhibits tumor growth, but promotes tumor metastasis, which is closely correlated with hypercoagulability.
Neoplasms
HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI.
Neoplasms
Human and canine mammary tumors: A role for urokinase plasminogen activator?
Neoplasms
Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.
Neoplasms
Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator.
Neoplasms
Human primary colon carcinomas xenografted into nude mice. I. Characterization of plasminogen activators expressed by primary tumors and their xenografts.
Neoplasms
Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells.
Neoplasms
Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.
Neoplasms
Human sprouty1 suppresses urokinase receptor-stimulated cell migration and invasion.
Neoplasms
Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.
Neoplasms
Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels.
Neoplasms
Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells.
Neoplasms
Hyaluronan-oligosaccharide-induced transcription of metalloproteases.
Neoplasms
Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid.
Neoplasms
Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications.
Neoplasms
Hypoxia Effects: Implications for Maspin Regulation of the uPA/uPAR Complex.
Neoplasms
Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression.
Neoplasms
Identification and preclinical development of an anti-proteolytic uPA antibody for rheumatoid arthritis.
Neoplasms
Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (?M).
Neoplasms
Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression.
Neoplasms
Identification of differential pathways in papillary thyroid carcinoma utilizing pathway co-expression analysis.
Neoplasms
Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography.
Neoplasms
Identification of Ras suppressor-1 (RSU-1) as a potential breast cancer metastasis biomarker using a three-dimensional in vitro approach.
Neoplasms
Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging.
Neoplasms
IFN-gamma, tumor necrosis factor-alpha, and urokinase regulate the expression of urokinase receptors on human monocytes.
Neoplasms
IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma.
Neoplasms
IL-1 beta induces urokinase-plasminogen activator expression and cell migration through PKC alpha, JNK1/2, and NF-kappaB in A549 cells.
Neoplasms
Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET.
Neoplasms
Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of mesothelial cells.
Neoplasms
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Neoplasms
Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response.
Neoplasms
Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: correlation with CEA distribution and tumor cell kinetics.
Neoplasms
Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours.
Neoplasms
Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
Neoplasms
Immunohistochemical Detection of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor in Canine Vascular Endothelial Tumours.
Neoplasms
Immunohistochemical evaluation of urokinase plasminogen activator receptor in noninvasive and early invasive urothelial papillary neoplasia.
Neoplasms
Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma.
Neoplasms
Immunohistochemical expression of Ets-1 transcription factor and the urokinase-type plasminogen activator is correlated with the malignant and invasive potential in meningiomas.
Neoplasms
Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
Neoplasms
Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
Neoplasms
Immunohistochemical profile of cystosarcoma phyllodes of the breast: a study of 23 cases.
Neoplasms
Immunologic detection of the cellular receptor for urokinase plasminogen activator.
Neoplasms
Immunological analysis of plasminogen activators from cultured human cancer cells.
Neoplasms
Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer.
Neoplasms
Impact of Saskatoon berry powder on insulin resistance and relationship with intestinal microbiota in high fat-high sucrose diet-induced obese mice.
Neoplasms
Impact of uPA system gene polymorphisms on the susceptibility of environmental factors to carcinogenesis and the development of clinicopathology of oral cancer.
Neoplasms
Impaired MicroRNA Processing Facilitates Breast Cancer Cell Invasion by Upregulating Urokinase-Type Plasminogen Activator Expression.
Neoplasms
Improved Immuno-PET Imaging of HER2-Positive Tumors in Mice: Urokinase Injection-Triggered Clearance Enhancement of 64Cu-Trastuzumab.
Neoplasms
Improved positron emission tomography imaging of glioblastoma cancer using novel
Neoplasms
In papillary thyroid carcinoma BRAF(V) (600E) is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Neoplasms
In vitro activity of probiotic Lactobacillus reuteri against gastric cancer progression by downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor gene expression.
Neoplasms
In vitro and in vivo antimetastatic effects of Terminalia catappa L. leaves on lung cancer cells.
Neoplasms
In vitro inhibition of human sarcoma cells' invasive ability by bis(5-amidino-2-benzimidazolyl)methane--a novel esteroprotease inhibitor.
Neoplasms
In vitro receptor imaging for characterization of human solid tumors.
Neoplasms
In vitro suppression of urokinase plasminogen activator in breast cancer cells--a comparison of two antisense strategies.
Neoplasms
In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer.
Neoplasms
In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase.
Neoplasms
In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model.
Neoplasms
In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.
Neoplasms
In-vivo imaging of tumor associated urokinase-type plasminogen activator activity.
Neoplasms
Inactivation of human tumor cell pro-urokinase by granulocyte elastase.
Neoplasms
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Neoplasms
Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate.
Neoplasms
Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas.
Neoplasms
Increased cell-surface urokinase in advanced ovarian cancer.
Neoplasms
Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas.
Neoplasms
Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas.
Neoplasms
Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Neoplasms
Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis.
Neoplasms
Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Neoplasms
Increased plasminogen activator inhibition levels in malignancy.
Neoplasms
Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
Neoplasms
Increased urokinase activity to antigen ratio in human renal-cell carcinoma.
Neoplasms
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
Neoplasms
Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Neoplasms
Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis.
Neoplasms
Indirect activation of blood coagulation in colon cancer.
Neoplasms
Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer.
Neoplasms
Inducible changes in cell size and attachment area due to expression of a mutant SWI/SNF chromatin remodeling enzyme.
Neoplasms
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.
Neoplasms
Induction of IL-8 and monoclyte chemoattractant protein-1 by doxorubicin in human small cell lung carcinoma cells.
Neoplasms
Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells.
Neoplasms
Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Neoplasms
Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells.
Neoplasms
Induction of Urokinase Activity by Retinoic Acid in Two Cell Lines of Neuronal Origin.
Neoplasms
Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells.
Neoplasms
Inflammation and post-operative recovery in patients undergoing total knee arthroplasty-secondary analysis of a randomized controlled trial.
Neoplasms
Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer.
Neoplasms
Inflammatory markers associated with abdominal aortic aneurysm.
Neoplasms
Inflammatory mediators after endovascular aortic aneurysm repair.
Neoplasms
Influence of drinking green tea on breast cancer malignancy among Japanese patients.
Neoplasms
Influence of freeze-drying on the recovery of the tumour invasion markers uPA and PAI-1 from prostate cancer resections.
Neoplasms
Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue.
Neoplasms
Inhibition activities of natural products on serine proteases.
Neoplasms
Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
Neoplasms
Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist.
Neoplasms
Inhibition of fibrinolysis by a synthetic urokinase inhibitor enhances lung colonization of metastatic murine mammary tumor cells.
Neoplasms
Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer.
Neoplasms
Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.
Neoplasms
Inhibition of human tumor cell-associated fibrinolysis by vascular bovine smooth muscle cells.
Neoplasms
Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors.
Neoplasms
Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor.
Neoplasms
Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428.
Neoplasms
Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones.
Neoplasms
Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates.
Neoplasms
Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.
Neoplasms
Inhibition of nuclear factor-?B signaling suppresses Spint-1-deletion-induced tumor susceptibility in the ApcMin/+ model.
Neoplasms
Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade.
Neoplasms
Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif.
Neoplasms
Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells.
Neoplasms
Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.
Neoplasms
Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
Neoplasms
Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: the influence of the ester group on their biological activity.
Neoplasms
Inhibition of Tumor Growth and Metastasis by ATF-Fc, an Engineered Antibody: Targeting Urokinase Receptor.
Neoplasms
Inhibition of tumor implantation at sites of trauma by plasminogen activators.
Neoplasms
Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.
Neoplasms
Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model.
Neoplasms
Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, WXC-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases.
Neoplasms
Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells.
Neoplasms
Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse.
Neoplasms
Inhibitors of proteases as anticancer drugs.
Neoplasms
Inhibitors of the protease domain of urokinase-type plasminogen activator.
Neoplasms
Inhibitors of the proteolytic activity of urokinase type plasminogen activator.
Neoplasms
Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
Neoplasms
Inhibitors of urokinase type plasminogen activator and cytostatic activity from crude plants extracts.
Neoplasms
Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro.
Neoplasms
Inhibitory effect of a synthetic prostacyclin analogue, beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells.
Neoplasms
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Neoplasms
Inhibitory Effects of a Reengineered Anthrax Toxin on Canine Oral Mucosal Melanomas.
Neoplasms
Inhibitory role of plasminogen activator inhibitor-1 in invasion and proliferation of HLE hepatocellular carcinoma cells.
Neoplasms
Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Neoplasms
Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.
Neoplasms
Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.
Neoplasms
Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA).
Neoplasms
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
Neoplasms
Interventions to obstructive long-term central venous catheter in cancer patients: a meta-analysis.
Neoplasms
Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.
Neoplasms
Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients.
Neoplasms
Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Neoplasms
Invasion and metastasis.
Neoplasms
Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display.
Neoplasms
Invasion-Metastasis by Hepatocyte Growth Factor/c-Met Signaling Concomitant with Induction of Urokinase Plasminogen Activator in Human Pancreatic Cancer: Role as Therapeutic Target.
Neoplasms
Invasive capacity of heterotopic endometrium.
Neoplasms
Invasiveness of hepatocellular carcinoma cell lines: contribution of membrane-type 1 matrix metalloproteinase.
Neoplasms
Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer.
Neoplasms
Involvement of fibronectin in the regulation of urokinase production and binding in murine mammary tumor cells.
Neoplasms
Involvement of Platelets in Cancers.
Neoplasms
Involvement of TNF-alpha in enhancement of invasion and metastasis of colon 26-L5 carcinoma cells in mice by social isolation stress.
Neoplasms
Involvement of Urokinase-Type Plasminogen Activator System in Cancer: An Overview.
Neoplasms
IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts.
Neoplasms
Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells.
Neoplasms
Is inhibition process better described with MD(QM/MM) simulations? The case of urokinase type plasminogen activator inhibitors.
Neoplasms
Is the circulating urokinase plasminogen activator upregulated by the circulating p105 fraction of the HER-2/neu proto-oncogene in patients with cervical cancer?
Neoplasms
Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
Neoplasms
Is urokinase gene 3'-UTR polymorphism associated with prostate cancer?
Neoplasms
Isolated splenic metastasis of sigmoid colon cancer: a case report.
Neoplasms
Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA.
Neoplasms
JNK Suppression is Essential for 17beta-Estradiol Inhibits Prostaglandin E2-Induced uPA and MMP-9 Expressions and Cell Migration in Human LoVo Colon Cancer Cells.
Neoplasms
JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation.
Neoplasms
Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
Neoplasms
Knock-down of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells.
Neoplasms
Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: a multicentre randomised comparison of urokinase versus heparin.
Neoplasms
Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.
Neoplasms
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.
Neoplasms
Lanthanide-doped NaScF4 nanoprobes: crystal structure, optical spectroscopy and biodetection.
Neoplasms
Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Neoplasms
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Neoplasms
Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array.
Neoplasms
Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
Neoplasms
LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system.
Neoplasms
Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.
Neoplasms
Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus.
Neoplasms
Local function of urokinase receptor at the adhesion contact sites of a metastatic tumor cell.
Neoplasms
Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients.
Neoplasms
Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Neoplasms
Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas.
Neoplasms
Loss of Inhibitor of Growth (ING-4) Is Implicated in the Pathogenesis and Progression of Human Astrocytomas.
Neoplasms
Loss of mitochondrial DNA enhances angiogenic and invasive potential of hepatoma cells.
Neoplasms
Loss of the metastatic phenotype by a human epidermoid carcinoma cell line, HEp-3, is accompanied by increased expression of tissue inhibitor of metalloproteinase 2.
Neoplasms
Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.
Neoplasms
Low molecular weight heparin suppresses tumor necrosis factor expression from deep vein thrombosis.
Neoplasms
Low-dose urokinase infusions to treat fibrinous obstruction of venous access devices in cancer patients.
Neoplasms
Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells.
Neoplasms
Lysosome labilizers potentiate the antitumor effects of tumor necrosis factor-alpha.
Neoplasms
Macrophage colony-stimulating factor could evaluate both disease activity and renal involvement in systemic lupus erythematosus.
Neoplasms
Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.
Neoplasms
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Neoplasms
MAGE-A gene expression pattern in primary breast cancer.
Neoplasms
Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ.
Neoplasms
Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.
Neoplasms
Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.
Neoplasms
Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography.
Neoplasms
Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer.
Neoplasms
Markers of the uPA system and common prognostic factors in breast cancer.
Neoplasms
Maspin inhibits cell migration in the absence of protease inhibitory activity.
Neoplasms
Mathematical modeling of cancer cell invasion of tissue: biological insight from mathematical analysis and computational simulation.
Neoplasms
Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions.
Neoplasms
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.
Neoplasms
Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.
Neoplasms
Melanoma antigen-encoding gene-1 expression in invasive gastric carcinoma: correlation with stage of disease.
Neoplasms
Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme.
Neoplasms
Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways.
Neoplasms
Mesenchymal stem cells from adipose and bone marrow promote angiogenesis via distinct cytokine and protease expression mechanisms.
Neoplasms
Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer.
Neoplasms
Metabolism and distribution of two highly potent and selective peptidomimetic inhibitors of matriptase.
Neoplasms
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice.
Neoplasms
Metalloproteases and urokinase in angiogenesis and tumor progression.
Neoplasms
Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
Neoplasms
Metastatic behavior of prostatic tumor as influenced by the hematopoietic and hematogenous factors.
Neoplasms
Metastatic brain tumour and fibrinopeptides.
Neoplasms
Metastatic effect of LY-6K gene in breast cancer cells.
Neoplasms
Methods to analyze the effects of the urokinase system on cancer cell adhesion, proliferation, migration, and signal transduction events.
Neoplasms
Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo.
Neoplasms
MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.
Neoplasms
Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
Neoplasms
Mistletoe Extract Targets the STAT3-FOXM1 Pathway to Induce Apoptosis and Inhibits Metastasis in Breast Cancer Cells.
Neoplasms
MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate.
Neoplasms
Modified Panax ginseng Extract Inhibits uPAR-Mediated ?[Formula: see text]?1-Integrin Signaling by Modulating Caveolin-1 to Induce Early Apoptosis in Lung Cancer Cells.
Neoplasms
Modulation of growth and urokinase secretion by vasopressin and closely related nonapeptides in metastatic mouse mammary tumor cells.
Neoplasms
Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Neoplasms
Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells.
Neoplasms
Modulation of the urokinase-type plasminogen activator receptor by the beta6 integrin subunit.
Neoplasms
Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines.
Neoplasms
Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human glioblastoma cell lines.
Neoplasms
Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.
Neoplasms
Modulation of urokinase-type plasminogen activator and metalloproteinase activities in cultured mouse mammary-carcinoma cells: enhancement by paclitaxel and inhibition by nocodazole.
Neoplasms
Modulation of urokinase-type plasminogen activator gene expression by inflammatory cytokines in human pre-B lymphoma cell line RC-K8.
Neoplasms
Modulation of urokinase-type plasminogen-activator expression by the wild-type and mutated p53 tumor-suppressor gene.
Neoplasms
Modulations of functional activity in differentiated macrophages are accompanied by early and transient increase or decrease in c-fos gene transcription.
Neoplasms
Modulators of the urokinase-type plasminogen activation system for cancer.
Neoplasms
Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Neoplasms
Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.
Neoplasms
Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles.
Neoplasms
Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer.
Neoplasms
Molecular interactions in cancer cell metastasis.
Neoplasms
Molecular mechanisms of anticancer activity of deoxyelephantopin in cancer cells.
Neoplasms
Molecular mechanisms of malignant conversion in skin carcinogenesis.
Neoplasms
Molecular mechanisms of protease-mediated tumor invasiveness.
Neoplasms
Molecular modeling as a new approach to the development of urokinase inhibitors.
Neoplasms
Molecular photoacoustic tomography of breast cancer using receptor targeted magnetic iron oxide nanoparticles as contrast agents.
Neoplasms
Molecular regulation of an invasion-related molecule--options for tumour staging and clinical strategies.
Neoplasms
Molecular targeted NIR-II probe for image-guided brain tumor surgery.
Neoplasms
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Neoplasms
Mortality and major complications after emergency laparotomy: A pilot study of risk prediction model development by preoperative blood-based immune parameters.
Neoplasms
MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-?B p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells.
Neoplasms
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Neoplasms
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review).
Neoplasms
Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.
Neoplasms
Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
Neoplasms
Multiparametric prognostic evaluation of biological factors in primary breast cancer.
Neoplasms
Multiple forms of plasminogen activator in human breast tumors.
Neoplasms
Multiple pathways of cell invasion are regulated by multiple families of serine proteases.
Neoplasms
Multiscale Modelling of Cancer Response to Oncolytic Viral Therapy.
Neoplasms
Mutant K-ras regulates cathepsin B localization on the surface of human colorectal carcinoma cells.
Neoplasms
Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
Neoplasms
Nanoparticle Binding to Urokinase Receptor on Cancer Cell Surface Triggers Nanoparticle Disintegration and Cargo Release.
Neoplasms
Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells.
Neoplasms
New cancer therapy using genetically-engineered oncolytic Sendai virus vector.
Neoplasms
New ELISA for quantitation of human urokinase receptor (CD87) in cancer.
Neoplasms
NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4.
Neoplasms
NFkappaB-dependent regulation of urokinase plasminogen activator by proanthocyanidin-rich grape seed extract: effect on invasion by prostate cancer cells.
Neoplasms
Nicotine stimulates urokinase-type plasminogen activator receptor expression and cell invasiveness through mitogen-activated protein kinase and reactive oxygen species signaling in ECV304 endothelial cells.
Neoplasms
Nimbolide inhibits invasion and migration, and down-regulates uPAR chemokine gene expression, in two breast cancer cell lines.
Neoplasms
Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
Neoplasms
Node-Negative Breast Cancer: Which Patients Should Be Treated?
Neoplasms
Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks.
Neoplasms
Novel immunologic tolerance of human cancer cell xenotransplants in zebrafish.
Neoplasms
Novel inhibitors of urokinase-type plasminogen activator and matrix metalloproteinase expression in metastatic cancer cell lines.
Neoplasms
Novel patents and cancer therapies for transforming growth factor-beta and urokinase type plasminogen activator: potential use of their interplay in tumorigenesis.
Neoplasms
Novel protein interactors of urokinase-type plasminogen activator receptor.
Neoplasms
Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation.
Neoplasms
Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue.
Neoplasms
Nuclear Translocation of Hand-1 Acts as a Molecular Switch to Regulate Vascular Radiosensitivity in Medulloblastoma Tumors: The Protein uPAR Is a Cytoplasmic Sequestration Factor for Hand-1.
Neoplasms
Occupancy of the cancer cell urokinase receptor (uPAR): effects of acid elution and exogenous uPA on cell surface urokinase (uPA).
Neoplasms
Okadaic acid-dependent induction of the urokinase-type plasminogen activator gene associated with stabilization and autoregulation of c-Jun.
Neoplasms
One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.
Neoplasms
Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral uPAR-targeted chimera.
Neoplasms
Organization of GPI-anchored proteins at the cell surface and its physiopathological relevance.
Neoplasms
Orientation-controlled conjugation of haloalkane dehalogenase fused homing peptides to multifunctional nanoparticles for the specific recognition of cancer cells.
Neoplasms
Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management.
Neoplasms
Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
Neoplasms
Overexpression of forkhead box M1 and urokinase-type plasminogen activator in gastric cancer is associated with cancer progression and poor prognosis.
Neoplasms
Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
Neoplasms
Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis.
Neoplasms
Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis.
Neoplasms
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
Neoplasms
Overexpression of VEGF189 in breast cancer cells induces apoptosis via NRP1 under stress conditions.
Neoplasms
p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells.
Neoplasms
P38 MAPK pathway is involved in the urokinase plasminogen activator expression in human gastric SNU-638 cells.
Neoplasms
p38? MAPK Mediates 17?-Estradiol Inhibition of MMP-2 and -9 Expression and Cell Migration in Human LoVo Colon Cancer Cells.
Neoplasms
p53 and miR-34a Feedback Promotes Lung Epithelial Injury and Pulmonary Fibrosis.
Neoplasms
p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
Neoplasms
PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
Neoplasms
PAI-1 and functional blockade of SNAI1 in breast cancer cell migration.
Neoplasms
PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells.
Neoplasms
PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis.
Neoplasms
Paracrine factor and cell-cell contact-mediated induction of protease and c-ets gene expression in malignant keratinocyte/dermal fibroblast cocultures.
Neoplasms
Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression.
Neoplasms
PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.
Neoplasms
Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation.
Neoplasms
Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator.
Neoplasms
pH-Sensitive Shell-Core Platform Block DNA Repair Pathway To Amplify Irreversible DNA Damage of Triple Negative Breast Cancer.
Neoplasms
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
Neoplasms
Phorbol-ester-stimulated human lymphoid cell lines produce a plasminogen activator modulator inducing cell-bound urokinase-type plasminogen activator in malignant tumor cell lines.
Neoplasms
PI3K, Erk signaling in BMP7-induced epithelial-mesenchymal transition (EMT) of PC-3 prostate cancer cells in 2- and 3-dimensional cultures.
Neoplasms
Plasma level of soluble urokinase plasminogen activator receptor (suPAR) predicts long-term mortality after first acute alcohol-induced pancreatitis.
Neoplasms
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Neoplasms
Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Neoplasms
Plasmin-tumour necrosis factor interaction in the ovulatory process.
Neoplasms
Plasminogen activation in human leukemia and in normal hematopoietic cells.
Neoplasms
Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior.
Neoplasms
Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.
Neoplasms
Plasminogen activator content of gynecological tumors and their metastases.
Neoplasms
Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells.
Neoplasms
Plasminogen activator inhibitor 2 (PAI-2) is not inactivated by exposure to oxidants which can be released from activated neutrophils.
Neoplasms
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Neoplasms
Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
Neoplasms
Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin.
Neoplasms
Plasminogen activator inhibitor type 2 in breast cancer.
Neoplasms
Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Neoplasms
Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis.
Neoplasms
Plasminogen activator inhibitor-1 in cancer research.
Neoplasms
Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.
Neoplasms
Plasminogen activator inhibitor-2 in patients with monocytic leukemia.
Neoplasms
Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.
Neoplasms
Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.
Neoplasms
Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors.
Neoplasms
Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine.
Neoplasms
Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
Neoplasms
Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer.
Neoplasms
Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells.
Neoplasms
Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Neoplasms
Plasminogen activator/plasminogen activator inhibitor-1 and cytokine modulation by the PROACT System.
Neoplasms
Plasminogen activators and plasmin in lung cancer.
Neoplasms
Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid.
Neoplasms
Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
Neoplasms
Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas.
Neoplasms
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Neoplasms
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Neoplasms
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?
Neoplasms
Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype.
Neoplasms
Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas.
Neoplasms
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
Neoplasms
Plasminogen binding and cancer: promises and pitfalls.
Neoplasms
Plasticity in Urokinase-Type Plasminogen Activator Receptor (uPAR) Display in Colon Cancer Yields Metastable Subpopulations Oscillating in Cell Surface uPAR Density--Implications in Tumor Progression.
Neoplasms
PLAU Promotes Cell Proliferation and Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.
Neoplasms
Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Neoplasms
PLOD3 promotes lung metastasis via regulation of STAT3.
Neoplasms
Polymer Nanoparticles Mediated Codelivery of AntimiR-10b and AntimiR-21 for Achieving Triple Negative Breast Cancer Therapy.
Neoplasms
Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.
Neoplasms
Polymorphonuclear cells stimulate the migration and metastatic potential of rat sarcoma cells.
Neoplasms
Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system.
Neoplasms
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Neoplasms
Post-transcriptional regulation of urokinase plasminogen activator gene expression occurs in the nucleus of BC1 rat mammary tumor cells.
Neoplasms
Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Neoplasms
Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Neoplasms
Preclinical evaluation of [(111) In]MICA-401, an activity-based probe for SPECT imaging of in vivo uPA activity.
Neoplasms
Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2.
Neoplasms
Predicting the sites of metastases from lung cancer using molecular biologic markers.
Neoplasms
Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
Neoplasms
Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
Neoplasms
Presence of Myofibroblasts and Expression of Matrix Metalloproteinase-2 (MMP-2) in Ameloblastomas Correlate with Rupture of the Osseous Cortical.
Neoplasms
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
Neoplasms
Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance.
Neoplasms
Prevention of intraperitoneal adhesions and abscesses by polysaccharides isolated from Phellinus spp in a rat peritonitis model.
Neoplasms
Prevention of metastasis by inhibition of the urokinase receptor.
Neoplasms
Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA).
Neoplasms
Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
Neoplasms
Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
Neoplasms
Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha.
Neoplasms
Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.
Neoplasms
Probing inhibitors binding to human urokinase crystals by Raman microscopy: implications for compound screening.
Neoplasms
Production of a urokinase plasminogen activator-IgG fusion protein (uPA-IgG) in the baculovirus expression system.
Neoplasms
Production of an active urokinase by leukemia cells: a novel distinction from cell lines of solid tumors.
Neoplasms
Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.
Neoplasms
Production of recombinant lethal factor of Bacillus anthracis in Bacillus subtilis.
Neoplasms
Profibrinolytic properties characterize a stably transformed human endothelial cell line.
Neoplasms
Profiling the evolution of human metastatic bladder cancer.
Neoplasms
Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction, and cardia evaluated by uPAR-immunohistochemistry.
Neoplasms
Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
Neoplasms
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Neoplasms
Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma.
Neoplasms
Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.
Neoplasms
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Neoplasms
Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Neoplasms
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Neoplasms
Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Neoplasms
Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer.
Neoplasms
Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma.
Neoplasms
Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer.
Neoplasms
Prognostic role of urokinase-type plasminogen activator in human gliomas.
Neoplasms
Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients.
Neoplasms
Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.
Neoplasms
Prognostic significance of proteolytic enzymes in human brain tumors.
Neoplasms
Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
Neoplasms
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Neoplasms
Prognostic significance of uPA and uPAR expression in patients with cervical cancer undergoing radiotherapy.
Neoplasms
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
Neoplasms
Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
Neoplasms
Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.
Neoplasms
Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Neoplasms
Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
Neoplasms
Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC).
Neoplasms
Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.
Neoplasms
Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Neoplasms
Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma.
Neoplasms
Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.
Neoplasms
Prognostic value of urokinase plasminogen activator system in non-small cell lung cancer: A systematic review and meta-analysis.
Neoplasms
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.
Neoplasms
Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer.
Neoplasms
Proliferation of a human epidermal tumor cell line stimulated by urokinase.
Neoplasms
Properties of urokinase type-plasminogen activator found in chest fluid.
Neoplasms
Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study.
Neoplasms
Prophylaxis with urokinase in pediatric oncology patients with central venous catheters.
Neoplasms
Prostaglandin E2 regulates tumor angiogenesis in prostate cancer.
Neoplasms
Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.
Neoplasms
Prostate-specific antigen activates single-chain urokinase-type plasminogen activator.
Neoplasms
Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth.
Neoplasms
Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion.
Neoplasms
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Neoplasms
Proteases and metastasis: clinical relevance nowadays?
Neoplasms
Proteases as prognostic markers in cancer.
Neoplasms
Proteases associated with gynecological tumors.
Neoplasms
Proteases in brain tumour progression.
Neoplasms
Proteases in gastrointestinal neoplastic diseases.
Neoplasms
Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
Neoplasms
Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue.
Neoplasms
Protein C inhibitor inhibits breast cancer cell growth, metastasis and angiogenesis independently of its protease inhibitory activity.
Neoplasms
Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection.
Neoplasms
Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB.
Neoplasms
Protein kinase C is inhibited by bisphosphonates in prostate cancer PC-3 cells.
Neoplasms
Protein Kinase C Synergistically Stimulates Tumor Necrosis Factor-alpha-Induced Secretion of Urokinase-Type Plasminogen Activator in Human Dental Pulp Cells.
Neoplasms
Proteinases, their inhibitors, and cytokine profiles in acute wound fluid.
Neoplasms
Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor.
Neoplasms
Proteolysis in human breast and colorectal cancer.
Neoplasms
Proteolytic and cellular death mechanisms in ovulatory ovarian rupture.
Neoplasms
Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy.
Neoplasms
Proteolytic enzymes in proliferation and neoplastic metastases formation.
Neoplasms
Proteolytic mechanisms in the ovulatory folliculo-luteal transformation.
Neoplasms
Proteolytic networks in cancer.
Neoplasms
Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy.
Neoplasms
Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach.
Neoplasms
Proteomics Reveals Cell-Surface Urokinase Plasminogen Activator Receptor Expression Impacts Most Hallmarks of Cancer.
Neoplasms
Pulmonary epithelial cell urokinase-type plasminogen activator. Induction by interleukin-1 beta and tumor necrosis factor-alpha.
Neoplasms
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Neoplasms
Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay.
Neoplasms
Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion.
Neoplasms
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Neoplasms
Quercetin Has Antimetastatic Effects on Gastric Cancer Cells via the Interruption of uPA/uPAR Function by Modulating NF-?b, PKC-?, ERK1/2, and AMPK?.
Neoplasms
Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3).
Neoplasms
Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures.
Neoplasms
Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor.
Neoplasms
RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases.
Neoplasms
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Neoplasms
Rapid detection of urokinase plasminogen activator using flexible paper-based graphene-gold platform.
Neoplasms
Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes.
Neoplasms
Rationale for clinical trials of coagulation: reactive drugs in hepatocellular carcinoma.
Neoplasms
Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite.
Neoplasms
Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor.
Neoplasms
Recent advances in the field of anti-cancer immunotherapy.
Neoplasms
Receptor for plasmin on human carcinoma cells.
Neoplasms
Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.
Neoplasms
Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice.
Neoplasms
Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.
Neoplasms
Reduced gene expression of bikunin as a prognostic marker for renal cell carcinoma.
Neoplasms
Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy.
Neoplasms
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Neoplasms
Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 ru(ii)-dmso complexes in mice bearing lewis lung-carcinoma.
Neoplasms
Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
Neoplasms
Regulation by interleukin-3 of human monocyte pro-inflammatory mediators. Similarities with granulocyte-macrophage colony-stimulating factor.
Neoplasms
Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding.
Neoplasms
Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma.
Neoplasms
Regulation of cell signalling by uPAR.
Neoplasms
Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Neoplasms
Regulation of DNA repair mechanism in human glioma xenograft cells both in vitro and in vivo in nude mice.
Neoplasms
Regulation of fibrin deposition by malignant mesothelioma.
Neoplasms
Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines.
Neoplasms
Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1).
Neoplasms
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Neoplasms
Regulation of tumor dormancy and role of microenvironment: a mathematical model.
Neoplasms
Regulation of u-PAR gene expression by H2A.Z is modulated by the MEK-ERK/AP-1 pathway.
Neoplasms
Regulation of urokinase plasminogen activator (uPA) activity by E-cadherin and hormones in mammary epithelial cells.
Neoplasms
Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo.
Neoplasms
Regulation of Urokinase Production by Androgens in Human Prostate Cancer Cells: Effect on Tumor Growth and Metastases in Vivo1.
Neoplasms
Regulation of urokinase receptor mRNA stability by hnRNP C in lung epithelial cells.
Neoplasms
Regulation of urokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity.
Neoplasms
Regulatory Mechanism of Collagen Degradation by Keratocytes and Corneal Inflammation: The Role of Urokinase-Type Plasminogen Activator.
Neoplasms
Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells.
Neoplasms
Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.
Neoplasms
Relationship between expression of plasminogen activator system and metastatic ability in human cancers.
Neoplasms
Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes.
Neoplasms
Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies.
Neoplasms
Relationship between tumorigenicity, in vitro invasiveness, and plasminogen activator production of human breast cell lines.
Neoplasms
Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer.
Neoplasms
Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Neoplasms
Reprogramming urokinase into an antibody-recruiting anticancer agent.
Neoplasms
Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor.
Neoplasms
Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Neoplasms
Retinoic acid priming potentiates the induction of urokinase-type plasminogen activator by cyclic adenosine monophosphate in mouse mammary carcinoma cells.
Neoplasms
Retinoids inhibit protein kinase C-dependent transduction of 1,2-diglyceride signals in human colonic tumor cells.
Neoplasms
Retraction: Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.
Neoplasms
Retraction: Small Interfering RNA-Directed Reversal of Urokinase Plasminogen Activator Demethylation Inhibits Prostate Tumor Growth and Metastasis.
Neoplasms
Retraction: Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.
Neoplasms
Retroviral display of urokinase-binding domain fused to amphotropic envelope protein.
Neoplasms
Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis.
Neoplasms
Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling.
Neoplasms
Review and update of the use of urokinase in the prevention and management of CVAD-related complications in pediatric oncology patients.
Neoplasms
Revisiting the biological roles of PAI2 (SERPINB2) in cancer.
Neoplasms
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Neoplasms
RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.
Neoplasms
RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo.
Neoplasms
RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth.
Neoplasms
RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.
Neoplasms
Role of DHX33 in c-Myc-induced cancers.
Neoplasms
Role of epigenetics in cancer initiation and progression.
Neoplasms
Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
Neoplasms
ROLE OF PLASMINOGEN ACTIVATOR INHIBITOR-1 IN UROKINASE'S PARADOXICAL IN VIVO TUMOR SUPPRESSING OR PROMOTING EFFECTS.
Neoplasms
Role of protein kinase C in tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator.
Neoplasms
Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer.
Neoplasms
Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.
Neoplasms
Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies.
Neoplasms
Role of urokinase in colorectal neoplasia.
Neoplasms
Role of urokinase inhibitors in choroidal neovascularization.
Neoplasms
Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Neoplasms
Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer.
Neoplasms
Role of urokinase plasminogen activator receptor in gastric cancer: a potential therapeutic target.
Neoplasms
Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Neoplasms
Role of urokinase receptor in tumor progression and development.
Neoplasms
Role of urokinase-type plasminogen activator and inhibitory effect of protease inhibitor in invasion and metastasis of pancreatic cancer.
Neoplasms
Roles of the ovarian surface epithelium in ovulation and carcinogenesis.
Neoplasms
Safety, dosimetry and tumor detection ability of 68Ga-NOTA-AE105 - a novel radioligand for uPAR PET imaging: first-in-humans study.
Neoplasms
Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.
Neoplasms
Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors.
Neoplasms
Secreted proteases. Regulation of their activity and their possible role in metastasis.
Neoplasms
Secretion of plasminogen activators by human colorectal and gastric tumor explants.
Neoplasms
Secretion of urokinase and metalloproteinase-9 induced by staurosporine is dependent on a tyrosine kinase pathway in mammary tumor cells.
Neoplasms
Selection criteria for epirubicin-based adjuvant chemotherapy in node-negative breast cancer.
Neoplasms
Selective Growth Inhibition of Cancer Cells by L-Methioninase-Containing Fusion Protein Targeted to the Urokinase Receptor.
Neoplasms
Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro.
Neoplasms
Self-assembled chitosan polymer intercalating peptide functionalized gold nanoparticles as nanoprobe for efficient imaging of urokinase plasminogen activator receptor in cancer diagnostics.
Neoplasms
Self-Reported Fatigue Common among Optimally Treated HIV Patients: No Correlation with Cerebral FDG-PET Scanning Abnormalities.
Neoplasms
Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
Neoplasms
Separation, purification and N-terminal sequence analysis of a novel leupeptin-sensitive serine endopeptidase present in chemically induced rat mammary tumour.
Neoplasms
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China.
Neoplasms
Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin.
Neoplasms
Serpins for diagnosis and therapy in cancer.
Neoplasms
Serum biomarkers in the diagnosis of periprosthetic joint infection: consolidated evidence and recent developments.
Neoplasms
Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers.
Neoplasms
Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy.
Neoplasms
Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma.
Neoplasms
Signal transduction-mediated regulation of urokinase gene expression in human prostate cancer.
Neoplasms
Signaling pathways responsible for cancer cell invasion as targets for cancer therapy.
Neoplasms
Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with {beta}1 integrins.
Neoplasms
Significant association of urokinase plasminogen activator Pro141Leu with serum lipid profiles in a Japanese population.
Neoplasms
Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Neoplasms
Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction.
Neoplasms
Silencing of Growth Differentiation Factor-15 Promotes Breast Cancer Cell Invasion by Down-regulating Focal Adhesion Genes.
Neoplasms
Silencing of uPAR via RNA interference inhibits invasion and migration of oral tongue squamous cell carcinoma.
Neoplasms
Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.
Neoplasms
Simultaneous downregulation of uPAR and MMP-9 induces overexpression of the FADD-associated protein RIP and activates caspase 9-mediated apoptosis in gliomas.
Neoplasms
Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors.
Neoplasms
Single-chain, urokinase-type plasminogen activator in a tumor model linked to metastatic potential.
Neoplasms
siRNA-mediated downregulation of MMP-9 and uPAR in combination with radiation induces G2/M cell-cycle arrest in Medulloblastoma.
Neoplasms
siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells.
Neoplasms
Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta.
Neoplasms
Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis.
Neoplasms
Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
Neoplasms
Smoking-induced changes in cancer-related factors in patients with upper tract urothelial cancer.
Neoplasms
Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid.
Neoplasms
Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cells.
Neoplasms
Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.
Neoplasms
Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis.
Neoplasms
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations are Elevated in Patients with Neuroendocrine Malignancies.
Neoplasms
Soluble urokinase plasminogen activator receptor (suPAR) is lower in disease-free patients but cannot rule out incident disease in patients with suspected cancer.
Neoplasms
Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening.
Neoplasms
Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.
Neoplasms
Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
Neoplasms
Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Neoplasms
Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.
Neoplasms
Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
Neoplasms
Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
Neoplasms
Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.
Neoplasms
Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study.
Neoplasms
Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report.
Neoplasms
Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia.
Neoplasms
Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling.
Neoplasms
Species specificity of amidine-based urokinase inhibitors.
Neoplasms
Specific immunofluorimetric assay detecting the chemotactic epitope of the urokinase receptor (uPAR).
Neoplasms
Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.
Neoplasms
Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.
Neoplasms
SPRY1 promotes the degradation of uPAR and inhibits uPAR-mediated cell adhesion and proliferation.
Neoplasms
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
Neoplasms
Stable antisense RNA expression neutralizes the activity of low-density lipoprotein receptor-related protein and promotes urokinase accumulation in the medium of an astrocytic tumor cell line.
Neoplasms
Stable expression of antisense urokinase mRNA inhibits the proliferation and invasion of human hepatocellular carcinoma cells.
Neoplasms
Staurosporine stimulates expression of the urokinase-type (u-PA) plasminogen activator in LLC-PK1 cells.
Neoplasms
Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules.
Neoplasms
Stromal cell-derived factor-1/CXC receptor 4 and b1 integrin interaction regulates urokinase-type plasminogen activator expression in human colorectal cancer cells.
Neoplasms
Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect.
Neoplasms
Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression.
Neoplasms
Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Neoplasms
Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
Neoplasms
Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.
Neoplasms
Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
Neoplasms
Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
Neoplasms
Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
Neoplasms
Structural modification of protease inducible preprogrammed nanofiber precursor.
Neoplasms
Structure and function analysis of urinary trypsin inhibitor (UTI): identification of binding domains and signaling property of UTI by analysis of truncated proteins.
Neoplasms
Structure of human urokinase plasminogen activator in complex with its receptor.
Neoplasms
Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis.
Neoplasms
Structure-based design, synthesis and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors.
Neoplasms
Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy.
Neoplasms
Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite.
Neoplasms
Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist.
Neoplasms
Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.
Neoplasms
Studies of possible mechanisms for the effect of urokinase therapy in small cell carcinoma of the lung.
Neoplasms
Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy.
Neoplasms
Subpopulations of uPAR(+) contribute to vasculogenic mimicry and metastasis in large cell lung cancer.
Neoplasms
Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation.
Neoplasms
suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits human prostate cancer cell growth and invasion.
Neoplasms
Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences.
Neoplasms
Suppression of hepatocarcinoma model in vitro and in vivo by ECRG2 delivery using adenoviral vector.
Neoplasms
Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin.
Neoplasms
Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor.
Neoplasms
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Neoplasms
Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428.
Neoplasms
Suppression of tumor growth and invasion in 9,10 dimethyl benz(a) anthracene induced mammary carcinoma by the plant bioflavonoid quercetin.
Neoplasms
Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.
Neoplasms
Suppression of urokinase expression and tumor metastasis by bikunin overexpression [mini-review].
Neoplasms
Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade.
Neoplasms
Suppression of Urokinase-Type Plasminogen Activator Receptor by Docosahexaenoic Acid Mediated by Heme Oxygenase-1 in 12-O-Tetradecanoylphorbol-13-Acetate-Induced Human Endothelial Cells.
Neoplasms
Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.
Neoplasms
Surgical treatment of tumor metastases: general considerations and results.
Neoplasms
SV40 T/t-common polypeptide inhibits angiogenesis and growth of HER2-overexpressing human ovarian cancer.
Neoplasms
Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth.
Neoplasms
Synergistic inhibitory effects of an engineered antibody-like molecule ATF-Fc and trastuzumab on tumor growth and invasion in a human breast cancer xenograft mouse model.
Neoplasms
Synthesis and Characterization of an (111)In-Labeled Peptide for the in Vivo Localization of Human Cancers Expressing the Urokinase-Type Plasminogen Activator Receptor (uPAR).
Neoplasms
Synthesis and in vivo preclinical evaluation of an (18)F labeled uPA inhibitor as a potential PET imaging agent.
Neoplasms
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Neoplasms
Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Neoplasms
Synthetic urokinase inhibitors as potential anti-invasive drugs.
Neoplasms
Synthetic urokinase inhibitors as potential antitumor drugs.
Neoplasms
Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
Neoplasms
Systemic administration of anti-urokinase plasminogen activator receptor monoclonal antibodies induces hepatic fibrin deposition in tissue-type plasminogen activator deficient mice.
Neoplasms
Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029.
Neoplasms
T1 breast cancer: identification of patients at low risk of axillary lymph node metastases.
Neoplasms
Targeted Delivery with Imaging Assessment of siRNA Expressing Nanocassettes into Cancer.
Neoplasms
Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis.
Neoplasms
Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin.
Neoplasms
Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation.
Neoplasms
Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells.
Neoplasms
Targeting of the ?6 gene to suppress degradation of ECM via inactivation of the MAPK pathway in breast adenocarcinoma cells.
Neoplasms
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Neoplasms
Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Neoplasms
Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.
Neoplasms
Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.
Neoplasms
Targeting the urokinase plasminogen activator receptor with synthetic self-assembly nanoparticles.
Neoplasms
Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.
Neoplasms
Targeting uPA/uPAR in prostate cancer.
Neoplasms
Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance.
Neoplasms
Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growth.
Neoplasms
Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
Neoplasms
Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.
Neoplasms
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Neoplasms
TGF-?-mediated regulation of plasminogen activators is human telomerase reverse transcriptase dependent in cancer cells.
Neoplasms
The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP.
Neoplasms
The Apparent uPA/PAI-1 Paradox in Cancer: More than Meets the Eye.
Neoplasms
The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer.
Neoplasms
The Associations of Plasma Biomarkers of Inflammation With Histopathologic Lesions, Kidney Disease Progression, and Mortality-The Boston Kidney Biopsy Cohort Study.
Neoplasms
The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer.
Neoplasms
The complete recanalization of PICC-related venous thrombosis in cancer patients: A series of case reports.
Neoplasms
The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.
Neoplasms
The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.
Neoplasms
The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
Neoplasms
The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors.
Neoplasms
The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer.
Neoplasms
The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer.
Neoplasms
The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.
Neoplasms
The effect of EGFR-related tyrosine kinase activity inhibition on the growth and invasion mechanisms of prostate carcinoma cell lines.
Neoplasms
The effect of essential fatty acids on growth and urokinase-type plasminogen activator production in human prostate DU-145 cells.
Neoplasms
The effect of gamma-linolenic acid and eicosapentaenoic acid on urokinase activity.
Neoplasms
The effect of platelets on invasiveness and protease production of human mammary tumor cells.
Neoplasms
The effect of polysaccharides and carboxymethylcellulose combination to prevent intraperitoneal adhesion and abscess formation in a rat peritonitis model.
Neoplasms
The effect of thrombospondin on invasion of fibrin gels by human A549 lung carcinoma.
Neoplasms
The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.
Neoplasms
The effect of TNP-470 on cell proliferation and urokinase-type plasminogen activator and its inhibitor in human lung cancer cell lines.
Neoplasms
The effects of amino-acid mutations on specific interactions between urokinase-type plasminogen activator and its receptor: Ab initio molecular orbital calculations.
Neoplasms
The expression of urokinase type plasminogen activator is a novel prognostic factor in dukes B and C colorectal cancer.
Neoplasms
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
Neoplasms
The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice.
Neoplasms
The importance of selected markers of inflammation and blood-brain barrier damage for short-term ischemic stroke prognosis.
Neoplasms
The influence of opioid peptides on matrix metalloproteinase-9 and urokinase plasminogen activator expression in three cancer cell lines.
Neoplasms
The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line.
Neoplasms
The interaction between urokinase receptor and vitronectin in cell adhesion and signalling.
Neoplasms
The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase.
Neoplasms
The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
Neoplasms
The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy.
Neoplasms
The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target.
Neoplasms
The p38 SAPK pathway is required for Ha-ras induced in vitro invasion of NIH3T3 cells.
Neoplasms
The plasmin system in human colonic tumors: an immunofluorescence study.
Neoplasms
The plasminogen activation system and its role in lung cancer. A review.
Neoplasms
The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.
Neoplasms
The plasminogen activation system in melanoma cell lines and in melanocytic lesions.
Neoplasms
The plasminogen activator inhibitor "paradox" in cancer.
Neoplasms
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
Neoplasms
The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
Neoplasms
The Plasminogen System in Microdissected Colonic Mucosa Distant from an Isolated Adenoma.
Neoplasms
The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis.
Neoplasms
The possible role of angiogenesis in the metastatic potential of human melanoma. Clinicopathological aspects.
Neoplasms
The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer.
Neoplasms
The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer.
Neoplasms
The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia.
Neoplasms
The prognostic value of BCAR1 in patients with primary breast cancer.
Neoplasms
The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Neoplasms
The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
Neoplasms
The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease.
Neoplasms
The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).
Neoplasms
The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.
Neoplasms
The protease inhibitor bikunin, a novel anti-metastatic agent.
Neoplasms
The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style.
Neoplasms
The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor.
Neoplasms
The relationship of plasminogen activators and oncogenes to tumour invasion.
Neoplasms
The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.
Neoplasms
The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model.
Neoplasms
The role of Ly49E receptor expression on murine intraepithelial lymphocytes in intestinal cancer development and progression.
Neoplasms
The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells.
Neoplasms
The Role of Urokinase, Tumor Necrosis Factor, and Matrix Metalloproteinase-9 in Monocyte Activation.
Neoplasms
The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.
Neoplasms
The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.
Neoplasms
The Root Extract of Gentiana macrophylla Pall. Alleviates B19-NS1-Exacerbated Liver Injuries in NZB/W F1 Mice.
Neoplasms
The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface.
Neoplasms
The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products.
Neoplasms
The uPA/uPA receptor system as a target for tumor therapy.
Neoplasms
The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice.
Neoplasms
The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Neoplasms
The urokinase plasminogen activator binding to its receptor: a quantum biochemistry description within an in/homogeneous dielectric function framework with application to uPA-uPAR peptide inhibitors.
Neoplasms
The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer.
Neoplasms
The urokinase plasminogen activator receptor as a gene therapy target for cancer.
Neoplasms
The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer.
Neoplasms
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.
Neoplasms
The urokinase plasminogen activator system in breast cancer invasion and metastasis.
Neoplasms
The urokinase plasminogen activator system in cancer: a putative therapeutic target?
Neoplasms
The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis.
Neoplasms
The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.
Neoplasms
The Urokinase Plasminogen Activator System in Human Cancers: An Overview of Its Prognostic and Predictive Role.
Neoplasms
The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Neoplasms
The urokinase plasminogen activator system: role in malignancy.
Neoplasms
The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?
Neoplasms
The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction.
Neoplasms
The urokinase receptor and integrins in cancer progression.
Neoplasms
The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition.
Neoplasms
The urokinase receptor as a potential target in cancer therapy.
Neoplasms
The urokinase receptor as an entertainer of signal transduction.
Neoplasms
The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres.
Neoplasms
The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.
Neoplasms
The Urokinase Receptor Supports Tumorigenesis of Human Malignant Pleural Mesothelioma Cells.
Neoplasms
The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications.
Neoplasms
The urokinase receptor: involvement in cell surface proteolysis and cancer invasion.
Neoplasms
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Neoplasms
The urokinase type of plasminogen activator in cancer of digestive tracts.
Neoplasms
The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Neoplasms
The urokinase-system--role of cell proliferation and apoptosis.
Neoplasms
The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies.
Neoplasms
The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
Neoplasms
The urokinase-type plasminogen activator system in cancer and other pathological conditions: introduction and perspective.
Neoplasms
The urokinase-type plasminogen activator system in cancer metastasis: a review.
Neoplasms
The urokinase-type plasminogen activator system in prostate cancer metastasis.
Neoplasms
The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group.
Neoplasms
The use of a uPAR-targeted probe for photothermal cancer therapy prolongs survival in a xenograft mouse model of glioblastoma.
Neoplasms
Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.
Neoplasms
Three types of human lung tumour cell lines can be distinguished according to surface expression of endogenous urokinase and their capacity to bind exogenous urokinase.
Neoplasms
Three-dimensional type I collagen gel system containing MG-63 osteoblasts-like cells as a model for studying local bone reaction caused by metastatic cancer cells.
Neoplasms
Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.
Neoplasms
Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells.
Neoplasms
Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
Neoplasms
Tissue extraction procedures for investigation of urokinase plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in human breast carcinomas.
Neoplasms
Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer.
Neoplasms
Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator.
Neoplasms
Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Neoplasms
Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients.
Neoplasms
Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
Neoplasms
TMPRSS4 induces cancer cell invasion through pro-uPA processing.
Neoplasms
TMPRSS4 upregulates uPA gene expression through JNK signaling activation to induce cancer cell invasion.
Neoplasms
TMPRSS4: an emerging potential therapeutic target in cancer.
Neoplasms
Toxicodendron vernicifluum Stokes extract inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice.
Neoplasms
Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein-2alpha-related factor.
Neoplasms
Transcatheter thrombolysis in cancer patients.
Neoplasms
Transcription factor PEA3 participates in the induction of urokinase plasminogen activator transcription in murine keratinocytes stimulated with epidermal growth factor or phorbol-ester.
Neoplasms
Transcriptional activation of the urokinase receptor gene in invasive colon cancer.
Neoplasms
Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.
Neoplasms
Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells.
Neoplasms
Transcriptional complexity and roles of Fra-1/AP-1 at the uPA/Plau locus in aggressive breast cancer.
Neoplasms
Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation.
Neoplasms
Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.
Neoplasms
Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells.
Neoplasms
Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa.
Neoplasms
Transforming growth factor-?, matrix metalloproteinases, and urokinase-type plasminogen activator interaction in the cancer epithelial to mesenchymal transition.
Neoplasms
Transforming growth factor-beta 1, beta 2, and beta 3, urokinase and parathyroid hormone-related peptide expression in 8701-BC breast cancer cells and clones.
Neoplasms
Transforming Growth Factor-Beta and Urokinase Type Plasminogen Interplay in Cancer.
Neoplasms
Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.
Neoplasms
Transforming Growth Factor-Beta Signaling Leads to uPA/PAI-1 Activation and Metastasis: A Study on Human Breast Cancer Tissues.
Neoplasms
Transforming growth factor-beta stimulates urokinase expression in tumor-associated macrophages of the breast.
Neoplasms
Transforming growth factor-beta1-dependent activation of Smad2/3 and up-regulation of PAI-1 expression is negatively regulated by Src in SKOV-3 human ovarian cancer cells.
Neoplasms
Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells.
Neoplasms
Translational research on u-PAR.
Neoplasms
Triclosan inhibits tumor necrosis factor-alpha-stimulated urokinase production in human gingival fibroblasts.
Neoplasms
Triptolide inhibits tumor promoter-induced uPAR expression via blocking NF-kappaB signaling in human gastric AGS cells.
Neoplasms
Tristetraprolin: A novel target of diallyl disulfide that inhibits the progression of breast cancer.
Neoplasms
Tspan9 inhibits the proliferation, migration and invasion of human gastric cancer SGC7901 cells via the ERK1/2 pathway.
Neoplasms
Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Neoplasms
Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.
Neoplasms
Tumor cell surface-associated binding site for the M(r) 72,000 type IV collagenase.
Neoplasms
Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells.
Neoplasms
Tumor cell-expressed SerpinB2 is present on microparticles and inhibits metastasis.
Neoplasms
Tumor cells secrete an angiogenic factor that stimulates basic fibroblast growth factor and urokinase expression in vascular endothelial cells.
Neoplasms
Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Neoplasms
Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling.
Neoplasms
Tumor growth inhibition mediated by trypsin inhibitor or urokinase inhibitors.
Neoplasms
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
Neoplasms
Tumor necrosis factor ? stimulates expression and secretion of urokinase plasminogen activator in human dental pulp cells.
Neoplasms
Tumor necrosis factor alpha, CYP 17, urokinase, and interleukin 10 gene polymorphisms in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis.
Neoplasms
Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells.
Neoplasms
Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by gamma-interferon.
Neoplasms
Tumor necrosis factor induction of urokinase-type plasminogen activator in human endothelial cells.
Neoplasms
Tumor necrosis factor regulation of endothelial cell extracellular proteolysis: the role of urokinase plasminogen activator.
Neoplasms
Tumor necrosis factor stimulates urokinase-type plasminogen activator and inhibitor type 1 production in A549 lung carcinoma cells: treatment of monolayer and tridimensional cultures.
Neoplasms
Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines.
Neoplasms
Tumor necrosis factor-alpha stimulates the biosynthesis of matrix metalloproteinases and plasminogen activator in cultured human chorionic cells.
Neoplasms
Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells: molecular basis linking ovulation and cancer risk.
Neoplasms
Tumor promoter PMA stimulates the synthesis and secretion of mouse pro-urokinase in MSV-transformed 3T3 cells: this is mediated by an increase in urokinase mRNA content.
Neoplasms
Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Neoplasms
Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors.
Neoplasms
Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
Neoplasms
Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.
Neoplasms
Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.
Neoplasms
Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.
Neoplasms
Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
Neoplasms
Tumor-associated soluble uPAR-directed endothelial cell motility and tumor angiogenesis.
Neoplasms
Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.
Neoplasms
Tumor-associated urokinase-type plasminogen activator: significance in breast cancer.
Neoplasms
Tumoral and macrophage uPAR and MMP-9 contribute to the invasiveness of B16 murine melanoma cells.
Neoplasms
Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer.
Neoplasms
Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.
Neoplasms
Tumour cell u-PA as a cause of fibrinolytic bleeding in metastatic disease.
Neoplasms
Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes.
Neoplasms
Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Neoplasms
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Neoplasms
Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1.
Neoplasms
u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression.
Neoplasms
Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator.
Neoplasms
Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene.
Neoplasms
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
Neoplasms
uPA and uPA-receptor are involved in cancer-associated myeloid-derived suppressor cell accumulation.
Neoplasms
uPA and uPAR contribute to NK cell invasion through the extracellular matrix.
Neoplasms
uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.
Neoplasms
uPA receptor expression in benign and malignant thyroid tumors.
Neoplasms
uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
Neoplasms
uPA/PAI-1 ratios distinguish benign prostatic hyperplasia and prostate cancer.
Neoplasms
uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo.
Neoplasms
uPAR and cathepsin B inhibition enhanced radiation-induced apoptosis in gliomainitiating cells.
Neoplasms
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.
Neoplasms
uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions.
Neoplasms
uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
Neoplasms
uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.
Neoplasms
uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line.
Neoplasms
uPAR induces expression of transforming growth factor ? and interleukin-4 in cancer cells to promote tumor-permissive conditioning of macrophages.
Neoplasms
uPAR Knockout Results in a Deep Glycolytic and OXPHOS Reprogramming in Melanoma and Colon Carcinoma Cell Lines.
Neoplasms
uPAR peptide antagonist alters regulation of MAP kinases and Bcl-2 family members in favor of apoptosis in MDA-MB-231 cell line.
Neoplasms
uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180.
Neoplasms
uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors.
Neoplasms
uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
Neoplasms
uPAR-deficient mouse keratinocytes fail to produce EGFR-dependent laminin-5, affecting migration in vivo and in vitro.
Neoplasms
uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery.
Neoplasms
uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection.
Neoplasms
Upper tract urokinase instillation for nephrostomy tube patency.
Neoplasms
Upregulation of circulating cytokeratin 20, urokinase plasminogen activator and C-reactive protein is associated with poor prognosis in gastric cancer.
Neoplasms
Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice.
Neoplasms
Urinary trypsin inhibitor efficiently inhibits urokinase production in tumor necrosis factor-stimulated cells.
Neoplasms
Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines.
Neoplasms
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
Neoplasms
Urokinase activity in corneal fibroblasts may be modulated by DNA damage and secreted proteins.
Neoplasms
Urokinase and macrophages in tumour angiogenesis.
Neoplasms
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
Neoplasms
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Neoplasms
Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Neoplasms
Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors.
Neoplasms
Urokinase and tissue plasminogen activators and their PAI-1 inhibitor in tumors of patients with oral mucosal cancer: relationship with the main clinical morphological factors.
Neoplasms
Urokinase and type I plasminogen activator inhibitor production by normal human hepatocytes: modulation by inflammatory agents.
Neoplasms
Urokinase Exerts Antimetastatic Effects by Dissociating Clusters of Circulating Tumor Cells-Letter.
Neoplasms
Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells.
Neoplasms
Urokinase expression by tumor suppressor protein p53: a novel role in mRNA turnover.
Neoplasms
Urokinase expression in course of benign and malignant mammary lesions: comparison between nodular and healthy tissues.
Neoplasms
Urokinase expression in mononuclear phagocytes: cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha.
Neoplasms
Urokinase gene 3'-UTR T/C polymorphism is associated with malignancy and ESRD in idiopathic membranous nephropathy.
Neoplasms
Urokinase gene 3'-UTR T/C polymorphism is associated with oral cancer.
Neoplasms
Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer.
Neoplasms
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.
Neoplasms
Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer.
Neoplasms
Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
Neoplasms
Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Neoplasms
Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer.
Neoplasms
Urokinase plasminogen activator expression by primary and HPV 16-transformed keratinocytes.
Neoplasms
Urokinase plasminogen activator in ovarian cancer.
Neoplasms
Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer.
Neoplasms
Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain.
Neoplasms
Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer.
Neoplasms
Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.
Neoplasms
Urokinase Plasminogen Activator Receptor (uPAR): A Potential Indicator of Invasion for In Situ Breast Cancer.
Neoplasms
Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
Neoplasms
Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy.
Neoplasms
Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma.
Neoplasms
Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes.
Neoplasms
Urokinase Plasminogen Activator Receptor-Mediated Targeting of a Stable Nanocomplex Coupled with Specific Peptides for Imaging of Cancer.
Neoplasms
Urokinase Plasminogen Activator Receptor-PET with (68)Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand.
Neoplasms
Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer.
Neoplasms
Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma.
Neoplasms
Urokinase plasminogen activator system as a potential target for cancer therapy.
Neoplasms
Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Neoplasms
Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay.
Neoplasms
Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
Neoplasms
Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease.
Neoplasms
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
Neoplasms
Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy.
Neoplasms
Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
Neoplasms
Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.
Neoplasms
Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth.
Neoplasms
Urokinase receptor antagonists: novel agents for the treatment of cancer.
Neoplasms
Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
Neoplasms
Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer.
Neoplasms
Urokinase receptor deficiency results in EGFR-mediated failure to transmit signals for cell survival and neurite formation in mouse neuroblastoma cells.
Neoplasms
Urokinase receptor expression is upregulated by cell culture sparsity in breast cancer cell line BT-20.
Neoplasms
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.
Neoplasms
Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis.
Neoplasms
Urokinase receptor is a key player in tumour progression.
Neoplasms
Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression.
Neoplasms
Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598.
Neoplasms
Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
Neoplasms
Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells.
Neoplasms
Urokinase receptor mRNA stability involves tyrosine phosphorylation in lung epithelial cells.
Neoplasms
Urokinase Receptor Promotes Skin Tumor Formation by Preventing Epithelial Cell Activation of Notch1.
Neoplasms
Urokinase receptor up-regulation in head and neck squamous cell carcinoma.
Neoplasms
Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Neoplasms
Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells.
Neoplasms
Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells.
Neoplasms
Urokinase receptors in lung cancer and normal lung.
Neoplasms
Urokinase secretion from human colon carcinomas induced by endogenous diglycerides.
Neoplasms
Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels.
Neoplasms
Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines.
Neoplasms
Urokinase type plasminogen activator and the molecular mechanisms of its regulation in cancer.
Neoplasms
Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer.
Neoplasms
Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer.
Neoplasms
Urokinase type plasminogen activator receptor expression in colorectal neoplasms.
Neoplasms
Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
Neoplasms
Urokinase-dependent cell surface proteolysis and cancer.
Neoplasms
Urokinase-dependent human vascular smooth muscle cell adhesion requires selective vitronectin phosphorylation by ectoprotein kinase CK2.
Neoplasms
Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid.
Neoplasms
Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
Neoplasms
Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec.
Neoplasms
Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay.
Neoplasms
Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
Neoplasms
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.
Neoplasms
Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas.
Neoplasms
Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo.
Neoplasms
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Neoplasms
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Neoplasms
Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
Neoplasms
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Neoplasms
Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Neoplasms
Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK).
Neoplasms
Urokinase-type plasminogen activator activity increases during the growth of two murine mammary adenocarcinomas with different metastasizing abilities.
Neoplasms
Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Neoplasms
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Neoplasms
Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
Neoplasms
Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.
Neoplasms
Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.
Neoplasms
Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
Neoplasms
Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Neoplasms
Urokinase-type plasminogen activator expression in human prostate carcinomas.
Neoplasms
Urokinase-type plasminogen activator in carcinomatous pleural fluid.
Neoplasms
Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.
Neoplasms
Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells.
Neoplasms
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
Neoplasms
Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction.
Neoplasms
Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications.
Neoplasms
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
Neoplasms
Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
Neoplasms
Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.
Neoplasms
Urokinase-type plasminogen activator receptor (uPAR)-mediated regulation of WNT/?-catenin signaling is enhanced in irradiated medulloblastoma cells.
Neoplasms
Urokinase-type plasminogen activator receptor expression in adenoid cystic carcinoma of the skull base.
Neoplasms
Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models.
Neoplasms
Urokinase-type plasminogen activator regulates neurodegeneration and neurogenesis but not vascular changes in the mouse hippocampus after status epilepticus.
Neoplasms
Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients.
Neoplasms
Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Neoplasms
Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor.
Neoplasms
Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
Neoplasms
Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
Neoplasms
Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers.
Neoplasms
Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-beta(1) (TGF beta(1)) compared with factor(s) released by human epithelial-carcinoma cells.
Neoplasms
Use of urokinase in pediatric hematology/oncology patients.
Neoplasms
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.
Neoplasms
Uterine fibrinolytic enzymes in endometrial cancer.
Neoplasms
Utility of Serum and Urine uPAR Levels for Diagnosis of Breast Cancer.
Neoplasms
Vasodilator-Stimulated Phosphoprotein (VASP) depletion from breast cancer MDA-MB-231 cells inhibits tumor spheroid invasion through downregulation of Migfilin, ?-catenin and urokinase-plasminogen activator (uPA).
Neoplasms
Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines.
Neoplasms
Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells.
Neoplasms
Weight loss is superior to exercise in improving the atherogenic lipid profile in a sedentary, overweight population with stable coronary artery disease: A randomized trial.
Neoplasms
Whole genome expression analysis for biologic rational pathway modeling: application in cancer prognosis and therapy prediction.
Neoplasms
Zinc phthalocyanine conjugated with the amino-terminal fragment of urokinase for tumor-targeting photodynamic therapy.
Neoplasms
[Antisense inhibition of urokinase in a human osteosarcoma cell line]
Neoplasms
[Assay and detection methods for urokinase-type plasminogen activator and its related-factors]
Neoplasms
[Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma]
Neoplasms
[Autocrine-generated matrix metalloproteinases of tumor cells and the cascade network of protease activation mediated by membrane associated urokinase-type plasminogen activator: involvement in the degradation of extracellular matrices]
Neoplasms
[Cell phenotype determines PAI-1 antiproliferative effect - suppressed proliferation of the lung cancer but not prostate cancer cells]
Neoplasms
[Correlation between the expression of urokinase-type plasminogen activator, E-cadherin and malignancy in gastric cancer]
Neoplasms
[Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer]
Neoplasms
[Effect of inhalation of aerosolized unfractioned heparin on peri alveolar coagulability and inflammatory response in endotoxin induced acute lung injury rat model.]
Neoplasms
[Effect of urokinase on the tumor blood flow studied by Xenon-133 method (author's transl)]
Neoplasms
[Effects of urokinase on the transfer of 1-hexylcarbamoyl-5-fluorouracil (HCFU) into the blood, bile and pancreatic juice]
Neoplasms
[Endothelial cell proteases and their modulation by platelets]
Neoplasms
[Establishment of urokinase receptor gene antisense RNA transfer system and its application in leukemia research]
Neoplasms
[Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients]
Neoplasms
[Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer]
Neoplasms
[Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone]
Neoplasms
[Fibrin deposition and fibrinolysis in the pathogenesis of pulmonary fibrosis]
Neoplasms
[Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]
Neoplasms
[Immunohistochemical evidences of prognostic parameters associated with tumor development of pulmonary adenocarcinoma]
Neoplasms
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
Neoplasms
[Increase of cellular fibrinolysis in human lung cancer cell line by radiation: relationship between urokinase-type plasminogen activator (uPA) and metastasis and invasion]
Neoplasms
[Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis]
Neoplasms
[Modern prospects for molecular-biochemical methods for evaluating biological "behavior" of breast neoplasms]
Neoplasms
[Molecular mechanism of liver metastasis from colorectal cancer]
Neoplasms
[Molecular pathways of pancreatic carcinogenesis]
Neoplasms
[Molecular structure of the receptor for urokinase plasminogen activator and its physiological modulation of a tumor cell line]
Neoplasms
[New molecular targets in pancreatic cancer]
Neoplasms
[Plasminogen activator system and its clinical significance in patients with a malignant disease].
Neoplasms
[Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases]
Neoplasms
[Prognostic factors and therapeutic strategy of breast cancer]
Neoplasms
[Prognostic factors in carcinoma of the breast. Thereupon depends success of the treatment]
Neoplasms
[Prognostic implications of biologic markers in intracranial meningiomas: 120 cases]
Neoplasms
[Prognostic role of cisteine and serin proteases in gastriC cancer]
Neoplasms
[Prognostic value of immunohistochemical determination of urokinase plasminogen activator in primary breast cancers]
Neoplasms
[Regulation of angiogenesis and tumor growth]
Neoplasms
[Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis]
Neoplasms
[Significance in gene expression of matrix metalloproteinase-9, urokinase-type plasminogen activator and tissue inhibitor of metalloproteinase for metastases of gastric and/or colo-rectal cancer]
Neoplasms
[Significance of urokinase and its inhibitors in the invasiveness and metastasing of malignant tumors].
Neoplasms
[Study on cases of D dimer values were dissociated from FDP-E]
Neoplasms
[Test for urokinase-type plasminogen activator inhibitor of edible plants in vitro]
Neoplasms
[The clinical prospects for the study of the plasminogen activation system in breast cancer]
Neoplasms
[The expression of urokinase-type plasminogen activator in oral squamous cell carcinoma]
Neoplasms
[The location of components of fibrinolytic system in laryngeal cancer]
Neoplasms
[The urokinase-type plasminogen activator system and its role in tumor progression].
Neoplasms
[Tumor affinity of 99mTc-labeled radiopharmaceuticals, 99mTc-Sn-urokinase and 99mTc-Sn-mannitol]
Neoplasms
[Tumor metastasis and the fibrinolytic system]
Neoplasms
[uPA expression of gastric cancer cell lines and its correlation with peritoneal seeding]
Neoplasms
[Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer]
Neoplasms
[Urokinase plasminogen activation system and its role in cancer progression]
Neoplasms
[Urokinase plasminogen activator /U-PA/in blood of patients with lung cancer]
Neoplasms
[Urokinase-type plasminogen activator (uPA) and its inhibitor--new prognostic factors in oral squamous cell carcinoma]
Neoplasms
[Urokinase-type plasminogen activator (uPA), uPA receptor (uPA-R) and inhibitors (PA I -1) expression in hepatocellular carcinoma in relation to cancer invasion/metastasis and prognosis]
Neoplasms
[Urokinase-type plasminogen activator antigen as a prognostic factor in bladder cancer]
Neoplasms
[Urokinase-type plasminogen activator as a predictor for lymph nodes metastasis of uterine cervical cancer]
Neoplasms
[Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma]
Neoplasms, Germ Cell and Embryonal
A personalized approach to cancer treatment: how biomarkers can help.
Neoplasms, Germ Cell and Embryonal
Evidence for the clinical use of tumour markers.
Neoplasms, Squamous Cell
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Neoplastic Cells, Circulating
Molecular interactions in cancer cell metastasis.
Neoplastic Cells, Circulating
Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
Neoplastic Cells, Circulating
Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells.
Nephritis
Analysis of urinary and circulating FDP subfragments and subunits: application of the western-blot technique.
Nephritis
Comparative effects of heparin, urokinase, and ancrod on intraglomerular coagulation induced in progressive Masugi nephritis.
Nephritis
Effect of the nephritogenic autoantibody of Heymann's nephritis on plasminogen-binding to gp330 and activation by urokinase.
Nephritis
Effects of fibrinolytic treatment on rabbit Masugi nephritis.
Nephritis
Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study.
Nephritis
Efficacy of methylprednisolone and urokinase pulse therapy for severe Henoch-Schönlein nephritis.
Nephritis
Induction of urokinase receptor expression in nephrotoxic nephritis.
Nephritis
Methylprednisolone pulse plus mizoribine in children with Henoch-Schoenlein purpura nephritis.
Nephritis
Pathological improvement of IgA nephropathy and Henoch-Schönlein purpura nephritis with urokinase therapy.
Nephritis
Successful therapy with tonsillectomy for severe ISKDC grade VI Henoch-Schönlein purpura nephritis and persistent nephrotic syndrome.
Nephritis
Therapy for children with henoch-schonlein purpura nephritis: a systematic review.
Nephritis
[A role of fibrin deposits in the development of rabbit Masugi nephritis and effect of urokinase on the experimental glomerulonephritis (author's transl)]
Nephritis
[Combined use of heparin and urokinase in the patients with nephritis resistant to the conventional treatment and the significance of alpha 2-plasmin inhibitor in the therapy (author's transl)]
Nephritis
[Comparative effects of ancrod, urokinase and heparin on intraglomerular coagulation induced by progressive Masugi nephritis (author's transl)]
Nephritis
[Effect of urokinase on renal structure and function in experimental immune nephritis]
Nephritis
[Fibrin deposits in Masugi nephritis and effects of urokinase, non-steroidal anti-inflammatory agents, anti-inflammatory enzymes and prostaglandins]
Nephritis
[Functional state of the kidneys in experimental immune nephritis during the use of heparin, urokinase and uroplasmin]
Nephritis
[Significance of the markers of endothelial dysfunction and hemorheological disorders for assessing the activity and prognosis of chronic glomerulonephritis]
Nephritis
[State of the thrombin-plasmin system in nephrotoxic nephritis treated with heparin, urokinase, and uroplasmin]
Nephritis, Interstitial
[The fibrinolytic system in uric acid dysmetabolism]
Nephrolithiasis
Association of urokinase gene 3'-UTR polymorphism with calcium oxalate nephrolithiasis.
Nephrolithiasis
[Urinary urokinase and blood fibrinolytic activity in patients with nephrolithiasis and other urinary tract diseases]
Nephrosis, Lipoid
CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
Nephrosis, Lipoid
CD80, suPAR and Nephrotic Syndrome in a case of NPHS2 mutation.
Nephrosis, Lipoid
Circulating Permeability Factors in Idiopathic Nephrotic Syndrome and Focal Segmental Glomerulosclerosis.
Nephrosis, Lipoid
Nephrotic syndrome complicated with portal, splenic, and superior mesenteric vein thrombosis.
Nephrosis, Lipoid
Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.
Nephrosis, Lipoid
Urokinase treatment of pulmonary artery thrombosis complicating the pediatric nephrotic syndrome.
Nephrotic Syndrome
Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.
Nephrotic Syndrome
CD80, suPAR and Nephrotic Syndrome in a case of NPHS2 mutation.
Nephrotic Syndrome
Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.
Nephrotic Syndrome
Circulating Permeability Factors in Idiopathic Nephrotic Syndrome and Focal Segmental Glomerulosclerosis.
Nephrotic Syndrome
Clinical significance of serum and urinary soluble urokinase receptor (suPAR) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese.
Nephrotic Syndrome
Evaluation of serum soluble urokinase plasminogen activator receptor as a marker for steroid-responsiveness in children with primary nephrotic syndrome.
Nephrotic Syndrome
Hemostatic abnormalities in nephrotic syndrome.
Nephrotic Syndrome
High dose urokinase against massive pulmonary embolism in nephrotic syndrome.
Nephrotic Syndrome
Plasmin in nephrotic urine activates the epithelial sodium channel.
Nephrotic Syndrome
Plasminogen activator in nephrotic syndrome.
Nephrotic Syndrome
Regulation of sodium transport by ENaC in the kidney.
Nephrotic Syndrome
Relationship between soluble urokinase-type plasminogen activator receptor and serum biomarkers of endothelial activation in patients with idiopathic nephrotic syndrome.
Nephrotic Syndrome
Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children.
Nephrotic Syndrome
Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.
Nephrotic Syndrome
Simultaneous renal arterial and venous thrombosis associated with idiopathic nephrotic syndrome: treatment with intra-arterial urokinase.
Nephrotic Syndrome
Successful therapy with tonsillectomy for severe ISKDC grade VI Henoch-Schönlein purpura nephritis and persistent nephrotic syndrome.
Nephrotic Syndrome
The clinical pattern of nephrotic syndrome in children has no effect on the concentration of soluble urokinase receptor (suPAR) in serum and urine.
Nephrotic Syndrome
The glomerular permeability factors in idiopathic nephrotic syndrome.
Nephrotic Syndrome
Urokinase and AT-III concentrate treatment in inferior vena cava thrombosis associated with nephrotic syndrome.
Nephrotic Syndrome
Urokinase treatment of pulmonary artery thrombosis complicating the pediatric nephrotic syndrome.
Nephrotic Syndrome
Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome.
Nephrotic Syndrome
[A study on the urokinase treatment in patients with glomerulonephritis and nephrotic syndrome]
Nephrotic Syndrome
[Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome].
Nephrotic Syndrome
[Effect of urokinase therapy in patients with glomerulonephritis and nephrotic syndrome. Trial at multiple institutes in Japan]
Nephrotic Syndrome
[Nephrotic syndrome complicated with intracranial venous thrombosis treated with urokinase: report of 5 cases]
Nephrotic Syndrome
[Primary nephrotic syndrome treated with urokinase--a report of 20 cases]
Nephrotic Syndrome
[Successful lysis therapy in acute unilateral renal vein thrombosis]
Nervous System Diseases
[Intra-arterial fibrinolysis in acute thrombosis of the basilar artery]
Nervous System Neoplasms
Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms.
Neuralgia
Induction of plasminogen activator inhibitor-1 and -2 in dorsal root ganglion neurons after peripheral nerve injury.
Neuroblastoma
Changes in gene expression of kringle domain-containing proteins in murine brains and neuroblastoma cells infected by prions.
Neuroblastoma
Characterization and partial purification of the plasminogen activator from human neuroblastoma cell line, SK-N-SH. A comparison with human urokinase.
Neuroblastoma
CRISPR/Cas9 nickase mediated targeting of urokinase receptor gene inhibits neuroblastoma cell proliferation.
Neuroblastoma
Downregulation of uPAR promotes urokinase translocation into the nucleus and epithelial to mesenchymal transition in neuroblastoma.
Neuroblastoma
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Neuroblastoma
Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Neuroblastoma
The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis.
Neuroblastoma
Urokinase receptor deficiency results in EGFR-mediated failure to transmit signals for cell survival and neurite formation in mouse neuroblastoma cells.
Neurodegenerative Diseases
Organization of GPI-anchored proteins at the cell surface and its physiopathological relevance.
Neuroinflammatory Diseases
Suppression of PKC-? attenuates TNF-?-evoked cerebral barrier breakdown via regulations of MMP-2 and plasminogen-plasmin system.
Neuroinflammatory Diseases
The fibrinolytic system: A new target for treatment of depression with psychedelics.
Neurologic Manifestations
Effects of Intra-arterial Urokinase on a Non-human Primate Thromboembolic Stroke Model.
Neurologic Manifestations
The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.
Neurologic Manifestations
Twist drill craniostomy for traumatic acute subdural hematoma in the elderly: case series and literature review.
Neurosyphilis
Cytokines in cerebrospinal fluid of neurosyphilis patients: Identification of Urokinase plasminogen activator using antibody microarrays.
Nevus
[Histochemical studies of transepidermal elimination of nevus cells in nevus cell nevi of the corium]
Nevus, Blue
Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Non-alcoholic Fatty Liver Disease
Changes in the levels of endothelium-derived coagulation parameters in nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker.
Non-alcoholic Fatty Liver Disease
Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease.
Non-ST Elevated Myocardial Infarction
Multibiomarker analysis in patients with acute myocardial infarction.
Obesity
A superactive leptin antagonist alters metabolism and locomotion in high leptin mice.
Obesity
Association analyses of porcine SERPINE1 reveal sex-specific effects on muscling, growth, fat accretion and meat quality.
Obesity
Influence of t-pA and u-PA on adipose tissue development in a murine model of diet-induced obesity.
Obesity
Inhibition of Plasminogen Activator Inhibitor-1 Activation Suppresses High Fat Diet-Induced Weight Gain via Alleviation of Hypothalamic Leptin Resistance.
Obesity
Plasma levels of soluble urokinase plasminogen activator receptor (suPAR) and high-sensitivity C-reactive protein after Roux-en-Y gastric bypass or sleeve gastrectomy: a 1-year prospective observational study.
Obesity
Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss.
Obesity
Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity.
Odontogenic Tumors
Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
Osteoarthritis
Antisense targeting of the urokinase receptor blocks urokinase-dependent proliferation, chemoinvasion, and chemotaxis of human synovial cells and chondrocytes in vitro.
Osteoarthritis
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Osteoarthritis
Construction and verification of the targeted uPA-shRNA lentiviral vector and evaluation of the transfection and silencing rate.
Osteoarthritis
Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Osteoarthritis
Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues.
Osteoarthritis
Effects of different molecular weight hyaluronan products on the expression of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis.
Osteoarthritis
Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Osteoarthritis
Establishment of a rat model of lumbar facet joint osteoarthritis using intraarticular injection of urinary plasminogen activator.
Osteoarthritis
Expression of stromelysin and urokinase type plasminogen activator protein in resection specimens and biopsies at different stages of osteoarthritis of the knee.
Osteoarthritis
Expression of the urokinase-type plasminogen activator receptor in human articular chondrocytes: association with caveolin and beta 1-integrin.
Osteoarthritis
Glucosamine sulfate suppresses the expressions of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis.
Osteoarthritis
Increased proteolytic activity on the surface of monocytes from patients with rheumatoid arthritis.
Osteoarthritis
Interleukin-1beta-induced expression of the urokinase-type plasminogen activator receptor and its co-localization with MMPs in human articular chondrocytes.
Osteoarthritis
Naproxen, meloxicam and methylprednisolone inhibit urokinase plasminogen activator and inhibitor and gelatinases expression during the early stage of osteoarthritis.
Osteoarthritis
Significance of serine proteinase and matrix metalloproteinase systems in the destruction of human articular cartilage.
Osteoarthritis
Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts.
Osteoarthritis
Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.
Osteoarthritis
Urokinase plasminogen activator system in synovial fibroblasts from osteoarthritis patients: modulation by inflammatory mediators and neuropeptides.
Osteoarthritis
Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Osteoarthritis
Variation patterns of two degradation enzyme systems in articular cartilage in different stages of osteoarthritis: regulation by dehydroepiandrosterone.
Osteoarthritis
[Expression of urokinase-type plasminogen activator and its receptor protein in synovial tissues from osteoarthritis]
Osteoarthritis
[Levels of matrix metalloproteinase-3 and urokinase-type plasminogen activator in knee synovial fluids from patients with rheumatoid arthritis and osteoarthritis]
Osteoarthritis
[Study of molecular mechanisms of fuyuan capsule, icariin and arasaponin R1 in treatment of osteoarthritis].
Osteoarthritis, Knee
Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans.
Osteoarthritis, Knee
Expression of stromelysin and urokinase type plasminogen activator protein in resection specimens and biopsies at different stages of osteoarthritis of the knee.
Osteoarthritis, Knee
Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.
Osteomyelitis
The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine.
Osteoporosis
Tumor necrosis factor alpha, CYP 17, urokinase, and interleukin 10 gene polymorphisms in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis.
Osteosarcoma
Antisense inhibition of urokinase: effect on malignancy in a human osteosarcoma cell line.
Osteosarcoma
Binding and activation of plasminogen on the surface of osteosarcoma cells.
Osteosarcoma
Dihydromyricetin suppresses cell metastasis in human osteosarcoma through SP-1- and NF-?B-modulated urokinase plasminogen activator inhibition.
Osteosarcoma
Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines.
Osteosarcoma
Function of hepatocyte growth factor in gastric cancer proliferation and invasion.
Osteosarcoma
Glucocorticoid regulation of plasminogen activator inhibitor-1 messenger ribonucleic acid and protein in normal and malignant rat osteoblasts.
Osteosarcoma
Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells.
Osteosarcoma
Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line.
Osteosarcoma
Plasminogen activator regulation in osteoblasts: parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA.
Osteosarcoma
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Osteosarcoma
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Osteosarcoma
Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha.
Osteosarcoma
Regulation of the production of plasminogen activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells.
Osteosarcoma
Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2.
Osteosarcoma
Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
Osteosarcoma
Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1.
Osteosarcoma
The course of fibrinolytic proteins in children with malignant bone tumours.
Osteosarcoma
The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model.
Osteosarcoma
The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells.
Osteosarcoma
[Antisense inhibition of urokinase in a human osteosarcoma cell line]
Out-of-Hospital Cardiac Arrest
The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.
Ovarian Hyperstimulation Syndrome
Concentration of soluble urokinase plasminogen activator receptor (suPAR) in the pre-ovulatory follicular fluid is associated with development of ovarian hyperstimulation syndrome during ovarian stimulation.
Ovarian Neoplasms
A kunitz-type protease inhibitor bikunin disrupts ligand-induced oligomerization of receptors for transforming growth factor (TGF)-beta and subsequently suppresses TGF-beta signalings.
Ovarian Neoplasms
A Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-beta 1 signaling cascade.
Ovarian Neoplasms
A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
Ovarian Neoplasms
A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer.
Ovarian Neoplasms
A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation.
Ovarian Neoplasms
Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice.
Ovarian Neoplasms
Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
Ovarian Neoplasms
Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Ovarian Neoplasms
Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
Ovarian Neoplasms
Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer.
Ovarian Neoplasms
Comparing SILAC and two-dimensional gel electrophoresis image analysis for profiling urokinase plasminogen activator signaling in ovarian cancer cells.
Ovarian Neoplasms
Critical involvement of ILK in TGFbeta1-stimulated invasion/migration of human ovarian cancer cells is associated with urokinase plasminogen activator system.
Ovarian Neoplasms
Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1).
Ovarian Neoplasms
Designing tracers for PET imaging of the urokinase-type plasminogen activator receptor from a cyclic uPA-derived peptide: first in vitro evaluations.
Ovarian Neoplasms
Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma.
Ovarian Neoplasms
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
Ovarian Neoplasms
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Ovarian Neoplasms
Effect of bFGF on invasion of ovarian cancer cells through the regulation of Ets-1 and urokinase-type plasminogen activator.
Ovarian Neoplasms
EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
Ovarian Neoplasms
Evidence for the clinical use of tumour markers.
Ovarian Neoplasms
Expression and anticancer activity analysis of recombinant human uPA1?43-melittin.
Ovarian Neoplasms
Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Ovarian Neoplasms
Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Ovarian Neoplasms
Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
Ovarian Neoplasms
GPI-specific phospholipase D mRNA expression in tumor cells of different malignancy.
Ovarian Neoplasms
High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
Ovarian Neoplasms
High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
Ovarian Neoplasms
Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer.
Ovarian Neoplasms
Increased cell-surface urokinase in advanced ovarian cancer.
Ovarian Neoplasms
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Ovarian Neoplasms
Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Ovarian Neoplasms
Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells.
Ovarian Neoplasms
Induction of c-fos Gene Expression by Urokinase-Type Plasminogen Activator in Human Ovarian Cancer Cells.
Ovarian Neoplasms
Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B.
Ovarian Neoplasms
Inhibition of lysophosphatidic acid receptor-2 expression by RNA interference decreases lysophosphatidic acid-induced urokinase plasminogen activator activation, cell invasion, and migration in ovarian cancer SKOV-3 cells.
Ovarian Neoplasms
Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.
Ovarian Neoplasms
Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.
Ovarian Neoplasms
Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
Ovarian Neoplasms
Lysophosphatidic acid signaling in ovarian cancer.
Ovarian Neoplasms
Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer.
Ovarian Neoplasms
Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.
Ovarian Neoplasms
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice.
Ovarian Neoplasms
Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
Ovarian Neoplasms
Overexpression of a hybrid gene consisting of the amino-terminal fragment of urokinase and carboxyl-terminal domain of bikunin suppresses invasion and migration of human ovarian cancer cells in vitro.
Ovarian Neoplasms
Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
Ovarian Neoplasms
Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
Ovarian Neoplasms
Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
Ovarian Neoplasms
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
Ovarian Neoplasms
Proteases as prognostic markers in cancer.
Ovarian Neoplasms
Protein C and its inhibitor in malignancy.
Ovarian Neoplasms
Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
Ovarian Neoplasms
Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.
Ovarian Neoplasms
Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.
Ovarian Neoplasms
Self-assembled chitosan polymer intercalating peptide functionalized gold nanoparticles as nanoprobe for efficient imaging of urokinase plasminogen activator receptor in cancer diagnostics.
Ovarian Neoplasms
Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
Ovarian Neoplasms
Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.
Ovarian Neoplasms
SPARC ameliorates ovarian cancer-associated inflammation.
Ovarian Neoplasms
Suppression of urokinase expression and invasion by a soybean Kunitz trypsin inhibitor are mediated through inhibition of Src-dependent signaling pathways.
Ovarian Neoplasms
Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways.
Ovarian Neoplasms
Suppression of urokinase expression and tumor metastasis by bikunin overexpression [mini-review].
Ovarian Neoplasms
Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor kappaB activation and subsequently suppressed ovarian cancer dissemination.
Ovarian Neoplasms
Suppression of urokinase-type plasminogen activator expression from human ovarian cancer cells by urinary trypsin inhibitor.
Ovarian Neoplasms
Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.
Ovarian Neoplasms
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Ovarian Neoplasms
The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Ovarian Neoplasms
Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells.
Ovarian Neoplasms
Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells.
Ovarian Neoplasms
Tumor markers for ovarian cancer.
Ovarian Neoplasms
Upregulation of bikunin in tumor-infiltrating macrophages as a factor of favorable prognosis in ovarian cancer.
Ovarian Neoplasms
Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.
Ovarian Neoplasms
Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
Ovarian Neoplasms
Urokinase plasminogen activator in ovarian cancer.
Ovarian Neoplasms
Urokinase Plasminogen Activator System Targeted Delivery of Nanobins as a Novel Ovarian Cancer Therapeutics.
Ovarian Neoplasms
Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence.
Ovarian Neoplasms
[Study of the effect of TF/FVIIa complex on the expression of u-PAR mRNA in human ovarian cancer]
Overweight
The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status.
Pancreatic Neoplasms
Action of antiproteases on pancreatic cancer cells.
Pancreatic Neoplasms
Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system.
Pancreatic Neoplasms
Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells.
Pancreatic Neoplasms
Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.
Pancreatic Neoplasms
Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer.
Pancreatic Neoplasms
Expression of kallikrein 7 diminishes pancreatic cancer cell adhesion to vitronectin and enhances urokinase-type plasminogen activator receptor shedding.
Pancreatic Neoplasms
FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis via Upregulation of Expression of the Urokinase Plasminogen Activator System.
Pancreatic Neoplasms
Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells.
Pancreatic Neoplasms
Imaging of human pancreatic cancer xenografts by single-photon emission computed tomography with (99m)Tc-Hynic-PEG-AE105.
Pancreatic Neoplasms
Inhibition and mechanism of action of a protease inhibitor in human pancreatic cancer cells.
Pancreatic Neoplasms
Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
Pancreatic Neoplasms
Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Pancreatic Neoplasms
Invasion-Metastasis by Hepatocyte Growth Factor/c-Met Signaling Concomitant with Induction of Urokinase Plasminogen Activator in Human Pancreatic Cancer: Role as Therapeutic Target.
Pancreatic Neoplasms
Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles.
Pancreatic Neoplasms
Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.
Pancreatic Neoplasms
Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice.
Pancreatic Neoplasms
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer.
Pancreatic Neoplasms
Pre-clinical Study of (213)Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer.
Pancreatic Neoplasms
Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.
Pancreatic Neoplasms
Role of urokinase-type plasminogen activator and inhibitory effect of protease inhibitor in invasion and metastasis of pancreatic cancer.
Pancreatic Neoplasms
TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system.
Pancreatic Neoplasms
Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells.
Pancreatic Neoplasms
Transcriptional silencing of ETS-1 efficiently suppresses angiogenesis of pancreatic cancer.
Pancreatic Neoplasms
Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.
Pancreatic Neoplasms
Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models.
Pancreatic Neoplasms
Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.
Pancreatic Neoplasms
[Inhibitory effect of FOY-305 on liver metastasis of the pancreatic cancer]
Pancreatitis
Correlation of Serum and Ascitic Fluid Soluble Form Urokinase Plasminogen Activator Receptor Levels With Patient Complications, Disease Severity, Inflammatory Markers, and Prognosis in Patients With Severe Acute Pancreatitis.
Pancreatitis
Detection of low molecular weight urokinase in plasma of patient with acute pancreatitis followed by disseminated intravascular coagulation.
Pancreatitis
Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis.
Pancreatitis
Neutrophil to lymphocyte ratio at the early phase of acute pancreatitis correlates with serum urokinase-type plasminogen activator receptor and interleukin 6 and predicts organ failure.
Pancreatitis
Plasma level of soluble urokinase plasminogen activator receptor (suPAR) predicts long-term mortality after first acute alcohol-induced pancreatitis.
Pancreatitis
Plasma Level of Soluble Urokinase-type Plasminogen Activator Receptor Predicts the Severity of Acute Alcohol Pancreatitis.
Pancreatitis
Serum Urokinase-Type Plasminogen Activator Receptor Does Not Outperform C-Reactive Protein and Procalcitonin as an Early Marker of Severity of Acute Pancreatitis.
Pancreatitis
Soluble urokinase plasminogen activator receptor associates with higher risk, advanced disease severity as well as inflammation, and might serve as a prognostic biomarker of severe acute pancreatitis.
Pancreatitis
Soluble urokinase-type plasminogen activator receptor (suPAR) in patients with acute pancreatitis (AP) - Progress in prediction of AP severity.
Pancreatitis
The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
Pancreatitis
The role of soluble urokinase plasminogen activator receptor (SuPAR) as an indicator of
the severity of acute pancreatitis
Pancreatitis, Acute Necrotizing
The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
Pancreatitis, Chronic
Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis.
Papilledema
Ischemic optic neuropathy in a female carrier with Fabry's disease.
Papilledema
The modality of huoxue-huayu in treatment of retinal vein occlusion.
Papilloma
Immunohistochemical evaluation of urokinase plasminogen activator receptor in noninvasive and early invasive urothelial papillary neoplasia.
Papilloma
Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice.
Paralysis
Intraarterial therapy for acute ischemic stroke: investigation of prognostic factors.
Parasitemia
Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection.
Paresis
[Clinical effects of urokinase and sodium ozagrel in patients with acute symptomatic lacunar infarction]
Pediatric Obesity
Serum levels of soluble urokinase plasminogen activator receptor as a new inflammatory marker in adolescent obesity.
Pelvic Inflammatory Disease
Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
Pemphigoid Gestationis
An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid.
Pemphigoid, Bullous
Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.
Pemphigoid, Bullous
Plasminogen activation in bullous pemphigoid immunohistology reveals urokinase type plasminogen activator, its receptor and plasminogen activator inhibitor type-2 in lesional epidermis.
Pemphigus
American Academy of Dermatology 1999 Awards for Young Investigators in Dermatology. Pemphigus vulgaris IgG regulates expression of urokinase receptor and junctional proteins that may contribute to acantholysis.
Pemphigus
Functional involvement of urokinase-type plasminogen activator receptor in pemphigus acantholysis.
Pemphigus
In vivo studies on the involvement of urokinase in pemphigus acantholysis.
Pemphigus
Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG.
Pemphigus
No activation of urokinase plasminogen activator by anti-desmoglein 3 monoclonal IgG antibodies in cultured human keratinocytes.
Pemphigus
Pemphigus IgG induces expression of urokinase plasminogen activator receptor on the cell surface of cultured keratinocytes.
Pemphigus
Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice.
Pemphigus
Phosphatidylinositol-specific-phospholipase C cleaves urokinase plasminogen activator receptor from the cell surface and leads to inhibition of pemphigus-IgG-induced acantholysis in DJM-1 cells, a squamous cell carcinoma line.
Pemphigus
Plasmin induces acantholysis in skin organ cultures.
Pemphigus
Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann.
Pemphigus
Strict correlation between uPAR and plakoglobin expression in pemphigus vulgaris.
Pemphigus
Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis.
Pemphigus
UVB increases urokinase-type plasminogen activator receptor (uPAR) expression.
Pemphigus
[The role of urokinase-type plasminogen activator in the pathogenesis of pemphigus]
Pemphigus, Benign Familial
Cantharidin-induced acantholysis: adhesion molecules, proteases, and related proteins.
Peptic Ulcer
The release of thromboxane B2 and 6-keto-PGF1 alpha following pulmonary embolism.
Pericardial Effusion
Prevention of pericardial constriction by transcatheter intrapericardial fibrinolysis with urokinase.
Pericarditis
Intrapericardial infusion of urokinase for the treatment of purulent pericarditis.
Pericarditis
Intrapericardial urokinase irrigation and systemic corticosteroids: an alternative to pericardectomy for persistent fibrino-purulent pericarditis.
Pericarditis
Prevention of pericardial constriction by transcatheter intrapericardial fibrinolysis with urokinase.
Pericarditis
Treatment of exudative fibrinous pericarditis with intrapericardial urokinase.
Pericarditis, Constrictive
Treatment of exudative fibrinous pericarditis with intrapericardial urokinase.
Periodontal Diseases
Association of gene polymorphisms for plasminogen activators with alveolar bone loss.
Periodontal Diseases
Differential uPA Expression by TGF-{beta}1 in Gingival Fibroblasts.
Periodontal Diseases
Plasmin is essential in preventing periodontitis in mice.
Periodontitis
Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase-type plasminogen activator receptor (suPAR) levels.
Periodontitis
Porphyromonas gingivalis-derived RgpA-Kgp Complex Activates the Macrophage Urokinase Plasminogen Activator System: IMPLICATIONS FOR PERIODONTITIS.
Periodontitis
Soluble urokinase-type plasminogen activator receptor is associated with signs of periodontitis in adolescents.
Peripheral Arterial Disease
Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
Peripheral Arterial Disease
Cost-effectiveness of urokinase and alteplase for treatment of acute peripheral artery disease: comparison in a decision analysis model.
Peripheral Arterial Disease
Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes.
Peripheral Nerve Injuries
Crohn's disease but not chronic ulcerative colitis induces the expression of PAI-1 in enteric neurons.
Peripheral Vascular Diseases
Peripheral intra-arterial thrombolytic therapy for acute arterial occlusion.
Peripheral Vascular Diseases
Relative cost-effectiveness of urokinase versus streptokinase in the treatment of peripheral vascular disease.
Peripheral Vascular Diseases
Urokinase infusion in total occlusion of peripheral vascular disease.
Peripheral Vascular Diseases
Using efficacy, safety, and cost data to support a formulary decision regarding thrombolytic therapy.
Peritonitis
Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat.
Peritonitis
Candidate host marker for peritoneal dissemination.
Peritonitis
Evidence for peritonitis treatment and prophylaxis: Indications for the use of urokinase in peritoneal dialysis-associated peritonitis.
Peritonitis
Intraperitoneal thrombolytic agents in relapsing or persistent peritonitis of patients on continuous ambulatory peritoneal dialysis.
Peritonitis
Intraperitoneal urokinase and oral rifampicin for persisting asymptomatic dialysate infection following acute coagulase-negative Staphylococcus peritonitis.
Peritonitis
Laparoscopic implantation of the Tenckhoff catheter for the treatment of end-stage renal failure and congestive heart failure: experience with the pelvic fixation technique.
Peritonitis
Peritoneal fluid neutrophil counts and cultures after intraperitoneal infusion of urokinase for relapsing serratia peritonitis.
Peritonitis
Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients.
Peritonitis
Successful use of recombinant tissue plasminogen activator in a patient with relapsing peritonitis.
Peritonitis
Tenckhoff catheter replacement or intraperitoneal urokinase: a randomised trial in the management of recurrent continuous ambulatory peritoneal dialysis (CAPD) peritonitis.
Peritonitis
Treatment for peritoneal dialysis-associated peritonitis.
Peritonitis
Treatment of relapsing peritonitis in pediatric patients on peritoneal dialysis.
Peritonitis
Treatment of resistant peritonitis in continuous ambulatory peritoneal dialysis with intraperitoneal urokinase: a double-blind clinical trial.
Peritonitis
Urokinase for recurrent CAPD peritonitis.
Peritonitis
Urokinase-type plasminogen activator receptor plays a role in neutrophil migration during lipopolysaccharide-induced peritoneal inflammation but not during Escherichia coli-induced peritonitis.
Peritonitis
Urokinase: a treatment for relapsing peritonitis due to coagulase-negative staphylococci.
Peritonitis
Use of intraperitoneal urokinase for resistant bacterial peritonitis in continuous ambulatory peritoneal dialysis.
Peritonitis
Use of streptokinase or urokinase in recurrent CAPD peritonitis.
Peritonitis
[Peritoneal dialysis catheter sterilization by urokinase administration in case of relapsing peritonitis: About four observations].
Pheochromocytoma
The urokinase plasminogen activator receptor (UPAR) is preferentially induced by nerve growth factor in PC12 pheochromocytoma cells and is required for NGF-driven differentiation.
Phlebitis
Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients.
Phlebitis
Thrombolytic therapy for catheter-related thrombosis.
Phlebitis
[Phlebitis of the legs. Comparison of streptokinase and urokinase therapy]
Pituitary ACTH Hypersecretion
Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Pituitary Neoplasms
Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
plasmin deficiency
Serine proteases, inhibitors and receptors in renal fibrosis.
Pleural Diseases
Asbestos upregulates expression of the urokinase-type plasminogen activator receptor on mesothelial cells.
Pleural Diseases
Effects of intrapleural heparin or urokinase on the extent of tetracycline-induced pleural disease.
Pleural Effusion
A study of loculated tuberculous pleural effusions treated with intrapleural urokinase.
Pleural Effusion
Diagnostic value of suPAR in differentiating noncardiac pleural effusions from cardiac pleural effusions.
Pleural Effusion
Elevated levels of angiostatin in effusions from patients with malignant disease.
Pleural Effusion
Evaluation of a pediatric protocol of intrapleural urokinase for pleural empyema: A prospective study.
Pleural Effusion
Evolving experience in the management of pleural empyema.
Pleural Effusion
Fibrinolytic and inflammatory processes in pleural effusions.
Pleural Effusion
Image-guided drainage of complicated pleural effusions and adjunctive use of intrapleural urokinase. What would Hippocrates think?
Pleural Effusion
Intra-pleural fibrinolytic therapy vs. conservative management in the treatment of parapneumonic effusions and empyema.
Pleural Effusion
Intrapleural alteplase in a patient with complicated pleural effusion.
Pleural Effusion
Intrapleural fibrinolysis in the management of empyemas and haemothoraces. Our experience.
Pleural Effusion
Intrapleural Fibrinolysis with Urokinase Versus Alteplase in Complicated Parapneumonic Pleural Effusions and Empyemas: A Prospective Randomized Study.
Pleural Effusion
Intrapleural instillation of urokinase in the treatment of loculated pleural effusions in children.
Pleural Effusion
Intrapleural Urokinase Directly Under Medical Thoracoscopy for the Diagnosis of Malignant Pleural Mesothelioma With Severe Multiloculated Pleural Effusions.
Pleural Effusion
Intrapleural urokinase directly under medical thoracoscopy for the diagnosis of tuberculous pleurisy.
Pleural Effusion
Intrapleural urokinase in the treatment of complicated parapneumonic pleural effusions and empyema.
Pleural Effusion
Intrapleural urokinase in the treatment of loculated pleural effusions.
Pleural Effusion
Intrapleural urokinase treatment in children with complicated parapneumonic effusion.
Pleural Effusion
Proteolytic Regulation of Epithelial Sodium Channels by Urokinase Plasminogen Activator: CUTTING EDGE AND CLEAVAGE SITES.
Pleural Effusion
Streptokinase and urokinase for the treatment of pleural effusions and empyemas.
Pleural Effusion
The effects of urokinase instillation therapy via percutaneous transthoracic catheter in loculated tuberculous pleural effusion: a randomized prospective study.
Pleural Effusion
Transcatheter instillation of urokinase into loculated pleural effusion: analysis of treatment effect.
Pleural Effusion
Transcatheter intracavitary fibrinolysis of loculated pleural effusions: experience in 102 patients.
Pleural Effusion
Transcatheter intrapleural urokinase for loculated pleural effusion.
Pleural Effusion
Treatment of complicated pleural effusion with intracavitary urokinase in children.
Pleural Effusion
Treatment of loculated pleural effusion with intrapleural urokinase in children.
Pleural Effusion
Treatment of loculated pleural effusions with transcatheter intracavitary urokinase.
Pleural Effusion
[Drainage of loculated and/or multiloculated pleural effusions using a small caliber catheter and urokinase (pleuro-fibrinolysis)]
Pleural Effusion
[Intrapleural urokinase in the treatment of parapneumonic effusions]
Pleural Effusion
[The study of intrapleural urokinase in the prevention of pleural thickening and loculated effusions by tuberculous pleurisy]
Pleural Effusion
[Urokinase in the treatment of complicated pleural effusion]
Pleural Effusion
[Use of intrapleural urokinase in children]
Pleural Effusion
[Usefulness of urokinase in multilocular pleural effusion]
Pleural Effusion, Malignant
Erratum: Randomized Controlled Trial of Urokinase versus Placebo for Nondraining Malignant Pleural Effusion.
Pleural Effusion, Malignant
Intrapleural urokinase for the treatment of loculated malignant pleural effusions and trapped lungs in medically inoperable cancer patients.
Pleural Effusion, Malignant
Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study.
Pleural Effusion, Malignant
Randomised Controlled Trial of Urokinase versus Placebo for Non-draining Malignant Pleural Effusion.
Pleural Effusion, Malignant
Using urokinase to treat malignant pleural effusions.
Pleurisy
Properties of urokinase type-plasminogen activator found in chest fluid.
Pleurisy
Single-chain urokinase alone or complexed to its receptor in tetracycline-induced pleuritis in rabbits.
Pleurisy
Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles.
Pneumoconiosis
Gene polymorphisms of fibrinolytic enzymes in coal workers' pneumoconiosis.
Pneumonia
Angiostrongylus cantonensis: Induction of urokinase-type PA and degradation of type IV collagen in rat lung granulomatous fibrosis.
Pneumonia
Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Level as a Predictor of the Severity of Community-Acquired Pneumonia.
Pneumonia
Properties of urokinase type-plasminogen activator found in chest fluid.
Pneumonia
Regulation of urokinase receptor mRNA stability by hnRNP C in lung epithelial cells.
Pneumonia
Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients.
Pneumonia
Selective use of the intensive care unit after nonaortic arterial surgery.
Pneumonia
Soluble receptor for urokinase plasminogen activator in community-acquired pneumonia in children.
Pneumonia
Soluble urokinase plasminogen activator receptor: an indicator of pneumonia severity in children.
Pneumonia
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.
Pneumonia
The plasminogen activation system: new targets in lung inflammation and remodeling.
Pneumonia
The role of the soluble urokinase plasminogen activator (suPAR) in children with pneumonia.
Pneumonia
Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia.
Pneumonia
Urokinase receptor mRNA stability involves tyrosine phosphorylation in lung epithelial cells.
Pneumonia
Urokinase-Type Plasminogen Activator Inhibits Efferocytosis of Neutrophils.
Pneumonia
[Regulation of fibrinolysis by lymphocytes in inflammatory diseases of the bronchopulmonary system]
Pneumonia, Bacterial
Procoagulant and fibrinolytic activities in bronchoalveolar fluid of HIV-positive and HIV-negative patients.
Pneumonia, Pneumococcal
Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia.
Pneumonia, Ventilator-Associated
Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis.
Pneumonia, Ventilator-Associated
Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia.
Pneumoperitoneum
The plasminogen activator inhibitor system in colon cancer cell lines is influenced by the CO(2) pneumoperitoneum.
Pneumothorax
Use of urokinase in childhood pleural empyema.
Polycystic Kidney Diseases
Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.
Polycystic Kidney, Autosomal Dominant
Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.
Polycythemia
Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia.
Polycythemia Vera
Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia.
Polycythemia Vera
Right hepatic artery thrombosis in an essential polycythemia vera patient following pancreato-biliary surgery for severe pancreatitis.
Postthrombotic Syndrome
[Thrombolysis in deep venous thrombosis: critical review]
Pre-Eclampsia
Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors.
Pre-Eclampsia
Hyperglycemia impairs cytotrophoblast function via stress signaling.
Pre-Eclampsia
Leukemia inhibitory factor promote trophoblast invasion via urokinase-type plasminogen activator receptor in preeclampsia.
Pre-Eclampsia
Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: possible markers of placental function.
Pre-Eclampsia
Serum soluble urokinase plasminogen activator receptor (suPAR) in early pregnancy prior to clinical onset of preeclampsia.
Pre-Eclampsia
Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia.
Pre-Eclampsia
The fibrinolytic system in pre-eclampsia.
Pre-Eclampsia
The role of placental urokinase inhibitor in toxemia of pregnancy.
Pre-Eclampsia
Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia.
Pre-Eclampsia
Urinary coagulation-fibrinolysis, kallirein-kinin systems and kininase in cases of preclampsia.
Pre-Eclampsia
[Fibrinolytic therapy for toxemia of late pregnancy--experimental studies of pregnant rabbits treated with urokinase]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[The use of urokinase and ammonium chloride in unblocking a central venous catheter in a child with acute lymphoblastic leukemia]
Pregnancy, Ectopic
Immunohistochemical localization of urokinase-type plasminogen activator and the plasminogen activator inhibitors 1 and 2 in early human implantation sites.
Pressure Ulcer
Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Priapism
[Embolization of the bilateral internal pudendal arteries for intractable priapism in a child with chronic myelogenous leukemia]
Primary Myelofibrosis
Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.
Prolactinoma
Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Prostatic Diseases
Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
Prostatic Hyperplasia
Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Prostatic Hyperplasia
Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue.
Prostatic Hyperplasia
In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer.
Prostatic Hyperplasia
Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues.
Prostatic Hyperplasia
Post-operative blood loss after transurethral prostatectomy is dependent on in situ fibrinolysis.
Prostatic Hyperplasia
Prognostic value of urokinase plasminogen activator for prostatic carcinoma.
Prostatic Hyperplasia
Tissue plasminogen activator activity in prostatic cancer.
Prostatic Intraepithelial Neoplasia
Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion.
Prostatic Neoplasms
(±)Equol inhibits invasion in prostate cancer DU145 cells possibly via down-regulation of matrix metalloproteinase-9, matrix metalloproteinase-2 and urokinase-type plasminogen activator by antioxidant activity.
Prostatic Neoplasms
213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model.
Prostatic Neoplasms
A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
Prostatic Neoplasms
A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines.
Prostatic Neoplasms
A piece in prostate cancer puzzle: Future perspective of novel molecular signatures.
Prostatic Neoplasms
A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis.
Prostatic Neoplasms
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Prostatic Neoplasms
Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
Prostatic Neoplasms
Amplification and overexpression of Elongin C gene discovered in prostate cancer by cDNA microarrays.
Prostatic Neoplasms
Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors.
Prostatic Neoplasms
Amplification of urokinase gene in prostate cancer.
Prostatic Neoplasms
An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells.
Prostatic Neoplasms
Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer.
Prostatic Neoplasms
Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor.
Prostatic Neoplasms
Application of in-gel protease assay in a biological sample: characterization and identification of urokinase-type plasminogen activator (uPA) in secreted proteins from a prostate cancer cell line PC-3.
Prostatic Neoplasms
Aspirin Inhibits IKK-?-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.
Prostatic Neoplasms
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Prostatic Neoplasms
Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.
Prostatic Neoplasms
Cadherin switching and activation of beta-catenin signaling underlie proinvasive actions of calcitonin-calcitonin receptor axis in prostate cancer.
Prostatic Neoplasms
Calcitonin increases tumorigenicity of prostate cancer cells: evidence for the role of protein kinase A and urokinase-type plasminogen receptor.
Prostatic Neoplasms
Calcitonin receptor-stimulated migration of prostate cancer cells is mediated by urokinase receptor-integrin signaling.
Prostatic Neoplasms
Calcitonin stimulates the secretion of urokinase-type plasminogen activator from prostate cancer cells: its possible implications on tumor cell invasion.
Prostatic Neoplasms
CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer.
Prostatic Neoplasms
Characterization of protease expression in human prostate-cancer cell-lines.
Prostatic Neoplasms
Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer.
Prostatic Neoplasms
Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Prostatic Neoplasms
Decreased expression of the low-density lipoprotein receptor-related protein-1 (LRP-1) in rats with prostate cancer.
Prostatic Neoplasms
Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.
Prostatic Neoplasms
Deregulated Expression of Urokinase and its Inhibitor Type 1 in Prostate Cancer Cells: Role of Epigenetic Mechanisms.
Prostatic Neoplasms
Dexamethasone plus Somatostatin-analog Manipulation as Bone Metastasis Microenvironment-targeting Therapy for the Treatment of Castration-resistant Prostate Cancer: A Meta-analysis of Uncontrolled Studies.
Prostatic Neoplasms
Differential expression of uPA in an aggressive (DU 145) and a nonaggressive (1013L) human prostate cancer xenograft.
Prostatic Neoplasms
Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway.
Prostatic Neoplasms
Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer.
Prostatic Neoplasms
Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145.
Prostatic Neoplasms
Dual regulation of urokinase gene expression in human prostate cancer.
Prostatic Neoplasms
Effect of hepatocyte growth factor on invasion of prostate cancer cell lines.
Prostatic Neoplasms
Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases.
Prostatic Neoplasms
Effects of hepatocyte growth factor on urokinase-type plasminogen activator (uPA) and uPA receptor in DU145 prostate cancer cells.
Prostatic Neoplasms
Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue.
Prostatic Neoplasms
Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer.
Prostatic Neoplasms
Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer.
Prostatic Neoplasms
Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA).
Prostatic Neoplasms
Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.
Prostatic Neoplasms
Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Prostatic Neoplasms
Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Prostatic Neoplasms
Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer.
Prostatic Neoplasms
Explication of the roles of prostate health index (PHI) and urokinase plasminogen activator (uPA) as diagnostic and predictor tools for prostate cancer in equivocal PSA range of 4-10 ng/mL.
Prostatic Neoplasms
Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.
Prostatic Neoplasms
Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines.
Prostatic Neoplasms
Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers.
Prostatic Neoplasms
Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer.
Prostatic Neoplasms
Expression of urokinase-type plasminogen activator system in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Prostatic Neoplasms
Extending preclinical models of skeletal manifestations of malignancy to the clinical setting.
Prostatic Neoplasms
Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer.
Prostatic Neoplasms
First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.
Prostatic Neoplasms
Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
Prostatic Neoplasms
Ganoderma lucidum inhibits proliferation and induces apoptosis in human prostate cancer cells PC-3.
Prostatic Neoplasms
Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer.
Prostatic Neoplasms
Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications.
Prostatic Neoplasms
Imaging Active Urokinase Plasminogen Activator in Prostate Cancer.
Prostatic Neoplasms
Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET.
Prostatic Neoplasms
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
Prostatic Neoplasms
In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer.
Prostatic Neoplasms
Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis.
Prostatic Neoplasms
Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Prostatic Neoplasms
Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase.
Prostatic Neoplasms
Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3.
Prostatic Neoplasms
Induction of urokinase-type plasminogen activator by lipopolysaccharide in PC-3 human prostatic cancer cells.
Prostatic Neoplasms
Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells.
Prostatic Neoplasms
Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer.
Prostatic Neoplasms
Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade.
Prostatic Neoplasms
Inhibitors of tyrosine kinase inhibit the production of urokinase plasminogen activator in human prostatic cancer cells.
Prostatic Neoplasms
Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
Prostatic Neoplasms
Inhibitory effect of amiloride on the urokinase plasminogen activators in prostatic cancer.
Prostatic Neoplasms
Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer.
Prostatic Neoplasms
Integrin alpha6 cleavage: a novel modification to modulate cell migration.
Prostatic Neoplasms
Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4.
Prostatic Neoplasms
Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines.
Prostatic Neoplasms
Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells.
Prostatic Neoplasms
Is urokinase gene 3'-UTR polymorphism associated with prostate cancer?
Prostatic Neoplasms
Lycopene increases urokinase receptor and fails to inhibit growth or connexin expression in a metastatically passaged prostate cancer cell line: a brief communication.
Prostatic Neoplasms
Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis.
Prostatic Neoplasms
Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo.
Prostatic Neoplasms
New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.
Prostatic Neoplasms
New circulating biomarkers for prostate cancer.
Prostatic Neoplasms
NFkappaB-dependent regulation of urokinase plasminogen activator by proanthocyanidin-rich grape seed extract: effect on invasion by prostate cancer cells.
Prostatic Neoplasms
Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells.
Prostatic Neoplasms
Nutraceutical inhibitors of urokinase: potential applications in prostate cancer prevention and treatment.
Prostatic Neoplasms
Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion.
Prostatic Neoplasms
Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment.
Prostatic Neoplasms
Other biomarkers for detecting prostate cancer.
Prostatic Neoplasms
Pamidronate down-regulates urokinase-type plasminogen activator expression in PC-3 prostate cancer cells.
Prostatic Neoplasms
PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives.
Prostatic Neoplasms
PET Tracers Beyond FDG in Prostate Cancer.
Prostatic Neoplasms
PKD2 and PKD3 Promote Prostate Cancer Cell Invasion via uPA by Shifting Balance Between NF-?B and HDAC1.
Prostatic Neoplasms
Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer.
Prostatic Neoplasms
Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence.
Prostatic Neoplasms
Predicting high risk disease using serum and DNA biomarkers.
Prostatic Neoplasms
Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.
Prostatic Neoplasms
Prognostic value of urokinase plasminogen activator for prostatic carcinoma.
Prostatic Neoplasms
Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.
Prostatic Neoplasms
Prostate cancer cells show elevated urokinase receptor in a mouse model of metastasis.
Prostatic Neoplasms
Prostate-specific antigen activates single-chain urokinase-type plasminogen activator.
Prostatic Neoplasms
Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion.
Prostatic Neoplasms
Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1.
Prostatic Neoplasms
Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3).
Prostatic Neoplasms
Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo.
Prostatic Neoplasms
Regulation of Urokinase Production by Androgens in Human Prostate Cancer Cells: Effect on Tumor Growth and Metastases in Vivo1.
Prostatic Neoplasms
Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Prostatic Neoplasms
Retraction: Demethylation-Linked Activation of Urokinase Plasminogen Activator Is Involved in Progression of Prostate Cancer.
Prostatic Neoplasms
Retraction: RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Prostatic Neoplasms
Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel.
Prostatic Neoplasms
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Prostatic Neoplasms
Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies.
Prostatic Neoplasms
Signal transduction-mediated regulation of urokinase gene expression in human prostate cancer.
Prostatic Neoplasms
Skip Regulates TGF- ? 1-Induced Extracellular Matrix Degrading Proteases Expression in Human PC-3 Prostate Cancer Cells.
Prostatic Neoplasms
Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis.
Prostatic Neoplasms
Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening.
Prostatic Neoplasms
suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits human prostate cancer cell growth and invasion.
Prostatic Neoplasms
Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.
Prostatic Neoplasms
Synthesis of thiophene-2-carboxamidines containing 2-aminothiazoles and their biological evaluation as urokinase inhibitors.
Prostatic Neoplasms
Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator.
Prostatic Neoplasms
Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.
Prostatic Neoplasms
The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer.
Prostatic Neoplasms
The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.
Prostatic Neoplasms
The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer.
Prostatic Neoplasms
The superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells.
Prostatic Neoplasms
The urokinase-type plasminogen activator system in prostate cancer metastasis.
Prostatic Neoplasms
Transforming growth factor beta1 stimulates urokinase plasminogen activator system on prostate cancer cells.
Prostatic Neoplasms
Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells.
Prostatic Neoplasms
uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
Prostatic Neoplasms
Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo.
Prostatic Neoplasms
Urokinase plasminogen activator is necessary but not sufficient for prostate cancer cell invasion.
Prostatic Neoplasms
Urokinase Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Non-invasive Evaluation of Aggressiveness: a Prospective Phase II Clinical Trial Comparing with Gleason Score.
Prostatic Neoplasms
Urokinase-type plasminogen activator expression in human prostate carcinomas.
Prostatic Neoplasms
Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines.
Protein S Deficiency
Mesenteric and portal vein thrombosis in a young patient with protein S deficiency treated with urokinase via the superior mesenteric artery.
Protein S Deficiency
[A case of portal and superior mesenteric thrombosis associated with protein S deficiency treated with urokinase via the superior mesenteric vein]
Protein-Losing Enteropathies
Resolution of protein-losing enteropathy with standard high molecular heparin and urokinase after Fontan repair in a patient with tricuspid atresia.
Proteinuria
A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation.
Proteinuria
A perspective on chronic kidney disease progression.
Proteinuria
Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.
Proteinuria
Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria.
Proteinuria
Amiloride, a urokinase-type plasminogen activator receptor (uTPA) inhibitor, reduces proteinurea in podocytes.
Proteinuria
CD80, suPAR and Nephrotic Syndrome in a case of NPHS2 mutation.
Proteinuria
Effects of a "single shot" of urokinase on fibrinolytic activities in patients with IgA nephropathy.
Proteinuria
Efficacy of cyclosporine A for steroid-resistant severe Henoch-Schönlein purpura nephritis.
Proteinuria
Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.
Proteinuria
Epidemiology, Major Outcomes, Risk Factors, Prevention and Management of Chronic Kidney Disease in China.
Proteinuria
Glomerular filtration barrier dysfunction in a self-limiting, RNA virus-induced glomerulopathy resembles findings in idiopathic nephrotic syndromes.
Proteinuria
Immunoglobulin A nephropathy in China: progress and challenges.
Proteinuria
Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura.
Proteinuria
Plasmin activates epithelial Na+ channels by cleaving the gamma subunit.
Proteinuria
Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor.
Proteinuria
Resolution of proteinuria secondary to bilateral renal vein thrombosis after treatment with systemic thrombolytic therapy.
Proteinuria
Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children.
Proteinuria
Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling.
Proteinuria
The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury.
Proteinuria
The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.
Proteinuria
Urinary plasmin inhibits TRPV5 in nephrotic-range proteinuria.
Proteinuria
Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection.
Proteinuria
Urokinase-type plasminogen activator contributes to amiloride-sensitive sodium retention in nephrotic range glomerular proteinuria in mice.
Proteinuria
[Significance of the markers of endothelial dysfunction and hemorheological disorders for assessing the activity and prognosis of chronic glomerulonephritis]
Pseudomonas Infections
Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection.
Pseudotumor Cerebri
A case of pseudotumor cerebri following glucocorticoid therapy in which warfarin prevented recurrence.
Psoriasis
Expression of plasminogen activator enzymes in psoriatic epidermis.
Psoriasis
Immunohistochemical characterization of the plasminogen activator system in psoriatic epidermis.
Psoriasis
Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in psoriasis patients and correlation with disease severity.
Psoriasis
[Expression of bioinformatically identified genes in skin of psoriasis patients].
Pterygium
Overexpression of collagenase (MMP-1) and stromelysin (MMP-3) by pterygium head fibroblasts.
Pterygium
Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts.
Pterygium
Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines.
Pterygium
Ultraviolet-A irradiation upregulated urokinase-type plasminogen activator in pterygium fibroblasts through ERK and JNK pathways.
Pulmonary Arterial Hypertension
Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis.
Pulmonary Atelectasis
[Intrathoracic washing with urokinase was effective for empyema with atelectasis].
Pulmonary Disease, Chronic Obstructive
Efficacy and safety of low-dose urokinase for the treatment of hemodynamically stable AECOPD patients with acute pulmonary thromboembolism.
Pulmonary Disease, Chronic Obstructive
Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
High suPAR and Low Blood Eosinophil Count are Risk Factors for Hospital Readmission and Mortality in Patients with COPD.
Pulmonary Disease, Chronic Obstructive
Levels of Components of the Urokinase-type Plasminogen Activator System are Related to Chronic Obstructive Pulmonary Disease Parenchymal Destruction and Airway Remodelling.
Pulmonary Disease, Chronic Obstructive
Role of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD).
Pulmonary Disease, Chronic Obstructive
Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD.
Pulmonary Disease, Chronic Obstructive
Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.
Pulmonary Disease, Chronic Obstructive
Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD.
Pulmonary Disease, Chronic Obstructive
Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD.
Pulmonary Disease, Chronic Obstructive
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
Pulmonary Disease, Chronic Obstructive
The role of serum soluble urokinase-type plasminogen activator receptor in stable chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Urokinase-type plasminogen activator system and human cationic antimicrobial protein 18 in serum and induced sputum of patients with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
[Effect of amiloride on the pathology of a rat model of chronic obstructive pulmonary disease]
Pulmonary Disease, Chronic Obstructive
[Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]
Pulmonary Edema
A change of position for neurogenic pulmonary edema.
Pulmonary Edema
Proteolytic Regulation of Epithelial Sodium Channels by Urokinase Plasminogen Activator: CUTTING EDGE AND CLEAVAGE SITES.
Pulmonary Edema
Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema.
Pulmonary Edema
Urokinase-type plasminogen activator (uPA) induces pulmonary microvascular endothelial permeability through low density lipoprotein receptor-related protein (LRP)-dependent activation of endothelial nitric-oxide synthase.
Pulmonary Embolism
A controlled clinical trial on the effect of heparin infusion and two regimens of urokinase in acute pulmonary embolism.
Pulmonary Embolism
A national cooperative trial of thrombolysis in pulmonary embolism: phase I results of urokinase therapy.
Pulmonary Embolism
A new "wonder" drug to dissolve clots. The results of urokinase therapy in acute myocardial infarction, pulmonary embolism and deep vein thrombosis.
Pulmonary Embolism
Acute pulmonary embolism treated with thrombolytic agents: current status of tPA and future implications for emergency medicine.
Pulmonary Embolism
Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.
Pulmonary Embolism
An evaluation of fibrinolytic therapy of pulmonary thromboembolism using non-invasive examinations and the relationship of urokinase dosage to clinical outcome and coagulation-fibrinolytic changes.
Pulmonary Embolism
Angiographic observations on the treatment of pulmonary thromboembolism with urokinase.
Pulmonary Embolism
Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer.
Pulmonary Embolism
Catheter-directed thrombolysis for thromboembolic disease during pregnancy: a viable option.
Pulmonary Embolism
Changes in the plasma fibrinolytic system during urokinase therapy: comparison of tissue culture urokinase with urinary source urokinase in patients with pulmonary embolism.
Pulmonary Embolism
Combined modality of mechanical breakdown and intraembolus thrombolysis in failed systemic thrombolysis of subacute pulmonary embolism patients.
Pulmonary Embolism
Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up.
Pulmonary Embolism
Comparative tolerability profiles of thrombolytic agents. A review.
Pulmonary Embolism
Comparison of urokinase and reteplase thrombolytic treatment in patients with high-risk pulmonary embolism.
Pulmonary Embolism
Deep venous thrombosis and pulmonary embolism after lung transplantation.
Pulmonary Embolism
Effect of low-molecular-weight heparin and urokinase on pulmonary arteries involved in pulmonary embolism.
Pulmonary Embolism
Effect of Recombinant Single-Chain Urokinase-Type Plasminogen Activator on Experimental Pulmonary Embolism.
Pulmonary Embolism
Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism.
Pulmonary Embolism
Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial.
Pulmonary Embolism
Efficacy and safety of low-dose urokinase for the treatment of hemodynamically stable AECOPD patients with acute pulmonary thromboembolism.
Pulmonary Embolism
Experimental pulmonary embolism: effects of urokinase therapy on organizing thrombi.
Pulmonary Embolism
Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial.
Pulmonary Embolism
Hemodynamic effects of bolus infusion of urokinase in pulmonary thromboembolism.
Pulmonary Embolism
High dose urokinase against massive pulmonary embolism in nephrotic syndrome.
Pulmonary Embolism
High-dose bolus injection of urokinase. Use during cardiopulmonary resuscitation for massive pulmonary embolism.
Pulmonary Embolism
High-dose intra-arterial urokinase for the treatment of hepatic artery thrombosis in liver transplantation.
Pulmonary Embolism
History and physical examination in acute pulmonary embolism in patients without preexisting cardiac or pulmonary disease.
Pulmonary Embolism
Implications of the urokinase study concerning the surgical treatment of pulmonary embolism.
Pulmonary Embolism
Interventions in pulmonary embolism.
Pulmonary Embolism
Intra pulmonary thrombolytic therapy with balloon dilatation in recurrent acute pulmonary embolism.
Pulmonary Embolism
Intraarterial infusion of urokinase in the treatment of acute pulmonary thromboembolism: preliminary observations.
Pulmonary Embolism
Intrapulmonary artery infusion of urokinase for treatment of massive pulmonary embolism: a review of 26 patients with and without contraindications to systemic thrombolytic therapy.
Pulmonary Embolism
Intravascular ultrasound in patients with acute pulmonary embolism after treatment with intravenous urokinase and high-dose heparin.
Pulmonary Embolism
Life-threatening pulmonary embolism with right-sided heart thrombus. Rapid recovery with recombinant tissue plasminogen activator.
Pulmonary Embolism
Local low-dose urokinase thrombolysis for the management of hemodynamically stable pulmonary embolism with right ventricular dysfunction.
Pulmonary Embolism
Low-dose urokinase in major pulmonary embolism.
Pulmonary Embolism
Low-dose urokinase in massive pulmonary embolism when standard thrombolysis is contraindicated.
Pulmonary Embolism
Low-dose urokinase in pulmonary embolism.
Pulmonary Embolism
Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk pulmonary embolism: A retrospective cohort study.
Pulmonary Embolism
Lung endothelium targeting for pulmonary embolism thrombolysis.
Pulmonary Embolism
Massive pulmonary embolism: treatment with the hydrolyser thrombectomy catheter.
Pulmonary Embolism
Mechanical fragmentation and pharmacologic thrombolysis in massive pulmonary embolism.
Pulmonary Embolism
Midterm Results of Endovascular Treatment for Iliac Vein Compression Syndrome from a Single Center.
Pulmonary Embolism
P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.
Pulmonary Embolism
Pharmacomechanical thrombolysis of experimental pulmonary emboli. Rapid low-dose intraembolic therapy.
Pulmonary Embolism
Plasminogen and moderate doses of urokinase in the treatment of acute pulmonary embolism.
Pulmonary Embolism
Possible use of monoclonal antibodies to standardize the production and use of human urokinase.
Pulmonary Embolism
Preparation and characterization of a disulfide-linked bioconjugate of annexin V with the B-chain of urokinase: an improved fibrinolytic agent targeted to phospholipid-containing thrombi.
Pulmonary Embolism
Principles of thrombolysis in pulmonary embolism.
Pulmonary Embolism
Pro-urokinase up-regulates the expression of urokinase-type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells.
Pulmonary Embolism
Progress in fibrinolysis.
Pulmonary Embolism
Pulmonary embolism after local urokinase instillation in a Hickman catheter.
Pulmonary Embolism
Pulmonary embolism and the urokinase pulmonary embolism trial.
Pulmonary Embolism
Pulmonary embolism from pulse-spray pharmacomechanical thrombolysis of clotted hemodialysis grafts: urokinase versus heparinized saline.
Pulmonary Embolism
Pulmonary Embolism in 2017: How We Got Here and Where Are We Going?
Pulmonary Embolism
Pulmonary embolism: a review of medical treatment.
Pulmonary Embolism
Pulmonary perfusion after rt-PA therapy for acute embolism: early improvement assessed with segmental perfusion scanning.
Pulmonary Embolism
Pulmonary thromboembolism. 2. New trends in prophylaxis and therapy.
Pulmonary Embolism
Radiographic, haemodynamic and biochemical findings related to the National Heart and Lung Institute's urokinase pulmonary embolism trial.
Pulmonary Embolism
Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism.
Pulmonary Embolism
Recombinant tissue plasminogen activator in patients with pulmonary embolism: correlation of fibrinolytic specificity and efficacy.
Pulmonary Embolism
Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial.
Pulmonary Embolism
Role of echocardiography in acute pulmonary embolism.
Pulmonary Embolism
Streptokinase and urokinase in the treatment of pulmonary thromboemboli; from a national cooperative study.
Pulmonary Embolism
Successful post-cardiopulmonary resuscitation urokinase therapy for massive perioperative pulmonary embolism - a case report.
Pulmonary Embolism
Successful urokinase treatment of massive pulmonary embolism in pregnancy.
Pulmonary Embolism
The Efficacy and Safety of Intermittent Low-Dose Urokinase Thrombolysis for the Treatment of Senile Acute Intermediate-High-Risk Pulmonary Embolism: A Pilot Trial.
Pulmonary Embolism
The phase II urokinase-streptokinase pulmonary embolism trial: a national cooperative study.
Pulmonary Embolism
The UKEP study: multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism. The UKEP Study Research Group.
Pulmonary Embolism
The urokinase pulmonary embolism trial.
Pulmonary Embolism
The urokinase pulmonary embolism trial. A national cooperative study.
Pulmonary Embolism
Thrombolysis for pulmonary embolism.
Pulmonary Embolism
Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.
Pulmonary Embolism
Thrombolytic therapy with urokinase for pulmonary embolism in patients with stable hemodynamics.
Pulmonary Embolism
Thrombolytic therapy: overview of results in major vascular occlusions.
Pulmonary Embolism
Thrombosis of a mechanical tricuspid valve prosthesis and of the left subclavian vein: successful therapy with thrombolysis.
Pulmonary Embolism
TPA versus urokinase in acute pulmonary embolism: results of a randomized controlled trial.
Pulmonary Embolism
Treatment of massive pulmonary thromboembolism with low intrapulmonary dosages of urokinase. Short-term angiographic and hemodynamic evolution.
Pulmonary Embolism
Treatment of pulmonary embolism with urokinase. Results of clinical trial (phase 1).
Pulmonary Embolism
Treatment of urokinase-related anaphylactoid reaction with intravenous famotidine.
Pulmonary Embolism
Urokinase & streptokinase in pulmonary embolism.
Pulmonary Embolism
Urokinase Attenuates Pulmonary Thromboembolism in an Animal Model by Inhibition of Inflammatory Response.
Pulmonary Embolism
Urokinase for the treatment of acute pulmonary thromboembolism.
Pulmonary Embolism
Urokinase in pulmonary embolism.
Pulmonary Embolism
Urokinase in pulmonary thromboembolism.
Pulmonary Embolism
Urokinase in thromboembolic disease: Pulmonary embolism.
Pulmonary Embolism
Urokinase pulmonary embolism trial.
Pulmonary Embolism
Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study.
Pulmonary Embolism
Urokinase therapy for a catheter-related right atrial thrombus and pulmonary embolism in a 2-month-old infant.
Pulmonary Embolism
Urokinase therapy in clinical pulmonary embolism. A new thrombolytic agent.
Pulmonary Embolism
Urokinase therapy in pulmonary thromboembolism.
Pulmonary Embolism
Urokinase thrombolytic therapy of pulmonary embolism in neurosurgically treated patients.
Pulmonary Embolism
Urokinase versus tissue plasminogen activator in pulmonary embolism.
Pulmonary Embolism
[2 cases of pulmonary embolism treated with urokinase]
Pulmonary Embolism
[A case of pulmonary embolism treated with urokinase]
Pulmonary Embolism
[A case of pulmonary thromboembolism with heparin-induced thrombocytopenia]
Pulmonary Embolism
[A case of renal vein thrombosis and pulmonary embolism associated with diffuse membranous glomerulonephritis: the usefulness of low-molecular-weight heparin and urokinase therapy]
Pulmonary Embolism
[Actual state of thrombolytic treatment of recent vein thrombosis and pulmonary embolism (author's transl)]
Pulmonary Embolism
[Clinical outcome of catheter fragmentation and aspiration therapy in patients with acute pulmonary embolism]
Pulmonary Embolism
[Comparison of curative effect and thrombolysis time between r-tPA application and urokinase in the interventional thrombectomy and thrombolysis for acute and severe pulmonary embolism].
Pulmonary Embolism
[Cost-benefit study of different thrombolytic strategies in treating 156 patients with symptomatic pulmonary thromboembolism].
Pulmonary Embolism
[Diagnosis and therapy of perioperative lung embolism]
Pulmonary Embolism
[Diagnostic problems in acute pulmonary embolism]
Pulmonary Embolism
[Early diagnosis of pulmonary embolism in patients with skin and soft tissue defects after trauma].
Pulmonary Embolism
[Experimental study of the thrombolytic effects in a canine model of pulmonary thromboembolism induced by autologous radioactive blood clots]
Pulmonary Embolism
[Hemodynamic course during fibrinolysis in severe pulmonary embolism]
Pulmonary Embolism
[High-dose short time fibrinolytic treatment with streptokinase of massive lung embolism in the early postoperative period]
Pulmonary Embolism
[Indications and results of thrombolytic treatment with urokinase of very severe pulmonary embolism]
Pulmonary Embolism
[Indications for thrombolytics]
Pulmonary Embolism
[Inefficiency of high doses of urokinase in a massive pulmonary embolism. Possible role of an oral contraceptive]
Pulmonary Embolism
[Local thrombolysis with urokinase in acute massive pulmonary embolism]
Pulmonary Embolism
[Long-term results after local thrombolysis in acute massive pulmonary embolism]
Pulmonary Embolism
[Massive pulmonary thromboembolism. Thrombolytic therapy with urokinase: proposed common protocol]
Pulmonary Embolism
[Moderate doses of urokinase (UK) in the treatment of myocardial infarct and pulmonary embolism]
Pulmonary Embolism
[Multicenter clinical trial on the efficacy of thrombolytic therapy with urokinase and/or anticoagulant with low molecular weight heparin in acute pulmonary embolism]
Pulmonary Embolism
[Multicenter study of 2 urokinase protocols in severe pulmonary embolism. Research Group on Urokinase and Pulmonary Embolism]
Pulmonary Embolism
[Postoperative pulmonary embolism in neurosurgical practice: report of two cases]
Pulmonary Embolism
[Pulmonary embolism in neurosurgery. Treatment with urokinase through selective route]
Pulmonary Embolism
[Pulmonary infarct hardly differentiated from lung cancer--a case report]
Pulmonary Embolism
[Successful treatment of a fulminant pulmonary embolism using a high-dose bolus injection of urokinase during cardiopulmonary resuscitation]
Pulmonary Embolism
[Survey of diagnosis and treatment of acute pulmonary embolism in 21 hospitals in China]
Pulmonary Embolism
[The effect of low molecular heparin and urokinase on MCP-1 of acute experimental pulmonary embolism in rabbits].
Pulmonary Embolism
[The value of thrombolysis for the treatment of acute pulmonary embolism]
Pulmonary Embolism
[Therapeutic approach to pulmonary embolism]
Pulmonary Embolism
[Thrombolysis of rabbit's pulmonary embolism with thrombus-targeted urokinase immune liposome]
Pulmonary Embolism
[Thrombolytic therapy with urokinase in 8 patients with massive pulmonary thromboembolism]
Pulmonary Embolism
[Thrombolytic urokinase treatment of very severe pulmonary embolism. Apropos of 6 cases]
Pulmonary Embolism
[Treatment of acute pulmonary embolism with urokinase compared with the combination plasminogen-urokinase. Apropos of 67 cases]
Pulmonary Embolism
[Treatment of pulmonary embolism. Current status and future prospects]
Pulmonary Embolism
[Treatment of recurrent pulmonary thromboembolism with direct infusion of urokinase into the pulmonary artery]
Pulmonary Embolism
[Treatment of severe pulmonary embolism by the in situ injection of urokinase]
Pulmonary Embolism
[Ultrahigh-dosage urokinase lysis during pulmonary embolism prophylaxis by means of an extractable caval filter]
Pulmonary Embolism
[Use of streptokinase and urokinase in deep venous thrombosis and pulmonary embolism: indications and clinical experience]
Pulmonary Embolism
[Value of moderate doses of urokinase combined with heparin in the treatment of massive pulmonary embolism. A retrospective study of 33 cases]
Pulmonary Fibrosis
Aerosolized urokinase in pulmonary fibrosis.
Pulmonary Fibrosis
Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis.
Pulmonary Fibrosis
Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?
Pulmonary Fibrosis
Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model.
Pulmonary Fibrosis
Role of the urokinase-fibrinolytic system in epithelial-mesenchymal transition during lung injury.
Pulmonary Fibrosis
Systemic sclerosis-like histopathological features in the myocardium of uPAR-deficient mice.
Pulmonary Fibrosis
The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system.
Pulmonary Fibrosis
The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability.
Pulmonary Fibrosis
The matrix unloaded: aerosolized heparin or urokinase for pulmonary fibrosis.
Pulmonary Fibrosis
The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy.
Pulmonary Fibrosis
Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes.
Pulmonary Fibrosis
UROKINASE RECEPTOR MEDIATES LUNG FIBROBLAST ATTACHMENT AND MIGRATION TOWARDS PROVISIONAL MATRIX PROTEINS THROUGH INTERACTION WITH MULTIPLE INTEGRINS.
Pulmonary Fibrosis
[Fibrin deposition and fibrinolysis in the pathogenesis of pulmonary fibrosis]
Purpura
Analysis of urinary and circulating FDP subfragments and subunits: application of the western-blot technique.
Purpura
Endovascular stent infection.
Purpura
Pathological improvement of IgA nephropathy and Henoch-Schönlein purpura nephritis with urokinase therapy.
Purpura
Successful therapy with tonsillectomy for severe ISKDC grade VI Henoch-Schönlein purpura nephritis and persistent nephrotic syndrome.
Purpura Fulminans
Anticoagulant combination therapy of gabexate mesilate and urokinase in purpura fulminans.
Purpura Fulminans
[Prevention of distal necrosis in purpura fulminans. Value of sodium nitroprusside and urokinase]
Purpura, Thrombotic Thrombocytopenic
Urokinase treatment for severe neurological complications in a patient with thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
[A case of thrombotic thrombocytopenic purpura (TTP), clinically diagnosed and cured by dipyridamole, urokinase and aspirin]
Pyelonephritis
Pyelonephritis: renal urokinase activity in rats on essential fatty acid diets.
Pyelonephritis
Pyelonephritis: renal urokinase and sialidase (neuraminidase) activity in rats fed a standard laboratory diet.
Pyelonephritis
Successful thrombolytic therapy in two patients with renal vein thrombosis.
Pyelonephritis
The urokinase plasminogen activator receptor is crucially involved in host defense during acute pyelonephritis.
Rectal Neoplasms
Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Rectal Neoplasms
Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells.
Rectal Neoplasms
Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer.
Rectal Neoplasms
Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer.
Rectal Neoplasms
Epithelial and stromal cell urokinase plasminogen activator receptor expression differentially correlates with survival in rectal cancer stages B and C patients.
Rectal Neoplasms
Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers.
Rectal Neoplasms
Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
Rectal Neoplasms
uPA and PAI-1 in Rectal Cancer-Relationship to Radiotherapy and Clinical Outcome.
Rectal Prolapse
The pathophysiology of pelvic floor disorders: evidence from a histomorphologic study of the perineum and a mouse model of rectal prolapse.
Renal Insufficiency
Acute renal vein thrombosis: successful treatment with intraarterial urokinase.
Renal Insufficiency
Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion.
Renal Insufficiency
Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit.
Renal Insufficiency
Urinary plasminogen activator activity in progressive renal failure.
Renal Insufficiency
[Central venous access for hemodialysis: use and practice with the child in France]
Renal Insufficiency, Chronic
A tripartite complex of suPAR, APOL1 risk variants and ?v?3 integrin on podocytes mediates chronic kidney disease.
Renal Insufficiency, Chronic
Association between Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Renal Insufficiency, Chronic
Biomarkers of Immune Activation and Incident Kidney Failure With Replacement Therapy: Findings From the African American Study of Kidney Disease and Hypertension.
Renal Insufficiency, Chronic
Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.
Renal Insufficiency, Chronic
Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study.
Renal Insufficiency, Chronic
Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients.
Renal Insufficiency, Chronic
Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease.
Renal Insufficiency, Chronic
Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery.
Renal Insufficiency, Chronic
Mechanisms underlying modulation of podocyte TRPC6 channels by suPAR: Role of NADPH oxidases and Src family tyrosine kinases.
Renal Insufficiency, Chronic
Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study.
Renal Insufficiency, Chronic
Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.
Renal Insufficiency, Chronic
Serum levels of soluble urokinase plasminogen activator receptor in Japanese patients with chronic kidney disease.
Renal Insufficiency, Chronic
Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus.
Renal Insufficiency, Chronic
Soluble Urokinase Receptor and Chronic Kidney Disease.
Renal Insufficiency, Chronic
Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease.
Renal Insufficiency, Chronic
Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study.
Renal Insufficiency, Chronic
Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.
Renal Insufficiency, Chronic
Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes.
Renal Insufficiency, Chronic
Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease.
Renal Insufficiency, Chronic
uPAR isoform 2 forms a dimer and induces severe kidney disease in mice.
Renal Insufficiency, Chronic
Urokinase and its receptors in chronic kidney disease.
Renal Insufficiency, Chronic
Urokinase excretion in chronic renal diseases of different histological types.
Reperfusion Injury
A Combined Treatment with Taurine and Intra-arterial Thrombolysis in an Embolic Model of Stroke in Rats: Increased Neuroprotective Efficacy and Extended Therapeutic Time Window.
Reperfusion Injury
Renal urokinase-type plasminogen activator (uPA) receptor but not uPA deficiency strongly attenuates ischemia reperfusion injury and acute kidney allograft rejection.
Reperfusion Injury
[Effects of acupoint-embedment of medicated-thread and acupoint-injection on expression of cortical urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in rats with cerebral ischemia-reperfusion injury].
Reperfusion Injury
[Study on effect of shenmai injection in protecting myocardium against ischemia-reperfusion injury in thrombolytic therapy with urokinase for acute myocardial infarction patients evaluated by 99mTc-MIBI myocardial imaging]
Respiratory Distress Syndrome
Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome.
Respiratory Distress Syndrome
Novel aspects of urokinase function in the injured lung: role of ?2-macroglobulin.
Respiratory Distress Syndrome
Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients.
Respiratory Distress Syndrome
Recombinant production of a hybrid plasminogen activator composed of surfactant protein B and low-molecular-weight urokinase.
Respiratory Distress Syndrome
Serum plasminogen activator urokinase receptor predicts elevated risk of acute respiratory distress syndrome in patients with sepsis and is positively associated with disease severity, inflammation and mortality.
Respiratory Distress Syndrome
The fibrinolysin system and its relationship to disease in the newborn.
Respiratory Distress Syndrome
Wood Bark Smoke Induces Lung and Pleural Plasminogen Activator Inhibitor 1 and Stabilizes its mRNA in Porcine Lung Cells.
Respiratory Distress Syndrome
[Ventilator bundle treatment of acute respiratory distress syndrome and its correlation with biomarkers of inflammation].
Respiratory Insufficiency
Acute hypoxemic respiratory failure following intrapleural thrombolytic therapy for hemothorax.
Respiratory Insufficiency
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Respiratory Insufficiency
Mitral stenosis with bacterial myocarditis in a cat.
Respiratory Insufficiency
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.
Respiratory Insufficiency
[Intensive care of acute respiratory distress syndrome in septic shock--a case report (author's transl)]
Respiratory Tract Infections
Levels of Soluble Urokinase Plasminogen Activator Receptor in Pediatric Lower Respiratory Tract Infections.
Respiratory Tract Infections
Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia.
Retinal Artery Occlusion
Intra-arterial thrombolysis for acute central retinal artery occlusion.
Retinal Artery Occlusion
Microcatheter urokinase infusion in central retinal artery occlusion.
Retinal Artery Occlusion
Selective thrombolysis of central retinal artery occlusion without long-term systemic heparinization.
Retinal Artery Occlusion
[A case of central retinal artery occlusion after anterior posterior fusion of the lumbar spine]
Retinal Artery Occlusion
[A case of nonarteritic anterior ischemic optic neuropathy with cilioretinal artery occlusion]
Retinal Artery Occlusion
[Fibrinolysis: indications in ophthalmology]
Retinal Artery Occlusion
[Local fibrinolytic treatment in occlusions of the central retinal artery]
Retinal Artery Occlusion
[Systemic fibrinolytic therapy using urokinase in central retinal artery occlusion. A case study]
Retinal Detachment
Effect of urokinase on posterior penetrating eye injuries.
Retinal Diseases
The Urokinase Receptor-Derived Peptide UPARANT Recovers Dysfunctional Electroretinogram and Blood-Retinal Barrier Leakage in a Rat Model of Diabetes.
Retinal Neovascularization
Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor.
Retinal Neovascularization
The urokinase/urokinase receptor system in retinal neovascularization: inhibition by A6 suggests a new therapeutic target.
Retinal Vasculitis
[Two cases of frosted retinal angiitis with central retinal vein occlusion]
Retinal Vein Occlusion
[Medical treatment for experimental retinal vein occlusion--thrombolytic effect of nasaruplase]
Retinal Vein Occlusion
[The modality of Huoxue-Huayu in treatment of retinal vein occlusion]
Retinal Vein Occlusion
[Two cases of frosted retinal angiitis with central retinal vein occlusion]
Retinitis Pigmentosa
The urokinase-type plasminogen activator system as drug target in retinitis pigmentosa: New pre-clinical evidence in the rd10 mouse model.
Retinoblastoma
Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation.
Retinoblastoma
Regulation of the urokinase gene by the retinoblastoma protein.
Retinoblastoma
SerpinB2 is an inducible host factor involved in enhancing HIV-1 transcription and replication.
Rhabdomyosarcoma
Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
Rhabdomyosarcoma
Serine enzymes released by cultured neoplastic cells.
Rhabdomyosarcoma
Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
Rhinitis, Allergic
The urokinase system in patients with intermittent and persistent allergic rhinitis.
Sagittal Sinus Thrombosis
Case report: treatment of superior sagittal sinus thrombosis with urokinase.
Sagittal Sinus Thrombosis
Expansion of a haematoma after urokinase thrombolysis of superior sagittal sinus thrombosis.
Sagittal Sinus Thrombosis
Nonrandomized comparison of local urokinase thrombolysis versus systemic heparin anticoagulation for superior sagittal sinus thrombosis.
Sagittal Sinus Thrombosis
Sagittal sinus thrombosis following minor head injury treated with continuous urokinase infusion.
Sagittal Sinus Thrombosis
Superior sagittal sinus thrombosis due to lithium: local urokinase thrombolysis treatment.
Sagittal Sinus Thrombosis
Urokinase treatment of sagittal sinus thrombosis with venous hemorrhagic infarction.
Sarcoidosis
A case of granulomatous renal sarcoidosis with a dramatic response to corticosteroid and urokinase therapy.
Sarcoidosis
Depressed urokinase activity in bronchoalveolar lavage fluid from patients with sarcoidosis, silicosis or idiopathic pulmonary Rbrosis: relationship to disease severity.
Sarcoma
Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
Sarcoma
Clonal variation of expression of the genes coding for plasminogen activators, their inhibitors and the urokinase receptor in HT1080 sarcoma cells.
Sarcoma
Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.
Sarcoma
Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients.
Sarcoma
Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells.
Sarcoma
Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids.
Sarcoma
Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma.
Sarcoma
One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity.
Sarcoma
Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages.
Sarcoma
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.
Sarcoma
Quercetin inhibits migration and invasion of SAS human oral cancer cells through inhibition of NF-?B and matrix metalloproteinase-2/-9 signaling pathways.
Sarcoma
Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.
Sarcoma
Targeting angiogenesis for the treatment of sarcoma.
Sarcoma
Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors.
Sarcoma
Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells.
Sarcoma
Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts.
Sarcoma
Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas.
Sarcoma, Avian
An inhibitor of plasminogen activator in rabbit endothelial cells.
Sarcoma, Avian
Direct fluorescent assay of urokinase and plasminogen activators of normal and malignant cells: kinetics and inhibitor profiles.
Sarcoma, Avian
Plasminogen activator gene expression is induced by the src oncogene product and tumor promoters.
Sarcoma, Avian
Receptors for plasminogen activator, urokinase, in normal and Rous sarcoma virus-transformed mouse fibroblasts.
Sarcoma, Avian
Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.
Sarcoma, Avian
Serine protease and metallo protease cascade systems involved in pericellular proteolysis.
Sarcoma, Ewing
The course of fibrinolytic proteins in children with malignant bone tumours.
Sarcoma, Kaposi
Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells.
Sarcoma, Kaposi
Over-expression of hepatocyte growth factor in human Kaposi's sarcoma.
Sarcoma, Kaposi
The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study.
Sarcoma, Kaposi
The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
Sarcopenia
Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls.
Schistosomiasis
A case control study on the structural equation model of the mechanism of coagulation and fibrinolysis imbalance in chronic schistosomiasis.
Schistosomiasis
The pathogenesis of accelerated fibrinolysis in hepatosplenic schistosomiasis.
Scleroderma, Diffuse
Neural blockade, urokinase and prostaglandin E1 combination therapy for acute digital ischemia of progressive systemic sclerosis.
Scleroderma, Diffuse
Successful treatment of continuous intra-arterial administration of prostaglandin E1, urokinase and heparin for intractable digital ulcers by upper extremity arterial occlusion in diffuse cutaneous systemic sclerosis patient.
Scleroderma, Systemic
A placebo-controlled study on urokinase therapy in systemic sclerosis.
Scleroderma, Systemic
Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis.
Scleroderma, Systemic
Clinical improvement in systemic sclerosis resulting from urokinase therapy explained by light and electron microscopy skin examination.
Scleroderma, Systemic
Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells.
Scleroderma, Systemic
Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression.
Scleroderma, Systemic
Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis.
Scleroderma, Systemic
Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis.
Scleroderma, Systemic
N-Formyl Peptide Receptors Induce Radical Oxygen Production in Fibroblasts Derived From Systemic Sclerosis by Interacting With a Cleaved Form of Urokinase Receptor.
Scleroderma, Systemic
Successful treatment of continuous intra-arterial administration of prostaglandin E1, urokinase and heparin for intractable digital ulcers by upper extremity arterial occlusion in diffuse cutaneous systemic sclerosis patient.
Scleroderma, Systemic
Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor.
Seizures
Deficiency of urokinase-type plasminogen activator and its receptor affects social behavior and increases seizure susceptibility.
Seizures
Hepatocyte growth factor (HGF) modulates GABAergic inhibition and seizure susceptibility.
Seizures
Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.
Seizures
Treatment of severe intraventricular hemorrhage by intraventricular infusion of urokinase.
Seizures
Urokinase receptor and tissue plasminogen activator as immediate-early genes in pentylenetetrazole-induced seizures in the mouse brain.
Seizures
Urokinase-type plasminogen activator deficiency has little effect on seizure susceptibility and acquired epilepsy phenotype but reduces spontaneous exploration in mice.
Seminoma
Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas.
Sepsis
A case of intractable methicillin-resistant Staphylococcus aureus sepsis after an operation for tetralogy of Fallot that was successfully resolved by combined treatment with vancomycin and urokinase.
Sepsis
A Comparative Study of the Diagnostic and Prognostic Utility of Soluble Urokinase-type Plasminogen Activator Receptor and Procalcitonin in Patients with Sepsis and Systemic Inflammation Response Syndrome.
Sepsis
A prospective randomized double-blind trial of bolus urokinase in the treatment of established Hickman catheter sepsis in children.
Sepsis
A prospective randomized trial of urokinase as an adjuvant in the treatment of proven Hickman catheter sepsis.
Sepsis
A Retrospective Study of Preferable Alternative Route to Right Internal Jugular Vein for Placing Tunneled Dialysis Catheters: Right External Jugular Vein versus Left Internal Jugular Vein.
Sepsis
Are urokinase rinses needed to reduce catheter-related bloodstream infections when standard preventive guidelines are observed?
Sepsis
Assessment of Fibrinolysis in Sepsis Patients with Urokinase Modified Thromboelastography.
Sepsis
Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice.
Sepsis
Blood suPAR, Th1 and Th17 cell may serve as potential biomarkers for elderly sepsis management.
Sepsis
Catheter-related sepsis refractory to antibiotics treated successfully with adjunctive urokinase infusion.
Sepsis
Clinical value of plasma soluble urokinase-type plasminogen activator receptor levels in term neonates with infection or sepsis: a prospective study.
Sepsis
Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis.
Sepsis
Diagnostic value of decoy receptor 3 combined with procalcitonin and soluble urokinase-type plasminogen activator receptor for sepsis.
Sepsis
Effect of ascorbate on fibrinolytic factors in septic mouse skeletal muscle.
Sepsis
Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Sepsis
Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission.
Sepsis
Neutrophils are a main source of circulating suPAR predicting outcome in critical illness.
Sepsis
Plasma soluble vascular endothelial growth factor receptor-1 levels predict outcomes of pneumonia-related septic shock patients: a prospective observational study.
Sepsis
Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
Sepsis
Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group.
Sepsis
Prospective analysis of urokinase in the treatment of catheter sepsis in pediatric hematology-oncology patients.
Sepsis
Prospective randomized comparison of valved versus nonvalved peripherally inserted central vein catheters.
Sepsis
Protein kinase C-? mediates sepsis-induced activation of complement 5a and urokinase-type plasminogen activator signaling in macrophages.
Sepsis
Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor.
Sepsis
Role of suPAR and Lactic Acid in Diagnosing Sepsis and Predicting Mortality in Elderly Patients.
Sepsis
Serum Levels of Soluble Urokinase Plasminogen Activator Receptor in Infants with Late-onset Sepsis.
Sepsis
Serum plasminogen activator urokinase receptor predicts elevated risk of acute respiratory distress syndrome in patients with sepsis and is positively associated with disease severity, inflammation and mortality.
Sepsis
Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis.
Sepsis
Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit.
Sepsis
Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients.
Sepsis
Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study.
Sepsis
suPAR as a marker of infection in acute kidney injury - a prospective observational study.
Sepsis
suPAR remains uninfluenced by surgery in septic patients with bloodstream infection.
Sepsis
The effect of perirenal puncture and drainage with urokinase treatment of perirenal hematoma complicated by infection: Two cases' report.
Sepsis
The Prognostic Value of suPAR Compared to Other Inflammatory Markers in Patients with Severe Sepsis.
Sepsis
The role of the soluble urokinase plasminogen activator (suPAR) in children with pneumonia.
Sepsis
The use of soluble urokinase plasminogen activator receptor (suPAR) as a marker of sepsis in the emergency department setting. A current review.
Sepsis
Thrombolysis of occluded synthetic bypass grafts in the lower limb: technical success and 1-year follow-up in 32 patients.
Sepsis
Urokinase lock or flush solution for prevention of bloodstream infections associated with central venous catheters for chemotherapy: a meta-analysis of prospective randomized trials.
Sepsis
Urokinase-type plasminogen activator protects human umbilical vein endothelial cells from apoptosis in sepsis.
Sepsis
[Cannulation of the internal jugular vein with 2 silastic catheters. A new method of vascular access for hemodialysis]
Sepsis
[Diagnostic therapeutic problems of defibrination syndrome in shock, sepsis, and neonatal hypoxia (author's transl)]
Sepsis
[Usefulness of sCD14-ST in the diagnosis of sepsis in patient with renal failure].
Severe Combined Immunodeficiency
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.
Severe Combined Immunodeficiency
Cross-species transmission of gibbon and orangutan hepatitis B virus to uPA/SCID mice with human hepatocytes.
Severe Combined Immunodeficiency
Current status of prediction of drug disposition and toxicity in humans using chimeric mice with humanized liver.
Severe Combined Immunodeficiency
Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes.
Severe Combined Immunodeficiency
Human hepatocyte propagation system in the mouse livers: functional maintenance of the production of coagulation and anticoagulation factors.
Severe Combined Immunodeficiency
Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens.
Severe Combined Immunodeficiency
Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin.
Severe Combined Immunodeficiency
Practical Evaluation of a Mouse with Chimeric Human Liver Model for Hepatitis C Virus Infection Using an NS3-4A Protease Inhibitor.
Shock, Septic
Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Shock, Septic
The effect of perirenal puncture and drainage with urokinase treatment of perirenal hematoma complicated by infection: Two cases' report.
Sigmoid Neoplasms
Isolated splenic metastasis of sigmoid colon cancer: a case report.
Silicosis
Depressed urokinase activity in bronchoalveolar lavage fluid from patients with sarcoidosis, silicosis or idiopathic pulmonary Rbrosis: relationship to disease severity.
Sinus Thrombosis, Intracranial
Acute thrombosis of the intracranial dural sinus: direct thrombolytic treatment.
Sinus Thrombosis, Intracranial
An acute cerebral venous sinus thrombosis: successful treatment by combining mechanical thrombolysis with continuous urokinase infusion.
Sinus Thrombosis, Intracranial
Direct endovascular thrombolytic therapy for dural sinus thrombosis.
Sinus Thrombosis, Intracranial
Heparin-urokinase treatment in aseptic dural sinus thrombosis.
Sinus Thrombosis, Intracranial
Intrasinus thrombolysis by mechanical and urokinase for severe cerebral venous sinus thrombosis : a case report.
Sinus Thrombosis, Intracranial
Mechanical thrombolysis for treatment of acute sinus thrombosis--case report.
Sinus Thrombosis, Intracranial
Sagittal sinus thrombosis following minor head injury treated with continuous urokinase infusion.
Sinus Thrombosis, Intracranial
Selective infusion of urokinase and thrombectomy in the treatment of acute cerebral sinus thrombosis.
Sinus Thrombosis, Intracranial
Thrombolytic therapy in acute stroke.
Sinus Thrombosis, Intracranial
Treatment of dural sinus thrombosis by urokinase infusion.
Sinus Thrombosis, Intracranial
Treatment of dural sinus thrombosis using selective catheterization and urokinase.
Sinus Thrombosis, Intracranial
Treatment of dural sinus thrombosis with local urokinase infusion. Case report.
Sinus Thrombosis, Intracranial
Urokinase treatment of sagittal sinus thrombosis with venous hemorrhagic infarction.
Sinus Thrombosis, Intracranial
Use of thrombolytic therapy in cerebral venous sinus thrombosis with ulcerative colitis.
Sinus Thrombosis, Intracranial
[Effects of injecting urokinase via carotid artery in treatment of cerebral venous sinus thrombosis: an experiment with rabbit models]
Sinus Thrombosis, Intracranial
[Nephrotic syndrome complicated with intracranial venous thrombosis treated with urokinase: report of 5 cases]
Sinus Thrombosis, Intracranial
[Nursing care of patients with sinus thrombosis treated with urokinase administered via transcarotid injection]
Sinusitis
Urokinase-type plasminogen activator and plasminogen activator inhibitor antigen in tissue extracts of paranasal sinus mucous membranes affected by chronic sinusitis and antrochoanal polyps.
Skin Diseases
Expression of plasminogen activator enzymes in psoriatic epidermis.
Skin Diseases
UVB increases urokinase-type plasminogen activator receptor (uPAR) expression.
Skin Neoplasms
Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.
Skin Neoplasms
Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.
Small Cell Lung Carcinoma
Amurubicinol-induced eotaxin-3 expression in human NCI-H69 small cell lung carcinoma cells.
Small Cell Lung Carcinoma
Camptothecin induces urokinase-type plasminogen activator gene-expression in human RC-K8 malignant lymphoma and H69 small cell lung cancer cells.
Small Cell Lung Carcinoma
Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells.
Small Cell Lung Carcinoma
Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells.
Small Cell Lung Carcinoma
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Small Cell Lung Carcinoma
Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer.
Small Cell Lung Carcinoma
The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
Small Cell Lung Carcinoma
Urokinase combination chemotherapy in small cell lung cancer. A phase II study.
Small Cell Lung Carcinoma
[Effects of MnSOD silence on in vitro tumorigenicity in NCI-H446 cells].
Solitary Kidney
Fibrinolytic therapy for renal vein thrombosis in the child.
Solitary Kidney
Upper tract urokinase instillation for nephrostomy tube patency.
Spasm
Neural blockade, urokinase and prostaglandin E1 combination therapy for acute digital ischemia of progressive systemic sclerosis.
Spinal Dysraphism
Amniotic fluid fibrinolytic system in fetal neural tube defects.
Spondylitis, Ankylosing
Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
A novel 3-dimensional culture system as an in vitro model for studying oral cancer cell invasion.
Squamous Cell Carcinoma of Head and Neck
Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - ?1 (TGF-?1) and potential effects on migration and invasion.
Squamous Cell Carcinoma of Head and Neck
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Squamous Cell Carcinoma of Head and Neck
Differential expression levels of urokinase-type plasminogen activator and cathepsin D in locally advanced laryngeal squamous cell carcinoma: clinical implications.
Squamous Cell Carcinoma of Head and Neck
Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin.
Squamous Cell Carcinoma of Head and Neck
Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Squamous Cell Carcinoma of Head and Neck
Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Squamous Cell Carcinoma of Head and Neck
Keratinocytes and head and neck squamous cell carcinoma cells regulate urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in fibroblasts.
Squamous Cell Carcinoma of Head and Neck
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Squamous Cell Carcinoma of Head and Neck
PLAU1 Facilitated Proliferation, Invasion, and Metastasis via Interaction With MMP1 in Head and Neck Squamous Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.
Squamous Cell Carcinoma of Head and Neck
Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo.
Squamous Cell Carcinoma of Head and Neck
SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Silencing of uPAR via RNA interference inhibits invasion and migration of oral tongue squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes.
Squamous Cell Carcinoma of Head and Neck
Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC).
Squamous Cell Carcinoma of Head and Neck
Urokinase receptor up-regulation in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Squamous Cell Carcinoma of Head and Neck
Urokinase-type plasminogen activator expression and proliferation stimulation in head and neck squamous cell carcinoma in vitro and in situ.
Squamous Cell Carcinoma of Head and Neck
Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.
Squamous Cell Carcinoma of Head and Neck
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma]
Squamous Cell Carcinoma of Head and Neck
[Expressions and clinical significance of urokinase-type activator (uPA) and uPA receptor (uPAR) in laryngeal squamous cell carcinoma]
Squamous Cell Carcinoma of Head and Neck
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
Squamous Cell Carcinoma of Head and Neck
[Methylation status of uPA promoter in laryngeal squamous cell carcinoma]
Squamous Cell Carcinoma of Head and Neck
[The expression of urokinase-type plasminogen activator in oral squamous cell carcinoma]
Squamous Cell Carcinoma of Head and Neck
[The relationship between the activation of ERK and the up-regulation of uPA in laryngeal squamous cell carcinoma]
Squamous Cell Carcinoma of Head and Neck
[Urokinase-type plasminogen activator (uPA) and its inhibitor--new prognostic factors in oral squamous cell carcinoma]
ST Elevation Myocardial Infarction
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
ST Elevation Myocardial Infarction
Long-term outcome of patients with ST-segment elevation myocardial infarction treated with low-dose intracoronary thrombolysis during primary percutaneous coronary intervention: the 5-year results of the DISSOLUTION Trial.
ST Elevation Myocardial Infarction
Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction.
Staphylococcal Infections
Persistent catheter-related bacteremia: clearance with antibiotics and urokinase.
Status Epilepticus
Epileptogenesis after traumatic brain injury in Plau-deficient mice.
Status Epilepticus
Urokinase-type plasminogen activator regulates neurodegeneration and neurogenesis but not vascular changes in the mouse hippocampus after status epilepticus.
Stomach Diseases
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.
Stomach Neoplasms
Cadmium induces urokinase-type plasminogen activator receptor expression and the cell invasiveness of human gastric cancer cells via the ERK-1/2, NF-?B, and AP-1 signaling pathways.
Stomach Neoplasms
CD87-positive tumor cells in bone marrow aspirates identified by confocal laser scanning fluorescence microscopy.
Stomach Neoplasms
Clinicopathological significance of urokinase-type plasminogen activator genotypes in gastric cancer.
Stomach Neoplasms
Correlation between expression of urokinase-type plasminogen activator receptor and metastasis in gastric carcinoma.
Stomach Neoplasms
Defining the invasive phenotype of proximal gastric cancer cells.
Stomach Neoplasms
Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer.
Stomach Neoplasms
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.
Stomach Neoplasms
Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis.
Stomach Neoplasms
Effects of angiopoietin-1 on attachment and metastasis of human gastric cancer cell line BGC-823.
Stomach Neoplasms
EGF stimulates uPAR expression and cell invasiveness through ERK, AP-1, and NF-kappaB signaling in human gastric carcinoma cells.
Stomach Neoplasms
EGF-induced urokinase plasminogen activator receptor promotes epithelial to mesenchymal transition in human gastric cancer cells.
Stomach Neoplasms
Expression of HLA-DR and urokinase-type plasminogen activator in stage IV gastric cancer.
Stomach Neoplasms
Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
Stomach Neoplasms
Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Stomach Neoplasms
Extracellular signal-regulated kinase and AP-1 pathways are involved in reactive oxygen species-induced urokinase plasminogen activator receptor expression in human gastric cancer cells.
Stomach Neoplasms
Fibrinolysis-inhibitory activity of cultured human cancer cell lines.
Stomach Neoplasms
Helicobacter pylori stimulates urokinase plasminogen activator receptor expression and cell invasiveness through reactive oxygen species and NF-kappaB signaling in human gastric carcinoma cells.
Stomach Neoplasms
Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer.
Stomach Neoplasms
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Stomach Neoplasms
High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer.
Stomach Neoplasms
IL-1?-stimulated urokinase plasminogen activator expression through NF-?B in gastric cancer after HGF treatment.
Stomach Neoplasms
Immunological analysis of plasminogen activators from cultured human cancer cells.
Stomach Neoplasms
In vitro activity of probiotic Lactobacillus reuteri against gastric cancer progression by downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor gene expression.
Stomach Neoplasms
Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer.
Stomach Neoplasms
Lysophosphatidic acid promotes cell invasion by up-regulating the urokinase-type plasminogen activator receptor in human gastric cancer cells.
Stomach Neoplasms
Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
Stomach Neoplasms
Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
Stomach Neoplasms
MSP-induced RON activation upregulates uPAR expression and cell invasiveness via MAPK, AP-1 and NF-?B signals in gastric cancer cells.
Stomach Neoplasms
Overexpression of forkhead box M1 and urokinase-type plasminogen activator in gastric cancer is associated with cancer progression and poor prognosis.
Stomach Neoplasms
Overexpression of urokinase-type plasminogen activator in human gastric cancer cell line (AGS) induces tumorigenicity in severe combined immunodeficient mice.
Stomach Neoplasms
p75 neurotrophin receptor inhibits invasion and metastasis of gastric cancer.
Stomach Neoplasms
Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid.
Stomach Neoplasms
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Stomach Neoplasms
Prognostic factors in gastric cancer.
Stomach Neoplasms
Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
Stomach Neoplasms
Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.
Stomach Neoplasms
Prognostic role of urokinase plasminogen activator receptor in gastric and colorectal cancer: A systematic review and meta-analysis.
Stomach Neoplasms
Prognostic value of urokinase-type plasminogen activators in gastric-cancer.
Stomach Neoplasms
Prostaglandin E2 stimulates urokinase-type plasminogen activator receptor via EP2 receptor-dependent signaling pathways in human AGS gastric cancer cells.
Stomach Neoplasms
Reactive oxygen species regulate urokinase plasminogen activator expression and cell invasion via mitogen-activated protein kinase pathways after treatment with hepatocyte growth factor in stomach cancer cells.
Stomach Neoplasms
Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines.
Stomach Neoplasms
Relationship between expression of plasminogen activator system and metastatic ability in human cancers.
Stomach Neoplasms
Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer.
Stomach Neoplasms
Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer.
Stomach Neoplasms
Role of urokinase plasminogen activator receptor in gastric cancer: a potential therapeutic target.
Stomach Neoplasms
Semaphorin 5A promotes gastric cancer invasion/metastasis via urokinase-type plasminogen activator/phosphoinositide 3-kinase/protein kinase B.
Stomach Neoplasms
Seroprevalence of Helicobacter pylori/CagA Antibodies in Guatemalan Gastric Cancer Patients: Association of Seropositivity with Increased Plasma Levels of Pepsinogens but not Soluble Urokinase Plasminogen Activator Receptor.
Stomach Neoplasms
Src/ERK but not phospholipase D is involved in keratinocyte growth factor-stimulated secretion of matrix metalloprotease-9 and urokinase-type plasminogen activator in SNU-16 human stomach cancer cell.
Stomach Neoplasms
Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells.
Stomach Neoplasms
The Clinical Study of Urokinase-Type Plasminogen Activator and Vascular Endothelial Growth Factor in Gastric Cancer.
Stomach Neoplasms
The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells.
Stomach Neoplasms
The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer.
Stomach Neoplasms
The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.
Stomach Neoplasms
Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
Stomach Neoplasms
Upregulation of circulating cytokeratin 20, urokinase plasminogen activator and C-reactive protein is associated with poor prognosis in gastric cancer.
Stomach Neoplasms
Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries.
Stomach Neoplasms
Urokinase plasminogen activator receptor is upregulated by Helicobacter pylori in human gastric cancer AGS cells via ERK, JNK, and AP-1.
Stomach Neoplasms
Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma.
Stomach Neoplasms
Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines.
Stomach Neoplasms
Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Stomach Neoplasms
Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
Stomach Neoplasms
[Clinical evaluation of various antineoplastic agents combined with urokinase--a comparison between urokinase from tissue culture (TCUK) and urine-derived urokinase (UUK)]
Stomach Neoplasms
[Correlation between the expression of urokinase-type plasminogen activator, E-cadherin and malignancy in gastric cancer]
Stomach Neoplasms
[Effects of S-adenosylmethionine on gastric cancer cell lines SGC-7901 and BGC-823].
Stomach Neoplasms
[Relationship between urokinase-type plasminogen activator expression and peritoneal metastatic potency in different gastric cancer cell lines]
Stomach Neoplasms
[uPA expression of gastric cancer cell lines and its correlation with peritoneal seeding]
Stomach Neoplasms
[Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer]
Stomach Ulcer
Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease.
Streptococcal Infections
A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection.
Stroke
A Combined Treatment with Taurine and Intra-arterial Thrombolysis in an Embolic Model of Stroke in Rats: Increased Neuroprotective Efficacy and Extended Therapeutic Time Window.
Stroke
Acute stroke intervention with intraarterial urokinase infusion.
Stroke
Amino acid supplementation enhances urokinase production by HT-1080 cells.
Stroke
Angioplasty of the occluded internal carotid artery.
Stroke
Clinical potential of intra-arterial thrombolytic therapy in patients with acute ischaemic stroke.
Stroke
Clinical, Biochemical and Neuroimaging Parameters after Thrombolytic Therapy Predict Long-Term Stroke Outcome.
Stroke
Comparative Analysis of Endovascular Stroke Therapy Using Urokinase, Penumbra System and Retrievable (Solitare) Stent.
Stroke
Comparative study on the efficacy and safety of alteplase and urokinase in the treatment of acute cerebral infarction.
Stroke
Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign.
Stroke
Corrigendum to "Comparative Analysis of Fibrinolytic Properties of Alteplase, Tenecteplase and Urokinase in an in Vitro Clot Model of Intracerebral Haemorrhage. [Journal of Stroke and Cerebrovascular Diseases, Vol. 29, No. 9 (September), 2020: 105073]".
Stroke
CT after intracranial intraarterial thrombolysis for acute stroke.
Stroke
Dynamical levels of plasma F(1+2) and D-dimer in patients with acute cerebral infarction during intravenous urokinase thrombolysis.
Stroke
Early infarct growth predicts long-term clinical outcome after thrombolysis.
Stroke
Effects of Intra-arterial Urokinase on a Non-human Primate Thromboembolic Stroke Model.
Stroke
Efficacy of intraarterial thrombolysis of basilar artery stroke.
Stroke
Emergent middle cerebral artery embolectomy: a useful technique for cranial base surgery.
Stroke
Emerging technologies in therapeutic ultrasound: thermal ablation to gene delivery.
Stroke
Endovascular neuroradiological treatment of acute ischemic stroke: techniques and results in 350 patients.
Stroke
Factors predicting hemorrhagic complications after multimodal reperfusion therapy for acute ischemic stroke.
Stroke
Fiber-Reinforced Silk Composite for Enhanced Urokinase Production Using High-Density Perfusion Culture and Bioactive Molecule Supplementation.
Stroke
In vitro simulation of therapeutic plasmatic fibrinolysis.
Stroke
Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase.
Stroke
Initial angiographic appearance of intracranial vascular occlusions in acute stroke as a predictor of outcome of thrombolysis: initial experience.
Stroke
Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion.
Stroke
Intra-arterial thrombolysis in 24 consecutive patients with internal carotid artery T occlusions.
Stroke
Intra-arterial thrombolysis in basilar artery occlusion and recent haemorrhagic stroke due to arteriovenous malformation.
Stroke
Intra-arterial urokinase for acute ischemic stroke: factors associated with complications.
Stroke
Intraarterial thrombolytic therapy within 3 hours of the onset of stroke.
Stroke
Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke.
Stroke
Intracranial thrombolysis via a catheter embedded in the clot.
Stroke
Intraoperative high-dose regional urokinase infusion for cerebrovascular occlusion after carotid endarterectomy.
Stroke
Intraoperative intraarterial urokinase in early postoperative stroke following carotid endarterectomy: a useful adjunct.
Stroke
Intravenous glycoprotein IIb/IIIa inhibitor (tirofiban) followed by intra-arterial urokinase and mechanical thrombolysis in stroke.
Stroke
Intravenous Glycoprotein IIb/IIIa Inhibitor (Tirofiban) Followed by Low-Dose Intra-Arterial Urokinase and Mechanical Thrombolysis for the Treatment of Acute Stroke.
Stroke
Intravenous Glycoprotein IIb/IIIa inhibitor (Tirofiban) Followed by Low-dose Intra-arterial Urokinase and Mechanical Thrombolysis for the Treatment of Stroke.
Stroke
Intravenous thrombolysis guided by a telemedicine consultation system for acute ischaemic stroke patients in China: the protocol of a multicentre historically controlled study.
Stroke
Intravenous tirofiban with intra-arterial urokinase and mechanical thrombolysis in stroke: preliminary experience in 11 cases.
Stroke
Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA).
Stroke
Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan.
Stroke
Long-term effect of intra-arterial thrombolysis in stroke.
Stroke
Medical therapy for ischemic stroke.
Stroke
Multivariable analysis of predictive factors related to outcome at 6 months after intra-arterial thrombolysis for acute ischemic stroke.
Stroke
Oral urokinase: absorption, mechanisms of fibrinolytic enhancement and clinical effect on cerebral thrombosis.
Stroke
Outcome evaluation of intravenous infusion of urokinase for acute ischemic stroke.
Stroke
Outcome in acute stroke with different intra-arterial infusion rate of urokinase on thrombolysis.
Stroke
Randomized clinical stroke trials in 2007.
Stroke
Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan.
Stroke
Rationale and design of a phase 3b, prospective, randomized, open label, blinded-endpoint, multicenter trial of the efficacy and safety of urokinase thrombolysis comparing with antiplatelet agents for patients with minor stroke.
Stroke
Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Stroke
Reocclusion and stroke due to immediate plaque protrusion following endovascular treatment of carotid artery successfully treated with intra-arterial urokinase and stent in stent in a patient with Takayasu arteritis with severe disease of all arch vessels.
Stroke
Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke.
Stroke
Safety and efficacy of delayed intraarterial urokinase therapy with mechanical clot disruption for thromboembolic stroke.
Stroke
Safety and Efficacy of Intra-arterial Urokinase After Failed, Unsuccessful, or Incomplete Mechanical Thrombectomy in Anterior Circulation Large-Vessel Occlusion Stroke.
Stroke
Selective intra arterial thrombolysis in acute carotid territory stroke.
Stroke
Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
Stroke
Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA.
Stroke
Successful recanalization post endovascular therapy is associated with a decreased risk of intracranial haemorrhage: a retrospective study.
Stroke
Symptomatic intracranial haemorrhage after intra-arterial thrombolysis in acute ischaemic stroke: assessment of 294 patients treated with urokinase.
Stroke
Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke.
Stroke
The beneficial effect of intracarotid urokinase on acute stroke in a baboon model.
Stroke
The importance of selected markers of inflammation and blood-brain barrier damage for short-term ischemic stroke prognosis.
Stroke
Thrombolysis in acute stroke without angiographically documented occlusion.
Stroke
[Intraarterial urokinase infusion therapy for the acute intracranial major artery occlusion]
Stroke
[New methods of intensive therapy in stroke: hemicraniectomy in patients with complete middle cerebral artery infarction and treatment of intracerebral and intraventricular hemorrhage with urokinase]
Stroke
[Risk factors for intracerebral hemorrhage after intravenous thrombolysis in acute cerebral infarction]
Stroke
[Thrombolytic therapy in ischemic infarct]
Stroke, Lacunar
[Clinical effects of urokinase and sodium ozagrel in patients with acute symptomatic lacunar infarction]
Subarachnoid Hemorrhage
Cisternal irrigation therapy with urokinase and ascorbic acid for prevention of vasospasm after aneurysmal subarachnoid hemorrhage. Outcome in 217 patients.
Subarachnoid Hemorrhage
Combined cisternal drainage and intrathecal urokinase injection therapy for prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
Subarachnoid Hemorrhage
Comparison of Intrathecally Administered Urokinase, Tissue-type Plasminogen Activator, and Combination of Urokinase and Lysine-Plasminogen for Clot Lysis after Experimental Subarachnoid Hemorrhage in Dogs.
Subarachnoid Hemorrhage
Development of a kit to treat subarachnoid hemorrhage by intrathecal simple urokinase infusion (ITSUKI) therapy: preliminary results in patients with World Federation of Neurological Surgery (WFNS) grade V subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Effectiveness of the head-shaking method combined with cisternal irrigation with urokinase in preventing cerebral vasospasm after subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Intrathecal urokinase infusion through a microcatheter into the cisterna magna to prevent cerebral vasospasm: experimental study in dogs.
Subarachnoid Hemorrhage
Microthrombosis after experimental subarachnoid hemorrhage: time course and effect of red blood cell-bound thrombin-activated pro-urokinase and clazosentan.
Subarachnoid Hemorrhage
Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Is Not Associated with Neurological Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage.
Subarachnoid Hemorrhage
Stereotactic cisternal lavage in patients with aneurysmal subarachnoid hemorrhage with urokinase and nimodipine for the prevention of secondary brain injury (SPLASH): study protocol for a randomized controlled trial.
Subarachnoid Hemorrhage
The effect of urokinase in preventing the formation of epidural fibrosis and/or leptomeningeal arachnoiditis.
Subarachnoid Hemorrhage
Thrombus in vertebrobasilar dolichoectatic artery treated with intravenous urokinase.
Subarachnoid Hemorrhage
Urokinase cisternal irrigation therapy for prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage: a study of urokinase concentration and the fibrinolytic system.
Subarachnoid Hemorrhage
[Combining exchange of cerebrospinal fluid with small dose of urokinase injection for subarachnoid hemorrhage]
Superior Vena Cava Syndrome
Late vascular occlusion of central lines in pediatric malignancies.
Superior Vena Cava Syndrome
Successful treatment of superior vena cava syndrome with urokinase in an infant with a central venous catheter.
Superior Vena Cava Syndrome
Successful treatment of superior vena cava syndrome with urokinase in an infant.
Superior Vena Cava Syndrome
Successful urokinase therapy for superior vena cava syndrome in a premature infant.
Superior Vena Cava Syndrome
Urokinase. A cost-effective alternative treatment of superior vena cava thrombosis and obstruction.
Syncope
Kawasaki Disease Complicated by Late-Onset Fatal Cerebral Infarction: A Case Report and Literature Review.
Syncope
Tumor necrosis factor (TNF) stimulates plasminogen activator inhibitor (PAI) production by endothelial cells and decreases blood fibrinolytic activity in the rat.
t-plasminogen activator deficiency
Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity.
Takayasu Arteritis
Reocclusion and stroke due to immediate plaque protrusion following endovascular treatment of carotid artery successfully treated with intra-arterial urokinase and stent in stent in a patient with Takayasu arteritis with severe disease of all arch vessels.
Takayasu Arteritis
Suction thrombectomy of thrombotic occlusion of the subclavian artery in a case of Takayasu's arteritis.
Telangiectasis
Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis.
Temporomandibular Joint Disorders
Gene expression of fibrinolytic factors urokinase plasminogen activator and plasminogen activator inhibitor-1 in rabbit temporo-mandibular joint cartilage with disc displacement.
Temporomandibular Joint Disorders
[Expression of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in synovial fluid of patients with temporomandibular disorders]
Teratocarcinoma
Teratocarcinoma F9 cells induced to differentiate with sodium butyrate produce both tissue-type and urokinase-type plasminogen activators.
Teratocarcinoma
The expression and localization of urokinase-type plasminogen activator and its type 1 inhibitor are regulated by retinoic acid and fibroblast growth factor in human teratocarcinoma cells.
Tetralogy of Fallot
A case of intractable methicillin-resistant Staphylococcus aureus sepsis after an operation for tetralogy of Fallot that was successfully resolved by combined treatment with vancomycin and urokinase.
Thoracic Outlet Syndrome
Treatment of a case of thromboembolism resulting from thoracic outlet syndrome with intra-arterial urokinase infusion.
Thromboangiitis Obliterans
Assessment of plasma prothrombotic factors in patients with Buerger's disease.
Thromboangiitis Obliterans
Superselective urokinase infusion therapy for dorsalis pedis artery occlusion in Buerger's disease.
Thromboangiitis Obliterans
[Intrathrombotic injection of urokinase in Buerger's disease]
Thrombocythemia, Essential
Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia.
Thrombocytopenia
Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice.
Thrombocytopenia
Heparin-induced thrombocytopenia II-induced critical limb ischaemia treated with urokinase and argatroban.
Thrombocytopenia
Heparin-induced thrombocytopenia in a glioblastoma multiforme patient with inferior vena cava filter placement for deep venous thrombosis.
Thrombocytopenia
Intraoperative urokinase as an alternative to heparin for patients with suspected heparin-induced thrombocytopenia requiring arterial reconstruction: report of a case and review of the literature.
Thrombocytopenia
Pulse-spray catheter-directed thrombolysis with urokinase and argatroban for thrombo-occlusion of an inferior vena cava filter due to heparin-induced thrombocytopenia with thrombosis.
Thrombocytopenia
Successful treatment of veno-occlusive disease of the liver with urokinase in a patient with non-Hodgkin's lymphoma.
Thrombocytopenia
The heparin-induced thrombocytopenia and thrombosis syndrome: treatment with intraarterial urokinase and systemic platelet aggregation inhibitors.
Thrombocytopenia
Thrombolytic therapy in heparin-associated thrombocytopenia with thrombosis.
Thrombocytopenia
[Calcium heparin-induced immunologic thrombocytopenia complicated with venous gangrene of the legs. Report of a clinical case]
Thromboembolism
Fiber-Reinforced Silk Composite for Enhanced Urokinase Production Using High-Density Perfusion Culture and Bioactive Molecule Supplementation.
Thromboembolism
Local Intra-Arterial Administration of Urokinase in the Treatment of a Feline Distal Aortic Thromboembolism.
Thromboembolism
Local urokinase in arterial thromboembolism.
Thromboembolism
Recombinant tissue plasminogen activator treatment of pulmonary embolism also improves deep venous thrombosis.
Thromboembolism
Stenting the stent: alternative strategy for treating in-stent restenosis.
Thromboembolism
Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.
Thromboembolism
Treatment of a case of thromboembolism resulting from thoracic outlet syndrome with intra-arterial urokinase infusion.
Thromboembolism
[Possibilities and limits of local intra-arterial fibrinolysis in thromboembolic vascular occlusions of the central nervous system]
Thromboembolism
[Thrombolysis of cerebral thromboembolism by urokinase in an animal model]
Thromboembolism
[Thrombolytic therapy in patients with pulmonary artery thromboembolism and deep vein thrombosis].
Thrombophilia
Hypofibrinolysis in patients with hypercoagulability: the roles of urokinase and of plasminogen activator inhibitor.
Thrombophilia
[A method for determining plasminogen with a Russian chromogenic substrate and its diagnostic significance]
Thrombophlebitis
A case of idiopathic deep vein thrombosis improved with glucocorticoid therapy.
Thrombophlebitis
[Non-Hodgkin's lymphoma with marked infiltration in calf muscle]
Thrombosis
A Bi-Functional Anti-Thrombosis Protein Containing Both Direct-Acting Fibrin(ogen)olytic and Plasminogen-Activating Activities.
Thrombosis
A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation.
Thrombosis
A comparative study of urokinase and heparin in the treatment of deep vein thrombosis.
Thrombosis
A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators.
Thrombosis
A critical appraisal of the small-diameter portacaval H-graft.
Thrombosis
A highly reproducible model of arterial thrombosis in rats.
Thrombosis
A new "wonder" drug to dissolve clots. The results of urokinase therapy in acute myocardial infarction, pulmonary embolism and deep vein thrombosis.
Thrombosis
A prospective randomized trial of urokinase as an adjuvant in the treatment of proven Hickman catheter sepsis.
Thrombosis
A protocol of urokinase infusion and warfarin for the management of the thrombosed haemodialysis catheter.
Thrombosis
A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters.
Thrombosis
A randomized, placebo-controlled pilot study of patients with spontaneous intraventricular haemorrhage treated with intraventricular thrombolysis.
Thrombosis
A targeted antithrombotic conjugate with antiplatelet and fibrinolytic properties which reduces in vivo thrombus formation.
Thrombosis
A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2]).
Thrombosis
Acute bilateral renal vein thrombosis superimposed on calcified thrombus of the inferior vena cava in a patient with membranous lupus nephritis.
Thrombosis
Acute Early Carotid Stent Thrombosis: A Case Series.
Thrombosis
Acute extensive portal and mesenteric venous thrombosis after splenectomy: treated by interventional thrombolysis with transjugular approach.
Thrombosis
Acute myocardial infarction in a patient with essential thrombocythemia: successful treatment with percutaneous transluminal coronary recanalization.
Thrombosis
Acute portal vein thrombosis due to chronic relapsing pancreatitis: a fistula between a pancreatic pseudocyst and the splenic vein.
Thrombosis
Acute renal allograft dysfunction in the setting of deep venous thrombosis: a case of successful urokinase thrombolysis and a review of the literature.
Thrombosis
Acute renal vein thrombosis: successful treatment with intraarterial urokinase.
Thrombosis
Acute symptomatic mesenteric venous thrombosis: treatment by catheter-directed thrombolysis with transjugular intrahepatic route.
Thrombosis
Acute thrombosis of a vena cava filter with a clot above the filter. Successful treatment with low-dose urokinase.
Thrombosis
Additive fibrinolysis by recombinant tissue-type plasminogen activator (r-t-PA) and recombinant single-chain urokinase type plasminogen activator (r-scu-PA) in rabbit pulmonary thrombosis.
Thrombosis
Adenoviral urokinase-type plasminogen activator (uPA) gene transfer enhances venous thrombus resolution.
Thrombosis
Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA Trial. TAUSA Investigators. Thrombolysis and Angioplasty in Unstable Angina trial.
Thrombosis
Admixture of heparin with urokinase to decrease thrombolysis time and urokinase dose in polytetrafluoroethylene dialysis graft recanalization.
Thrombosis
Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis.
Thrombosis
Ancrod enhances the thrombolytic effect of streptokinase and urokinase.
Thrombosis
Angiographic features in the infarct-related artery after intracoronary urokinase followed by prolonged anticoagulation. Role of ruptured atheromatous plaque and adherent thrombus in acute myocardial infarction in vivo.
Thrombosis
AngioJet Aspiration Thrombectomy Combined with Transcatheter Thrombolysis in Treatment of Acute Portal Venous Systemic Thrombosis.
Thrombosis
AngioJet rheolytic thrombectomy versus local intrapulmonary thrombolysis in massive pulmonary embolism: a retrospective data analysis.
Thrombosis
Anterograde injection of low-dose urokinase salvages free anterolateral thigh flap: A case report of safe and effective treatment.
Thrombosis
Anterograde intra-arterial urokinase injection for salvaging fibular free flap.
Thrombosis
Antithrombotic benefit of subendothelium-bound urokinase: an experimental study.
Thrombosis
Antithrombotic effects by oral administration of novel proteinase fraction from earthworm Eisenia andrei on venous thrombosis model in rats.
Thrombosis
Aortic thrombosis in a neonate: failure of urokinase thrombolytic therapy.
Thrombosis
Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.
Thrombosis
Approach to thrombotic occlusion related to long-term catheters of hemodialysis patients: a narrative review.
Thrombosis
Arterial thrombus dissolution in vivo using a transducer-tipped, high-frequency ultrasound catheter and local low-dose urokinase delivery.
Thrombosis
Arthritis simulating thrombosis on urokinase scan.
Thrombosis
Augmented pulse-spray thrombolysis with tPA by early pulsed intrathrombic plasminogen enrichment.
Thrombosis
Axillary artery compression and thrombosis in throwing athletes.
Thrombosis
Beneficial effect of aspirin in maintaining the patency of small-caliber prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen activator.
Thrombosis
Bilateral renal venous thrombosis in a neonate associated with resistance to activated protein C.
Thrombosis
Binding of human tissue plasminogen activator (t-PA) to blood clots and clot-lytic activity of clot-bound t-PA.
Thrombosis
Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.
Thrombosis
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
Thrombosis
Bleeding complications after basilar artery fibrinolysis with tissue plasminogen activator.
Thrombosis
Blood coagulation changes during effective thrombolysis using urokinase and heparin.
Thrombosis
Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
Thrombosis
Catheter occlusion by calcium carbonate during simultaneous infusion of 5-FU and calcium folinate.
Thrombosis
Catheter-based local thrombolysis with urokinase: comparative efficacy of intraluminal clot lysis with conventional urokinase infusion techniques in an in vivo porcine thrombus model.
Thrombosis
Catheter-directed thrombolysis following vena cava filtration for severe deep venous thrombosis.
Thrombosis
Catheter-directed thrombolytic therapy combined with angioplasty for hepatic vein obstruction in Budd-Chiari syndrome complicated by thrombosis.
Thrombosis
Catheter-directed thrombolytic therapy for thoracic deep vein thrombosis is safe and effective in selected patients with and without cancer.
Thrombosis
Central venous line thrombosis in premature infants: a case management and literature review.
Thrombosis
Cerebral venous congestion as indication for thrombolytic treatment.
Thrombosis
Characterization of wild-type and mutant alpha2-antiplasmins: fibrinolysis enhancement by reactive site mutant.
Thrombosis
Chronic and acute consequences of a post-dialysis urokinase lock on permanent hemodialysis catheter function.
Thrombosis
Circumferential venolysis and paraclavicular thoracic outlet decompression for "effort thrombosis" of the subclavian vein.
Thrombosis
Clinical improvement related to thrombolysis of third ventricular blood clot in a patient with thalamic hemorrhage.
Thrombosis
Clinical outcomes of transcatheter selective superior mesenteric artery urokinase infusion therapy
Thrombosis
Collateral circulation and outcome after basilar artery thrombolysis.
Thrombosis
Combination of Surgical Thrombectomy and Direct Thrombolysis in Acute Abdomen with Portal and Superior Mesenteric Vein Thrombosis.
Thrombosis
Combined catheter thrombus fragmentation and fibrinolysis for acute pulmonary embolism.
Thrombosis
Combined Low-Frequency Ultrasound and Urokinase-Containing Microbubbles in Treatment of Femoral Artery Thrombosis in a Rabbit Model.
Thrombosis
Combined modality of mechanical breakdown and intraembolus thrombolysis in failed systemic thrombolysis of subacute pulmonary embolism patients.
Thrombosis
Combined thrombolytic and anticoagulant therapy for venous thrombosis in children.
Thrombosis
Combined thrombolytic therapy for atrial thrombus in a preterm infant.
Thrombosis
Combined, superselective pharmacological management of large coronary thrombus burden.
Thrombosis
Comparative results of thrombolysis treatment with rt-PA and urokinase: a pilot study.
Thrombosis
Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
Thrombosis
Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator.
Thrombosis
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Thrombosis
Comparative tolerability profiles of thrombolytic agents. A review.
Thrombosis
Comparison of catheter-directed thrombolysis with and without percutaneous mechanical thrombectomy for subacute iliofemoral deep vein thrombosis.
Thrombosis
Comparison of cost effectiveness of streptokinase and urokinase in the treatment of deep vein thrombosis.
Thrombosis
Comparison of Direct Iliofemoral Stenting Following AngioJet Rheolytic Thrombectomy vs Staged Stenting After AngioJet Rheolytic Thrombectomy Plus Catheter-Directed Thrombolysis in Patients With Acute Deep Vein Thrombosis.
Thrombosis
Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
Thrombosis
Comparison of ReoPro((R)) (abciximab) versus intracoronary thrombolysis for early coronary stent thrombosis.
Thrombosis
Comparison of retavase and urokinase for management of spontaneous subclavian vein thrombosis.
Thrombosis
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Thrombosis
Comparison of the thrombolytic efficacy of defibrase and urokinase on canine coronary artery thrombosis and the mechanism of urokinase-induced hemorrhage.
Thrombosis
Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis.
Thrombosis
Complex tumors of the glomus jugulare: criteria, treatment, and outcome.
Thrombosis
Concentrated sodium chloride catheter lock solution - a new effective alternative method for hemodialysis patients with high bleeding risk.
Thrombosis
Congenital protein C deficiency causing major arterial thrombosis in a neonate.
Thrombosis
Continuous infusion of low-dose urokinase in the treatment of central venous catheter thrombosis in infants and children.
Thrombosis
Continuous local intra-arterial infusion of anticoagulants for digit replantation and treatment of damaged arteries.
Thrombosis
Contrast-enhanced sonothrombolysis in a porcine model of acute peripheral arterial thrombosis and prevention of anaphylactic shock.
Thrombosis
Copper vapor laser and optical fiber catheter system for liquefaction and removal of thrombus in occluded arteries.
Thrombosis
Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis.
Thrombosis
Coronary spasm in two sisters.
Thrombosis
Coronary thrombolysis and endothelin-1 release.
Thrombosis
Coronary thrombolysis. Comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase.
Thrombosis
Cost-effectiveness of intra-arterial thrombolytic therapy.
Thrombosis
Criteria for use of regional urokinase infusion for deep vein thrombosis.
Thrombosis
Crucial Involvement of IL-6 in Thrombus Resolution in Mice via Macrophage Recruitment and the Induction of Proteolytic Enzymes.
Thrombosis
Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis.
Thrombosis
Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Thrombosis
Defibrotide is equipotent to urokinase in stimulating arterial and venous thrombolysis.
Thrombosis
Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema.
Thrombosis
Dependence of blood clot lysis on the mode of transport of urokinase into the clot--a magnetic resonance imaging study in vitro.
Thrombosis
Diabetes decreases patency of tunneled catheters in hemodialysis patients after first effective thrombolysis with urokinase.
Thrombosis
Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model.
Thrombosis
Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
Thrombosis
Dilution of urokinase used to treat thrombus formation in central venous catheters.
Thrombosis
Ditazole activity and its interaction with urokinase on experimental thrombosis.
Thrombosis
Documentation of successful treatment of prosthetic mitral valve thrombosis with intravenous urokinase infusion for twenty-four hours.
Thrombosis
Dural sinus thrombosis and pseudotumor cerebri: unexpected complications of suboccipital craniotomy and translabyrinthine craniectomy.
Thrombosis
Early diagnosis and precision treatment of right ovarian vein and inferior vena cava thrombosis following caesarean section: A case report.
Thrombosis
Early operative intervention after thrombolytic therapy for primary subclavian vein thrombosis: an effective treatment approach.
Thrombosis
Early thrombosis of a tricuspid valve prosthesis: two-dimensional echocardiographic demonstration.
Thrombosis
Economic assessment of rheolytic thrombectomy versus intracoronary urokinase for treatment of extensive intracoronary thrombus: Results from a randomized clinical trial.
Thrombosis
Effect of drug administration on experimental renal glomerular thrombosis.
Thrombosis
Effect of Recombinant Single-Chain Urokinase-Type Plasminogen Activator on Experimental Pulmonary Embolism.
Thrombosis
Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Thrombosis
Effect of urokinase on fibrinolysis and fibrinogenolysis.
Thrombosis
Effectiveness of low dose urokinase on dialysis catheter thrombolysis.
Thrombosis
Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase. Evidence for a possible role of inhibiting platelet activity in thrombolysis.
Thrombosis
Effects of streptokinase and urokinase on microarterial thrombosis and haemostasis. An experimental study in rabbits.
Thrombosis
Efficacy of angioscopy in determining the effectiveness of intracoronary urokinase and TEC atherectomy thrombus removal from an occluded saphenous vein graft prior to stent implantation.
Thrombosis
Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage.
Thrombosis
Efficacy of tissue plasminogen activator and urokinase in a canine model of prosthetic graft thrombosis.
Thrombosis
Elevation of plasminogen activators in cerebrospinal fluid of mice with eosinophilic meningitis caused by Angiostrongylus cantonensis.
Thrombosis
Embolization of cardiac mural thrombus: complication of intraarterial fibrinolysis.
Thrombosis
Endoarterial treatment of acute ischemia of the limbs with urokinase. Italian Cooperative Study "Bologna".
Thrombosis
Endothelial dysfunction following thrombolysis in vitro.
Thrombosis
Endovascular management of acute extensive iliofemoral deep venous thrombosis caused by May-Thurner syndrome.
Thrombosis
Endovascular recanalization of chronic long-segment occlusions of the inferior vena cava: midterm results.
Thrombosis
Endovascular revascularization of renal artery stenosis: technical and clinical results.
Thrombosis
Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis: a prospective study.
Thrombosis
Endovascular thrombolysis for symptomatic cerebral venous thrombosis.
Thrombosis
Endovascular treatment of acute arterial complications after living-donor liver transplantation.
Thrombosis
Endovascular treatment of traumatic dural sinus thrombosis: case report.
Thrombosis
Enhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system. In vitro, in vivo, and clinical studies.
Thrombosis
Enhanced Venous Thrombus Resolution in Plasminogen Activator Inhibitor Type-2 Deficient Mice.
Thrombosis
Enhancement of fibrinolysis in vitro by ultrasound.
Thrombosis
Evaluation of thrombolysis in a porcine model of chronic deep venous thrombosis: an endovascular model.
Thrombosis
Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis.
Thrombosis
Experience of an implantable central venous access system in a district general hospital.
Thrombosis
Experience with subcutaneous infusion ports in three hundred patients.
Thrombosis
Experience with the double lumen Silastic catheter for hemoaccess.
Thrombosis
Experimental evaluation of small intestinal submucosa as a microvascular graft material.
Thrombosis
Experimental study on the comparative thrombolytic effects of intracoronary and intravenous administration of urokinase.
Thrombosis
Failure of peripheral arterial thrombolysis due to elevated plasminogen activator inhibitor type 1.
Thrombosis
Failure of systemic thrombolytic and heparin therapy in the treatment of neonatal aortic thrombosis.
Thrombosis
Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells.
Thrombosis
Feasibility examination of isolated zonal thrombolysis using Raman spectroscopy.
Thrombosis
Feasibility of low-dose infusion of alteplase for unsuccessful thrombolysis with urokinase in deep venous thrombosis.
Thrombosis
Femur fracture with limb shortening causing occlusion of a polytetrafluoroethylene femoral popliteal graft.
Thrombosis
Fiberoptic observation of thrombosis and thrombolysis in isolated human coronary arteries.
Thrombosis
Fibrin-specific fibrinolysis induced by recombinant staphylokinase.
Thrombosis
Fibrinogen-fibrin related antigen pattern in human blood. Incomplete lysis of whole blood clots by urokinase.
Thrombosis
Fibrinogenolysis and fibrinolysis in normal volunteers and patients with thrombosis after infusion of urokinase.
Thrombosis
Fibrinolysis with intrathrombic injection of urokinase and tissue-type plasminogen activator. Results in a new model of subacute venous thrombosis.
Thrombosis
Fibrinolysis: from blood to the brain.
Thrombosis
Fibrinolytic therapy for renal vein thrombosis in the child.
Thrombosis
Fibrinolytic therapy with streptokinase and urokinase in deep vein thrombosis.
Thrombosis
Fibrinolytic Treatment after Transient Ischaemic Attack Caused by Prosthetic Mitral Valve Thrombosis.
Thrombosis
Fibrinolytic treatment of portal vein thrombosis after umbilical catheterization using systemic urokinase.
Thrombosis
Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis.
Thrombosis
Hemorrhagic bullae as a complication of urokinase therapy for hemodialysis catheter thrombosis.
Thrombosis
Hemostatic abnormalities in nephrotic syndrome.
Thrombosis
Heparin and urokinase in situ for partial thrombosis of indwelling hemodialysis catheters.
Thrombosis
Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children.
Thrombosis
Heparin, urokinase, and ancrod alter neutrophil function.
Thrombosis
High dose urokinase for restoration of patency of occluded permanent central venous catheters in hemodialysis patients.
Thrombosis
High-dose intra-arterial urokinase for the treatment of hepatic artery thrombosis in liver transplantation.
Thrombosis
High-dose urokinase therapy for the lysis of a central venous catheter-related thrombus in a young patient with Hodgkin's disease.
Thrombosis
High-dose urokinase therapy in newborn infants with major vessel thrombosis.
Thrombosis
Hydrodynamic thrombectomy system versus pulse-spray thrombolysis for thrombosed hemodialysis grafts: a multicenter prospective randomized comparison.
Thrombosis
Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses.
Thrombosis
Immediate postoperative thrombolytic therapy: an aggressive strategy for neurologic salvage when cerebral thromboembolism complicates carotid endarterectomy.
Thrombosis
Implantation of permanent jugular catheters in patients on regular dialysis treatment: ten years' experience.
Thrombosis
In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Thrombosis
In utero brachial artery thrombosis: limb salvage with postnatal urokinase infusion.
Thrombosis
In vitro evaluation of the relative thrombolytic efficiency of forced intrathrombic injections: saline versus urokinase.
Thrombosis
In vitro model to evaluate the relative efficacy of catheter-directed thrombolytic strategies.
Thrombosis
In vitro Simulation of Therapeutic Thrombolysis With Microtiter Plate Clot-Lysis Assay.
Thrombosis
In vivo behaviour of vesicular urokinase.
Thrombosis
In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase.
Thrombosis
Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects.
Thrombosis
Incompatibility of Isovue 370 and papaverine in peripheral arteriography.
Thrombosis
Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth.
Thrombosis
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Thrombosis
Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase.
Thrombosis
Influence of catheter technology and adjuvant medication on acute complications in percutaneous coronary angioplasty.
Thrombosis
Inhibition of Plasminogen Activator Inhibitor-1 Activation Suppresses High Fat Diet-Induced Weight Gain via Alleviation of Hypothalamic Leptin Resistance.
Thrombosis
Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons.
Thrombosis
Insertion of fibrin peptides into urokinase enhances fibrin affinity.
Thrombosis
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.
Thrombosis
Interaction analyses of human monocytes co-cultured with different forms of Aspergillus fumigatus.
Thrombosis
Interpreting the results of pediatric central venous catheter studies.
Thrombosis
Interventional radiologic placement of Hohn central venous catheters: results and complications in 100 consecutive patients.
Thrombosis
Intra pulmonary thrombolytic therapy with balloon dilatation in recurrent acute pulmonary embolism.
Thrombosis
Intra-arterial reteplase for the treatment of acute limb ischemia.
Thrombosis
Intra-arterial thrombolysis in acute basilar artery thromboembolism: the initial Mayo Clinic experience.
Thrombosis
Intra-arterial thrombolytic therapy for acute intracranial large artery occlusive disease in patients selected by magnetic resonance image.
Thrombosis
Intra-arterial Thrombolytic Therapy for Acute Vertebrobasilar Artery Occlusion.
Thrombosis
Intra-arterial urokinase for treatment of retrograde thrombosis following resection of an arteriovenous malformation. Case report.
Thrombosis
Intraarterial thrombolysis in a pig model: a preliminary note.
Thrombosis
Intraarterial thrombolysis in vertebrobasilar occlusion.
Thrombosis
Intraarterially administered abciximab as an adjuvant thrombolytic therapy: report of three cases.
Thrombosis
Intracameral urokinase for dissolution of fibrin or blood clots after glaucoma surgery.
Thrombosis
Intracoronary thrombus: chronic urokinase infusion and evaluation with intravascular ultrasound.
Thrombosis
Intracoronary urokinase as an adjunct to percutaneous transluminal coronary angioplasty in patients with complex coronary narrowings or angioplasty-induced complications.
Thrombosis
Intracoronary urokinase for intracoronary thrombus accumulation complicating percutaneous transluminal coronary angioplasty in acute ischemic syndromes.
Thrombosis
Intracoronary urokinase in Kawasaki disease: treatment and prevention of myocardial infarction.
Thrombosis
Intraluminal thrombus enhances proteolysis in abdominal aortic aneurysms.
Thrombosis
Intraoperative infusion of lytic drugs for thrombotic complications of revascularization.
Thrombosis
Intraoperative urokinase infusion for embolic stroke during carotid endarterectomy.
Thrombosis
Intrathrombic urokinase reverses neonatal renal artery thrombosis.
Thrombosis
Intravenous Targeted Microbubbles Carrying Urokinase versus Urokinase Alone in Acute Peripheral Arterial Thrombosis in a Porcine Model.
Thrombosis
Intravenous thrombolytic treatment of mechanical prosthetic valve thrombosis: a study using serial transesophageal echocardiography.
Thrombosis
Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial.
Thrombosis
Involvement of Platelets in Cancers.
Thrombosis
Islets surface modification prevents blood-mediated inflammatory responses.
Thrombosis
Isolated limb perfusion with urokinase for acute ischemia.
Thrombosis
Isolated limb perfusion with urokinase in the treatment of extensive vascular thrombosis of the lower limbs.
Thrombosis
K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man.
Thrombosis
Late complication of classic Fontan operation: giant right atrial thrombus and massive pulmonary thromboembolism.
Thrombosis
Late stent blockage by blood clot successfully treated by urokinase.
Thrombosis
Late vascular occlusion of central lines in pediatric malignancies.
Thrombosis
Left ventricular thromboembolic occlusion of the popliteal artery treated nonoperatively with local urokinase infusion--a case report.
Thrombosis
Life-threatening pulmonary embolism with right-sided heart thrombus. Rapid recovery with recombinant tissue plasminogen activator.
Thrombosis
Local fibrinolysis in cerebral venous thrombosis.
Thrombosis
Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients.
Thrombosis
Local inhibition of thrombosis using urokinase linked to a monoclonal antibody which recognises damaged endothelium.
Thrombosis
Local Intra-arterial Thrombolysis during Mechanical Thrombectomy for Refractory Large-Vessel Occlusion: Adjunctive Chemical Enhancer of Thrombectomy.
Thrombosis
Local intra-arterial thrombolysis in a 4-year-old male with vertebrobasilar artery thrombosis.
Thrombosis
Local intra-arterial thrombolysis with urokinase combined with balloon angioplasty in the lower extremities.
Thrombosis
Local intraarterial fibrinolysis of thromboemboli occurring during endovascular treatment of intracerebral aneurysm: a comparison of anatomic results and clinical outcome.
Thrombosis
Local intraarterial thrombolysis: in vitro comparison between automatic and manual pulse-spray infusion.
Thrombosis
Local intraarterial thrombolysis: in vitro comparison of various infusion catheters.
Thrombosis
Local thrombolysis in patients with dural venous thrombosis unresponsive to heparin.
Thrombosis
Local thrombolytic therapy as part of a multidisciplinary approach to acute axillosubclavian vein thrombosis (Paget-Schroetter syndrome).
Thrombosis
Local thrombolytic therapy for thromboembolic occlusion of the middle cerebral artery.
Thrombosis
Local thrombolytic therapy in deep cerebral venous thrombosis.
Thrombosis
Local urokinase delivery with the Channel balloon: device safety, pharmacokinetics of intracoronary drug delivery, and efficacy of thrombolysis.
Thrombosis
Long-term performance and complications of the Tesio twin catheter system for hemodialysis access.
Thrombosis
Long-term results of treatment of benign central venous obstructions unrelated to dialysis with expandable Z stents.
Thrombosis
Low-dose antithrombotic treatment in coronary thrombosis of kawasaki disease.
Thrombosis
Lysing patterns of retracted blood clots with diffusion or bulk flow transport of plasma with urokinase into clots--a magnetic resonance imaging study in vitro.
Thrombosis
Lysis of a right atrial thrombus of more than a week's duration by high dose urokinase in a one-year-old child.
Thrombosis
Lysis of intravascular thrombus prior to coronary stenting using the dispatch infusion catheter.
Thrombosis
Lysis of intraventricular blood clot with urokinase in a canine model: Part 1. Canine intraventricular blood cast model.
Thrombosis
Lysis of intraventricular blood clot with urokinase in a canine model: Part 2. In vivo safety study of intraventricular urokinase.
Thrombosis
Lysis of intraventricular blood clot with urokinase in a canine model: Part 3. Effects of intraventricular urokinase on clot lysis and posthemorrhagic hydrocephalus.
Thrombosis
Lysis of left ventricular thrombus with urokinase in a patient with alcohol heart disease.
Thrombosis
Lytic solution of platelet-rich plasma clots potentiated platelet response to agonists by action on Ca2+ homeostasis.
Thrombosis
Magnetic resonance imaging of retracted and nonretracted blood clots during fibrinolysis in vitro.
Thrombosis
Maintaining the patency of double-lumen silastic jugular catheters for haemodialysis.
Thrombosis
Management and immediate outcome of patients with intracoronary thrombus during percutaneous transluminal coronary angioplasty.
Thrombosis
Management of acute superior mesenteric artery occlusion.
Thrombosis
Management of complicated coronary angioplasty by intracoronary urokinase and immediate re-angioplasty.
Thrombosis
Management of intracoronary thrombosis complicating percutaneous transluminal coronary angioplasty.
Thrombosis
Management of venous thromboembolism.
Thrombosis
Managing dysfunctional central venous access devices: a practical approach to urokinase thrombolysis.
Thrombosis
May-Thurner syndrome, a diagnosis to consider in young males with no risk factors: a case report and review of the literature.
Thrombosis
Mechanical fragmentation and pharmacologic thrombolysis in massive pulmonary embolism.
Thrombosis
Mechanical thrombectomy of acute iliofemoral deep vein thrombosis with use of an arrow-trerotola percutaneous thrombectomy device.
Thrombosis
Mechanical versus chemical thrombolysis: an in vitro differentiation of thrombolytic mechanisms.
Thrombosis
Mesenteric and portal vein thrombosis in a young patient with protein S deficiency treated with urokinase via the superior mesenteric artery.
Thrombosis
Metformin prevents endotoxin-induced liver injury after partial hepatectomy.
Thrombosis
Middle cerebral artery thrombolysis through the contralateral internal carotid artery--case report.
Thrombosis
Molecular mechanism of action of newer thrombolytic agents.
Thrombosis
Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis.
Thrombosis
Multifunctional Thrombin-Activatable Polymer Capsules for Specific Targeting to Activated Platelets.
Thrombosis
Multiple coronary artery aneurysms in an adult associated with extensive thrombus formation resulting in acute myocardial infarction: successful treatment with intracoronary urokinase, intravenous heparin, and oral anticoagulation.
Thrombosis
Multiple coronary thrombosis in a patient with thrombocytosis.
Thrombosis
Multiple stent implantation in single coronary arteries: acute results and six-month angiographic follow-up.
Thrombosis
Mutant Prourokinase with Adjunctive C1-Inhibitor Is an Effective and Safer Alternative to tPA in Rat Stroke.
Thrombosis
Mycoplasma pneumoniae induced popliteal artery thrombosis treated with urokinase.
Thrombosis
Nanoscaled ultrasound contrast agents for enhanced sonothrombolysis.
Thrombosis
Neonatal aortic thrombosis treated with intra-arterial urokinase therapy.
Thrombosis
Neonatal thrombosis: treatment with heparin and thrombolytics.
Thrombosis
Nephrotic syndrome complicated with portal, splenic, and superior mesenteric vein thrombosis.
Thrombosis
Neurovascular compression in the thoracic outlet: changing management over 50 years.
Thrombosis
Nonsurgical correction for thrombosis of a St. Jude Medical tricuspid prosthesis: report of a case.
Thrombosis
Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cells (PBSC).
Thrombosis
Novel and emerging therapies: thrombus-targeted fibrinolysis.
Thrombosis
Obstructed central venous catheters. Restoring function with a 12-hour infusion of low-dose urokinase.
Thrombosis
Optimizing the bolus/infusion ratio for intravenous administration of urokinase in dogs.
Thrombosis
Original approach for thrombolytic therapy in patients with Ilio-femoral deep vein thrombosis : 2 years follow-up.
Thrombosis
Outcome after Preoperative or Intraoperative Use of Intra-arterial Urokinase Thrombolysis for Acute Popliteal Artery Thrombosis and Leg Ischemia.
Thrombosis
Outcome of treatment of deep-vein thrombosis with urokinase: relationship to dosage, duration of therapy, age of the thrombus and laboratory changes.
Thrombosis
Outpatient High-Dose Urokinase Infusion Improves Dialysis Catheter Longevity: A Prospective Observational Study.
Thrombosis
PAI-1 Leads to G1-Phase Cell-Cycle Progression through Cyclin D3/cdk4/6 Upregulation.
Thrombosis
Partial venous thrombosis of the pancreatic allografts after simultaneous pancreas-kidney transplantation.
Thrombosis
Patho-physiological studies on lactic acid-induced pulmonary thrombosis in rat. I. Effect of heparin, acetylsalicylic acid, urokinase and tranexamic acid.
Thrombosis
Percutaneous aspiration thrombectomy for the treatment of acute lower extremity deep vein thrombosis: is thrombolysis needed?
Thrombosis
Percutaneous iliac artery stent: angiographic long-term follow-up.
Thrombosis
Percutaneous transhepatic portography for the treatment of early portal vein thrombosis after surgery.
Thrombosis
Percutaneous transluminal coronary angioplasty, alone or in combination with urokinase therapy, during acute myocardial infarction.
Thrombosis
Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone--a randomized pilot trial (the PROMPT Study). Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis.
Thrombosis
Pharmacologic and clinical characteristics of thrombolytic agents.
Thrombosis
Pharmacologic treatment of catheter-related thrombus in pediatrics.
Thrombosis
Pharmacological thrombolysis: the last choice for salvaging free flaps.
Thrombosis
Pharmacomechanical thrombolysis with use of the brush catheter in canine thrombosed femoropopliteal arterial PTFE bypass grafts.
Thrombosis
Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.
Thrombosis
Plasminogen acceleration of urokinase thrombolysis.
Thrombosis
Plasminogen activation and lysis of blood clots induced by cells in vitro.
Thrombosis
Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis.
Thrombosis
Platelet-derived porous nanomotor for thrombus therapy.
Thrombosis
Platelet-Mimic uPA Delivery Nanovectors Based on Au Rods for Thrombus Targeting and Treatment.
Thrombosis
Popliteal artery occlusion caused by cystic adventitial disease: successful treatment by urokinase followed by nonresectional cystotomy.
Thrombosis
Popliteal venous aneurysm with pulmonary embolism.
Thrombosis
Portal thrombosis due to intrahepatic cholangiocarcinoma following successful treatment for hepatocellular carcinoma.
Thrombosis
Portal vein thrombosis after laparoscopic colectomy: thrombolytic therapy via the superior mesenteric vein.
Thrombosis
Portal vein thrombosis successfully treated with a colectomy in active ulcerative colitis: report of a case.
Thrombosis
Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
Thrombosis
Prevention and Treatment of Thrombosis Associated With Long-Term Hemodialysis Catheters.
Thrombosis
Prevention of clot formation in cat retinal vein by systemic and subconjunctival urokinase.
Thrombosis
Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies.
Thrombosis
Prevention of tunneled cuffed catheter dysfunction with prophylactic use of a taurolidine urokinase lock: A randomized double-blind trial.
Thrombosis
Preventive effects of batroxobin on experimental canine coronary thrombosis.
Thrombosis
Primary subclavian venous thrombosis which developed after sleeping with the arm in an outstretched position: report of a case.
Thrombosis
Progress in fibrinolysis.
Thrombosis
Prolonged intracoronary urokinase infusion for acute stent thrombosis.
Thrombosis
Prolonged intragraft urokinase with a new infusion wire: improved short-term results.
Thrombosis
Prolonged intravenous urokinase infusion: an alternative pharmacologic approach in the treatment of thrombus-containing saphenous vein graft stenoses.
Thrombosis
Prolonged selective urokinase infusion in totally occluded coronary arteries and bypass grafts: two case reports.
Thrombosis
Prospective analysis of urokinase in the treatment of catheter sepsis in pediatric hematology-oncology patients.
Thrombosis
Prospective evaluation of a Dacron cuffed hemodialysis catheter for prolonged use.
Thrombosis
Prototype therapeutic ultrasound emitting catheter for accelerating thrombolysis.
Thrombosis
Pulmonary artery thrombolysis and stenting after a bilateral sequential lung transplantation.
Thrombosis
Pulse-spray catheter-directed thrombolysis with urokinase and argatroban for thrombo-occlusion of an inferior vena cava filter due to heparin-induced thrombocytopenia with thrombosis.
Thrombosis
Pulse-spray thrombolysis of inferior vena cava thrombosis complicating filter placement.
Thrombosis
Pulsed-spray pharmacomechanical thrombolysis: preliminary clinical results.
Thrombosis
Purification and characterization of a novel fibrinolytic enzyme from Whitmania pigra Whitman.
Thrombosis
Radial Arterial Approach with Adjunctive Urokinase for Treating Occluded Autogenous Radial-Cephalic Fistulas.
Thrombosis
Radial arterial approach with adjunctive urokinase for treating occluded autogenous radial-cephalic fistulas.
Thrombosis
Radioactive urokinase for blood clot scanning.
Thrombosis
Rapid thrombus dissolution by continuous infusion of urokinase through an intracoronary perfusion wire prior to and following PTCA: results in native coronaries and patent saphenous vein grafts.
Thrombosis
Recanalization of occluded large arteries with broadened therapeutic window for acute cerebral infarction.
Thrombosis
Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
Thrombosis
Recombinant tissue plasminogen activator in patients with pulmonary embolism: correlation of fibrinolytic specificity and efficacy.
Thrombosis
Reduced fibrinolytic potential in patients with arterial occlusive disease (AOD) in comparison with normal subjects.
Thrombosis
Reduction of thrombus formation in vivo using a thrombolytic agent targeted at damaged endothelial cells.
Thrombosis
Regional low dosage thrombolytic therapy for peripheral arterial occlusions.
Thrombosis
Regional thrombolysis with urokinase for central venous catheter-related thrombosis in patients undergoing high-dose chemotherapy with autologous blood stem cell rescue.
Thrombosis
Relationship between clot location and outcome after basilar artery thrombolysis.
Thrombosis
Repeated phlebographic examination during and after fibrinolytic therapy with streptokinase and urokinase.
Thrombosis
Resolution of proteinuria secondary to bilateral renal vein thrombosis after treatment with systemic thrombolytic therapy.
Thrombosis
Restoration of thrombosed Brescia-Cimino dialysis fistulas by using percutaneous transluminal angioplasty.
Thrombosis
Right atrial thrombosis in two premature infants: successful treatment with urokinase and heparin.
Thrombosis
Role of endothelin in thrombolysis in rat abdominal aorta.
Thrombosis
Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis evaluation in transgenic animals.
Thrombosis
Role of thrombolysis in free-flap salvage.
Thrombosis
Safety and efficacy of abciximab use in conjunction with intracoronary urokinase in patients requiring angioplasty.
Thrombosis
Safety and Efficacy of Aspiration Thrombectomy or Pharmacomechanical Thrombectomy after Catheter-Directed Thrombolysis for the Treatment of Acute Iliofemoral Deep Vein Thrombosis.
Thrombosis
Safety and efficacy of extended urokinase infusion plus stent deployment for treatment of obstructed, older saphenous vein grafts.
Thrombosis
Safety and efficacy of urokinase during elective coronary angioplasty.
Thrombosis
Salvage of renal allograft function and lower extremity venous patency with thrombolytic therapy: case report and review of the literature.
Thrombosis
Scanning electron microscopy of experimental thrombus formation in canine lateral saphena vein.
Thrombosis
Selective infusion of urokinase and thrombectomy in the treatment of acute cerebral sinus thrombosis.
Thrombosis
Self-expanding stent for recanalization of acute embolic or dissecting intracranial artery occlusion.
Thrombosis
Sodium Citrate Versus Heparin Catheter Locks for Cuffed Central Venous Catheters: A Single-Center Randomized Controlled Trial.
Thrombosis
Spontaneous intrajugular migration of long-term central venous access catheters.
Thrombosis
Spontaneous Spinal Epidural Hematoma After Normal Spontaneous Delivery with Epidural Analgesia: Case Report and Literature Review.
Thrombosis
Streptokinase--a clinically useful thrombolytic agent.
Thrombosis
Streptokinase: An Efficient Enzyme in Cardiac Medicine.
Thrombosis
Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.
Thrombosis
Success of thrombolysis as a predictor of outcome in acute thrombosis of popliteal aneurysms.
Thrombosis
Successful intra-arterial thrombolysis for acute ischemic stroke in the immediate postpartum period: case report.
Thrombosis
Successful local low-dose urokinase treatment of acquired thrombosis early after cardiothoracic surgery.
Thrombosis
Successful thrombolytic therapy in two patients with renal vein thrombosis.
Thrombosis
Successful treatment of an acute thrombosis of an intracranial vertebral artery endarterectomy with urokinase.
Thrombosis
Successful treatment of superior vena cava syndrome with urokinase in an infant with a central venous catheter.
Thrombosis
Successful use of Tenecteplase in a patient with recurrence of prosthetic mitral valve thrombosis.
Thrombosis
Sudden appearance of coronary thrombus observed by angiography--a case report.
Thrombosis
Superior sagittal sinus thrombosis: a clinical and experimental study.
Thrombosis
Superior sagittal sinus thrombus secondary to occult meningioma: a case report.
Thrombosis
Superior vena cava syndrome after heart transplantation: percutaneous treatment of a complication of bicaval anastomoses.
Thrombosis
Surgery for effort thrombosis of the subclavian vein.
Thrombosis
Synergism of thrombolytic agents in vivo.
Thrombosis
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
Thrombosis
Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
Thrombosis
Synthesis of recombinant human single-chain urokinase-type plasminogen activator variants resistant to plasmin and thrombin.
Thrombosis
Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
Thrombosis
The beneficial effect of lys-plasminogen upon the thrombolytic efficacy of urokinase in a dog model of peripheral arterial thrombosis.
Thrombosis
The biotechnological potential of fibrinolytic enzymes in the dissolution of endogenous blood thrombi.
Thrombosis
The effect of intravenous infusion of urokinase on coronary artery thrombolysis in the dog.
Thrombosis
The Effectiveness of Subdural Drains Using Urokinase after Burr Hole Evacuation of Subacute Subdural Hematoma in Elderly Patients: A Prelimilary Report.
Thrombosis
The effects of thrombus, thrombectomy and thrombolysis on endothelial function.
Thrombosis
The efficacy of reteplase in the treatment of thrombosed hemodialysis venous catheters.
Thrombosis
The features of thrombus in a microvessel injury model and the antithrombotic efficacy of heparin, urokinase, and prostaglandin E1.
Thrombosis
The first 100 cases of intracoronary stent implantation in cardiac center, King Chulalongkorn Memorial Hospital.
Thrombosis
The heparin-induced thrombocytopenia and thrombosis syndrome: treatment with intraarterial urokinase and systemic platelet aggregation inhibitors.
Thrombosis
The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: effect of thrombomodulin.
Thrombosis
The influence of transport parameters and enzyme kinetics of the fibrinolytic system on thrombolysis: mathematical modelling of two idealised cases.
Thrombosis
The inhibitory role of recombinant P-selectin glycoprotein ligand immunoglobulin G on portal vein thrombosis based on a novel rat model.
Thrombosis
The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice.
Thrombosis
The intracoronary administration of urokinase following direct PTCA for acute myocardial infarction reduces early restenosis.
Thrombosis
The preparation of a new self-made microbubble-loading urokinase and its thrombolysis combined with low-frequency ultrasound in vitro.
Thrombosis
THE PREVENTION OF ARTERIAL THROMBOSIS BY FIBRINOLYTIC ACTIVATION WITH UROKINASE: AN EXPERIMENTAL STUDY.
Thrombosis
The rationale of prevention of thrombosis by enhancing blood levels of single-chain urokinase-type plasminogen activator (scuPA).
Thrombosis
The role of intracoronary thrombus in unstable angina: angiographic assessment and thrombolytic therapy during ongoing anginal attacks.
Thrombosis
The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis.
Thrombosis
The safety and efficacy of pharmaco-mechanical thrombolysis in lower-extremity deep venous thrombosis.
Thrombosis
The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
Thrombosis
The tissue plasminogen activator and urokinase response in vivo during natural resolution of venous thrombus.
Thrombosis
The transport of 125I-labeled human high molecular weight urokinase across the intestinal tract in a dog model with stimulation of synthesis and/or release of plasminogen activators.
Thrombosis
The usefulness of systemic administration of recombinant human tissue-type plasminogen activator in femoral arterial thrombolysis of rabbits.
Thrombosis
Thrombolysis Enhancing by Magnetic Manipulation of Fe?O? Nanoparticles.
Thrombosis
Thrombolysis for experimental deep venous thrombosis maintains valvular competence and vasoreactivity.
Thrombosis
Thrombolysis of occluded infrainguinal bypass grafts.
Thrombosis
Thrombolysis of the cervical internal carotid artery before balloon angioplasty and stent placement: report of two cases.
Thrombosis
Thrombolysis to treat arterial thrombotic complications of heparin-induced thrombocytopenia.
Thrombosis
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.
Thrombosis
Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
Thrombosis
Thrombolysis with reteplase for recurrent mechanical heartvalve thrombosis.
Thrombosis
Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
Thrombosis
Thrombolytic and endovascular treatment of peripartum iliac vein thrombosis: a case report.
Thrombosis
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons.
Thrombosis
Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model.
Thrombosis
Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
Thrombosis
Thrombolytic Therapy for Acute Myocardial Infarction : A Review.
Thrombosis
Thrombolytic therapy for femoral artery thrombosis after left cardiac catheterization in children.
Thrombosis
Thrombolytic therapy for prosthetic cardiac valve thrombosis.
Thrombosis
Thrombolytic therapy in acute stroke.
Thrombosis
Thrombolytic therapy in heparin-associated thrombocytopenia with thrombosis.
Thrombosis
Thrombolytic Therapy Using Urokinase for Management of Central Venous Catheter Thrombosis.
Thrombosis
Thrombolytic therapy: the treatment of choice for iliac vein thrombosis in the presence of kidney transplant.
Thrombosis
Thrombolytic treatment of prosthetic valve thrombosis: a study using Urokinase.
Thrombosis
Thrombosis and Urokinase: Proceedings of the Serono Symposia, vol 9.
Thrombosis
Thrombosis of a mechanical tricuspid valve prosthesis and of the left subclavian vein: successful therapy with thrombolysis.
Thrombosis
Thrombosis of tibial arteries in a patient receiving tamoxifen therapy.
Thrombosis
Thrombosis of Tunneled-Cuffed Hemodialysis Catheters: Treatment With High-Dose Urokinase Lock Therapy.
Thrombosis
Thrombosis recanalization by paeoniflorin through the upregulation of urokinase?type plasminogen activator via the MAPK signaling pathway.
Thrombosis
Thrombotic complications of subclavian apheresis catheters in cancer patients: prevention with heparin infusion.
Thrombosis
Thrombus age and tissue plasminogen activator mediated thrombolysis in rats.
Thrombosis
Thrombus aspiration as a bailout procedure during percutaneous renal angioplasty.
Thrombosis
Thrombus in vertebrobasilar dolichoectatic artery treated with intravenous urokinase.
Thrombosis
Thrombus-specific theranostic nanocomposite for codelivery of thrombolytic drug, algae-derived anticoagulant and NIR fluorescent contrast agent.
Thrombosis
Thrombus-targeted nanoparticles for thrombin-triggered thrombolysis and local inflammatory microenvironment regulation.
Thrombosis
Tissue plasminogen activator: an evaluation of clinical efficacy in acute myocardial infarction.
Thrombosis
tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor.
Thrombosis
Tracheobronchial Obstruction Due to Blood Clots in Acute Pulmonary Embolism with Cardiac Arrest Managed with Extracorporeal Membrane Oxygenation.
Thrombosis
Transcatheter closure of persistent ductus arteriosus with the Amplatzer duct occluder in very young symptomatic children.
Thrombosis
Transcatheter regional urokinase therapy in the management of inferior vena cava thrombosis.
Thrombosis
Transient left atrial mobile thrombus in acute myocardial infarction--a case report.
Thrombosis
Transient left ventricular apical ballooning in a patient with bicuspid aortic valve created a left ventricular thrombus leading to acute renal infarction.
Thrombosis
Transradial approach for transcatheter selective superior mesenteric artery urokinase infusion therapy in patients with acute extensive portal and superior mesenteric vein thrombosis.
Thrombosis
Treatment for mechanical valve thrombosis in the right heart: combined pharmacological and mechanical thrombolysis.
Thrombosis
Treatment of a case of thromboembolism resulting from thoracic outlet syndrome with intra-arterial urokinase infusion.
Thrombosis
Treatment of acute myocardial infarction with prolonged intracoronary urokinase delivery through intracoronary infusion catheter.
Thrombosis
Treatment of acute stent thrombosis with local urokinase therapy using catheter-based, drug delivery systems: a case report.
Thrombosis
Treatment of acute thromboembolic complication after stent-assisted coil embolization of ruptured intracranial aneurysm: a case report.
Thrombosis
Treatment of Budd-Chiari syndrome with urokinase following predilation in patients with old inferior vena cava thrombosis.
Thrombosis
Treatment of intracoronary thrombus with local urokinase infusion using a new, site-specific drug delivery system: the Dispatch catheter.
Thrombosis
Treatment of neonatal aortic thrombosis with urokinase.
Thrombosis
Treatment of right atrial thrombus with urokinase.
Thrombosis
Treatment of right ventricular thrombus with severe right ventricular dysfunction using urokinase.
Thrombosis
Treatment of subclavian-axillary vein thrombosis: long-term outcome of anticoagulation versus systemic thrombolysis.
Thrombosis
Treatment of thrombotic saphenous vein bypass grafts using local urokinase infusion therapy with the Dispatch catheter.
Thrombosis
Tricuspid valve replacement with the bileaflet St. Jude Medical valve prosthesis.
Thrombosis
Two-step targeting of urokinase to plasma clot provides efficient fibrinolysis.
Thrombosis
Ultrasound and Intra-Clot Microbubbles Enhanced Catheter-Directed Thrombolysis in Vitro and in Vivo.
Thrombosis
Ultrasound with Microbubble Contrast Agent and Urokinase for Thrombosis.
Thrombosis
Ultrasound-assisted thrombolysis.
Thrombosis
Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma.
Thrombosis
Upper tract urokinase instillation for nephrostomy tube patency.
Thrombosis
Urokinase and AT-III concentrate treatment in inferior vena cava thrombosis associated with nephrotic syndrome.
Thrombosis
Urokinase binding to bovine corneal endothelial cells.
Thrombosis
Urokinase dissolution of a right atrial thrombus.
Thrombosis
Urokinase in the management of vitreous hemorrhage.
Thrombosis
Urokinase in the treatment of shunt malfunctions caused by thrombus.
Thrombosis
Urokinase lysis for acute left subclavian artery thrombosis after placement of infusion catheter: report of two cases.
Thrombosis
Urokinase perfusion for axillary-subclavian vein thrombosis.
Thrombosis
Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism.
Thrombosis
Urokinase therapy for a catheter-related right atrial thrombus and pulmonary embolism in a 2-month-old infant.
Thrombosis
Urokinase therapy for a catheter-related right atrial thrombus.
Thrombosis
Urokinase therapy for a central venous catheter thrombus.
Thrombosis
Urokinase therapy for thrombosed hemodialysis access grafts.
Thrombosis
Urokinase therapy for thrombosis of tricuspid prosthetic valve.
Thrombosis
Urokinase therapy in neonates with catheter related central venous thrombosis.
Thrombosis
Urokinase therapy of subclavian-axillary vein thrombosis.
Thrombosis
Urokinase thrombolysis as initial therapy for acute and non-acute ischemic extremities.
Thrombosis
Urokinase treatment of neonatal aortoiliac thrombosis caused by umbilical artery catheterization: a case report.
Thrombosis
Urokinase treatment of pulmonary artery thrombosis complicating the pediatric nephrotic syndrome.
Thrombosis
Urokinase treatment of sagittal sinus thrombosis with venous hemorrhagic infarction.
Thrombosis
Urokinase treatment preserves endothelial and smooth muscle function in experimental acute arterial thrombosis.
Thrombosis
Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial.
Thrombosis
Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts with thrombosis.
Thrombosis
Urokinase-immobilization suppresses inflammatory responses to polyurethane tubes implanted in rabbit muscles.
Thrombosis
Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex.
Thrombosis
Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: results of the ECAPTURE study. European Concerted Action on Prevention from Thrombosis by URokinase Enhancement.
Thrombosis
Urokinase. A cost-effective alternative treatment of superior vena cava thrombosis and obstruction.
Thrombosis
Use of urokinase in dispersal of obstructive postoperative thrombus in the renal pelvis.
Thrombosis
Usefulness of Aspiration of Pulmonary Emboli and Prolonged Local Thrombolysis to Treat Pulmonary Embolism.
Thrombosis
Usefulness of intracoronary stenting in acute myocardial infarction.
Thrombosis
Usefulness of Local Delivery of Thrombolytics Before Thrombectomy in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (the Delivery of Thrombolytics Before Thrombectomy in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention [DISSOLUTION] Randomized Trial).
Thrombosis
Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia.
Thrombosis
Vertebrobasilar thrombosis in children: report of two cases and recommendations for treatment.
Thrombosis
Visible Thrombolysis Acceleration of a Nanomachine Powered by Light-Driving F0F1-ATPase Motor.
Thrombosis
[A case of arterial thrombosis successfully treated with a large dosage of urokinase--study on urokinase administration with special reference to alpha2-plasmin inhibitor (author's transl)]
Thrombosis
[A case of hypertrophic obstructive cardiomyopathy with left atrial giant thrombus during anti-platelet therapy]
Thrombosis
[A case of inferior vena cava thrombosis associated with cholelithiasis demonstrated by ultrasonic examination]
Thrombosis
[A case of portal and superior mesenteric thrombosis associated with protein S deficiency treated with urokinase via the superior mesenteric vein]
Thrombosis
[A case of renal vein thrombosis and pulmonary embolism associated with diffuse membranous glomerulonephritis: the usefulness of low-molecular-weight heparin and urokinase therapy]
Thrombosis
[A combination of arteriovenous impulse system and low-molecular-weight heparins calcium for prophylaxis of deep venous thrombosis following total knee arthroplasty]
Thrombosis
[A pilot study on recurrent thrombosis of the coronary vessels. Selective infusion of urokinase is an effective treatment]
Thrombosis
[A rat middle cerebral artery thrombosis model for evaluation of thrombolytic and antithrombotic agents]
Thrombosis
[A successful thrombolytic therapy for thrombosed ATS valve in the mitral position in a child; report of a case]
Thrombosis
[Actual state of thrombolytic treatment of recent vein thrombosis and pulmonary embolism (author's transl)]
Thrombosis
[Acute coronary syndrome due to coronary thrombus formed by severe coronary spasm: a case report]
Thrombosis
[Acute massive pulmonary embolism--report of a case]
Thrombosis
[Addition of antithrombosis in situ in the case of digital replantation: preliminary prospective study of 13 cases].
Thrombosis
[An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model]
Thrombosis
[Application of percutaneous AngioJet thrombectomy in patients with acute symptomatic portal and superior mesenteric venous thrombosis].
Thrombosis
[Atherosclerosis obliterance; thrombolytic therapy]
Thrombosis
[Balloon occlusion pulmonary angiography and anticoagulant-antithrombotic therapy in ARDS-associated pulmonary vascular thrombosis]
Thrombosis
[Cannulation of the internal jugular vein with 2 silastic catheters. A new method of vascular access for hemodialysis]
Thrombosis
[Case of mitral stenosis with regression and elimination of left atrial thrombus after combined therapy of urokinase, dipyridamole and aspirin]
Thrombosis
[Catheter-directed thrombolysis for iliofemoral vein thrombosis: report of 13 cases]
Thrombosis
[Central venous access for hemodialysis: use and practice with the child in France]
Thrombosis
[Cerebral venous thrombosis in a girl carrier of the prothrombin gene mutation 20210G--> A treated by local fibrinolysis of the superior sagittal sinus]
Thrombosis
[Clinical analysis of intravenous urokinase treatment of 10 cases with Kawasaki disease complicated with thrombus in coronary aneurysm]
Thrombosis
[Clinical application and efficacy of TIPS combined with AngioJet mechanical thrombectomy for liver cirrhosis with extensive portal vein thrombosis].
Thrombosis
[Clinical experience in 3 cases, 5 events of thrombosed Björk-Shiley mitral prostheses]
Thrombosis
[Clinical experience with the use of implantable vascular systems in advanced heart failure]
Thrombosis
[Comparative study of the morphologic behavior of fresh leg and pelvic vein thromboses treated with streptokinase, urokinase and heparin based on phlebography follow-up]
Thrombosis
[Comparison of mechanical thrombectomy with transcatheter thrombolysis for acute iliac femoral venous thrombosis].
Thrombosis
[Congenital deficiency of factor Xii and spontaenous venous thrombosis treated with urokinase]
Thrombosis
[Coronary spasm-induced acute myocardial infarction associated with intracoronary thrombosis]
Thrombosis
[Coronary vascular stent implantation--experiences with the first 100 implants]
Thrombosis
[Design of Intravascular Ultrasound-enhanced Thrombolysis Excitation System Based on FPGA].
Thrombosis
[Early and late results after local streptokinase administration in massive lung embolism]
Thrombosis
[Effect of urokinase on morphological changes of vein wall after acute thrombosis in rabbits]
Thrombosis
[Effectiveness of double fibrinolytic treatments in subacute deep vein thrombosis of the lower limbs]
Thrombosis
[Effort thrombosis of the subclavian vein].
Thrombosis
[Experimental and clinical studies on oral urokinase and lysyl-plasminogen. Thrombolytic therapy for cerebral thrombosis]
Thrombosis
[Experimental study of the thrombolytic effects in a canine model of pulmonary thromboembolism induced by autologous radioactive blood clots]
Thrombosis
[Fibrinogen-guided thrombolysis with urokinase of a portal and mesenterial venous thrombosis during an acute episode of ulcerative colitis]
Thrombosis
[Fibrinolytic properties and thrombolytic effect of a novel fibrinolytic enzyme from Streptomyces sp. Y405]
Thrombosis
[Fibrinolytic therapy for femoral artery thrombosis after left cardiac catheterization in children].
Thrombosis
[Fibrinolytic therapy of deep vein thrombosis of the leg and pelvis with streptokinase and urokinase]
Thrombosis
[Fibrinolytic therapy of lower limb deep vein thrombosis with urokinase (author's transl)]
Thrombosis
[Fibrinolytic treatment of acute and subacute thromboses of the deep veins of the shoulder girdle (author's transl)]
Thrombosis
[Fibrinolytic treatment with urokinase and streptokinase for recurrent thrombosis in two valve prostheses for the aortic and mitral valves during pregnancy]
Thrombosis
[High-dose urokinase for thrombolysis following replantation of severed limbs or fingers.]
Thrombosis
[In situ thrombolysis in the treatment of venous thrombosis of effort in the arm]
Thrombosis
[Intra-arterial lysis therapy in acute limb ischemia. Technical possibilities and limits of indication]
Thrombosis
[Intra-arterial urokinase in the treatment of acute thrombosis of the renal artery. A case report]
Thrombosis
[Intracoronary thrombolytic therapy in Kawasaki disease and the usefulness of two-dimensional echocardiography in detecting intracoronary thrombi]
Thrombosis
[Intracoronary thrombolytic treatment with urokinase in myocardial infarct: clinical angiographic findings and effects on left ventricular function]
Thrombosis
[Late effect of intracoronary urokinase. Apropos of a case of recurrent coronary thrombosis after angioplasty]
Thrombosis
[Local intravenous fibrinolysis in deep cerebral vein thrombosis]
Thrombosis
[Local low-dose thrombolytic treatment with sequential urokinase-plasminogen in deep central venous thrombosis]
Thrombosis
[Local therapeutic fibrinolysis in ischemic cerebrovascular insults: initial findings in 6 patients]
Thrombosis
[Loco-regional transcatheter thrombolysis]
Thrombosis
[Low dose thrombolytic treatment for revascularisation in arterial occlusion (author's transl)]
Thrombosis
[Neonatal subrenal abdominal aortic thrombosis. Recovery following urokinase]
Thrombosis
[Popliteal aneurysm and leg ischemia: thrombolysis first]
Thrombosis
[Portal vein thrombosis associated with idiopathic hypereosinophilic syndrome].
Thrombosis
[Preparation of thrombus-targeted urokinase liposomes and its thrombolytic effect in model rats]
Thrombosis
[Prevention of catheter-induced thromboses by low molecular weight heparins]
Thrombosis
[Primary nephrotic syndrome treated with urokinase--a report of 20 cases]
Thrombosis
[Pulmonary artery thrombosis during hormonal contraceptive therapy. Treatment with urokinase]
Thrombosis
[Recurrent thrombosis of an aortic valve prosthesis in a pregnant woman. Treatment with urokinase]
Thrombosis
[Role of thrombolytic treatment in thrombosis of valvular prostheses. Apropos of 2 cases and review of the world literature]
Thrombosis
[Selective thrombolytic therapy for deep venous thrombosis by using a small caliber catheter passed through a temporary vena cava filter]
Thrombosis
[Septic portal vein thrombosis. Its successful therapy by local fibrinolysis and a transjugular portasystemic stent-shunt (TIPS)]
Thrombosis
[Severe acquired protein S deficiency with thrombophlebitis after febrile infection in a 7-year-old girl]
Thrombosis
[Simultaneous urokinase perfusion in renal artery and vein in a case of renal vein thrombosis]
Thrombosis
[Subacute thrombosis of the abdominal aorta with suprarenal involvement and successful treatment with pharmacomechanical fibrinolysis]
Thrombosis
[Successful fibrinolytic treatment with urokinase six weeks after leg and pelvic vein thrombosis (author's transl)]
Thrombosis
[Successful lysis of a septic thrombosis of the superior vena cava using recombinant tissue-plasminogen activator]
Thrombosis
[Successful lysis of iliofemoral and inferior vena cava thrombi in heparin-induced type-II thrombocytopenia]
Thrombosis
[Successful lysis therapy in acute unilateral renal vein thrombosis]
Thrombosis
[Successful replantation of circularly severed palm and multiply severed fingers. A case report]
Thrombosis
[Successful treatment of a right atrial thrombus secondary to central venous catheterization]
Thrombosis
[Successful treatment of superior mesenteric artery thrombosis with local high-dose urokinase therapy]
Thrombosis
[t-PA in thrombolytic therapy of acute myocardial infarct]
Thrombosis
[Tesio twin catheter system for hemodialysis tunnelized using an echo-guided technique. Retrospective analysis of 210 catheters]
Thrombosis
[The fibrinolytic treatment with urokinase of acute arterial thrombosis]
Thrombosis
[The functional expression of humanized ScFv-urokinase fusion protein in Escherichia coli]
Thrombosis
[The use of endoprosthesis in superior vena cava syndrome caused by lung neoplasms]
Thrombosis
[Thrombolytic therapy in patients with pulmonary artery thromboembolism and deep vein thrombosis].
Thrombosis
[Thrombolytic therapy of thrombosed Björk-Shiley aortic valve prosthesis--report of four cases]
Thrombosis
[Thrombolytic therapy with urokinase in two systemic lupus erythematosus patients with deep vein thrombosis]
Thrombosis
[Thrombolytic therapy. Effect of urokinase on experimental thrombosis (author's transl)]
Thrombosis
[Thrombolytic treatment with urokinase (author's transl)]
Thrombosis
[Thrombosis of the renal veins in a premature infant. Treatment with heparin and urokinase]
Thrombosis
[Thrombosis on a mitral valve prosthesis: treatment with urokinase and color-Doppler monitoring]
Thrombosis
[Thrombus age as a determinant of lysis efficacy of in vitro produced platelet-fibrin thrombi]
Thrombosis
[TIPSS in the Budd-Chiari syndrome with portal vein thrombosis]
Thrombosis
[Treatment of a large intracoronary thrombus with urokinase and a chimeric monoclonal platelet aggregation inhibitor]
Thrombosis
[Treatment of massive arterial thrombosis caused by thrombocytopenia induced by heparin with local thrombolysis]
Thrombosis
[Treatment of obstruction and thrombosis due to central venous catheterization]
Thrombosis
[Treatment of thrombosis of the central retinal vein with urokinase. Complete cure]
Thrombosis
[Treatment possibilities for extensive pulmonary embolism as an alternative to the Trendelenburg operation]
Thrombosis
[Treatment with urokinase of systemic arterial thrombosis in the newborn infant]
Thrombosis
[Urokinase in a premature infant: its use in a case of right atrial thrombosis secondary to catheterization of the umbilical vein]
Thrombosis
[Urokinase recanalization of extensive thrombosis of the superior vena cava secondary to an implantable perfusion device]
Thrombosis
[Urokinase therapy of deep vein thrombosis (author's transl)]
Thrombosis
[Urokinase therapy of deep vein thrombosis]
Thrombosis
[Urokinase therapy of recurrent thrombosis of tricuspid prosthetic valve]
Thrombosis
[Use of urokinase in the occlusion of the vascular access routes in chronic hemodialysis. 7 years' experience]
Thrombosis
[Water-soluble modified derivatives of urokinase: fibrinolytic activity and other properties]
Thrombotic Microangiopathies
Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target?
Thrombotic Stroke
Circadian fluctuations in the efficacy of thrombolysis with streptokinase.
Thrombotic Stroke
Investigational use of tPA in acute stroke.
Thrombotic Stroke
The beneficial effect of intracarotid urokinase on acute stroke in a baboon model.
Thymoma
Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Thyroid Cancer, Papillary
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Thyroid Cancer, Papillary
High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Thyroid Cancer, Papillary
In papillary thyroid carcinoma BRAF(V) (600E) is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Thyroid Cancer, Papillary
Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells.
Thyroid Cancer, Papillary
The Urokinase Plasminogen Activator System in Metastatic Papillary Thyroid Carcinoma: A Potential Therapeutic Target.
Thyroid Diseases
[Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases]
Thyroid Neoplasms
Human thyroid carcinoma cell invasion is controlled by the low density lipoprotein receptor-related protein-mediated clearance of urokinase plasminogen activator.
Thyroid Neoplasms
Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
Thyroid Neoplasms
The urokinase plasminogen activating system in thyroid cancer: clinical implications.
Thyroid Neoplasms
Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity.
Thyroid Neoplasms
Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients.
Thyroid Neoplasms
Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study.
Toxemia
The role of placental urokinase inhibitor in toxemia of pregnancy.
Toxemia
[Fibrinolysis in pregnancy toxemia]
Toxemia
[Fibrinolytic therapy for toxemia of late pregnancy--experimental studies of pregnant rabbits treated with urokinase]
Tricuspid Atresia
Resolution of protein-losing enteropathy with standard high molecular heparin and urokinase after Fontan repair in a patient with tricuspid atresia.
Triple Negative Breast Neoplasms
Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography.
Triple Negative Breast Neoplasms
MicroRNA-645 targets urokinase plasminogen activator and decreases the invasive growth of MDA-MB-231 triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
N-Alkylisatin-Loaded Liposomes Target the Urokinase Plasminogen Activator System in Breast Cancer.
Triple Negative Breast Neoplasms
Urokinase-type plasminogen activator receptor inhibits apoptosis in triple-negative breast cancer through miR-17/20a suppression of death receptors 4 and 5.
Tuberculoma
[Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]
Tuberculosis
Concurrent upregulation of urokinase plasminogen activator receptor and CD11b during tuberculosis and experimental endotoxemia.
Tuberculosis
Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
Tuberculosis
Serum levels of soluble urokinase plasminogen activator receptor (suPAR) as a marker of tuberculosis treatment efficacy.
Tuberculosis
Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection.
Tuberculosis
Soluble urokinase plasminogen activator receptor levels in tuberculosis patients at high risk for multidrug resistance.
Tuberculosis
Soluble urokinase-type plasminogen activator receptor as a biomarker of treatment response in childhood tuberculosis.
Tuberculosis
The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau.
Tuberculosis
Utility of the Plasma Level of suPAR in Monitoring Risk of Mortality during TB Treatment.
Tuberculosis, Meningeal
Use of urokinase in the treatment of tuberculous meningitis hydrocephalus.
Tuberculosis, Pleural
Intrapleural urokinase directly under medical thoracoscopy for the diagnosis of tuberculous pleurisy.
Tuberculosis, Pleural
Treatment of free-flowing tuberculous pleurisy with intrapleural urokinase.
Tuberculosis, Pleural
[The study of intrapleural urokinase in the prevention of pleural thickening and loculated effusions by tuberculous pleurisy]
Tuberculosis, Pulmonary
Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients: still looking for a marker of treatment efficacy.
Tuberculosis, Pulmonary
Sedimentation rate and suPAR in relation to disease activity and mortality in patients with tuberculosis.
Tuberculosis, Pulmonary
[An attempt to enhance the antituberculous effect of chemotherapeutics by the combined administration of urokinase for pulmonary tuberculosis (author's transl)]
Tuberous Sclerosis
Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Typhoid Fever
Plasminogen- 125 I responses in dogs to a single injection of urokinase and typhoid vaccine and to vascular injury.
u-plasminogen activator deficiency
A urokinase-type plasminogen activator deficiency diminishes the frequency of intestinal adenomas in Apc(Min/+) mice.
u-plasminogen activator deficiency
Plasmin and matrix metalloproteinases in vascular remodeling.
u-plasminogen activator deficiency
Regulation of epithelial sodium channels in urokinase plasminogen activator deficiency.
u-plasminogen activator deficiency
Urokinase-type plasminogen activator deficiency (uPA-KO) prevented carotid artery ligation-induced vascular remodeling in mice.
u-plasminogen activator deficiency
Urokinase-type plasminogen activator deficiency has little effect on seizure susceptibility and acquired epilepsy phenotype but reduces spontaneous exploration in mice.
u-plasminogen activator deficiency
Urokinase-Type Plasminogen Activator Deficiency in Bone Marrow-Derived Cells Augments Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms.
u-plasminogen activator deficiency
Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice.
Upper Extremity Deep Vein Thrombosis
Comparison of retavase and urokinase for management of spontaneous subclavian vein thrombosis.
Upper Extremity Deep Vein Thrombosis
Continuous infusion of low-dose urokinase in the treatment of central venous catheter thrombosis in infants and children.
Upper Extremity Deep Vein Thrombosis
Thrombolytic Therapy Using Urokinase for Management of Central Venous Catheter Thrombosis.
Uremia
Impact of low-dose urokinase in peritoneal dialysis on serum oxidative stress, nitric oxide and endothelin in cerebral infarction complicated with uremia.
Uremia
The serum levels of MMP-9, MMP-2 and vWF in patients with low doses of urokinase peritoneal dialysis decreased uremia complicated with cerebral infarction.
Ureteral Obstruction
Serine proteases, inhibitors and receptors in renal fibrosis.
Ureteral Obstruction
Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.
Ureteral Obstruction
[Role of integrin-linked kinase in renal tubular epithelial-mesenchymal transition and the regulatory effect of urokinae on its expression in mice with obstructive nephropathy]
Urinary Bladder Neoplasms
An ATF24 peptide-functionalized ?-elemene-nanostructured lipid carrier combined with cisplatin for bladder cancer treatment.
Urinary Bladder Neoplasms
Anticancer drug sensitivity in vitro in the bladder cancer cell line, KK-47 and prophylactic use of carbazilquinone and urokinase in bladder cancer.
Urinary Bladder Neoplasms
Apigenin Suppresses the IL-1?-Induced Expression of the Urokinase-Type Plasminogen Activator Receptor by Inhibiting MAPK-Mediated AP-1 and NF-?B Signaling in Human Bladder Cancer T24 Cells.
Urinary Bladder Neoplasms
Association of Urokinase Gene 3'-UTR T/C polymorphism with bladder cancer.
Urinary Bladder Neoplasms
CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer.
Urinary Bladder Neoplasms
Combined intravesical therapy with doxorubicin (adriamycin) and urokinase in the management of superficial bladder tumours.
Urinary Bladder Neoplasms
Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancer.
Urinary Bladder Neoplasms
Expression of UPA and UPAR is associated with the clinical course of urinary bladder neoplasms.
Urinary Bladder Neoplasms
Fibrinolysis-inhibitory activity of cultured human cancer cell lines.
Urinary Bladder Neoplasms
First-in-human uPAR PET: Imaging of Cancer Aggressiveness.
Urinary Bladder Neoplasms
Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets.
Urinary Bladder Neoplasms
Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.
Urinary Bladder Neoplasms
Immunological analysis of plasminogen activators from cultured human cancer cells.
Urinary Bladder Neoplasms
Intravesical therapy of noninvasive bladder tumors (stage Ta) with doxorubicin and urokinase.
Urinary Bladder Neoplasms
Is interferon gamma one key of metastatic potential increase in human bladder carcinoma?
Urinary Bladder Neoplasms
mTORC2 activation is regulated by the urokinase receptor (uPAR) in bladder cancer.
Urinary Bladder Neoplasms
Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
Urinary Bladder Neoplasms
Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer.
Urinary Bladder Neoplasms
Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer.
Urinary Bladder Neoplasms
Re: Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Urinary Bladder Neoplasms
Re: urokinase and urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Urinary Bladder Neoplasms
Safety, dosimetry and tumor detection ability of 68Ga-NOTA-AE105 - a novel radioligand for uPAR PET imaging: first-in-humans study.
Urinary Bladder Neoplasms
Sinulariolide Suppresses Cell Migration and Invasion by Inhibiting Matrix Metalloproteinase-2/-9 and Urokinase through the PI3K/AKT/mTOR Signaling Pathway in Human Bladder Cancer Cells.
Urinary Bladder Neoplasms
The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.
Urinary Bladder Neoplasms
The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer.
Urinary Bladder Neoplasms
The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer.
Urinary Bladder Neoplasms
The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).
Urinary Bladder Neoplasms
The prophylactic use of thio-tepa and urokinase in transitional cell carcinoma of the bladder: a preliminary report.
Urinary Bladder Neoplasms
uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.
Urinary Bladder Neoplasms
Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines.
Urinary Bladder Neoplasms
Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Urinary Bladder Neoplasms
Urokinase inhibitor in patients with bladder cancer.
Urinary Bladder Neoplasms
Urokinase-type plasminogen activator and its receptor in bladder cancer.
Urinary Bladder Neoplasms
[Effect of polyphenols from the Mediterranean diet on proliferation and mediators of in vitro invasiveness of the MB-49 murine bladder cancer cell line]
Urinary Bladder Neoplasms
[Urokinase-type plasminogen activator antigen as a prognostic factor in bladder cancer]
Urinary Calculi
Meta-analysis of the urokinase gene 3'-UTR T/C polymorphism and susceptibility to urolithiasis.
Urinary Tract Infections
Plasma soluble urokinase plasminogen activator receptor in children with urinary tract infection.
Urolithiasis
ApaL1 urokinase and Taq1 vitamin D receptor gene polymorphisms in first-stone formers, recurrent stone formers, and controls in a Caucasian population.
Urolithiasis
Association of calcium urolithiasis with urokinase P141L and 3'-UTR C>T polymorphisms in a Japanese population.
Urolithiasis
Association of urokinase gene 3'-UTR T/C polymorphism with calcium oxalate urolithiasis in children.
Urolithiasis
Effects of bacteria involved with the pathogenesis of infection-induced urolithiasis on the urokinase and sialidase (neuraminidase) activity.
Urolithiasis
Erratum: interleukin-1?, calcium-sensing receptor, and urokinase gene polymorphisms in korean patients with urolithiasis.
Urolithiasis
In vivo effects of urease-producing bacteria involved with the pathogenesis of infection-induced urolithiasis on renal urokinase and sialidase activity.
Urolithiasis
Interleukin-1?, calcium-sensing receptor, and urokinase gene polymorphisms in korean patients with urolithiasis.
Urolithiasis
Meta-analysis of the urokinase gene 3'-UTR T/C polymorphism and susceptibility to urolithiasis.
Urolithiasis
The effect of calcium and magnesium ions on urinary urokinase and sialidase activity.
Urolithiasis
Urokinase alteration and its correlation with disease severity and oxidative/nitrosative stress in buffalo calves with obstructive urolithiasis.
Urolithiasis
Urokinase gene 3'-UTR T/C polymorphism is associated with urolithiasis.
Urologic Diseases
Immunohistochemical staining of urokinase plasminogen activator-like and urokinase plasminogen activator receptor-like proteins in the urinary tract of healthy dogs.
Urologic Diseases
[Urinary urokinase and blood fibrinolytic activity in patients with nephrolithiasis and other urinary tract diseases]
Urologic Neoplasms
Extract from Serenoa repens suppresses the invasion activity of human urological cancer cells by inhibiting urokinase-type plasminogen activator.
Urologic Neoplasms
Inhibition of aminopeptidase N (AP-N) and urokinase-type plasminogen activator (uPA) by zinc suppresses the invasion activity in human urological cancer cells.
Urticaria
Blood urokinase plasminogen activator system in chronic urticaria.
Uterine Cervical Neoplasms
A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix.
Uterine Cervical Neoplasms
Biochemical markers as a predictor for lymph-node involvement in patients with cervical-cancer of the uterus.
Uterine Cervical Neoplasms
Clinical significance of urokinase-type plasminogen activator (uPA) in invasive cervical cancer of the uterus.
Uterine Cervical Neoplasms
Construction of Urokinase-Type Plasminogen Activator Receptor-Targeted Heterostructures for Efficient Photothermal Chemotherapy against Cervical Cancer To Achieve Simultaneous Anticancer and Antiangiogenesis.
Uterine Cervical Neoplasms
Downregulation of Extracellular Matrix Metalloproteinase Inducer by scFv-M6-1B9 Intrabody Suppresses Cervical Cancer Invasion Through Inhibition of Urokinase-Type Plasminogen Activator.
Uterine Cervical Neoplasms
Effect of a synthetic inhibitor of urokinase plasminogen activator on the migration and invasion of human cervical cancer cells in vitro.
Uterine Cervical Neoplasms
Evaluating the value of uPAR of serum and tissue on patients with cervical cancer.
Uterine Cervical Neoplasms
Fisetin Inhibits Migration and Invasion of Human Cervical Cancer Cells by Down-Regulating Urokinase Plasminogen Activator Expression through Suppressing the p38 MAPK-Dependent NF-?B Signaling Pathway.
Uterine Cervical Neoplasms
Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway.
Uterine Cervical Neoplasms
Hypoxia inducible factor-1 mediates upregulation of urokinase-type plasminogen activator receptor gene transcription during hypoxia in cervical cancer cells.
Uterine Cervical Neoplasms
Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
Uterine Cervical Neoplasms
Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.
Uterine Cervical Neoplasms
Knockdown of Pentraxin 3 suppresses tumorigenicity and metastasis of human cervical cancer cells.
Uterine Cervical Neoplasms
Prognostic significance of uPA and uPAR expression in patients with cervical cancer undergoing radiotherapy.
Uterine Cervical Neoplasms
Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR).
Uterine Cervical Neoplasms
[Urokinase-type plasminogen activator as a predictor for lymph nodes metastasis of uterine cervical cancer]
Uterine Neoplasms
Clinical significance of urokinase-type plasminogen activator (uPA) in invasive cervical cancer of the uterus.
Uterine Neoplasms
Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
Vaccinia
Controlled gamma-irradiation mediated pathogen inactivation of human urokinase preparations with significant recovery of enzymatic activity.
Varicose Ulcer
Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Varicose Ulcer
Growth factors, tissue and urokinase-type plasminogen activators in venous ulcers.
Varicose Ulcer
Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds.
Varicose Ulcer
The soluble urokinase plasminogen activator receptor and its fragments in venous ulcers.
Varicose Ulcer
Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers.
Varicose Veins
Matrix metalloproteinase-9 and urokinase-type plasminogen activator in varicose veins.
Vascular Calcification
Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-?B pathway in osteoclasts.
Vascular Calcification
Urokinase receptor mediates osteogenic differentiation of mesenchymal stem cells and vascular calcification via the complement C5a receptor.
Vascular Diseases
ALKBH1 reduces DNA N6-methyladenine to allow for vascular calcification in chronic kidney disease.
Vascular Diseases
Influence of homocysteine on fibrin network lysis.
Vascular Diseases
Local thrombolytic therapy for cerebrovascular disease: current Oregon Health Sciences University experience (July 1991 through April 1995).
Vascular Diseases
Obstructive vascular disease treated by urokinase.
Vascular Diseases
Transgenic chickens expressing human urokinase-type plasminogen activator.
Vascular Diseases
Urokinase receptor associates with myocardin to control vascular smooth muscle cells phenotype in vascular disease.
Vascular Diseases
[Middle cerebral arterial occlusion secondary to brain tumor -- case report (author's transl)]
Vascular Malformations
Cellular markers that distinguish the phases of hemangioma during infancy and childhood.
Vascular System Injuries
A targeted antithrombotic conjugate with antiplatelet and fibrinolytic properties which reduces in vivo thrombus formation.
Vascular System Injuries
Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes.
Vascular System Injuries
Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro.
Vascular System Injuries
Native atherosclerosis and vein graft arterialization: association with increased urokinase receptor expression in vitro and in vivo.
Vascular System Injuries
Plasmin and matrix metalloproteinases in vascular remodeling.
Vascular System Injuries
Plasminogen- 125 I responses in dogs to a single injection of urokinase and typhoid vaccine and to vascular injury.
Vascular System Injuries
Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury.
Vascular System Injuries
Urokinase activates the Jak/Stat signal transduction pathway in human vascular endothelial cells.
Vasospasm, Intracranial
Case presentations of neuroradiologic interventions for acute cerebrovascular disease.
Vasospasm, Intracranial
Clot-clearance rate in the sylvian cistern is associated with the severity of cerebral vasospasm after subarachnoid hemorrhage.
Vasospasm, Intracranial
Effect on cerebral vasospasm of coil embolization followed by microcatheter intrathecal urokinase infusion into the cisterna magna: a prospective randomized study.
Vasospasm, Intracranial
Effectiveness of the head-shaking method combined with cisternal irrigation with urokinase in preventing cerebral vasospasm after subarachnoid hemorrhage.
Vasospasm, Intracranial
Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage.
Vasospasm, Intracranial
Intrathecal urokinase infusion through a microcatheter into the cisterna magna to prevent cerebral vasospasm: experimental study in dogs.
Vasospasm, Intracranial
Microcatheter intrathecal urokinase infusion into cisterna magna for prevention of cerebral vasospasm: preliminary report.
Vasospasm, Intracranial
Surgical procedure and results of cisternal washing therapy for the prevention of cerebral vasospasm following SAH.
Vasospasm, Intracranial
[Combined modality therapy for cerebral vasospasm: fibrinolytic therapy using urokinase and intravascular surgery]
Venous Thromboembolism
Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism.
Venous Thrombosis
A comparative study of urokinase and heparin in the treatment of deep vein thrombosis.
Venous Thrombosis
A new "wonder" drug to dissolve clots. The results of urokinase therapy in acute myocardial infarction, pulmonary embolism and deep vein thrombosis.
Venous Thrombosis
Acute renal allograft dysfunction in the setting of deep venous thrombosis: a case of successful urokinase thrombolysis and a review of the literature.
Venous Thrombosis
Adenoviral urokinase-type plasminogen activator (uPA) gene transfer enhances venous thrombus resolution.
Venous Thrombosis
Blood coagulation changes during effective thrombolysis using urokinase and heparin.
Venous Thrombosis
Bolus recombinant urokinase versus heparin in deep venous thrombosis: a randomized controlled trial.
Venous Thrombosis
Catheter-directed thrombolysis for thromboembolic disease during pregnancy: a viable option.
Venous Thrombosis
Catheter-Directed Thrombolysis With a Continuous Infusion of Low-Dose Alteplase for Subacute Proximal Venous Thrombosis: Efficacy and Safety Compared to Urokinase.
Venous Thrombosis
Catheter-directed thrombolysis with a continuous infusion of low-dose urokinase for non-acute deep venous thrombosis of the lower extremity.
Venous Thrombosis
Combined thrombolytic and anticoagulant therapy for venous thrombosis in children.
Venous Thrombosis
Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
Venous Thrombosis
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Venous Thrombosis
Comparison of cost effectiveness of streptokinase and urokinase in the treatment of deep vein thrombosis.
Venous Thrombosis
Comparison of Direct Iliofemoral Stenting Following AngioJet Rheolytic Thrombectomy vs Staged Stenting After AngioJet Rheolytic Thrombectomy Plus Catheter-Directed Thrombolysis in Patients With Acute Deep Vein Thrombosis.
Venous Thrombosis
Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
Venous Thrombosis
Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis.
Venous Thrombosis
Criteria for use of regional urokinase infusion for deep vein thrombosis.
Venous Thrombosis
Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Venous Thrombosis
Deep venous thrombosis associated with protein C and/or S deficiency: management with catheter-directed thrombolysis.
Venous Thrombosis
Direct thrombolysis of superior sagittal sinus thrombosis with coexisting intracranial hemorrhage.
Venous Thrombosis
Efficacy and safety of repeated boluses of urokinase in the treatment of deep venous thrombosis.
Venous Thrombosis
Enhanced Venous Thrombus Resolution in Plasminogen Activator Inhibitor Type-2 Deficient Mice.
Venous Thrombosis
Evaluation of thrombolysis in a porcine model of chronic deep venous thrombosis: an endovascular model.
Venous Thrombosis
Feasibility of continuous, catheter-directed thrombolysis using low-dose urokinase in combination with low molecular-weight heparin for acute iliofemoral venous thrombosis in patients at risk of bleeding.
Venous Thrombosis
Feasibility of low-dose infusion of alteplase for unsuccessful thrombolysis with urokinase in deep venous thrombosis.
Venous Thrombosis
Fibrinolysis with intrathrombic injection of urokinase and tissue-type plasminogen activator. Results in a new model of subacute venous thrombosis.
Venous Thrombosis
Fibrinolytic therapy with streptokinase and urokinase in deep vein thrombosis.
Venous Thrombosis
Free tissue transfer in pediatric patients.
Venous Thrombosis
Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis.
Venous Thrombosis
Increase in the degree of phosphorylation of circulating fibrinogen under thrombolytic therapy with urokinase.
Venous Thrombosis
Intermittent pneumatic compression of the foot and calf improves the outcome of catheter-directed thrombolysis using low-dose urokinase in patients with acute proximal venous thrombosis of the leg.
Venous Thrombosis
Isolated straight sinus and deep cerebral venous thrombosis: successful treatment with local infusion of urokinase. Case report.
Venous Thrombosis
Late vascular occlusion of central lines in pediatric malignancies.
Venous Thrombosis
Localisation of deep-venous thrombosis using technetium-99m-labelled urokinase.
Venous Thrombosis
Long-term follow-up of upper extremity implanted venous access devices in oncology patients.
Venous Thrombosis
Management of pelvic venous stenosis with intravascular stainless steel stents.
Venous Thrombosis
Mechanical thrombectomy of acute iliofemoral deep vein thrombosis with use of an arrow-trerotola percutaneous thrombectomy device.
Venous Thrombosis
Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis.
Venous Thrombosis
Mycoplasma pneumoniae-induced cerebral venous thrombosis treated with urokinase.
Venous Thrombosis
Outcome of treatment of deep-vein thrombosis with urokinase: relationship to dosage, duration of therapy, age of the thrombus and laboratory changes.
Venous Thrombosis
Proceedings: Thrombolytic therapy of deep venous thromboses with urokinase.
Venous Thrombosis
Progress in fibrinolysis.
Venous Thrombosis
Repeated phlebographic examination during and after fibrinolytic therapy with streptokinase and urokinase.
Venous Thrombosis
Safety and Efficacy of Low Dosage of Urokinase for Catheter-directed Thrombolysis of Deep Venous Thrombosis.
Venous Thrombosis
Sequential Release Platform of Heparin and Urokinase with Dual Physical (NIR-II and Bubbles) Assistance for Deep Venous Thrombosis.
Venous Thrombosis
Simultaneous renal arterial and venous thrombosis associated with idiopathic nephrotic syndrome: treatment with intra-arterial urokinase.
Venous Thrombosis
Spontaneous Spinal Epidural Hematoma After Normal Spontaneous Delivery with Epidural Analgesia: Case Report and Literature Review.
Venous Thrombosis
Successful local arterial urokinase infusion to reverse late postoperative venous thrombosis of a renal graft.
Venous Thrombosis
Sustained improvement of pulmonary hemodynamics in patients at rest and during exercise after thrombolytic treatment of massive pulmonary embolism.
Venous Thrombosis
Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
Venous Thrombosis
The complete recanalization of PICC-related venous thrombosis in cancer patients: A series of case reports.
Venous Thrombosis
The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis.
Venous Thrombosis
The safety and efficacy of pharmaco-mechanical thrombolysis in lower-extremity deep venous thrombosis.
Venous Thrombosis
The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
Venous Thrombosis
Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
Venous Thrombosis
Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Venous Thrombosis
Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
Venous Thrombosis
Thrombolytic therapy for inferior vena cava thrombosis in paroxysmal nocturnal hemoglobinuria.
Venous Thrombosis
Ultrasound with Microbubble Contrast Agent and Urokinase for Thrombosis.
Venous Thrombosis
Urokinase in iliofemoral venous thrombosis.
Venous Thrombosis
Urokinase in the management of acute arterial and venous thrombosis.
Venous Thrombosis
Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism.
Venous Thrombosis
Urokinase protocol for free-flap salvage following prolonged venous thrombosis.
Venous Thrombosis
Urokinase therapy in neonates with catheter related central venous thrombosis.
Venous Thrombosis
Urokinase treatment for arteriovenous fistulae declotting in dialyzed patients.
Venous Thrombosis
Urokinase-coated chitosan nanoparticles for thrombolytic therapy: preparation and pharmacodynamics in vivo.
Venous Thrombosis
Use of urokinase in pregnancy.
Venous Thrombosis
Use of urokinase in pregnancy. Two success stories.
Venous Thrombosis
[Actual state of thrombolytic treatment of recent vein thrombosis and pulmonary embolism (author's transl)]
Venous Thrombosis
[Color-coded Doppler sonography for phlebothrombosis]
Venous Thrombosis
[Comparison of mechanical thrombectomy with transcatheter thrombolysis for acute iliac femoral venous thrombosis].
Venous Thrombosis
[Congenital deficiency of factor Xii and spontaenous venous thrombosis treated with urokinase]
Venous Thrombosis
[Dosage of urokinase in venous thrombosis of the lower extremities]
Venous Thrombosis
[Effects of potentiation and rapid action in models of venous thrombosis in dogs upon combined administration of the plasminogen tissue activator and urokinase modified by fibrinogen]
Venous Thrombosis
[Efficacy and value of fibrinolytic agents in chronic proximal venous thrombosis of the lower limbs]
Venous Thrombosis
[Efficacy of regional administration of urokinase and argatroban via small saphenous vein catheter for treatment of acute deep venous thrombosis in the lower limb.]
Venous Thrombosis
[Experience with urokinase in chronic arterial occlusive disease and long-standing phlebothrombosis]
Venous Thrombosis
[Experiences with streptokinase and urokinase therapy of different dosages in deep venous thrombosis]
Venous Thrombosis
[Extensive cerebral venous thrombosis resistant to heparin: local fibrinolysis with urokinase]
Venous Thrombosis
[Fibrinogen-guided thrombolysis with urokinase of a portal and mesenterial venous thrombosis during an acute episode of ulcerative colitis]
Venous Thrombosis
[Fibrinolytic therapy of deep vein thrombosis of the leg and pelvis with streptokinase and urokinase]
Venous Thrombosis
[Fibrinolytic therapy of deep venous thrombosis. Streptokinase, urokinase, plasminogen substitution]
Venous Thrombosis
[Fibrinolytic therapy of lower limb deep vein thrombosis with urokinase (author's transl)]
Venous Thrombosis
[Fibrinolytic therapy with streptokinase and urokinase in deep venous thrombosis]
Venous Thrombosis
[Fibrinolytic treatment with urokinase in older phlebothrombosis (author's transl)]
Venous Thrombosis
[Fibrinolytic treatment with urokinase of post acute phlebothromboses (author's transl)]
Venous Thrombosis
[Indications and implementation of fibrinolytic therapy with streptokinase and urokinase in deep venous thrombosis]
Venous Thrombosis
[Individualized endovascular treatment of cerebral venous thrombosis: analysis of 168 patients]
Venous Thrombosis
[Local low-dose thrombolytic treatment with sequential urokinase-plasminogen in deep central venous thrombosis]
Venous Thrombosis
[Loco-regional fibrinolysis with urokinase in the treatment of deep venous thromboses]
Venous Thrombosis
[Loco-regional thrombolytic therapy with urokinase in deep venous thrombosis of the legs. Our experience]
Venous Thrombosis
[Nephrotic syndrome complicated with intracranial venous thrombosis treated with urokinase: report of 5 cases]
Venous Thrombosis
[Primary nephrotic syndrome treated with urokinase--a report of 20 cases]
Venous Thrombosis
[Studies on thrombolytic therapy for venous thrombosis in the extremities--dynamics of plasmin inhibitor and FDP following administration of urokinase (author's transl)]
Venous Thrombosis
[Thrombolysis using urokinase in acute phlebothrombosis]
Venous Thrombosis
[Thrombolysis with Urokinase after anaphylaxis caused by streptokinase treatment (author's transl)]
Venous Thrombosis
[Thrombolytic agents]
Venous Thrombosis
[Thrombolytic efficacy of a Lys-plasminogen-urokinase combination: studies in experimental animals and humans]
Venous Thrombosis
[Thrombolytic therapy in patients with pulmonary artery thromboembolism and deep vein thrombosis].
Venous Thrombosis
[Thrombolytic therapy with urokinase in two systemic lupus erythematosus patients with deep vein thrombosis]
Venous Thrombosis
[Treatment of obstruction and thrombosis due to central venous catheterization]
Venous Thrombosis
[Urokinase dosage in deep venous thromboses]
Venous Thrombosis
[Urokinase in deep venous thrombosis]
Venous Thrombosis
[Urokinase therapy of deep vein thrombosis (author's transl)]
Venous Thrombosis
[Urokinase therapy of deep vein thrombosis]
Venous Thrombosis
[Use of streptokinase and urokinase in deep venous thrombosis and pulmonary embolism: indications and clinical experience]
Venous Thrombosis
[Value of color-coded duplex sonography in diagnosis of acute and chronic venous diseases of the lower extremity]
Venous Thrombosis
[Venous thrombolysis and venous angioplasty]
Ventricular Dysfunction, Right
Local low-dose urokinase thrombolysis for the management of hemodynamically stable pulmonary embolism with right ventricular dysfunction.
Ventricular Dysfunction, Right
Treatment of right ventricular thrombus with severe right ventricular dysfunction using urokinase.
Ventricular Fibrillation
A novel modified tissue-type plasminogen activator (t-PA), E6010, gradually increases coronary blood flow after thrombolysis compared with native t-PA, urokinase and balloon catheter occlusion-reperfusion.
Ventricular Fibrillation
Ventricular fibrillation after intrapleural urokinase.
Vertebral Artery Dissection
[A case of basilar artery occlusion of traumatic vertebral artery dissection successfully managed by endovascular treatment]
Vertebrobasilar Insufficiency
Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor.
Vertebrobasilar Insufficiency
Thrombus in vertebrobasilar dolichoectatic artery treated with intravenous urokinase.
Viremia
Immunological predictors of survival in HIV type 2-infected rural villagers in Guinea-Bissau.
Virus Diseases
Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.
Virus Diseases
The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever.
Vision Disorders
Statistical analysis of visual prognosis following stellate ganglion block treatment on patients with retinal vessel obstruction.
Vitreous Detachment
The efficacy of plasminogen-urokinase combination in inducing posterior vitreous detachment.
Vitreous Detachment
The role of recombinant lysine-plasminogen and recombinant urokinase and sulfur hexafluoride combination in inducing posterior vitreous detachment.
Vitreous Detachment
[Preparation of high-purity and safe autologous plasmin and its clinical application]
Vitreous Hemorrhage
Intravitreal urokinase in the treatment of vitreous hemorrhage.
Vitreous Hemorrhage
Urokinase in experimental vitreous hemorrhage.
Vitreous Hemorrhage
Urokinase in the management of vitreous hemorrhage.
Vitreous Hemorrhage
[Intravitreal urokinase for vitreous hemorrhage]
Vitreous Hemorrhage
[Subconjunctival injection of urokinase in the treatment of diabetic vitreous hemorrhage]
von Willebrand Diseases
Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor.
Warts
[Immunohistologic alterations of epidermal cytokeratins following cryotherapy]
Whooping Cough
Activation of the {beta}-catenin/T-cell-specific transcription factor/lymphoid enhancer factor-1 pathway by plasminogen activators in ECV304 carcinoma cells.
Whooping Cough
Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of CD14 and urokinase receptor.
Whooping Cough
Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of Mac-1(CD11b/CD18) and urokinase receptor (CD87).
Whooping Cough
Pro-collagen I COOH-terminal trimer induces directional migration and metalloproteinases in breast cancer cells.
Whooping Cough
Urokinase/urokinase receptor and vitronectin/alpha(v)beta(3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways.
Xeroderma Pigmentosum
Insulin-like growth factors II exon 9 and E-cadherin-Pml I but not myeloperoxidase promoter-463, urokinase-ApaL I nor xeroderma pigmentosum polymorphisms are associated with higher susceptibility to leiomyoma.
Xeroderma Pigmentosum
UV irradiation induces the murine urokinase-type plasminogen activator gene via the c-Jun N-terminal kinase signaling pathway: requirement of an AP1 enhancer element.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.